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Abstract 
Epidemiological and experimental evidence suggests that non-digestible 
carbohydrates (NDCs) e.g. resistant starch (RS) are protective against 
colorectal cancer (CRC), resulting primarily from the production of the short-
chain fatty acid (SCFA) butyrate. The WNT signalling pathway is central to the 
maintenance of homeostasis within the large bowel through regulation of 
physiological processes and is frequently aberrantly activated in CRCs. 
Butyrate has been shown to positively modulate WNT signalling, affecting 
functional outcomes such as apoptosis and proliferation and, therefore, 
protecting against CRC.  
To investigate the molecular mechanisms through which NDCs may reduce 
CRC risk in humans, we undertook a double-blind, randomised, controlled trial 
(The DISC Study) in which 75 healthy participants were supplemented with two 
NDCs: RS (Hi-maize® 260) and polydextrose (PD) (Litesse® Ultra™) for 50 
days using a 2x2 factorial design. Colorectal mucosal biopsies were collected 
before and at the end of intervention and used to quantify expression of WNT 
pathway-related genes and of BAX and BCL-2 (two regulators of apoptosis) and 
to assess colonic crypt cell proliferation. WNT signalling pathway genes were 
also investigated in an additional 38 participants at higher risk of CRC because 
of quiescent ulcerative colitis or a history of adenomatous polyps.  
RS supplementation significantly reduced expression of CTNNB1 (p=0.045), 
encoding β-catenin (a key component of the WNT pathway), and c-MYC 
(p=0.037), suggesting a reduction in WNT signalling in these participants. RS 
and/or PD significantly reduced expression of two antagonists of WNT 
signalling, SFRP1 and SFRP2, suggesting an increase in WNT activity. RS and 
PD did not affect SFRP1 methylation or expression of miRNAs that may target 
this gene. RS increased total colonic crypt cell proliferation (p=0.030) but did 
not alter the proportion of mitotic cells in the top half of the crypt (a marker of 
crypt health). 
Participants at higher risk of CRC had increased expression of c-JUN (p=0.046) 
and WNT11 (p=0.040) and increased SFRP1 methylation. The BAX to BCL-2 
ratio was lower in higher-risk participants, suggesting a reduction in BCL-2 
   
 ii 
family-mediated apoptosis. Unexpectedly, crypt cell proliferation was also 
reduced in higher-risk participants (p=0.009). 
These findings suggest that the increased cell proliferation with RS 
supplementation may have resulted from induction of the WNT pathway. 
However, these effects were not mediated via alterations in SFRP1 methylation 
or expression of miRNAs. This study has also shown that WNT signalling is 
aberrantly active in the macroscopically-normal mucosa of people at higher risk 
of CRC. 
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Chapter 1 General Introduction 
1.1 The human large bowel 
The large bowel, or large intestine, is found in the lower section of the 
gastrointestinal (GI) tract and comprises the caecum, colon and rectum. The 
colon can be divided into the right side (proximal colon), comprising the 
ascending colon and proximal transverse colon, and left side (distal colon), 
which includes the distal transverse colon, descending colon, sigmoid colon and 
rectum (Figure 1.1).  
The colorectal epithelium, which forms a barrier separating the gut lumen from 
the rest of the body, consists of a single layer of columnar epithelial cells 
(Humphries and Wright, 2008). Although the intestinal luminal surface of the 
large bowel epithelium is flat, there are numerous invaginations, named crypts 
of Lieberkuhn, which house the stem cells responsible for populating this tissue.  
Figure 1.1 The large bowel. 
 
Reprinted with permission from Cancer Research UK (CRUK, 2013), Copyright (2013). 
1.1.1 Function of the large bowel 
The primary function of the large bowel is the fermentation of undigested 
carbohydrates, such as resistant starch (RS), by commensal colonic bacteria to 
produce energy with short-chain fatty acids (SCFAs) as major end-products. 
These SCFAs, including butyrate, are absorbed by the colonic epithelium and 
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contribute to host energy supply as well as the health of the mucosa (Lanham-
New et al., 2011). In addition, colonic bacteria synthesise amino acids and 
vitamins, including vitamin B12 and vitamin K. Another important function of the 
large bowel is the absorption of electrolytes and water, which aids the formation 
of semi-solid faeces (Lanham-New et al., 2011).  
1.1.2 The colonic crypt 
Colonic crypts are invaginations formed by the epithelium that penetrate into the 
connective tissue (Humphries and Wright, 2008). There are approximately ten 
million crypts within the human large bowel (Zhao and Michor, 2013). The 
average crypt is 80 cells in depth and 40 cells in circumference and comprises 
approximately 2,000 cells, including an average of five stem cells (Potten et al., 
1992b). Stem cells are constantly dividing and producing proliferating progenitor 
cells which then migrate towards the top of the crypts and differentiate into 
epithelial cells (Clevers, 2013). Four different cell types are found in the large 
bowel: colonocytes, enteroendocrine cells, goblet cells and Paneth cells (Kinzler 
et al., 1991; Schneikert and Behrens, 2007).  
The intestinal epithelium is continuously renewing and is completely renewed 
every two to seven days (Brittan and Wright, 2004). This is achieved through 
the constant upward migration of proliferating progenitor cells which, once 
differentiated into epithelial cells, cease proliferating, undergo apoptosis and are 
shed (Schneikert and Behrens, 2007) (Figure 1.2). Both the migration of 
progenitor cells and proliferation are controlled by WNT signalling (Clevers and 
Batlle, 2006).  
   
 3 
Figure 1.2 The colonic crypt. 
 
Within the colonic crypt, stem cells, which reside at the base of the crypt, produce cells 
that proliferate in the proliferative compartment (basal half of the crypt) and differentiate 
as they migrate upwards towards the mouth of the crypt. It is here that cells undergo 
apoptosis and are shed. The continuity of this process allows constant renewal of the 
colonic epithelium. 
1.1.2.1 The colonic crypt cell proliferative state 
Cell proliferation describes the growth and replication of cells. In the healthy 
colonic crypt, cell proliferation is a tightly regulated process that is confined to 
the lower compartments of the crypt, known as the proliferative compartment, 
towards the base of the crypt where the stem cells are found (Potten et al., 
1992a). It has been calculated that approximately 10% of all cells within the 
crypt are undergoing proliferation at one time (Potten et al., 1992b).  
Hyperproliferation is a characteristic of CRC and, importantly, an altered pattern 
of proliferating cells within the crypt, characterised by expansion of the 
proliferative compartment towards the luminal surface, is one of the earliest 
detectable alterations in the normal mucosa during colorectal carcinogenesis 
(Risio et al., 1991).  
1.1.2.2 Apoptosis in the colonic crypt 
Kerr, Wylie and Currie first described apoptosis in 1972 as “a distinctive process 
[…], which plays a complementary but opposite role to mitosis in the regulation 
of animal cell populations” (Kerr et al., 1972). Not only is apoptosis important in 
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the removal of aged cells through programmed cell death, but it also removes 
any cells with genetic damage, providing a defence mechanism against 
tumourigenesis.  
In the healthy colonic crypt, apoptosis is particularly important at the top of the 
crypt, towards the luminal surface, where there is a constant cell turnover and 
shedding of apoptotic cells from the surface of the colonic epithelium which 
maintains the homeostatic state. As in the case of cell proliferation, apoptosis is 
tightly controlled within the colonic epithelium. An imbalance between apoptosis 
and proliferation, favouring a hyperproliferative state, may lead to tumour 
development. This can result from an imbalance in pro- and anti-apoptotic 
genes, which has been associated with colorectal carcinogenesis (Evertsson et 
al., 1999). Any apoptosis in the lower compartments of the crypt, where 
proliferation predominates, is believed to be a defensive response to genetic 
damage in proliferating cells (Strater et al., 1995; Koornstra et al., 2003).  
A systematic review of studies investigating changes in apoptosis from normal 
mucosa to adenomas and ultimately carcinomas was completed by Koornstra 
and colleagues (Koornstra et al., 2003). The majority of studies reviewed found 
an increase in apoptosis when comparing adenomas with normal mucosa, and 
carcinomas with adenomas. When assessing changes in apoptosis in 
adenomas, a correlation between the level of dysplasia and an increase in 
apoptosis was observed. In adenomatous polyps, a reduction in apoptosis at 
the mouth of the crypts, where apoptotic cells are predominantly found in 
healthy crypts, was accompanied by an increase in apoptosis at the base of the 
crypts (Moss et al., 1996a; Sinicrope et al., 1996).  
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1.2 Colorectal cancer 
Colorectal cancer (CRC), or bowel cancer, is a common cause of morbidity and 
mortality in the United Kingdom (UK) and worldwide. It is therefore important 
that the molecular mechanisms responsible for the pathogenesis of this cancer 
are understood to predict predisposing factors and to develop suitable risk 
biomarkers which would facilitate CRC prevention and/or treatment. As 
discussed in section 1.2.3 below, CRC risk is significantly altered by 
environmental factors such as diet, suggesting that lifestyle modifications may 
prevent a large proportion of CRC cases.  
1.2.1 Colorectal cancer incidence 
CRC is the third most common cancer worldwide and second most common 
cancer in Europe (CRUK, 2014a). However, as can be observed in Figure 1.3, 
incidence varies greatly between different regions in the world. In 2012, CRC 
incidence rates were greatest in developed regions, such as Australia, New 
Zealand and Western Europe, and lowest in developing regions, particularly 
Africa and South-Central Asia (Ferlay et al., 2013).  
Figure 1.3 Worldwide colorectal cancer incidence (2012 estimates).  
 
Adapted with permission from Cancer Research UK (CRUK, 2014d), Copyright (2014). 
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In the UK, CRC is the fourth most common cancer, with close to 110 new CRC 
diagnoses each day (CRUK, 2014b). In 2010, it was calculated that males in the 
UK had a 1 in 14 lifetime risk of developing CRC and that this is slightly lower in 
females, who have a 1 in 19 lifetime risk (CRUK, 2014a). In the UK, CRC 
incidence has increased since the mid-1970s (CRUK, 2014a) and has risen by 
6% in the last decade (CRUK, 2014b). In 2011 there were over 40,000 new 
CRC diagnoses in the UK (CRUK, 2014b).  
1.2.2 Colorectal cancer mortality and survival 
Worldwide, CRC is the fourth most common cause of cancer-related death and 
is the second-most common cause of cancer-related death in Europe. In the 
UK, it is also the second most common cause of cancer-related death, which 
translates to approximately 10% of all cancer deaths or over 15,000 deaths in 
2011 (CRUK, 2014c). Although the incidence of CRC in the UK has risen since 
the 1970s, mortality rates have decreased by 63% from the early 1970s to 
between 2009 and 2011 (CRUK, 2014c). Survival rates have also improved, 
with one-year survival rates increasing from approximately 40% in the early 
1970s to over 70% between 2005 and 2009 (CRUK, 2012).  
1.2.3 Risk factors for colorectal cancer 
A number of factors have been demonstrated to alter CRC risk such as age, 
other diseases of the large bowel, genetic factors and lifestyle factors including 
diet, physical activity and smoking. 
1.2.3.1 Age 
There is a strong positive correlation between age and CRC incidence, 
particularly after the age of 50. Between 2009 and 2011, 95% of CRC cases 
diagnosed in the UK were observed in people aged 50 and over (CRUK, 2014a) 
(Figure 1.4). This correlation is particularly strong in males who, up to the age of 
80 years, have greater CRC incidence compared with females. 
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Figure 1.4 CRC incidence rates and average number of cases by year by 
age group, UK, 2009-2011.  
 
Reprinted with permission from Cancer Research UK (CRUK, 2014a), Copyright 
(2014). 
1.2.3.2 Diet and alcohol 
The American Institute for Cancer Research (AICR)/World Cancer Research 
Fund (WCRF) Continuous Update Project Report: ‘Food, Nutrition, Physical 
Activity and the Prevention of Colorectal Cancer’ released in 2011 concluded 
that a reduction in CRC risk could be achieved with higher consumption of 
dietary fibre (convincing evidence) (discussed in more depth in section 1.5), 
garlic, milk and calcium (probable evidence) (WCRF/AICR, 2011). On the 
contrary, higher intakes of red meat and processed meat (convincing evidence) 
and alcohol (convincing evidence for males, probable for females) were 
associated with increased CRC risk (WCRF/AICR, 2011). Limited/suggestive 
evidence was found for a protective effect of non-starchy vegetables, fruits and 
foods containing vitamin D, and for a detrimental effect of animal fats, cheese, 
sugars and foods containing iron (WCRF/AICR, 2011). A summary of the 
conclusions from this report are described in Table 1.1. 
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Table 1.1 Summary of the conclusions from the WCRF/AICR Continuous 
Update Report (2011): ‘Food, Nutrition, Physical Activity and the 
Prevention of Colorectal Cancer’. 
Evidence Decreases risk Increases risk 
Convincing 
 Physical activity of all types 
(occupational, household, 
transport and recreational) 
 Foods containing dietary 
fibre1 
 
 Red meat (beef, pork, lamb 
and goat) 
 Processed meat (preserved 
by smoking, curing, salting or 
addition of chemical 
preservatives) 
 Alcoholic drinks (men) 
 Body fatness 
 Abdominal fatness 
 Adult attained height 
Probable 
 Garlic 
 Cow milk 
 Calcium 
 Alcoholic drinks (women) 
Limited-
suggestive 
 Non-starchy vegetables 
 Fruits 
 Foods containing vitamin D1 
 Foods containing iron1 
 Cheese 
 Foods containing animal 
fats1 
 Foods containing non-milk 
extrinsic sugars 
Limited- no 
conclusion 
 Fish 
 Glycaemic index 
 Folate 
 Vitamin C 
 Vitamin E 
 Selenium 
 Low fat 
 Dietary pattern 
1Includes both foods naturally containing the constituent or with the constituent added 
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1.2.3.3 Body mass index and abdominal adiposity 
There is a positive correlation between both body mass index (BMI) and 
abdominal adiposity and CRC incidence. A recent systematic review concluded 
that obese people (BMI ≥ 30kg/m2) have a 33% greater CRC risk compared 
with those with a normal BMI (Ma et al., 2013). It has been estimated that 13% 
of the new CRC cases diagnosed in the UK in 2010 were attributable to 
overweight or obesity (Parkin and Boyd, 2011). Abdominal adiposity is also 
associated with an increased risk of CRC; those with the largest waist 
circumference have almost double the CRC risk observed in those with the 
smallest waist circumference (Ma et al., 2013). 
1.2.3.4 Physical activity 
The WCRF/AICR Continuous Update Report also concluded that convincing 
evidence exists for a protective effect of total physical activity against CRC and 
that greatest levels of overall physical activity were associated with the lowest 
risk of CRC (WCRF/AICR, 2011) (see Table 1.1). 
In a meta-analysis of three cohort studies conducted as part of the Continuous 
Update Project, the authors concluded that for every 5 metabolic equivalent of 
task (MET) per day of total physical activity there was a 3% reduction in CRC 
risk (WCRF/AICR, 2011). For recreational physical activity, a dose-response 
meta-analysis conducted in three studies revealed a significant inverse 
correlation between recreational physical activity and colorectal cancer risk, with 
an 11% reduction in CRC risk per 30 minutes of recreational physical activity 
per day (WCRF/AICR, 2011). Physical activity may protect against colorectal 
carcinogenesis through improving metabolic efficiency and capacity as a 
consequence of the increased metabolic rates and oxygen uptake associated 
with moderate levels of physical activity (Slattery, 2004). Physical activity is also 
associated with anti-inflammatory effects, a reduction in insulin and in insulin 
resistance. Another mechanism through which physical activity may protect 
against CRC is by reducing body fatness, which, as described in section 
1.2.3.3, is associated with an increased risk of CRC. 
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1.2.3.5 Smoking 
There is a strong association between tobacco smoking and CRC incidence. In 
the UK, 8.1% of CRCs in 2010 were attributable to tobacco smoking (Parkin et 
al., 2011). A meta-analysis which examined 36 prospective studies reported a 
17% and 25% greater risk of CRC in smokers and former smokers respectively 
compared with non-smokers (Liang et al., 2009). Furthermore, there is a dose 
response relationship between the daily number of cigarettes and CRC risk, 
with 20 cigarettes per day being associated with 17.5% greater CRC incidence 
which increased to 38.5% with 40 cigarettes per day (Liang et al., 2009).  
1.2.3.6 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) encompasses diseases characterised by 
inflammation of the GI tract, primarily Crohn’s disease and ulcerative colitis 
(UC). Patients with IBD are at greater risk of developing CRC and account for 
approximately 2% of new CRC diagnoses per year (Triantafillidis et al., 2009; 
Lutgens et al., 2013). 
1.2.3.6.1 Ulcerative colitis 
UC is characterised by inflammation in the mucosal layer of the colorectum 
(Ford et al., 2013; Rogler, 2014). Symptoms of UC include rectal bleeding, 
tenesmus and diarrhoea (Ford et al., 2013). UC normally develops in early 
adulthood between 20 and 30 years of age (Rogler, 2014) and is believed to 
result from an abnormal immunological response to an alteration in the colonic 
environment in genetically susceptible people (Ford et al., 2013).  
In a study of 600 patients with UC, CRC risk was 1.5-fold greater compared with 
healthy participants (Rutter et al., 2006). A meta-analysis investigated the 
prevalence of UC-associated CRCs in 116 studies and reported that CRC 
prevalence in UC patients was 3.7% (Eaden et al., 2001). Studies have 
reported a correlation between CRC risk and disease duration, with UC patients 
with a disease duration of 20 years having a 7% risk, doubling to up to 14% at 
25 years and may increase to up to 30% after 35 years (Rogler, 2014). 
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Eaden et al. proposed that increased CRC risk is apparent approximately eight 
to ten years following the onset of UC-related inflammation (Eaden et al., 2001), 
demonstrating that the associated risk results from inflammation in these 
patients. CRCs that develop as a result of UC, also known as colitis-associated 
cancers, are a consequence of the chronic inflammatory state associated with 
this disease (Rogler, 2014). This is confirmed by the observation that UC 
patients treated with anti-inflammatory agents, such as thiopurines, have 
reduced CRC risk (Eaden, 2003; Seidelin et al., 2013; Nieminen et al., 2014). 
Colitis-associated CRCs tend to develop from the progression of low-grade to 
high-grade dysplasia (Ullman and Itzkowitz, 2011). Although colitis-associated 
CRCs do not follow the adenoma-carcinoma sequence observed in sporadic 
cases, they do share similarities in pathogenetic alterations such as 
chromosome instability and DNA hypermethylation (Rogler, 2014). An early 
event in colitis-associated CRC is the loss of the p53 tumour suppressor, 
occurring in up to 85% of cases (Burmer et al., 1992), loss of heterozygosity 
(LOH) or loss of function (Hussain et al., 2000; Rosman-Urbach et al., 2004). 
Another shared event by sporadic and colitis-associated CRCs is the loss of the 
adenomatous polyposis coli (APC) tumour suppressor, a component of the 
WNT signalling pathway. However, in colitis-associated cancers this is a much 
rarer event and occurs at later stages of the progression to CRC (Tarmin et al., 
1995).  
Colitis-associated CRCs also have altered epigenetic mechanisms, particularly 
DNA methylation. Similarly to that in sporadic CRC, genes such as the hMLH1, 
a mismatch repair gene, are frequently hypermethylated and consequently 
downregulated in colitis-associated CRCs (Fleisher et al., 2000). The 
methylation state of several members of the WNT signalling pathway, which is 
frequently aberrantly activated in CRC, have also been reported in colitis-
associated CRC. WNT components such as SFRP1, SFRP4, DKK1 and WIF1 
showed greater methylation both in UC compared with normal tissue and in 
colitis-associated neoplasia compared with UC tissue (Dhir et al., 2008).  
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1.2.3.6.2 Crohn’s disease 
Crohn’s disease is the other common type of IBD and is an autoimmune 
disease that can develop in any part of the GI tract (Bandzar et al., 2013). 
Symptoms of Crohn’s disease include inflammation, loss of appetite and 
abdominal pain (Bandzar et al., 2013). Microscopically, up to two-thirds of 
patients with Crohn’s disease develop granulomas which are masses of 
inflamed tissue (Ramzan et al., 2002). Three disease subtypes have been 
described viz. inflammatory, obstructive and fistulating, however these may co-
exist (Maglinte et al., 2003). 
Although both UC and Crohn’s disease increase CRC risk, this relationship is 
greater, and has been explored more extensively, in UC (Andersen and Jess, 
2013). A meta-analysis of 20 clinical studies investigated the risk of cancers, 
including CRC, in patients with Crohn’s disease. Results from this study 
revealed that, in age-matched patients, CRC risk was two to three-fold greater 
in patients with Crohn’s disease compared with healthy people (Laukoetter et 
al., 2011). Results from another meta-analysis using six population-based 
studies suggested that overall risk estimates for patients with Crohn’s disease 
were almost two-fold greater compared with healthy people (Jess et al., 2005).  
1.2.3.7 Colorectal polyps 
Polyps have been defined as “any mass protruding into the lumen of a hollow 
viscus” (Shussman and Wexner, 2014). Macroscopically, colorectal polyps may 
be classified as sessile polyps or pendunculated polyps.  
Some polyps, such as hyperplastic polyps, do not appear to progress to 
carcinoma and several types of non-neoplastic polyps have been identified 
(Shussman and Wexner, 2014):  
 Hyperplastic: the most common colorectal polyp. Hyperplastic polyps 
are predominantly small in size and located in the distal colon and 
rectum. 
 Hamartomatous: smooth, pendunculated polyps that are predominantly 
made up of connective tissue. 
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 Inflammatory: masses of inflammatory infiltrations. These are 
commonly found in UC patients. 
Neoplastic polyps are known as adenomatous polyps. Although adenomatous 
polyps are benign, these could ultimately develop into carcinomas and therefore 
their removal is warranted because the majority of CRCs result from the 
progression of adenomatous polyps (Shussman and Wexner, 2014). Polyp size 
influences the risk of progression into carcinomas. Higher grades of neoplasia 
were observed with increasing polyp size from diminutive (<5mm) to small (6-
9mm) and ultimately large (≥10mm) polyps (Sakamoto et al., 2013). 
Histological analysis has been used to differentiate subtypes of adenomatous 
polyps (Shussman and Wexner, 2014): 
 Tubular: the most common subtype, found in up to 80% of polyps 
which are characterised by branched tubular glands.  
 Villous: constitute up to 10% of neoplastic polyps and have finger-like 
projections. 
 Tubule-villous: make up to 25% of polyps, and share combined 
characteristics of tubular and villous polyps. 
1.2.4 Inherited risk of colorectal cancer 
Although the majority of CRC cases develop sporadically, up to 10% occur due 
to hereditary defects such as familial adenomatous polyposis (FAP) syndrome 
or hereditary non-polyposis colorectal cancer (HNPCC), which are inherited in 
an autosomal dominant pattern (Lynch and de la Chapelle, 2003). Up to 80-
100% of those with FAP or HNPCC may develop CRC (Rustgi, 2007). In 
addition, up to 25% of CRCs may develop due to a strong family history 
(Bogaert and Prenen, 2014). 
1.2.4.1 Familial colorectal cancer 
Familial CRC describes a cancer which develops following an increased risk 
associated with the presence of CRC in more than two first- or second-degree 
relatives (Lynch and de la Chapelle, 2003). A systematic review and meta-
analysis revealed that people with one first-degree relative suffering from CRC 
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have more than double the risk of CRC compared with those without a family 
history (Johns and Houlston, 2001). This risk was more than four-fold greater in 
those with more than one relative with CRC (Johns and Houlston, 2001).  
1.2.4.2 Familial adenomatous polyposis syndrome 
FAP accounts for an estimated 1% of all CRCs and is characterised by the 
development of hundreds or thousands of adenomatous polyps in the 
colorectum of young adults. FAP develops due to a germline mutation in the 
APC tumour suppressor gene on chromosome 5q22 (Galiatsatos and Foulkes, 
2006). If left untreated, it is very likely that one or more of the polyps in those 
with FAP will progress into carcinomas by the age of 40 (Bisgaard et al., 1994). 
Although polyps are benign, the majority of CRC cases are a consequence of 
progression of an adenoma to a malignant carcinoma. Furthermore, FAP 
patients are also prone to other malignancies including desmoid tumours, 
hepatoblastoma and pancreatic cancer (Galiatsatos and Foulkes, 2006). 
1.2.4.3 Hereditary non-polyposis colorectal cancer 
HNPCC, also known as Lynch Syndrome, is responsible for approximately 4% 
of CRC cases (Rustgi, 2007). The lifetime risk of developing CRC is 80% in 
patients with HNPCC (Rustgi, 2007) and HNPCC patients are also prone to 
other cancers including gastric cancer, ovarian cancer and skin cancer (Umar et 
al., 2004).  
HNPCC results from an inherited defect in DNA mismatch-repair (MMR) genes, 
most commonly hMSH-2 or hMLH-1 (Chung and Rustgi, 2003; Umar et al., 
2004). MMRs encode proteins that correct mismatched DNA bases and small 
insertions or deletions and consequently lead to errors in DNA replication 
(Rustgi, 2007).  
1.2.5 Colorectal cancer pathogenesis 
Cancers develop from a multi-step process, comprising genomic and 
epigenomic alterations, whereby normal cells progressively transform into 
neoplastic cells. These alterations give tumour cells, and cells in pre-neoplastic 
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lesions such as polyps, novel properties, or hallmarks, that are not present in 
healthy cells. In 2000, Hanahan and Weinberg proposed six hallmarks of cancer 
that are acquired during carcinogenesis and give cells their tumorigenic and 
ultimately malignant properties and allow cancer cells to survive, proliferate and 
metastasise (Hanahan and Weinberg, 2000). These are: 
 Chronic proliferation 
 Evading tumour suppressors that regulate cell growth, such as tumour 
protein p53 (TP53) and retinoblastoma (Rb) 
 Resisting cell death 
 Immortalisation (unlimited replicative potential) 
 Angiogenesis  
 Invasion and metastasis 
In 2011, Hanahan and Weinberg updated their proposed hallmarks of cancer 
following the emergence of two novel hallmarks in the last decade  (Hanahan 
and Weinberg, 2011). These were (i) the modification of cellular metabolism to 
fuel cell proliferation and (ii) evasion of immunological destruction. In addition, 
the authors proposed a further two characteristics that enable cancer cells to 
acquire these hallmarks. These were (i) genomic instability and mutability and 
(ii) a tumour-promoting inflammatory response. The ten updated hallmarks and 
enabling characteristics of cancer proposed by Hanahan and Weinberg in 2011 
are shown in Figure 1.5. 
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Figure 1.5 Hallmarks and enabling characteristics of cancer proposed by 
Hanahan and Weinberg (2011). 
 
Adapted with permission from Elsevier: Cell (Hanahan and Weinberg, 2011), Copyright 
(2011). 
The majority of colorectal carcinomas develop following the adenoma-
carcinoma sequence, which is a multi-step process describing the progression 
from a normal epithelium to carcinoma (Figure 1.6). The sequence comprises 
several independent genetic and epigenetic alterations that result in aberrant 
expression of tumour-suppressor genes, including APC and TP53, proto-
oncogenes such as KRAS and c-MYC, and DNA MMR genes, for example 
MLH1 and MSH2 (Leslie et al., 2002; Shussman and Wexner, 2014). 
Consequently, the balance of proliferation and apoptosis is disturbed, favouring 
a hyperproliferative state which leads to tumour growth, carcinoma and 
ultimately metastasis into other tissues. Macroscopically, the different 
pathological stages have been well characterised, with progression from small 
adenomas increasing to large adenomas and ultimately to carcinoma.   
Eighty-five percent of sporadic CRCs are believed to result from defects in the 
‘gatekeeper’ pathway, that is genes involved in the control of cell proliferation 
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and tumour growth (Kinzler and Vogelstein, 1997), of which APC mutations are 
the most common. Patients with FAP inherit one defective copy of the APC 
gene and, following loss of function of the second copy, develop a large number 
of polyps during early-adulthood. Both copies of APC can be mutated 
somatically in sporadic CRC. The remaining 15% of sporadic CRCs develop 
following disruption of the ‘caretaker’ pathway, involved in maintaining genomic 
integrity and stability (Kinzler and Vogelstein, 1997). 
Figure 1.6 Colorectal adenoma-carcinoma sequence. 
 
Reprinted with permission from Nature Publishing Group: Nature Reviews Cancer 
(Davies et al., 2005), Copyright (2005). 
1.2.6 Colorectal cancer epigenetics 
Epigenetics describes heritable changes in chromatin without alterations in the 
DNA sequence (Dupont et al., 2009). Three epigenetic mechanisms have been 
described: DNA methylation, histone modification and the expression of micro 
riboxynucleic acids (RNAs) (miRNAs).  
1.2.6.1 DNA methylation 
DNA methylation is the addition of a methyl group to the carbon five position 
within a cytosine residue that is followed by a guanine, known as CpG sites, to 
produce 5-methylcytosine (5mC) (Bird, 2002) (Figure 1.7). The addition of 
methyl groups, which are donated by S-adenosyl methionine (SAM), is 
catalysed by DNA methyltransferases (DNMTs), primarily DNMT1, DNMT3a 
and DNMT3b (Robertson, 2001). Regions that are rich in CpG sites are 
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described as CpG islands and are not frequently methylated (Robertson, 2005). 
Hypermethylation, particularly of CpG sites close to, or within, the promoter 
region of a gene, is associated with reduced gene expression. This results from 
failure of transcription factor binding directly, because of the presence of 5mC, 
and also indirectly, because of blockage by methyl-CpG-binding proteins (Baylin 
and Herman, 2000; Robertson, 2005). 
Figure 1.7 DNA methylation. 
 
Low levels of methylation of CpG sites within CpG islands close to or within gene 
promoters are associated with active transcription and gene expression (top). The 
addition of a methyl group (DNA methylation) by DNA methyltransferases (DNMTs), 
donated by S-adenosyl methionine (SAM) to produce S-adenosyl homocysteine, is 
associated with repressed transcription (bottom). 
In cancers, such as CRC, hypermethylation and therefore reduced expression 
of tumour suppressor genes are observed (Toyota et al., 1999). Interestingly, an 
association between age and gene hypermethylation has been reported 
extensively for a number of genes (Ahuja et al., 1998), suggesting that this may 
be one of the mechanisms that contributes to the increase in CRC risk and 
incidence associated with ageing. Genes that are hypermethylated in CRC 
include members of the WNT signalling pathway e.g. SFRP1 (Suzuki et al., 
2004; Aguilera et al., 2006; Farkas et al., 2014; Zhang et al., 2014), genes 
involved in the regulation of transcription e.g. GATA4 (Akiyama et al., 2003; 
Herbst et al., 2009) and DNA repair genes e.g. MLH1 (Kane et al., 1997; Lahtz 
and Pfeifer, 2011; van Engeland et al., 2011). 
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Coincident with the hypermethylation of tumour suppressor genes, 
hypomethylation and consequently elevated expression of oncogenes occur in 
CRC. For example, hypomethylation of CDH3, encoding P-cadherin which is 
involved in the regulation of cell adhesion and differentiation via interactions 
with the WNT pathway (see section 1.3 below), and consequent upregulated 
expression have been found in the early stages of colorectal carcinogenesis 
(Milicic et al., 2008). The oncogene c-MYC is also frequently hypomethylated in 
CRC. Sharrard and colleagues observed a reduction in the DNA methylation of 
c-MYC in the progression from the normal mucosa to dysplasia, adenomas, 
carcinomas and ultimately metastases (Sharrard et al., 1992). Importantly, the 
enhanced expression of c-MYC resulting from hypomethylation during 
colorectal carcinogenesis has been associated with an increase in cell 
proliferation (Sharrard et al., 1992).  
Furthermore, cancers have also been observed to show global demethylation 
(Baylin and Herman, 2000). Global hypomethylation is an early event during 
colorectal carcinogenesis and has been linked to functional alterations such as 
chromosome instability and loss of imprinting (Cui et al., 2002; Eden et al., 
2003). Global DNA hypomethylation appears to increase with age (Suzuki et al., 
2006). A variety of methods exist to quantify levels of global DNA methylation, 
including the quantification of methyl cytosine by high-performance liquid 
chromatography (HPLC) and polymerase chain reaction (PCR)-based methods, 
which quantify methylation of specific genomic repeat elements such as long 
interspersed nuclear element-1 (LINE-1) (Lisanti et al., 2013). 
Studies have observed a reduction in global DNA methylation in adenomas and 
carcinomas compared with healthy tissue (Goelz et al., 1985; Feinberg et al., 
1988; Hernandez-Blazquez et al., 2000). In adenoma and cancer tissues, 
Feinberg et al. have reported an 8% and 10% decrease in global DNA 
methylation, assessed by HPLC, respectively when compared with matched 
normal tissue (Feinberg et al., 1988). This approach of comparing cancerous 
and adenoma tissue in CRC patients with tissue retrieved from healthy subjects 
has been used in several studies. Using a global DNA hypomethylation assay, 
Bariol et al. observed greater global demethylation in hyperplastic polyps, 
adenomas and carcinomas compared with both normal tissue from healthy 
subjects and normal tissue from cancer patients (Bariol et al., 2003). These 
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findings demonstrate that global hypomethylation is apparent in pre-neoplastic 
lesions such as hyperplastic polyps, and therefore is an early event in the 
adenoma-carcinoma sequence. 
When comparing different samples taken from within patients, LINE-1 
methylation has been observed to be significantly lower in cancerous tissue 
compared with adjacent normal tissue (Iacopetta et al., 2007). Chalitchagorn et 
al. have also reported significantly greater LINE-1 hypomethylation in cancerous 
tissue compared with normal colonic tissue, analysed by combined bisulphite 
restriction analysis (COBRA) PCR (Chalitchagorn et al., 2004). In addition, they 
observed a positive correlation between malignant progression and LINE-1 
hypomethylation, suggesting that this occurs early in colorectal carcinogenesis 
and is associated with cancer progression. 
1.2.6.2 Histone modifications 
Histones are proteins that form the core of the wound structure of DNA into 
chromatin. Histones may undergo post-translational modifications such as 
acetylation, methylation and phosphorylation, which regulate expression of DNA 
(Bannister and Kouzarides, 2011) (Figure 1.8). Certain modifications are 
associated with active transcription due to the accessibility of the chromatin, 
such as acetylation of lysine 14 on histone H3 or lysine 4 trimethylation on 
histone H3 (Sparmann and van Lohuizen, 2006). On the contrary, other 
modifications, including trimethylation of lysines 9 and 27 on histone 3, are 
associated with condensed chromatin and ultimately repressed transcription 
(Sparmann and van Lohuizen, 2006).  
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Figure 1.8 Histone modifications. 
 
 
Adapted with permission from Nature Publishing Group: Nature Reviews Cancer 
(Sparmann and van Lohuizen, 2006), Copyright (2006). 
For the purpose of this thesis, I will focus on histone acetylation as butyrate, a 
product of dietary fibre fermentation with anti-neoplastic effects in the large 
bowel (discussed in section 1.5.4), represses histone deacetylation through the 
inhibition of histone deacetylase. Histone acetylation describes the addition of 
acetyl groups by histone acetyltransferase (HAT) to the lysine residues within 
the tail regions of histones (Struhl, 1998). Alternatively, histone deacetylation is 
the removal of such acetyl groups by histone deacetylase (HDAC). The lysine 
residues are positively charged, thus contributing to the compact packaging of 
the DNA due to an attraction with negatively-charged DNA. The addition of a 
negatively-charged acetyl group results in a neutrally-charged histone, which 
causes relaxation of the DNA. Consequently, acetylated DNA, named 
euchromatin, is associated with greater gene expression as it is more easily 
accessed by transcription factors. On the contrary, deacetylation restores the 
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tight interaction between histones and DNA and is associated with a more 
condensed DNA structure known as heterochromatin. Histone deacetylation 
results in repressed transcription.  
Histone acetylation, in particular acetylation of histones H3 and H4, has been 
associated with cancer development and progression (Esteller, 2007). 
Karczmarski et al. found a total of 96 modifications, principally acetylation, to 
histones including H2A, H2B, H3 and H4 in CRC tissue compared with matched 
normal tissue (Karczmarski et al., 2014). The investigators reported the novel 
finding of the acetylation of lysine 27 within histone H3 in CRC compared with 
normal tissue. Altered acetylation may also result from abnormal expression of 
HATs and HDACs. For example, an increase in the expression of HDAC2, as a 
consequence of activated WNT signalling, was associated with inhibition of 
apoptosis and has been reported in colon cancer cells (Zhu et al., 2004). 
1.2.6.3 MicroRNA expression 
Approximately 1,000 miRNAs have been identified in humans (Bentwich et al., 
2005), some of which are implicated in colorectal carcinogenesis. miRNAs are 
short, non-coding RNAs typically 22 nucleotides long that regulate expression of 
their target genes. A single miRNA may have numerous target genes and, 
likewise, a single gene may be targeted by multiple miRNAs (Lewis et al., 
2005). 
Within the nucleus, miRNA genes are transcribed to primary miRNAs (pri-
miRNAs) by RNA polymerase II, which are then cleaved by Drosha (a RNase III 
endonuclease) and DGCR8/Pasha (a double-stranded RNA-binding domain 
(dsRBD) protein) to produce precursor miRNAs (pre-miRNAs) that are 
approximately 70 nucleotides long (Bushati and Cohen, 2007). The pre-miRNAs 
are then transported to the cytoplasm by Exportin-5 and are again cleaved by 
Dicer (RNase III endonuclease) and TRBP/Loquacious (dsRBD protein) to form 
a duplex comprising the mature miRNA and its complementary strand 
(miRNA*), each approximately 22 nucleotides long (He and Hannon, 2004). In 
most cases, the miRNA* strand is subsequently degraded and is normally found 
at a 100-times lower concentration of that of the functional miRNA. However, in 
some cases, the miRNA* strand may also be functional (Ruby et al., 2006).  
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The mature miRNA forms a complex, named the RNA-induced silencing 
complex (RISC), with proteins including dicer, Argonautes (AGO), such as 
Ago2, and the transactivating response RNA-binding protein (TRBP) (Bushati 
and Cohen, 2007) (please see Figure 1.9). RISC binds untranslated 3’ regions 
of target mRNAs through complementary seed regions (6-8 nucleotides long) 
within the miRNA (Bushati and Cohen, 2007). If these regions are perfectly 
complementary to those of the target mRNA, the latter is cleaved by Ago2, 
which has endonuclease activity, and the mRNA is degraded  (Bushati and 
Cohen, 2007). Otherwise, the translation of the mRNA into protein by the 
ribosome is inhibited. miRNAs may also result in destabilisation of the mRNA 
through deadenylation leading to degradation (Djuranovic et al., 2012). 
Figure 1.9 Regulation of target mRNAs by miRNAs. 
 
Mature miRNAs form RISC with proteins such as Ago2 and TRBP and bind to 
complementary sequences within their target mRNAs and lead to post-transcriptional 
repression through the inhibition of translation, mRNA degradation or mRNA 
deadenylation and consequent destabilisation.  
miRNAs regulate most cell functions including cell proliferation and 
differentiation, and aberrant miRNA expression may contribute to colorectal 
carcinogenesis. To date, irregular expression of more than 400 miRNAs have 
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been reported in CRC (Hogan et al., 2012). Furthermore, the proposed targets 
of miRNAs dysregulated in CRC include members of the WNT pathway, such 
as APC, CTNNBIP1 and c-MYC (Hogan et al., 2012). 
A systematic review found that six miRNAs were aberrantly expressed in each 
of seven studies viz. miR-125a, miR-133a, miR-145, miR-30a-3p and mir-139 
which were downregulated and miR-106a which was upregulated (Ma et al., 
2012). In addition, miRNAs from the miR-17-92 cluster (miR-17, miR-18a, miR-
19a, miR-19b, miR-20a and miR-92a), also known as oncomir-1, are commonly 
dysregulated in cancers including CRC. All six mature miRNAs are 
overexpressed in colorectal carcinomas and are associated with cancer 
progression (Diosdado et al., 2009). Additionally, the expression of certain 
dysregulated miRNAs have been associated with clinicopathological features. 
For example, downregulation of miR-143 and miR-145 has been reported early 
during the adenoma-carcinoma sequence (Michael et al., 2003). On the 
contrary, upregulation of miR-21 correlated with clinical stage and was 
associated with lymph node involvement and poor survival in CRC patients 
(Slaby et al., 2007).  
Abnormal miRNA expression in CRC is not restricted to colorectal tissue but 
has also been observed in plasma and faeces of CRC patients (Link et al., 
2010; Wu et al., 2012a) (Kalimutho et al., 2011; Ahmed et al., 2013). Luo and 
colleagues observed that nine miRNAs were differentially expressed in the 
plasma of CRC patients compared with healthy controls (Luo et al., 2013). 
These were miR-18a, miR-20a, miR-21, miR-29a, miR-92a, miR-106b, miR-
133a, miR-143 and miR-145. In stool samples, Ahmed et al. identified 12 
miRNAs that were overexpressed in patients with colorectal adenomas and 
cancers (miR-7, miR-17, miR-20a, miR-21, miR-92a, miR-96, miR-106, miR-
134, miR-183, miR-196a, miR-199a-3p and miR-214) (Ahmed et al., 2013). 
Altogether, these findings suggest that these differentially-expressed miRNAs 
have potential as non-invasive biomarkers of CRC.  
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1.3 The WNT signalling pathway 
The WNT signalling pathway is involved in normal developmental and 
physiological processes including cell proliferation, apoptosis, tissue self-
renewal and cell migration (Bienz and Clevers, 2000). WNT signalling occurs in 
several tissue and cell-types, particularly in self-renewing tissues where it is 
active throughout life (Clevers, 2006). Three different WNT pathways have been 
discovered: the canonical WNT/beta-catenin (β-catenin) pathway, the non-
canonical planar cell polarity (PCP) pathway and the WNT/calcium pathway. 
The canonical pathway is the best understood and most relevant in disease 
(especially cancer) pathophysiology.  
1.3.1 The canonical WNT signalling pathway 
The canonical WNT signalling cascade regulates functions such as proliferation, 
migration and apoptosis following activation of transcription of WNT target 
genes within the nucleus. A key player in this pathway is β-catenin which is 
regulated by the tumour suppressor APC (Groden et al., 1991; Kinzler et al., 
1991). APC forms a multiprotein complex named the β-catenin destruction 
complex which comprises APC, AXIN, glycogen synthase kinase 3β (GSK3β) 
and casein kinase 1 (CK1) (Schneikert and Behrens, 2007). AXIN is a 
scaffolding protein which is bound to each component of the complex and 
facilitates the phosphorylation of β-catenin by GSK3β (Bienz and Clevers, 2000) 
and may be the limiting factor in the formation and disassembly of the 
destruction complex (Lee et al., 2003).  
1.3.1.1 Inactive state 
When there is no binding of a WNT ligand to its transmembrane receptor 
Frizzled, or when WNT antagonists such as SFRP1 and WIF1 inhibit WNT 
pathway activation (Schneikert and Behrens, 2007), β-catenin is phosphorylated 
by the β-catenin destruction complex (see Figure 1.10 (A)). CK1 phosphorylates 
β-catenin at serine 45 which then enables GSK3β to phosphorylate β-catenin at 
serine/threonine residues 41, 37 and 33. The β-transducin repeat-containing 
protein (βTrCP) targets phosphorylated β-catenin for ubiquitination by the E3 
ubiquitin ligase complex (Schneikert and Behrens, 2007), which subsequently 
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labels β-catenin for degradation by the proteasome (Clevers, 2006). Inside the 
nucleus, Groucho and TLE co-repressors bind to and repress T cell factor 
(TCF) and lymphoid enhancer factor-1 (LEF) DNA-binding proteins, which 
inhibits transcription of WNT target genes (Clevers, 2006). 
1.3.1.2 Active state 
Activation of the WNT pathway by WNT ligands (see Figure 1.10 (B)), such as 
WNT1, binding to the Frizzled receptor leads to the interaction with the co-
receptors, low-density lipoprotein receptor-related proteins LRP5 and LRP6, 
and the initiation of signal transduction (Clevers, 2006). The cytoplasmic tail of 
LRP is phosphorylated by CK1 and GSK3β (Schneikert and Behrens, 2007). 
Dishevelled (Dvl), a cytoplasmic protein, translocates to the membrane where it 
binds to Frizzled. AXIN is recruited to the membrane where it is bound to and 
inhibited by Dvl (Bienz and Clevers, 2000). As the destruction complex is 
inactive, β-catenin is no longer phosphorylated nor degraded, so cytoplasmic 
levels of this protein rise. Stabilised cytoplasmic β-catenin translocates into the 
nucleus where it displaces Groucho/TLE and interacts with TCF/LEF 
transcription factors, leading to the transcription of target genes. TCF forms a 
complex with β-catenin and other components such as histone acetylases, C-
terminal-binding proteins (CtBP) and other proteins. These other interacting 
components are involved in the positive and negative regulation of the TCF/β-
catenin complex and, ultimately, transcription (Sierra et al., 2006). In addition, 
nuclear β-catenin activity can be repressed by the inhibitor Chibby and the 
inhibitor of β-catenin (ICAT). 
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Figure 1.10 The canonical WNT signalling pathway. 
 
(A) Inactive state: in absence of activation by a WNT ligand binding to the Frizzled 
receptor, β-catenin is phosphorylated by the β-catenin destruction complex (APC, 
AXIN, CK1 and GSK3β), which destabilises β-catenin and targets it for ubiquitination 
and subsequent proteasomal degradation. Within the nucleus, LEF/TCF transcription 
factors are bound to and repressed by co-repressors such as Groucho. (B) Upon 
activation of the WNT pathway by WNT ligands e.g. WNT1, the Frizzled receptor forms 
a complex with LRP5/6 to initiate signal transduction. Dvl is activated and inhibits the β-
catenin destruction complex. Levels of stabilised β-catenin accumulate in the 
cytoplasm, and β-catenin translocates into the nucleus where it binds to TCF/LEF to 
activate transcription of WNT target genes such as c-MYC and c-JUN.  
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1.3.2 The role of WNT signalling in the normal colonic mucosa 
WNT proteins are expressed in intestinal crypt cells where the WNT signalling 
pathway is essential for maintaining homeostasis within the large bowel 
(Gregorieff et al., 2005). Pericryptal myofibroblasts, which surround the stem 
cells at the base of the crypt, appear to be responsible for the production of 
WNT ligands, which then activate WNT signalling in the adjacent stem cells 
(Fevr et al., 2007). Towards the base of the crypt, where the stem cell and 
proliferating progenitor cell populations are found, there are increased levels of 
nuclear β-catenin and active TCF/LEF, indicative of a stimulated, active WNT 
cascade (Clevers and Batlle, 2006).  
WNT signalling is involved in the control of the continuous renewal of the 
colonic epithelium. Stimulation of the canonical WNT cascade results in 
activation of target genes that ultimately lead to the control of epithelial cell 
proliferation, organisation and fate (Schneikert and Behrens, 2007). Several in 
vivo studies have investigated the role of WNT signalling in the GI tract and 
have observed that loss or perturbed WNT signalling leads to an abnormal 
colonic phenotype (Korinek et al., 1998; Wong et al., 2002; Pinto et al., 2003; 
Ireland et al., 2004; Kuhnert et al., 2004). Studies in mice have shown that WNT 
signalling is essential in maintaining the correct intestinal epithelium structure 
and that permanent stimulation of this pathway is required for precursor cell 
proliferation (Schneikert and Behrens, 2007).  
Deletion of β-catenin in mice has been reported to result in crypt ablation and in 
alteration of the normal population of cell types in the epithelium, including a 
reduction in secretory cells and Paneth cells (Ireland et al., 2004). Similarly, 
Fevr et al. used mutant mice (villin-creERT2-β-catenin-/lox) to investigate the 
effects of complete ablation of β-catenin and found that these mice experienced 
complete loss of all colonocytes and the majority of crypts (Fevr et al., 2007). 
This was paralleled by cessation of proliferation and reduced expression of c-
MYC, (He et al., 1998), a target gene of the WNT pathway that is involved in the 
regulation of cell proliferation.  
Two other studies investigated the effect of overexpressing a WNT inhibitor, 
Dickkopf-related protein 1 (Dkk1), to reduce WNT pathway activity. Pinto et al. 
found a loss of proliferation and villi in the small intestine (Pinto et al., 2003). A 
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later study by Kuhnert et al. used adenoviral expression of Dkk1 and found a 
rapid cessation of WNT signalling and ultimately proliferation in the small 
intestine, caecum and colon (Kuhnert et al., 2004). They also observed 
structural disintegration with a progressive loss of crypts and villi, leading to 
ulceration and apoptosis. 
Together, these findings suggest that WNT signalling is essential for 
maintaining the normal continuous proliferative state found in the adult small 
and large intestine. Dysregulation of this normal colonic epithelium 
maintenance, for example following mutations in WNT pathway genes and 
leading to aberrant activation of WNT signalling, can result in colorectal 
carcinogenesis. 
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1.4 The role of WNT signalling in CRC  
Aberrant WNT signalling is implicated in the pathogenesis of several diseases 
including Alzheimer’s disease (Inestrosa and Toledo, 2008), Dupuytren’s skin 
disease (Dolmans et al., 2011) and renal fibrosis (Pulkkinen et al., 2008), as 
well as a number of cancers including CRC (Luo et al., 2007). The canonical 
WNT pathway is frequently altered in CRC and is a key player in the 
pathogenesis of both inherited and sporadic forms of this cancer. Constitutively 
active WNT signalling is present in approximately 90% of sporadic CRCs (Klaus 
and Birchmeier, 2008). In particular, loss of function of the APC tumour 
suppressor, resulting from defects in APC, is found in approximately 85% of all 
CRCs (Kinzler and Vogelstein, 1996), including up to 70% of sporadic cases 
(Powell et al., 1992). In the remaining 15% of CRC cases, other alterations to 
components of the WNT signalling pathway, such as mutations in the gene 
encoding β-catenin, CTNNB1, and epigenetic modifications of WNT inhibitors, 
have been identified.  
1.4.1 Mutations in WNT genes 
Most alterations to the WNT signalling pathway result from mutations in WNT 
genes. The principal mutations associated with CRC are those in APC. 
Germline mutations in APC, which are causal for the FAP syndrome, are found 
in 1% of all CRC cases (Segditsas and Tomlinson, 2006). In addition, mutations 
in APC are also found in over two-thirds of sporadic CRC cases (Segditsas and 
Tomlinson, 2006). Loss of APC, a member of the β-catenin destruction 
complex, leads to increased levels of dephosphorylated, active β-catenin (Bienz 
and Clevers, 2000). 
Gain of function mutations in WNT genes associated with increased pathway 
activity, such as those encoding β-catenin and WNT ligands, are also common. 
Activating mutations in β-catenin, which prevent its recognition by GSK3β and 
therefore degradation, occur in up to 5% of CRCs (Ilyas et al., 1997; Morin et 
al., 1997). Truncating mutations in AXIN and AXIN2 have also been discovered 
which, like loss of APC, lead to stabilisation of β-catenin (Liu et al., 2000). 
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1.4.2 Abnormal expression of WNT pathway-related genes in colorectal 
cancer 
Nguyen et al. investigated the expression of WNT pathway-related genes in the 
progression from normal colonic mucosa to tubular adenomas and ultimately to 
villous adenomas (Nguyen et al., 2010). They found significant differences in 
the pattern of expression of 34 WNT pathway-related genes among normal, 
tubular adenoma and villous adenoma tissues. For 15 WNT pathway-related 
genes, there were larger significant (p<0.01) differences in expression between 
villous adenoma tissue and normal tissue and seven of these also showed 
significant differences in expression between tubular and villous adenoma 
tissues. Expression of CTNNB1, the gene encoding β-catenin, was almost three 
times greater in tubular adenomas compared with normal tissue and over six-
fold higher in villous compared with tubular adenomas (Nguyen et al., 2010). 
These observations led the authors to conclude that elevated WNT signalling is 
involved in the progression of adenomas. 
Hlubek and colleagues demonstrated differential expression of several WNT 
target genes when comparing tumour with normal tissue and also in intra-
tumorous comparison of cells at the invasive front with those at the tumour 
centre (Hlubek et al., 2007). Twenty-nine WNT pathway-related genes, 
including WISP1, CCND1, LEF1 and TCF7, were overexpressed in the 
colorectal carcinoma tissue compared with normal tissue (Hlubek et al., 2007). 
1.4.3 Abnormal methylation of WNT pathway-related genes in colorectal 
cancer 
As discussed in Section 1.2.6.1, hypermethylation of specific genes has been 
associated with CRC. These genes include members of the WNT signalling 
pathway such as APC and WNT inhibitors e.g. SFRP1.  
In a study conducted in Iran, the methylation state of APC, AXIN1, AXIN2 and 
GSK3β was quantified by methylation-specific PCR and aberrant methylation 
was observed for APC and AXIN2 in CRC patients (Naghibalhossaini et al., 
2012). A Taiwanese study also utilised methylation-specific PCR to explore the 
methylation state of six genes including APC, AXIN1 and GSK3β in cancerous 
and normal tissue from sporadic CRC patients (Lin et al., 2004). The 
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investigators reported significantly greater methylation of APC in cancerous 
compared with matched healthy tissue. Hypermethylation of the promoter 
region of APC, resulting in transcriptional silencing, has also been reported in 
serrated adenomas (Fu et al., 2009) and was greater in colorectal carcinomas 
compared with adenomas, suggesting that it is an early event in colorectal 
carcinogenesis (Esteller et al., 2000). 
Promoter hypermethylation of WNT antagonists such as DKK1 (Aguilera et al., 
2006), WIF1 (Lee et al., 2009) and SFRP1 has also been reported (Qi et al., 
2007). Hypermethylation of WNT antagonists and consequent reduced 
expression would be expected to reduce the inhibition of WNT signalling and, 
therefore, permit increased pathway activity. 
Secreted Frizzled-related proteins (SFRPs) are an important family of WNT 
antagonists and are frequently downregulated in CRC. Hypermethylation of 
SFRP1, SFRP2, SFRP4 and SFRP5 has been reported in both colorectal 
adenomas and carcinomas compared with normal and adjacent tissues (Qi et 
al., 2006). Importantly, hypermethylation of these SFRPs was associated with 
downregulation or gene silencing. SFRP1 hypermethylation has been reported 
in vitro in CRC cells and also in vivo in primary colorectal carcinoma tissues 
(Suzuki et al., 2002). Furthermore, a recently-published meta-analysis, which 
included eight cohort studies with 942 participants, concluded that SFRP1 
promoter methylation was significantly increased in cancerous tissue compared 
with adjacent, normal and benign tissues (Chen et al., 2014b). Significantly 
greater SFRP1 methylation has also been reported in faecal samples from CRC 
patients compared with healthy subjects (Salehi et al., 2012). Higher degrees of 
hypermethylation of SFRP2 and WIF1 have also been observed in faecal 
samples from patients with hyperplastic polyps, adenomas and carcinomas 
compared with normal subjects (Zhang et al., 2014). Furthermore, SFRP2 
hypermethylation has also been reported in faecal, serum and tissue samples in 
CRC and polyp patients (Tang et al., 2011).  
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1.5 Diet and colorectal cancer  
The majority of CRC cases develop sporadically and various epidemiological 
studies, including migrant studies (Kolonel, 1980; Flood et al., 2000) and 
secular trend studies (Kono, 2004), have provided evidence for an important 
role of environmental factors, principally diet and physical activity, in modulating 
the risk of developing this cancer. The panel from the WCRF/AICR concluded 
that “food and nutrition have a highly important role in the prevention and 
causation of cancers of the colon and rectum” (WCRF/AICR, 2007). 
As described in Section 1.2.3.2, numerous dietary components have been 
associated with either a reduction or increase in CRC risk. Several studies, 
primarily migration studies, have investigated this impact of environmental 
factors on the risk of CRC and have found an increase in CRC risk when 
migrating from lower to higher-risk areas, such as from Asia to the western 
United States (Flood et al., 2000). Investigations into the role of diet in CRC 
have focused on dietary risk factors such as obesity and the consumption of red 
meat, fat and alcohol (WCRF/AICR, 2007). However, of particular relevance to 
the present project, in the early 1970s, Dr. Denis Burkitt used his observation of 
low CRC incidence in a Western African population consuming high intakes of 
dietary fibre intake to propose a protective role of dietary fibre against CRC 
(Burkitt, 1971). 
1.5.1 Dietary Fibre 
Dietary fibre has been defined by the Codex Alimentarius Committee (CAC) as 
“carbohydrate polymers with ten or more monomeric units which are not 
hydrolysed by the endogenous enzymes in the small intestine of humans” 
(CAC, 2009). It encompasses non-digestible carbohydrates (NDCs), which are 
not absorbed in the small bowel and therefore reach the large bowel undigested 
(Ha et al., 2000; DeVries, 2003). In the large bowel, NDCs are fermented by 
commensal bacteria which produce short chain fatty acids (SCFAs). The 
WCRF/AICR Continuous Update Project Report released in 2011 concluded 
that there is now convincing evidence for a protective role of dietary fibre 
against CRC (WCRF/AICR, 2011). 
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The WCFR/AICR Continuous Update Project Report analysed the effect of 
dietary fibre in 28 cohort studies (WCRF/AICR, 2011). In the majority of the 
studies, an increase in dietary fibre intake reduced the risk of developing CRC. 
A meta-analysis of the data from the cohort studies revealed a 10% reduction in 
CRC risk for every 10g per day of dietary fibre (WCRF/AICR, 2011).  
The European Prospective Investigation into Cancer and Nutrition (EPIC) study 
in 2003 examined the association between dietary fibre intake and CRC 
incidence in over 500,000 individuals (Bingham et al., 2003). An inverse 
correlation between dietary fibre consumption and CRC incidence [0.75 RR, 
95% CI 0.59-0.95] was observed. The investigators concluded that a 40% 
reduction in CRC cases could be achieved by doubling dietary fibre intake. 
Importantly, the greatest protective effect of dietary fibre was observed in the 
left-side of the bowel, which is where the majority of CRC cases arise. A more 
recent analysis of EPIC data, with a mean follow-up of 11 years and a three-fold 
increase in the number of CRC cases, showed a 17% reduction in CRC risk per 
10g of dietary fibre daily (Murphy et al., 2012). 
A systematic review and meta-analysis published in 2011 found inverse 
associations between intakes of dietary fibre and of wholegrains and CRC risk 
using data from 25 prospective studies (Aune et al., 2011). This supports results 
from a previous meta-analysis of case-control studies that also observed this 
association (Jacobs et al., 1998). However, in such observational studies it is 
impossible to attribute causality, and the authors discussed the possibility that 
some of the observed association between dietary fibre intake and CRC risk 
could result from other dietary or lifestyle confounding factors such as increased 
calcium and folate status, healthier weight and/or lower intakes of red meat, 
which could also reduce CRC risk (Aune et al., 2011).  
A more recently-published meta-analysis focussed on the protective effects of 
dietary fibre against colorectal adenomas, the precursor lesions of carcinomas, 
in 20 case-control and cohort studies with a total of just under 11,000 patients 
(Ben et al., 2014).  The results from this study also supported a protective role 
for dietary fibre against colorectal adenoma development. Analyses of twenty 
studies, which compared low versus high dietary fibre intake, showed a 28% 
reduction in adenoma risk per daily 10g of dietary fibre. However, a dose-
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response model performed in 14 studies suggested a 9% decrease in adenoma 
risk per daily 10g of dietary fibre. 
The mechanisms by which dietary fibre exerts its apparently protective effects 
are not completely understood and were originally proposed to result from a 
decrease in intestinal transit time, increase in stool bulk and the dilution of 
faecal content (Hylla et al., 1998), therefore reducing exposure to carcinogens 
(Lipkin et al., 1999). However, dietary fibre’s beneficial effects have been shown 
to result primarily from effects of its major fermentation products i.e. SCFAs 
(Lipkin et al., 1999). Although the molecular mechanisms by which dietary fibre 
produces these protective effects are not fully understood, there is compelling 
evidence of anti-neoplastic effects of butyrate, one of the major SCFAs. A 
summary of the effects of dietary fibre involved in the modulation of CRC risk, 
which will be discussed in more detail in the following sections of this chapter, 
as proposed by Zeng et al. (2014) are shown in Figure 1.11. 
Figure 1.11 Effects of dietary fibre involved in the modulation of CRC risk 
as proposed by Zeng et al. (2014). 
 
Reprinted with permission from Baishideng Publishing Group Inc: World Journal of 
Gastrointestinal Oncology (Zeng et al., 2014), Copyright (2014). 
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1.5.2 Resistant starch 
RS has been defined by Cummings and Stephen as “the sum of starch and 
products of starch digestion that are not absorbed in the small bowel” 
(Cummings and Stephen, 2007). RS therefore reaches the large bowel 
undigested, where it undergoes fermentation by colonic bacteria.  
1.5.2.1 Resistant starch sources and intake  
RS can be found naturally in different foods including cereals, vegetables and 
green (unripe) bananas (Niba, 2002). Particularly high sources of RS may be 
found in barley (16g/100g), chickpeas (6.6g/100g) and raw bananas (6.4g/100g) 
(Roberts et al., 2004).  
Four subtypes of RS have been described (Englyst et al., 1992; Topping and 
Clifton, 2001): 
 Type 1: physically inaccessible RS found in seeds; 
 Type 2: resistant granules found in uncooked potato and green bananas; 
 Type 3: retrograded RS which is present in bread and cooked, cooled 
potato; 
 Type 4: chemically modified RS used widely for technical reasons in 
processed foods.  
Baghurst and colleagues have recommended a RS intake of 20g per day, which 
may be up to four-times greater than that which is consumed daily in the 
Western diet (Baghurst et al., 1996). RS intakes of up to 45g per day are well-
tolerated in adults (Grabitske and Slavin, 2009). 
Hylla et al. have investigated the effects of a diet high in RS in the colon of 
healthy human volunteers (Hylla et al., 1998). The study demonstrated the 
feasibility of supplementing foods with RS without causing any unwanted 
gastrointestinal side effects. The supplementation of food and beverage 
products with RS may be a more effective means of increasing RS intake than 
recommending greater consumption of RS-containing foods as the average 
daily RS intake in the Western diet is very low.  
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1.5.2.2 Effects of resistant starch in the large bowel 
In the large bowel, RS promotes faecal bulking which consequently shortens 
faecal transit time, promotes laxation and relieves constipation (Topping and 
Clifton, 2001). RS, including both types 2 and 3, increases faecal mass 
significantly so that RS has a mild laxative effect (Cummings et al., 1996). RS 
also lowers pH (Noakes et al., 1996), ammonia, phenols and secondary bile 
acid concentrations in the colon (van Munster et al., 1994; Birkett et al., 1996; 
Hylla et al., 1998).  
RS may also be protective by enhancing the maintenance of the colonic 
mucosal barrier (Toden et al., 2005; Toden et al., 2006) which acts as the first-
line of defence in the colon (Gaudier et al., 2004). Nofrarías et al. found that 
long-term intake of raw potato starch, a source of RS, improved mucosal 
integrity in the colon of pigs (Nofrarias et al., 2007). This was indicated by 
increased mucin sulphation, reduced magnesium concentrations in the lumen 
and decreased epithelial proliferation. Improved mucosal integrity may help to 
protect against CRC as diseases which predispose to this cancer, such as IBD, 
often show a breakdown of this mucosal barrier (Itzkowitz and Yio, 2004). 
Furthermore, decreased mucin sulphation has been observed in patients with 
UC (Van Klinken et al., 1999).  
The principal physiological effect of RS consumption is the increase in levels of 
SCFAs, particularly butyrate (Scheppach et al., 1988; Cummings et al., 1996; 
Noakes et al., 1996). Mathers et al. demonstrated substantial increases in large 
bowel butyrate concentrations in Wistar rats fed raw potato starch as a source 
of RS (Mathers et al., 1997). Caecal butyrate concentrations were 70% greater 
and caecal butyrate pools were four-fold greater in rats fed a raw potato starch 
diet (80g/kg of diet) compared with the control diet (maize starch). It is thought 
that the consequential chemoprotective effects of RS consumption primarily 
result from an increase in butyrate levels, as well as other SCFAs, following RS 
fermentation. 
1.5.2.3 Resistant starch as a prebiotic 
Dietary prebiotics are described as “selectively fermented ingredients that result 
in specific changes, in the composition and/or activity of the gastrointestinal 
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microbiota, thus conferring benefit(s) upon host health” (Gibson, 2010).  RS is a 
substrate for fermentation by colonic bacteria and all four types of RS have 
been reported to increase levels of Bifidobacteria in vivo. 
One study randomised rats to a control diet, a granular potato starch diet (RS 
type 1) or a modified potato starch diet (RS type 2) for five months and 
observed modification of intestinal microflora with both types of RS (Kleessen et 
al., 1997). Rats on both RS diets had significantly greater caecal Bifidobacteria 
counts than rats on the control diet. Differences in caecal bacteria counts 
between the two types of RS were also apparent. RS type 2 significantly 
increased caecal bacteria of the Lactobacilli, Streptococci and Enterobacteria 
genera compared with both the control and RS type 1 diets. This was also 
reflected in the faecal analyses. In a porcine model, increased faecal 
Bifidobacteria have been observed in animals given a probiotic supplemented 
with RS compared with those without RS (Brown et al., 1997).  
Studies investigating the role of RS as a prebiotic have also been conducted in 
humans. In a double-blind, randomised, placebo-controlled study, 200 healthy 
participants were randomised to a placebo group or one of four NDCs, including 
retrograded tapioca maltodextrin, a RS type 3 (Bouhnik et al., 2004). Feeding 
10g of retrograded tapioca maltodextrin per day for seven days increased faecal 
concentrations of Bifidobacteria significantly compared with placebo. This was 
the first study to show the prebiotic effects of a type 3 RS in humans. A double-
blind, placebo-controlled crossover trial investigated the effects of RS types 2 
and 4 on faecal microbiota in ten healthy subjects (Martinez et al., 2010). This 
study revealed that only RS type 2 increased bacteria from the phylum 
Firmicutes compared with placebo. Bacteria from the Ruminococcaceae family 
and the R. bromii and E. rectale species were also significantly greater with RS 
type 2. On the other hand, RS type 4 increased faecal concentrations of the 
phyla Bacteroidetes and Actinobacteria and reduced Firmicutes compared with 
placebo. At the species level, significantly greater concentrations of B. 
adolescentis, P. distasonis, C. clostridioforme and significantly lower 
concentrations of F. prausnitzii and D. formicigenerans compared with placebo 
were observed. 
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1.5.2.4 Anti-neoplastic effects of resistant starch 
Studies that have investigated the chemoprotective effects of RS against 
colorectal carcinogenesis have yielded inconsistent findings. Although a 
reduction in colorectal lesions have been reported with RS, other studies have 
not observed a protective effect of RS and some have even reported a 
detrimental effect of RS.  
The pre-neoplastic lesions, aberrant crypt foci (ACF), can be used as an early 
marker of colorectal carcinogenesis in animal studies. Using the formation of 
ACF as an endpoint, Liu et al. investigated the effects of raw potato starch (RS 
type 2) in Wistar rats treated with the carcinogen azoxymethane (AOM) (Liu and 
Xu, 2008). They observed a significant reduction in ACF formation in rats that 
were given the RS-containing diets for three weeks post-carcinogen treatment 
compared with the control diet and there was a dose-dependent effect of RS in 
reducing ACF formation. Conversely, RS enhanced ACF formation when 
modelling the pre-initiation stage of carcinogenesis by administering the RS 
before exposure to AOM. These findings suggest that RS exerts its 
chemoprotective effects at the promotion stage of colorectal carcinogenesis but 
may have adverse effects at the pre-initiation stage, before the induction of 
carcinogenesis. It must be noted, however, that supplementation with RS at the 
pre-initiation stage increased faecal bulk and decreased faecal pH significantly 
which are regarded as positive markers of bowel health (Liu and Xu, 2008).  
Two additional studies have also shown protective effects of RS at the 
promotion stage of colorectal carcinogenesis following carcinogen treatment. 
Thorup et al. reported significantly lower ACF formation in AOM-treated rats fed 
a raw potato starch diet compared with rats on corn starch and control diets 
(Thorup et al., 1995). There was significantly reduced ACF formation in RS-fed 
rats (whether supplemented alone or synergistically with vitamin A for 12 
weeks) and then treated with the carcinogen, 1,2-dimethylhydrazine 
dihydrochloride (DMH) (Cassand et al., 1997). The ability of RS to reduce 
colorectal tumour formation has also been reported. Bauer-Marinovic et al., 
reported a significantly greater incidence of colonic tumours in DMH-treated 
Sprague-Dawley rats fed a standard diet compared with those given Novelose 
330, a type 3 RS, where there were no tumour-bearing animals (Bauer-
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Marinovic et al., 2006). A type 2 RS, high-amylose maize starch (HAMS), fed to 
rats for four weeks prior to injection with AOM also reduced the incidence and 
number of colonic adenocarcinomas (Le Leu et al., 2007). 
The Le Leu et al. group have also investigated the effects of symbiotic 
treatment of RS and Bifidobacterium lactis for four weeks on colorectal cancer 
development in AOM-treated Sprague-Dawley rats (Le Leu et al., 2010). When 
rats were given both RS and B. lactis in combination, the incidence and number 
of colonic tumours was reduced and, although there was a trend for a protective 
effect for RS administered alone, this was not statistically significant.  
Winter et al. investigated the effects of RS intake in mice fed red meat (which 
increases CRC risk) by measuring levels of a known mutagenic lesion 
implicated in colorectal carcinogenesis, O6-methyl-2-deoxyguanosine (O6-MeG) 
DNA adduct formation (Winter et al., 2011). Faecal analysis showed that RS 
supplementation significantly increased concentrations of SCFAs, including 
butyrate and total SCFAs, and lowered faecal pH, ammonia and phenol 
concentrations. Furthermore, the addition of RS to the diet significantly reduced 
DNA adduct formation that resulted from the consumption of red meat. This 
suggests that RS may abrogate some of the mutagenic effects of red meat 
consumption by providing extra carbohydrate for bacterial fermentation and, 
therefore, increasing butyrate concentrations (Winter et al., 2011). In a more 
recent study, RS, in the form of HAMS, was fed to rats which consumed both 
short-term (one month) and long-term (18 months) heme iron, believed to be 
the oncogenic component in red meat (Winter et al., 2014). As in their previous 
study, O6-MeG adduct formation as an indicator of colorectal carcinogenesis 
was one of the study endpoints. In addition, they quantified the formation of 
another pro-mutagenic adduct, 8-hydroxy-2-deoxyguanosine (8-oxo). After both 
short- and long-term feeding, there were no between-diet differences in O6-MeG 
or 8-oxo adduct formation but there was a trend for lower colonic tumour 
incidence in rats fed RS compared with those not given RS.  
In contrast with these positive effects of RS, some animal studies have reported 
no effect or adverse effects of RS on CRC risk. Despite increased butyrate 
concentrations following RS (3% or 10%) consumption, there were no effects on 
the development of colorectal tumours in DMH-treated rats compared with 
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those fed a control diet or cellulose (Sakamoto et al., 1996). Similarly, amylose 
maize, a type 3 RS, did not protect against the formation of the pre-neoplastic 
lesions, ACF, in DMH-treated rats (Maziere et al., 1998). In addition, ACF 
density and colonic tumour formation were increased in DMH-treated rats that 
were fed potato starch for 31 weeks (Young et al., 1996). In a study from the 
Mathers laboratory, a mouse model of sporadic CRC, where mice carry a 
mutation in APC causing them to develop intestinal tumours, raw potato starch 
and Hylon VII (both type 2 RS) were fed to mice for up to five months and 
resulted in an increase in tumour formation in the small intestine (Williamson et 
al., 1999). Interestingly, the co-administration of aspirin, a non-steroidal anti-
inflammatory drug (NSAID), prevented this adverse effect. 
In humans, the effects of RS (and of aspirin) on large bowel neoplasia have 
been investigated in a series of large-scale, multi-centre intervention studies led 
by Professors John Burn, Tim Bishop and John Mathers using individuals with 
familial bowel cancer. The first of these, known as the Colorectal 
Adenoma/carcinoma Prevention Programme (CAPP) 1, was a randomised, 
placebo-controlled study, which used a 2x2 factorial design to investigate the 
effects of RS (provided as a 1:1 mix of raw potato starch and Hylon VII) and/ or 
of aspirin on colorectal carcinogenesis in FAP patients (Burn et al., 2011a). The 
primary endpoint of CAPP1 was polyp formation with additional endpoints 
including assessment of the size of the largest polyp and colonic crypt cell 
proliferation. Following a median intervention of 17 months, results from this 
study suggested that neither RS (nor aspirin) had protective effects on the 
number of polyps formed in young FAP patients. A protective effect of aspirin, 
but not RS, was observed on the size of the largest polyp. However, the authors 
reported an increase in crypt cell proliferation by 28% in patients supplemented 
with RS compared with placebo.  
Using a similar randomised, double-blind placebo-controlled study with a 2x2 
factorial design in Lynch Syndrome patients, the CAPP2 study, the team 
observed no effects of either aspirin or RS on neoplasia at the end of the 
intervention (up to four years) (Burn et al., 2008). However, with longer follow 
up, those who had been randomised to aspirin has substantially reduced 
incidence of CRC and other Lynch Syndrome cancers (Burn et al., 2011b) but 
there was no protective, or adverse, effect in those randomised to RS (Mathers 
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et al., 2012). The authors concluded that RS did not emulate the apparently 
protective effects of diets rich in dietary fibre (Mathers et al., 2012). However, 
the findings from these studies, where a reduction in polyp size in young FAP 
patients and in CRC incidence in Lynch Syndrome patients with aspirin 
supplementation were observed, provided prima facie evidence that neoplasia 
of the colorectum are driven by inflammation and, therefore, reducing 
inflammation may reduce CRC risk (Burn et al., 2011a; Burn et al., 2011b). 
1.5.2.5 Additional beneficial effects of resistant starch 
Given that inflammation drives tumourigenesis in the large bowel (and in other 
tissues (Elinav et al., 2013)) RS may have anti-neoplastic actions through its 
anti-inflammatory effects. A rat model of inflammation, with symptoms similar to 
those observed in UC patients, has been used to investigate the effects of RS 
intake on inflammation (Jacobasch et al., 1999). The rats fed RS had increased 
concentrations of SCFAs and an accelerated regenerative response to induced 
colitis, including the development of new crypts in the epithelia.  
Anti-inflammatory effects have also been reported in mice fed RS, as well as 
other dietary fibres. Mice deficient in the anti-inflammatory cytokine interleukin-
10 (IL-10-/- mice) were used to investigate the potential prevention of 
inflammatory diseases by RS. Significant improvements in markers of disease, 
including reduced rectal bleeding and diarrhoea, as well as in the presence of 
inflammatory lesions, were observed in mice given RS compared with the 
control group (Bassaganya-Riera et al., 2011). These findings provide evidence 
for a reduction of gastrointestinal inflammation following RS consumption and 
therefore a possible prevention of the development of inflammatory diseases. 
The anti-inflammatory effects of RS may be mediated via changes in the 
microbiota (as described in section 1.5.2.3), as intestinal dysbiosis (microbial 
imbalance), such as an increase in the ratio of Firmicutes to Bacteroidetes (Lee 
and Hase, 2014), and pathogenic microbial colonisation may induce an 
inflammatory response and have been associated with CRC (Elinav et al., 
2013).  
Higgins et al. have investigated the effects of the ingestion of different 
carbohydrates on insulin sensitivity in rats (Higgins et al., 1996). Amylose, a 
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starch resistant to digestion, or amylopectin, a carbohydrate readily digested in 
the small intestine, were fed to rats and the insulinaemic response to glucose 
was measured. Results from the study showed the development of insulin 
resistance in amylose-fed rats at 26 weeks of feeding, but no further increase in 
resistance was observed after this (Higgins et al., 1996). In contrast, the group 
fed amylopectin showed increasing insulin resistance up to 26 weeks of 
feeding. The improved insulin sensitivity in rats fed RS compared to non-
resistant starch could suggest protection against the development of diabetes. 
A human study also investigating the effects of RS consumption on insulin 
sensitivity found that subjects supplemented with 60g of RS had significantly 
lower postprandial plasma glucose and insulin levels as well as better insulin 
sensitivity compared with controls (Robertson et al., 2003).  
RS has also been shown to improve satiety. In a randomised, double-blind, 
crossover study, Willis et al. investigated the effects of different dietary fibres, 
including RS, incorporated into five different muffins consumed in the fasted 
state on short-term satiety (Willis et al., 2009). The results from this study 
demonstrated that RS, as well as corn bran, improved satiety as assessed 
through indicators of hunger, prospective food intake and satisfaction. 
Furthermore, the duration of the satiety effect by RS was longer than the other 
tested fibres. Similar findings have been reported with the addition of RS to the 
evening meal of healthy subjects, which resulted in reduced consumption at 
breakfast compared with a low fibre meal (Nilsson et al., 2008). Moreover, a 
randomised, single-blinded, crossover study has reported a reduction in total 
energy intake in healthy subjects fed 48g of RS compared with a control diet 
(Bodinham et al., 2010). 
Higgins et al. have also demonstrated in human volunteers that RS can 
significantly increase lipid oxidation and therefore reduce accumulation as 
adipose tissue (Higgins et al., 2004). As increased adiposity can enhance the 
risk of several diseases including cancers and type 2 diabetes, this establishes 
another protective effect of RS.  
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1.5.3 Polydextrose 
Polydextrose (PD) is a synthetic NDC originally developed by Pfizer as a low-
calorie sweetener with bulking properties (Stowell, 2009b). It is a soluble fibre 
and a glucose polymer with sorbitol end groups (Stowell, 2009b). It has been 
proposed by many that PD can be classified as a dietary fibre and therefore is 
integrated into several foods to add its beneficial properties. Furthermore, 
several other health effects have been observed both in vitro and in vivo and a 
number of these have been attributed to the production of butyrate by PD 
fermentation.  
1.5.3.1 Polydextrose as a food ingredient 
PD has been incorporated as an ingredient in a variety of food and drink 
products including dairy products, confectionery and pasta (Stowell, 2009b). 
This is facilitated by the fact that PD is heat- and acid-stable and is compatible 
with the majority of food and drink matrices. Moreover, it can provide products 
with beneficial properties such as improving their moisture management due to 
its humectant properties and also as a thickening agent. PD has less energy 
content than that found in carbohydrates and fats, making it an ideal candidate 
to be added into products with low/lower energy content, low/lower glycaemic 
index, high fibre content and/or prebiotic properties (Stowell, 2009b).  
As GI side effects, including abdominal cramps and bloating (Sandler et al., 
2000), have been reported following increased dietary fibre consumption, Boler 
et al. investigated the physiological effects of PD and soluble maize fibre 
consumption (Boler et al., 2011). The results from tolerance tests indicated 
minor discomfort, including increased flatulence and distension. However, 
volunteers were consuming up to 21g of PD per day, which is more than that 
given in previous studies, indicating that this dose can be administered with 
minimal GI discomfort (Boler et al., 2011).  
1.5.3.2 Effects of polydextrose in the large bowel 
A number of human studies have reported an improvement in large bowel 
function following PD consumption, such as a dose-dependent improvement in 
defaecation, augmented faecal weight and reduced faecal pH in healthy human 
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participants (Jie et al., 2000). A placebo-controlled, randomised intervention 
supplemented 45 healthy participants with 8g of PD per day (Hengst et al., 
2009). PD supplementation in yoghurts was associated with a significant 
reduction in faecal PH, excretion of cholesterol degradation products, excretion 
of total bile acids and orofaecal transit time in addition to an improvement in 
ease of defaecation. A reduction in abdominal discomfort accompanied by an 
improvement in bowel habits has also been reported with PD consumption 
(Costabile et al., 2011). The former may be explained by reduced gas 
production, reported in vitro, resulting from PD fermentation compared with 
other dietary prebiotics (Hernot et al., 2009).  
A chronic state of inflammation in the large bowel has been associated with 
increasing the risk of CRC. Increased levels of the mucosal cyclooxygenase 
(COX) COX-2, which is associated with increased inflammation, have been 
reported in tumourigenesis and CRC development (Wendum et al., 2004), with 
at least 80% of colorectal carcinomas having raised COX-2 levels (Eberhart et 
al., 1994). Furthermore, COX-2 antagonists are able to reduce CRC risk or 
even reverse carcinogenesis (Krause and DuBois, 2001). In vitro and in vivo 
studies have demonstrated that PD reduces COX-2 expression in the large 
bowel in a dose-dependent manner (Makivuokko et al., 2005; Fava et al., 2007), 
suggesting another protective effect of PD against CRC.  
In addition, a reduction in levels of branched-chain fatty acids (BCFAs), markers 
of protein decomposition, have been observed in the large bowel following 
supplementation with PD (Smith and Macfarlane, 1997). This constitutes a 
protective effect against CRC as certain metabolites produced during this 
process are carcinogenic. More recently, Boler et al. investigated the digestive 
physiological effects of PD and soluble maize fibre, including gastrointestinal 
tolerance and SCFA concentrations, in healthy male volunteers (Boler et al., 
2011). This study also found a reduction in putrefactive compounds, including 
BCFAs and ammonia, which are produced by protein fermentation.  
1.5.3.3 Polydextrose as a prebiotic 
Adhering to the definition proposed by The WHO/FAO Codex Alimentarius 
Committee on Nutrition and Foods for Special Dietary Uses in 2005, PD falls 
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under the category of a dietary fibre (Stowell, 2009b). Furthermore, several 
studies have demonstrated comparable physiological effects to those of dietary 
fibre produced by PD.  
In 1981, Figdor and Rennhard  determined the disposition of PD in the rat to be 
approximately 35% (Figdor and Rennhard, 1981). This was later confirmed in 
humans by Figdor and Bianchine, where it was discovered that between 30% 
and 50% of PD is fermented in the intestine (Figdor and Bianchine, 1983). The 
effect of PD supplementation on the intestinal microbiota as well as on the 
immune function was investigated by Fava et al. in a porcine model (Fava et al., 
2007). The investigators observed the fermentation of PD in the distal colon, 
suggesting that this process occurs throughout the large bowel. This had 
previously been demonstrated in vitro by Makivuokko et al. in a human model of 
the large bowel (Makivuokko et al., 2005). These observations are particularly 
important as they imply that PD can exert its protective effects even in the distal 
colon, where the majority of colorectal tumours develop.  
In humans, a double-blind, crossover intervention study explored the prebiotic 
effects of a daily dose of 8g of PD, particularly focusing on its modulation of 
faecal microbiota (Costabile et al., 2011). The study demonstrated an effect of 
PD on colonic microbiota, including an increase in the microbiota responsible 
for the production of butyrate such as Faecalibacterium prausnitzii. Despite this, 
there were no significant changes observed in faecal butyrate content. A more 
recent randomised, double-blind, placebo-controlled trial supplemented 20 
healthy males with 21g of PD, placebo or soluble corn fibre for 21 days and 
assessed microbiota levels in faecal samples by pyrosequencing (Hooda et al., 
2012). Although the investigators did not observe an effect of either treatment 
on overall faecal bacteria diversity following PD supplementation, participants 
fed PD had greater faecal Clostridiaceae, Veillonellaceae and 
Verrucomicrobiaceae and reduced Lachnospiraceae, Eubacteriaceae, 
Lactobacillales, Bifidobacteriaceae, Coriobacteriaceae and Hyphomicrobiacea 
compared with the no fibre diet. PD added to chocolate as a sweetener and fed 
to 40 healthy participants for fourteen days has been reported to significantly 
increase faecal Bifidobacteria and Lactobacilli, and this remained apparent six 
weeks post-consumption (Beards et al., 2010). Interestingly, the investigators 
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also reported a significant increase in faecal butyrate and propionate 
concentrations. 
PD has been shown to increase levels of SCFAs, as well as decrease levels of 
BCFAs, both in vitro and in vivo in human studies. In vitro, Makivuokko et al. 
observed that total SCFAs increased progressively along the colon following PD 
fermentation (Makivuokko et al., 2005). In vivo, a rise in total SCFAs in the 
colon has also been observed. Jie et al. investigated PD supplementation in a 
randomised controlled study in Chinese volunteers and measured a number of 
physiological factors including SCFA production, faecal microflora and colonic 
mucosal cell proliferation (Jie et al., 2000). Following PD intake, the authors 
observed significantly increased levels of Lactobacilli and Bifidobacteria as well 
reduced levels of Bacteroides. Furthermore, a significant increase in butyrate 
concentrations was found in those volunteers given 8g or 12g of PD, suggesting 
a PD supplementation of more than 8g per day can yield the beneficial effects 
produced by butyrate in the colon (Jie et al., 2000). The augmented levels of 
butyrate observed were confirmed by measuring cell proliferation in colonic 
crypts, an indicator of SCFA production, where increased proliferation, 
particularly in the basal compartments, was observed for all PD doses. 
1.5.3.4 Anti-neoplastic effects of polydextrose 
Although not as extensively-studied as RS, several studies have reported an 
anti-carcinogenic activity of PD. However, these have either been in vitro or in 
vivo animal studies and human studies have not been conducted to date.  
In vitro, Putaala et al. used the Enteromix® colon stimulator to model the 
fermentation of PD and subsequently treated Caco-2 colon adenocarcinoma 
cells with the produced fermentation metabolome  (Putaala et al., 2011). 
Treatment of Caco-2 cells with PD fermentation products resulted in an 
induction of apoptosis and inhibition of proliferation. Furthermore, PD positively 
modulated the expression of genes reported to be dysregulated in CRC, such 
as the peroxisome proliferator-activated receptors (PPAR)-responsive genes, 
which have been reported to be downregulated in colon cancer tissue 
(Martinasso et al., 2007). 
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In a study using ACF formation as the primary endpoint, 35 male Wistar/ST rats 
were randomised to one of five groups fed a control fibre-free diet or PD at 7 
days prior to DMH injection or on days 0, 1 and 7 post-injection (Ishizuka et al., 
2003). All rats continued consuming their respective diets until five weeks post-
injection. Rats fed PD prior to DMH injection had a significantly lower number of 
aberrant crypts and ACF in the colorectum compared with the fibre-free diet. A 
similar finding was observed for all of the PD diets, however they were not 
statistically significant. Interestingly, the majority of PD’s effects were visible in 
the rectum, where a significantly lower number of aberrant crypts and ACF were 
counted in rats from all of the PD diet groups bar the one consumed seven days 
post-DMH injections compared with the fibre-free diet. Although PD appeared to 
be protective at all time-points of administration, this was only statistically 
significant when consumed prior to carcinogen exposure. This suggests that the 
timing of intervention is important and that PD may be particularly effective at 
the pre-promotion stage of colorectal carcinogenesis.  
Another study in DMH-treated rats investigated the effects of the replacement of 
sucrose with PD and varying concentrations of lactulose sweeteners in a guava 
preserve on ACF formation (Menezes et al., 2012). However, there were no 
protective effects of PD and lactulose observed in carcinogen-treated rats, 
which all developed ACF. Consistent with these findings, another study in DMH-
treated mice did not report an effect of PD on colon tumour formation 
(Kumemura et al., 1998). 
1.5.3.5 Other beneficial effects of polydextrose 
McMahon has demonstrated a glycaemic and insulinaemic response in 
volunteers with type 2 diabetes who administered a single 50g dose of PD or 
glucose (McMahon, 1974). Positive effects on other metabolic parameters in 
patients with type 2 diabetes, including total cholesterol and plasma 
triglycerides, as well as a reduction in body weight and BMI have also been 
observed in a dietary intervention study supplementing female volunteers with a 
combination of PD and oligofructose for six weeks (Cicek, 2009). Furthermore, 
an attenuation of the postprandial rise in plasma glucose and insulin response 
has been observed in response to PD (Stowell, 2009a).  
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PD may also be an appetite-suppressant as it has been reported that the 
addition of PD to yoghurt significantly increased post-prandial satiety and 
reduced energy intake in healthy human participants (King et al., 2005). A 
reduction in ad libitum energy intake has been confirmed by Astbury et al., who 
compared the effects of varying concentrations of PD administered in a 
liquidised form in a randomised, cross-over design of 21 healthy subjects 
(Astbury et al., 2013). All three doses of PD (6.3, 12.5 and 25g) resulted in a 
significantly lower energy intake during the test meal compared with the control. 
A significantly lower total daily energy intake was also observed with PD, 
however this was only statistically significant for the two highest doses.  
Additional health-benefitting effects of PD are its abilities to modulate serum 
cholesterol and triglyceride levels. Pronczuk et al. have reported a 
hypocholesterolemic effect of PD in gerbils and humans (Pronczuk and Hayes, 
2006). In the animal studies, gerbils were either given a 0.15% cholesterol diet 
with or without 6% PD for four weeks or a cholesterol-free diet for three weeks. 
Supplementation of both diets with 6% PD, equivalent to approximately 30g per 
day in humans, resulted in significantly reduced plasma and liver cholesterol 
concentrations compared with the control diet. In the human study, 15g and 30g 
of PD per day were given to 12 hypercholesterolemic participants for four 
weeks. Consequently, a significant reduction in low-density lipoprotein 
cholesterol and a trend for lower total cholesterol was observed in five 
responding participants given the 30g per day dose of PD. 
1.5.4 Butyrate 
Butyrate, one of the SCFAs generated by the fermentation of dietary fibre, is 
one of the principal SCFAs produced from RS (Noakes et al., 1996). Butyrate is 
primarily produced by bacteria of Clostridia, Roseburia and Eubacteria (Pryde et 
al., 2002; Louis et al., 2007). In the large bowel, butyrate plays an important role 
in the maintenance of large bowel function, particularly by providing energy to 
colonic epithelial cells (Hamer et al., 2008). Butyrate has also been proposed to 
be responsible for the majority of dietary fibre’s protective effects against CRC 
through the regulation of processes such as apoptosis and proliferation. A large 
array of in vitro and in vivo studies have investigated the effects of butyrate in 
the large bowel. However, the majority of these have utilised cancer cells or 
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tissues and findings from healthy compared with cancerous models have been 
conflicting. 
1.5.4.1 Effects of butyrate in the large bowel 
Butyrate is the preferred source of fuel for colonocytes, providing the majority of 
the energy requirement for these cells (Hamer et al., 2008). Butyrate provides 
between 60% and 70% of the total energy required by colonocytes (Roediger, 
1980). It also regulates many cellular processes such as proliferation, 
differentiation and apoptosis in both normal and cancerous tissues (Nofrarias et 
al., 2007). 
In the large bowel, the effects of butyrate are primarily on cell proliferation. 
Studies in the healthy crypt have observed an induction of proliferation by 
butyrate that maintains adequate levels necessary to preserve homeostasis 
(Kripke et al., 1989). The effects of butyrate on colonic crypt cell proliferation 
are discussed in more detail in section 4.5.1.4. On the other hand, levels of 
apoptosis in the healthy crypt have been shown to be reduced by butyrate 
(Wachtershauser and Stein, 2000).  
As SCFAs are acidic, another consequence of increased SCFA production 
following, for example, dietary fibre intake is a reduction in colonic pH (Topping 
and Clifton, 2001). This is another beneficial effect of butyrate in the large bowel 
as the lower pH may prevent the colonisation or over-growth of certain 
pathogenic bacteria.  
Butyrate has also been shown to have anti-inflammatory properties within the 
large bowel, particularly via the modulation of regulators of inflammation 
including Interleukins -8 (IL-8), -10 (IL-10), -12 (IL-12) and -32 alpha (IL-32α) 
(Huang et al., 1997; Kobori et al., 2010), suppression of the nuclear 
transcription factor kappa B (NFκB) (Russo et al., 2012) and downregulation of 
nitric oxide synthase (Stempelj et al., 2007). Furthermore, butyrate has been 
demonstrated to induce apoptosis of T cells and prevent the induction of 
inflammation by Interferon-gamma, which is implicated in the development of 
inflammation-associated CRCs (Zimmerman et al., 2012). Recently, Singh et al. 
have also reported an induction of anti-inflammatory signals via the activation of 
the GPR109A receptor by butyrate, promoting the differentiation of T cells and 
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consequently the production of the anti-inflammatory cytokine IL-10 (Singh et 
al., 2014). 
1.5.4.2 Anti-neoplastic effects of butyrate 
Following the observation of a lower CRC risk in native Africans by Burkitt 
(Burkitt, 1971), where native Africans have a <1:100,000 CRC risk compared 
with 65:100,000 in African Americans (O'Keefe et al., 2007), O’Keefe et al. have 
proposed a critical role of colonic microbiota in large bowel health (O'Keefe, 
2008). In further investigations of the observed differences in CRC risk, they 
hypothesised that this was at least partially mediated by differences in colonic 
bacterial metabolism (O'Keefe et al., 2009). Indeed, their results showed that 
colonic butyrate concentrations, as well as that of other major SCFAs, were 
significantly higher in native Africans, who have the lowest CRC risk, compared 
with African Americans. In addition, it was proposed that the increased levels of 
SCFAs observed in native Africans resulted from a higher intake of RS in their 
diet, such as from their maize meals. These findings suggested that the 
protective effects of dietary fibres such as RS resulted, at least in part, from the 
production of SCFAs and it was later revealed that butyrate in particular has 
anti-neoplastic properties, such as its role as a histone deacetylase inhibitor 
(HDACi) and through regulation of proliferation and apoptosis. The anti-
neoplastic effects of butyrate in normal and cancer cells are summarised in 
Figure 1.12. 
McIntyre et al. found that the protection against CRC observed in a rat model 
was associated with the dietary fibre type administered that resulted in the 
highest butyrate levels in the distal colon (McIntyre et al., 1993). Additionally, 
Weaver et al. observed lower butyrate levels in enema samples from polyp and 
CRC subjects compared with normal controls, suggesting that these reduced 
levels, possibly associated with reduced colonic fermentation, may be linked to 
polyp and CRC development (Weaver et al., 1988). A similar finding was 
discovered by Bradburn et al. who reported lower butyrate concentrations in 
faecal samples from patients at higher risk of developing CRC (FAP gene 
carriers) compared with the control group (Bradburn et al., 1993). Altogether, 
these findings suggest that butyrate is the key fermentation product associated 
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with anti-tumourigenic properties and that, furthermore, a reduction in butyrate 
may be associated with an increased risk of CRC. 
In vivo studies that have investigated the effects of butyrate on colorectal 
carcinogenesis have primarily been in rodents. Kameue et al. investigated the 
effects of dietary sodium gluconate, which increases the production of butyrate 
in the large bowel, on tumour development in rats (Kameue et al., 2004). Rats 
were treated with AOM and deoxycholic acid to initiate and promote colorectal 
carcinogenesis. The rats which ingested the sodium gluconate had a 
significantly lower incidence of colorectal tumours and a lower average number 
of tumours compared with the controls. These results were attributed to the 
production of butyrate as dietary sodium gluconate does not undergo significant 
digestion or absorption before reaching the large bowel, where it is fermented 
by bacteria to produce butyrate. The authors investigated the levels of butyrate 
and reported a 60% increase in caecal butyrate concentrations in rats given the 
sodium gluconate. The effects of butyrate delivered directly to the caecum via 
intra-caecal administration in DMH-treated rats have also been explored and a 
reduction in colorectal malignancies and carcinomas was observed in rats 
which were administered caecal butyrate (Medina et al., 1998). 
The formation of ACF has also been utilised as a study endpoint for 
investigations of butyrate on colorectal carcinogenesis. A significant inverse 
correlation between caecal butyrate concentrations and colonic ACF formation 
has been reported (Coleman et al., 2002). Rats fed a diet rich in α-cellulose, 
which resulted in higher butyrate levels, combined with fish oil conferred the 
greatest protective effect against ACF formation compared with RS or soy fibre 
diets, suggesting that the anti-neoplastic effects observed most likely resulted 
from butyrate production.  
The anti-neoplastic effects of butyrate result primarily from the modulation of 
colonic crypt cell proliferation and apoptosis. In CRC cells or tissues, where a 
state of hyperproliferation is apparent, butyrate has been shown to reduce cell 
proliferation and induce apoptosis (Hodin et al., 1996; Mortensen et al., 1999; 
Comalada et al., 2006; Clarke et al., 2012). The anti-neoplastic effects of 
butyrate on cell proliferation are discussed in more detail in section 4.5.1.5. The 
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observation that butyrate’s effects differ between healthy and cancerous cells 
suggest that it is highly selective (Fung et al., 2012).  
Figure 1.12 The effects of butyrate in the normal colon and in colorectal 
tumour cells. 
 
Reprinted with permission from Cambridge University Press: British Journal of Nutrition 
(Fung et al., 2012), Copyright (2012). 
1.5.4.3 Butyrate as a histone deacetylase inhibitor 
The effects of butyrate on histone acetylation have been studied extensively 
and its role as a HDACi is well established (Berni Canani et al., 2012). By 
inhibiting histone deacetylation, which is associated with reduced gene 
expression, butyrate restores the expression of genes and consequently levels 
of processes including cell proliferation and differentiation. Furthermore, it has 
been suggested that the induction of apoptosis in cancerous cells by butyrate 
results primarily from the inhibition of HDACs (Fung et al., 2012). In addition, 
butyrate has also been reported to modulate the acetylation of non-histone 
proteins, such as the transcription factors Sp1 and Sp3 (White et al., 2006; 
Waby et al., 2010).  
For example, modulation of the acetylation state of WNT5A, a WNT ligand 
whose expression is reduced in CRC, by butyrate is associated with restored 
WNT5A expression in SW620 metastatic colon cancer cells (Li and Chen, 
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2012). The effects of butyrate as a HDACi were confirmed using the chromatin 
immunoprecipitation assay, whereby the acetylation of histone 3 at the promoter 
region was significantly greater following treatment with 5mmol/L butyrate for 48 
hours. Furthermore, the investigators observed a significant increase in the 
expression of β-catenin at the protein level, suggesting that the restoration of 
WNT5A expression by butyrate through inhibition of histone deacetylation 
resulted in normal activation of the WNT signalling pathway.  
Recently, Wang and colleagues have reported the restored expression of 
selenium-binding protein 1 (SELENBP1), whose expression was increased in 
CRC compared with normal tissue and was associated with the regulation of 
differentiation, with 2mM sodium butyrate treatment of colon cancer cell lines 
(Wang et al., 2014). Similar findings were observed following treatment with 
another HDACi, trichostatin A, but not with an inhibitor of DNA methylation, 
suggesting that butyrate’s effects on SELENBP1 expression are mediated via 
modifications to histones. 
1.5.4.4 Effects of butyrate on the WNT signalling pathway 
More recently, the modulation of the WNT signalling pathway by butyrate has 
been investigated and has been the main focus of the group at The 
Commonwealth Medical College led by Dr. Michael Bordonaro, who primarily 
conduct in vitro studies to investigate the effects of butyrate on processes such 
as apoptosis through the regulation of WNT signalling. It has been proposed 
that the positive modulation of the WNT pathway, which is frequently aberrantly 
activated in CRC, is one of the mechanisms by which butyrate exerts its anti-
neoplastic effects and regulates processes such as cell proliferation and 
apoptosis. The effects of butyrate on the expression and epigenetic regulation 
of WNT pathway components are described in more detail in section 4.2.1.2. 
One of the Bordonaro group’s earliest investigations explored the effects of 
butyrate on apoptosis and to what extent this was a consequence of its effects 
on WNT signalling. In SW620 colon carcinoma cells, apoptosis was induced 
following treatment with 5mM butyrate for 24 hours (Bordonaro et al., 1999). 
Unexpectedly, this was associated with a stimulation of WNT pathway activity 
as indicated by enhanced activity of the TCF transcription factor and increased 
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formation of β-catenin-TCF complexes. Although WNT signalling regulated 
apoptosis, the observation that butyrate increased WNT pathway activity was 
surprising as this pathway is frequently hyperactive in CRC and previous 
studies had suggested that the induction of apoptosis was associated with 
reduced WNT signalling in CRC cells (Bordonaro et al., 2008a). The findings 
from this study were later confirmed in ten CRC cell lines, where the greatest 
apoptotic response was associated with the highest levels of WNT activity 
(Lazarova et al., 2004). Furthermore, an induction of WNT pathway activity by 
butyrate, demonstrated by an increase in active, dephosphorylated β-catenin, 
was reported in eight CRC cells (Bordonaro et al., 2007). 
Other studies have investigated the effects of butyrate on WNT pathway-
mediated cell differentiation. In LIM2537 colon cancer cells, Vincan et al. 
observed an induction of cell differentiation with butyrate treatment (Vincan et 
al., 2000). This was associated with an increase in WNT activity, particularly 
resulting from a reduction in the activity of GSK3β and, consequently, greater 
levels of stable β-catenin. Furthermore, an inverse correlation between the 
expression of GSK3β and differentiation was perceived.  
Despite an indication of an increase in WNT pathway activity, Vincan et al. did 
not observe an increase in the expression of CCND1 or c-MYC, two target 
genes of WNT signalling (Vincan et al., 2000). Interestingly, butyrate has been 
reported to reduce expression of four WNT target genes which have been found 
to be upregulated in CRC (CCND1, c-MYC, FOSL1 and FST) in CC531 rat 
colon carcinoma cells (Germann et al., 2003). More recently, Bordonaro and 
colleagues identified a total of 1587 direct and indirect targets of the WNT 
pathway, following analyses by microarray, including those involved in the 
regulation of processes such as cell differentiation, migration and DNA 
replication, whose expression was modulated by 5mM butyrate in HCT-116 
cells (Lazarova et al., 2014b). 
Bordonaro et al. have ultimately proposed the idea that a gradient of canonical 
WNT pathway activity occurs in the large bowel, whereby inactive WNT 
signalling is associated with cell differentiation and apoptosis, low levels of 
activity result in tissue self-renewal, moderate activity leads to uncontrolled 
proliferation and high levels result in apoptosis (Bordonaro et al., 2008a; 
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Bordonaro et al., 2008b). This proposition would explain previous findings 
where particular cells, which exhibited an induction of WNT signalling in 
response to butyrate treatment, consequently showed greater levels of 
apoptosis compared with those that did not show stimulation of the WNT 
pathway (Lazarova et al., 2004). Furthermore, Lazarova et al. have suggested 
that early-stage neoplasms may be more responsive to butyrate following the 
observation that LT97 cells, a  microadenoma cell line representative of an early 
stage of colorectal carcinogenesis, exhibited a greater induction of WNT activity 
and consequently stimulated apoptosis (Lazarova et al., 2014a). 
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1.6 Hypotheses, Aims & Objectives of this Ph.D. project 
1.6.1 Introduction to the DISC Study 
This Ph.D. project was part of the DISC Study, a large, double-blind, placebo-
controlled, randomised dietary intervention that supplemented 75 healthy 
participants with two NDCs, RS and PD, for seven weeks, and investigated the 
effects of the NDCs on biomarkers of colonic health. Furthermore, additional 
participants at differential risk of CRC, with quiescent UC and a history of 
adenomatous polyps, were recruited and did not take part in the dietary 
intervention.  
The DISC Study was not subject to a formal power calculation as it aimed to 
test the impact of NDCs, known to be beneficial to GI health, on a panel of 
novel and well-established biomarkers. A target of 75 participants, allowing for a 
10% dropout rate, was set. This number represented an achievable target, 
given the timeframe for recruitment and sample collection, predicted to identify 
effects of NDCs based on a previous study which detected significant effects of 
supplementing 65 CRC patients with RS for up to four weeks on colonic crypt 
cell kinetics and gene expression (Dronamraju et al., 2009).  
Samples, more specifically rectal mucosal biopsies, collected for the DISC 
Study were used for the investigations described in this Ph.D. thesis and to test 
the hypotheses defined below. The DISC Study is described in more detail in 
section 2.1. 
1.6.2 Hypotheses 
 Expression of WNT pathway-related genes is altered in the 
macroscopically-normal mucosa of participants at higher risk of CRC, with 
quiescent UC or prior history of polyps. 
 The altered expression of WNT pathway-related genes in the 
macroscopically-normal mucosa of participants at higher risk results from 
epigenetic mechanisms such as DNA methylation and abnormal 
expression of miRNAs. 
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 Participants at higher risk of CRC have altered levels of colonic crypt cell 
proliferation and apoptosis. 
 Dietary intervention in participants at normal risk of CRC with RS and/or 
PD will positively modulate the expression of WNT pathway-related 
genes. 
 Dietary intervention in participants at normal risk of CRC with RS and/or 
PD will regulate the expression of WNT pathway-related genes via 
epigenetic mechanisms such as DNA methylation and the expression of 
miRNAs. 
 Dietary intervention in participants at normal risk of CRC with RS and/or 
PD will positively modulate levels of colonic crypt cell proliferation and 
apoptosis. 
1.6.3 Aims 
This Ph.D. project aimed to test these hypotheses by investigating differences 
in the WNT signalling pathway and two of its functional outcomes, cell 
proliferation and apoptosis, in the macroscopically-normal mucosa of people at 
higher risk of CRC, with quiescent UC and a prior history of adenomatous 
polyps. Furthermore, it aimed to explore the effects of supplementing healthy 
human participants with two NDCs, RS and PD, on the WNT signalling pathway 
and its functional effects in the large bowel. 
1.6.4 Objectives 
 To identify a subset of WNT pathway-related genes which are 
differentially expressed in the macroscopically-normal colonic mucosa of 
participants with a prior history of polyps who are at higher risk of CRC; 
 To compare the expression of the selected WNT pathway-related genes 
in the macroscopically-normal mucosa of participants at normal and 
higher risk of CRC i.e. those with quiescent UC or a prior history of 
adenomatous polyps; 
   
 59 
 To investigate the roles of two epigenetic mechanisms (DNA methylation 
and miRNA expression) in the altered expression of the selected WNT 
pathway-related genes in the macroscopically-normal mucosa of 
participants at higher risk of CRC; 
 To examine differences in two functional outcomes of WNT signalling that 
are dysregulated in CRC i.e. colonic crypt cell proliferation and apoptosis 
in the macroscopically-normal mucosa of participants at higher risk of 
CRC; 
 To quantify the expression of the selected WNT pathway-related genes 
prior to, and following, a dietary intervention supplementing healthy 
participants with NDCs (the DISC Study); 
 To investigate the effects of the dietary intervention on two epigenetic 
mechanisms (DNA methylation and miRNA expression) which may 
regulate the expression of the selected WNT pathway-related genes; 
 To investigate the effects of the dietary intervention on two functional 
outcomes of WNT signalling that are dysregulated in CRC i.e. colonic 
crypt cell proliferation and apoptosis. 
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Chapter 2 Methods 
2.1 Participant Recruitment and Sample Collection 
This project is part of the DISC Study - a double-blind, randomised, placebo-
controlled dietary intervention study using healthy human participants. The 
study is a randomised controlled trial (RCT) in which participants underwent a 
dietary intervention for 7 weeks during which they were asked to consume 
supplements of RS (Hi-maize® 260) and/or PD (Litesse®Ultra™) or placebo (a 
carbohydrate that is digested completely in the small bowel) in a 2*2 factorial 
design. Both RS and PD NDCs were selected because of their positive effects 
within the large bowel (and rest of the gut) including their ability to 
reduce/prevent inflammation. This was a significant factor in the choice of these 
intervention agents because of the evidence that chronic inflammation can 
predispose to CRC.  
2.1.1 Study Approval 
Ethical approval for this project was provided as part of a larger application for 
the DISC Study by the Newcastle and North Tyneside Research Ethics 
Committee from which a favourable ethical opinion was received on 10th 
December 2009 (REC No. 09/H0907/77) (Appendix A). Caldicott approval for 
the storage of data was given by the Northumbria NHS Foundation Trust 
(C1792). The clinical trial is registered with ClinicalTrials.gov (ClinicalTrials.gov 
Identifier NCT01075893). 
2.1.2 Participant Recruitment 
The participants contributing to this project were recruited by the DISC Study 
Team (Dr. Naomi Willis, Mr. Iain McCallum and Dr. Long Xie) prior to the 
commencement of this Ph.D. as part of the DISC Study.  Endoscopy patient 
lists were used to identify potentially suitable participants from the 
gastroenterology out-patients departments at North Tyneside General Hospital, 
North Shields, UK and Wansbeck General Hospital, Ashington, UK.  After 
excluding a large number of patients who did not meet the inclusion criteria 
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(Section 2.1.3) by revising hospital databases and previous endoscopy reports, 
potential participants were sent a letter with detailed information about the study 
prior to their endoscopy appointment at the hospital. The letter sent to potential 
intervention participants describing the DISC Study can be found in Appendix B. 
Similar letters were sent to potential ‘UC’ and ‘Polyp’ group participants but did 
not describe the dietary intervention arm of the study. At endoscopy, potential 
study participants were screened for exclusion criteria (Appendix C).  
2.1.3 Exclusion Criteria 
2.1.3.1 Intervention study exclusion criteria 
 Aged <16 or >85 years 
 Being a prisoner at the time of endoscopy 
 Pregnancy or planning to become pregnant 
 Diabetes mellitus 
 Familial adenomatous polyposis syndrome 
 Lynch Syndrome (HNPCC) 
 Known colorectal tumour or prior CRC 
 Prior colorectal resection 
 Active colonic inflammation at endoscopy  
 Iatrogenic perforation at endoscopy 
 Incomplete left-sided colonic examination  
 Colorectal carcinoma discovered at endoscopy 
 CRC on histology 
 Chemotherapy in the last 6 months 
 Administering NSAIDs e.g. aspirin 
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 Administering other immunosuppressive medication e.g. methotrexate, 
steroids 
 Administering warfarin or other anticoagulants 
2.1.3.2 ‘Polyp’ group exclusion criteria 
 As described in Section 2.1.3 
2.1.3.3 ‘UC’ group exclusion criteria 
 As described in Section 2.1.3 
 Active colitis defined as a score >5 for Short Clinical Colitis Activity Index 
(SCCAI) 
Eligible patients willing to participate were given a leaflet with information about 
the DISC Study and contact details of the DISC Team and were offered the 
opportunity to ask further questions about the study before providing informed 
written consent (Appendix D). 
Four groups of participants were recruited as part of the DISC Study: 
 Intervention group (‘Normal’ participants): patients with macroscopically 
normal colons willing to participate in the dietary intervention arm of the 
study.  
 UC group: patients with quiescent UC, determined using the SCCAI, were 
recruited to this group.  
 Polyp group: patients with previous non-malignant colorectal neoplasia 
viz.  tubular adenoma, tubulovillous adenoma or villous adenoma that had 
been removed were recruited to join the ‘Polyp’ arm of the study and are 
referred to as the ‘Polyp’ group. 
 Stem cell study group: 11 “normal” patients who underwent a full 
colonoscopy were recruited to this group. This group was not used in the 
present Ph.D. project and will not be described further in this thesis. 
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Participants from the first three groups then formed two groups of participants at 
differential risk of CRC that were compared in the second section of this Ph.D. 
project: 
 ‘Normal’ group: those at normal risk of CRC, comprising baseline (pre-
intervention) samples from participants taking part in the dietary 
intervention as well as any dropout participants.  
 ‘Higher-risk’ group: those at higher risk of CRC, comprising participants 
from the ‘UC’ and ‘Polyp’ groups. 
2.1.4 Human sample collection 
Pre-intervention and post-intervention samples were collected from the dietary 
intervention participants. Samples from ‘UC’ and ‘Polyp’ participants were 
collected at the initial endoscopy appointment. Rectal mucosal biopsies were 
taken 10 cm from the anal margin (mid-rectum) from apparently-normal, healthy 
tissue during colonoscopy or flexible sigmoidoscopy pre-intervention and during 
rigid sigmoidoscopy post-intervention. In addition, participants provided blood, 
urine, stool and buccal cell samples. Anthropometric measurements were taken 
pre- and post-intervention and participants were asked to complete a Food 
Frequency Questionnaire (FFQ) (Appendix E) and Lifestyle Questionnaire 
(Appendix F).  
2.1.4.1 Rectal mucosal biopsy collection 
Rectal mucosal biopsies were collected by the DISC Study Team using biopsy 
forceps (Medical Innovations Biobite Biopsy forceps, diameter 2.3mm, length 
230cm with spike, coated, REF BF23230-S/C, Lot 20110218). Nine biopsies 
were taken from the mid-rectum of each participant and were processed and 
stored as described below: 
 Five biopsies were embedded in Tissue-Tek® OCT™ Compound (Sakura 
Finitek Europe), a cryoprotectant, snap-frozen in liquid nitrogen-cooled 
isopentane and stored at -80°C.  
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 Two biopsies were formalin-fixed paraffin-embedded (FFPE). These were 
fixed in 10% formalin and paraffin-embedded and blocked in the 
pathology laboratories at the Northumbria Healthcare NHS Foundation 
Trust.  
 One biopsy was placed in RNAlater® (Ambion, USA) and stored at -80°C. 
 One biopsy was preserved in 1ml of Carnoy’s solution (70% ethanol, 30% 
acetic acid) overnight at 4°C and then stored in 70% ethanol at 4°C. 
2.1.4.1.1 Rectal mucosal biopsy samples from intervention participants 
(‘Normal’) 
Nine rectal biopsies were taken from each healthy participant before 
(‘baseline’/‘pre-intervention’ samples) and after (‘post-intervention’ samples) 
intervention. Pre-intervention samples were collected during sigmoidoscopy or 
colonoscopy as described in Section 2.1.4.1.  Post-intervention biopsies were 
taken from the mid-rectum, 10cm from the ano-rectal verge, during a rigid 
sigmoidoscopy using biopsy forceps (4mm Sarratt, Stericom, UK). 
2.1.4.1.2 Rectal mucosal biopsy samples from the ‘higher-risk’ 
participants 
Nine biopsies were collected from each ‘UC’ and ‘Polyp’ participant as 
described in Section 2.1.4.1.  All samples from both groups were taken during 
their endoscopy appointment.  Mid-rectal biopsies were taken 10cm from the 
ano-rectal verge.  
2.1.4.2 Blood samples 
Blood samples were collected from the study participants in seven 4ml BD 
Vacutainer® K3EDTA (K3E) tubes (Becton Dickinson, Oxford, UK) and one 5ml 
BD Vacutainer® SST™ II Advance tube with gold hemogard closure (Becton 
Dickinson, Oxford, UK). At baseline, participants having a colonoscopy would 
have been fasting for 24 hours and consequently their blood samples, but not 
the samples of those having a flexible sigmoidoscopy, were fasted. Post-
intervention blood samples, collected at the time of the rigid sigmoidoscopy 
procedure, were un-fasted. 
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High-sensitivity C-reactive protein (hsCRP) levels in serum and vitamin B12 and 
red cell folate concentrations in plasma were analysed at the Department of 
Blood Sciences laboratories at the Freeman Hospital, Newcastle upon Tyne.  
Plasma selenium levels were quantified at the University of Liverpool.  
2.1.5 Dietary intervention 
The primary aim of the DISC Study dietary intervention was to investigate the 
response of a panel of established and novel biomarkers of CRC risk to each of 
the intervention agents and to assess the effectiveness of these outcomes as 
biomarkers of gut health. 
2.1.5.1 Participant randomisation 
The healthy participants (‘Normals’) took part in the dietary intervention study. 
Following their colonoscopy or flexible sigmoidoscopy at the endoscopy unit, 
participants were given at least a week to recover from the procedure to 
minimise any possible effects of the bowel preparation on the gut microflora and 
the colorectal epithelium. At this first visit, participants were randomised by 
choosing one of four sealed opaque envelopes labelled A, B, C and D. 
Participant randomisation was stratified by pre-intervention endoscopy 
procedure to avoid a confounding effect of the different bowel preparation 
methods associated with each procedure. Un-blinding was not performed until 
completion of all data collection and statistical analyses.  
2.1.5.2 Interventions 
Two active intervention agents, RS and PD, and their respective placebos were 
administered in a 2x2 factorial design. The intervention agents were provided in 
foil sachets labelled with a code which contained the agents in the form of a 
white powder. 
The participants were asked to consume 35g of intervention supplement per 
day, divided into four sachets (two sachets of each agent). These were given in 
boxes containing a week’s worth of sachets. The supplements were added to 
cold foods or liquids, such as yoghurt and orange juice, or mixed with cold 
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water.  Participants took the supplements for a total of 50 days. They were 
asked to keep all of their sachets, both those that were consumed and those 
that were not, for the assessment of compliance at the end of the intervention. 
2.1.5.2.1 Resistant starch 
The RS supplied was Hi-Maize® 260 (Ingredion™, formerly National Starch, 
Food Innovation, USA), a type 2 RS that is isolated from high-amylose corn 
hybrids and occurs in the natural granular form (Ingredion, 2014). The RS 
content of Hi-Maize® 260 is approximately 60%, with the remaining 40% 
comprising digestible starch. Hi-Maize® 260 has an energy content of 1.4 
kilocalories (kcal) per gram.  
2.1.5.2.2 Polydextrose 
PD was given in the form of Litesse® Ultra™ (DuPont™ Danisco®, Finland). 
Litesse® Ultra™ is a low-calorie (1kcal per gram), sugar-free soluble fibre 
developed as a sweetener (Danisco, 2011). It is a glucose polymer produced 
from sorbitol, dextrose and citric acid, which are derived naturally from corn.  
2.1.5.2.3 Placebos 
The placebos utilised for RS and PD were Maltodextrin and Amioca starch 
respectively. Maltodextrin is a polysaccharide produced from the partial 
hydrolysis of starches that can be derived from corn or wheat. Amioca starch is 
a low-amylose, waxy starch comprising amylopectin. Neither maltodextrin nor 
amioca starch contain RS and are easily digested and consequently absorbed 
in the small intestine (Kennedy et al., 1995). Therefore, they do not have any 
effects in the large bowel. 
  
   
 67 
2.1.5.3 Intervention groups 
The four intervention groups were the double placebo group, the RS group, the 
PD group and the double intervention group (see Figure 2.1).  
 Double placebo group: 12g of maltodextrin and 23g of amioca starch  
 RS group: 23g of Hi-maize® 260 and 12g of maltodextrin 
 Polydextrose group: 12g of Litesse® Ultra™ and 23g of amioca starch  
 Double intervention group: 23g of Hi-maize® 260 and 12g of Litesse® 
Ultra™ 
Figure 2.1 Four intervention groups of human dietary intervention. 
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2.2 Laboratory Methods 
2.2.1 Gene expression analyses 
Quantitative PCR (qPCR) amplifies specific DNA sequences for the detection 
and quantification of a target in real time. Synthesis of complementary DNA 
(cDNA) followed by reverse-transcription qPCR (RT-qPCR) is now regarded as 
the optimal approach for quantifying messenger ribonucleic acid (mRNA) 
abundance (Bustin, 2000). 
Primers are used to bind to a specific sequence of the template DNA to be 
amplified in the presence of DNA polymerase. Then a thermal cycler is used to 
produce cycles, customarily 40, of the following stages: 
1. Denaturation: denaturation of the double-stranded DNA (dsDNA) to 
single-stranded DNA (ssDNA) at a high temperature, typically 95°C. 
2. Annealing: Hybridisation of primers (and probes) to complementary 
template sequences, at approximately 60°C.  
3. Extension: Primer extension by DNA polymerase, typically 70-72°C 
where polymerase activity is optimal. 
Quantification by qPCR is based on the fluorescence intensity detected at the 
end of each cycle and this increases as the PCR product is amplified. This 
reaches 100% efficiency during the exponential amplification phase where the 
quantity of PCR product is doubled in each cycle (Edwards et al., 2004). A 
passive reference dye, such as carboxy-X-rhodamine (ROX), is also included in 
the reaction to normalise the fluorescent signals and to adjust for any 
differences between wells (Edwards et al., 2004). 
Two detection methodologies exist: primer-dye based assays and probe-based 
assays. The first uses a dye, commonly SYBR Green, that binds dsDNA, i.e. 
the PCR product, and fluoresces (Dorak, 2006). A downfall of the use of such 
dyes is that they are non-specific and are able to bind to any dsDNA, which can 
lead to inaccurate quantification of the target of interest.  Melting curve, or 
dissociation, analyses are run directly after the PCR reaction to confirm that the 
PCR has generated a single PCR product and identify whether primer-dimers 
have been detected. This is particularly important when running primer-dye 
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based assays where the dye binds non-specifically to dsDNA. Each target PCR 
product has a unique melting temperature (Tm), where half of the template is 
ssDNA (Dorak, 2006), and a single fluorescence peak should be visualised at, 
or close to, the Tm of the PCR product on the dissociation curve (Dorak, 2006). 
This issue of specificity associated with dye methods is overcome by using 
probe-based assays, labelled with a fluorescent reporter dye (5’ end) and a 
quencher (3’ end). When the probe is not bound and the reporter and quencher 
are in close proximity, the reporter signals are absorbed by the quencher by 
fluorescence resonance energy transfer (Dorak, 2006). During the extension 
stage of the reaction, the probe is degraded by exonuclease activity present in 
the polymerase. This releases and separates the reporter dye and quencher, 
allowing the reporter to emit fluorescent signals which are detected by the 
qPCR machine. Once the reaction has terminated, a threshold fluorescence 
value is set in the exponential phase for each gene and the threshold cycle (Ct 
value), which is the number of cycles taken for each sample to reach this 
fluorescence value, is determined (Edwards et al., 2004). The Ct value is 
inversely proportional to the amount of the target gene in the template sample. 
Two different methods may be used for gene expression quantification: 
quantification relative to the expression of reference genes or absolute 
quantification. In the present study, the relative quantification method was used 
where one or more reference, or housekeeping, genes that show stable 
expression in the tissue of interest and are not altered by treatment groups or 
condition are selected (Fink et al., 1998). The expression of the reference 
genes is quantified alongside that of the target genes, allowing for normalisation 
of gene expression which overcomes issues such as differences in template 
cDNA volumes and in quality of the extracted RNA.   
To investigate differences in gene expression, both between groups following 
the dietary intervention and between different CRC risk groups (‘Normal’, ‘UC’ 
and ‘Polyp’), two-step RT-qPCR was used to quantify and compare the 
expression of the selected genes to be analysed. The dye detection method 
using SYBR Green was utilised, followed by relative quantification by 
normalisation with 18S and β2M reference genes.  
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2.2.1.1 Extraction of RNA from rectal mucosal biopsies 
Total RNA was extracted using Qiagen’s RNeasy Mini Kit (Qiagen, UK) 
following the manufacturer’s instructions. OCT-embedded samples were 
removed from storage at -80°C and the biopsy was removed from the excess 
OCT using sterile pipette tips. Whole biopsies were cut in half using a new, 
sterile scalpel blade for each sample and RNA was extracted from half a biopsy. 
The remaining half biopsy not used was immediately placed back into its tube 
and returned to storage at -80°C. The tissue was scraped into a RNase-free 
tube containing 500μl RNAlater® and vortex mixed.  
Tissue disruption and homogenisation were performed using 3mm glass beads 
(VWR, UK) followed by QiaShredders (Qiagen, UK). Five glass beads were 
dispensed into 2ml tubes and 150μl of Buffer RLT were added. The tissue was 
transferred to the 2ml tube containing the beads and shaken for 1 minute using 
an amalgamator. An additional 450μl of Buffer RLT were added to the lysate, 
yielding a total volume of 600μl of Buffer RLT. The lysate and beads were 
poured into the QiaShredder column and centrifuged for 2 minutes at maximum 
speed. The lysate was then centrifuged for 3 minutes at maximum speed and 
the supernatant was removed and transferred into a new microcentrifuge tube. 
One volume of 70% nuclease-free ethanol (≥99.8%, Fluka Analytical, Ukraine) 
was added to the lysate and mixed immediately by pipetting. The sample 
(700μl) was loaded onto an RNeasy spin column placed in a 2ml collection tube 
and centrifuged for 15 seconds at 10,000rpm.  
The spin column membrane was washed with 700μl Buffer RW1 and 
centrifuged for 15 seconds at 10,000rpm. Two further wash steps were 
performed with Buffer RPE to prevent the carryover of ethanol during RNA 
elution. A final centrifugation step was performed in a new 2ml collection tube at 
maximum speed for 1 minute to eliminate any possible carryover of Buffer RPE.  
The RNA was eluted in 30μl of RNase-free water and only one elution step was 
performed in an attempt to maximise the total RNA concentration. All 
centrifugation steps were performed at room temperature.  
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2.2.1.1.1 RNA quantification 
The RNA concentration and purity, indicated by the A260/A280 ratio, were 
quantified using the NanoDrop 1000 spectrophotometer (Thermo Scientific) and 
the NanoDrop 1000 Software version 3.7.1. The mean RNA concentrations and 
A260/280 ratios for each participant group are described in Table 2.1. These 
were of sufficient concentration for subsequent analyses and of adequate purity 
as indicated by an A260/280 ratio between 2.0 and 2.1. 
The quality and integrity of the RNA were assessed using agarose gel 
electrophoresis and the presence and intensity of 18S and 28S ribosomal RNA 
bands were analysed. A 1% agarose gel was prepared using agarose powder 
(Fermentas) and 1x TBE buffer (gibco®) and heated until the agarose had 
dissolved. The gel was stained with 3µl of GelRed™ dye (10,000x) (Biotium, 
UK) and the cooled mixture was poured into the electrophoresis tray and left to 
set for 30 minutes. A volume of 4µl of extracted RNA mixed with 3µl of 6x 
loading dye (Fermentas) was loaded into each well alongside a DNA molecular 
weight marker ladder (Fermentas). The gel was run at 120V for approximately 
30 minutes using the Flowgen Bioscience CS-250V. UV light was used to 
visualise the RNA using the AlphaImage® (Alpha Innotech) gel documentation 
system and AlphaEase® FC Software Version 4.1.0. An example image is 
shown in Figure 2.2. 
Table 2.1 RNA concentrations and A260/280 ratios for Intervention, UC 
and Polyp samples. 
Measurement  Intervention UC Polyp 
RNA concentration (ng/µl) 
mean (SEM) 
121.2 (5.5) 153.6 (25.3) 148.9 (12.2) 
A260/A280 ratio 
mean (SEM) 
2.04 (0.01) 2.03 (0.02) 2.04 (0.01) 
Data are presented as means and standard error of the mean (SEM). 
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Figure 2.2 RNA agarose gel electrophoresis image showing 28S and 18S 
rRNA bands. 
 
A volume of 4µl of each RNA sample (equating to 0.665µg of 052 pre and 0.452µg of 
056 pre) were loaded onto a 1% agarose gel and electrophoresed for 30 minutes at 
120V. 
2.2.1.2 cDNA synthesis 
cDNA was synthesised by reverse transcription using the QuantiTect Reverse 
Transcription Kit (Qiagen, UK). A total amount of 1µg of RNA was reverse 
transcribed as described in the manufacturer’s manual.  
Firstly, a genomic DNA (gDNA) elimination step was performed by incubating 
the gDNA elimination reaction components (see Table 2.2) with the RNA for 2 
minutes at 42°C and then placing immediately on ice.  
Table 2.2 gDNA elimination reaction components. 
Component Volume per reaction (µl) 
gDNA  Wipeout Buffer (7x) 2 
Template RNA Variable (1µg) 
RNase-free water Variable (make up to 14µl) 
 
The reverse transcription master mix was prepared as summarised in Table 2.3. 
This mix (6µl) was added to the template RNA (14µl from the gDNA elimination 
reaction) to produce a total volume of 20µl of cDNA.  
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Table 2.3 Reverse transcription reaction components. 
Component Volume per reaction (μl) 
Quantiscript Reverse Transcriptase 1 
Quantiscript RT Buffer (5x) 4 
RT Primer Mix 1 
 
Alongside the samples, two negative controls were included to determine the 
presence of any contaminants. These were: 
 A no template control (NTC) containing all the reaction components 
except the template RNA, which was replaced with RNase-free water.  
 A no reverse transcriptase control (RTC) containing all the reaction 
components except the reverse transcriptase enzyme, which was 
replaced with 1µl of water. 
The tubes were mixed and incubated for 30 minutes at 42°C followed by 3 
minutes at 95°C to inactivate the Quantiscript Reverse Transcriptase. All 
incubation steps were performed using the Sensoquest lab cycler (Göttingen, 
Germany). The cDNA was stored at -20°C. Prior to running the qPCR analyses, 
the cDNA was diluted 10x with RNase-free water to a total volume of 200µl.  
2.2.1.3 Gene expression analysis 
The expression of WNT pathway-related genes was quantified by qPCR using 
the Applied Biosystems® StepOnePlus™ System. All samples, including RTC 
and NTC controls were run in duplicate on a 96-well plate. 
Assay validation was performed for the designed primers prior to analysing the 
samples by producing standard curves from serial dilution experiments and 
determining the amplification efficiency (Figure 2.3). For all qPCR reactions 
described in this thesis, data collection was performed during the extension 
stage of the 3-step cycling and melting curve analysis of the PCR products was 
performed following the cycling program to verify the specificity of the reactions 
(Figure 2.4).  
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A total of 12 WNT pathway-related genes were selected to be quantified by 
qPCR in the intervention study and in participants at differential risk of CRC. 
The process used for the selection of these genes is described in section 3.3. 
Figure 2.3 qPCR standard curve analysis of CTNNB1. 
 
 
Figure 2.4 qPCR melt curve analysis of CTNNB1. 
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2.2.1.3.1 Quantification of CCND1, c-MYC and SFRP1 
Quantification of CCND1, c-MYC and SFRP1, alongside the two reference 
genes 18S and B2M, was performed using primers designed and optimised by 
Dr. Nigel Belshaw and Dr. Wing Leung (IFR, Norwich) (Table 2.4). 
Table 2.4 Primer sequences for quantification of CCND1, c-MYC and 
SFRP1 by qPCR. 
Gene Forward primer sequence Reverse primer sequence 
18S 
GGCTCATTAAATCAGTTATG
GTTCCT 
GTATTAGCTCTAGAATTACCA
CAGTTATCC 
B2M 
AAAGATGAGTATGCCTGCCG
T 
ACTTAACTATCTTGGGCTGT
GACAA 
CCND1 
TTGTACCTGTAGGACTCTCA
TTCG 
ACAGCACTGTGAGCTGGCT 
c-MYC AGATCCGGAGCGAATAGGG GTCCTTGCTCGGGTGTTGTA 
SFRP1 TGGTGTGGATCTATTGGCTG TCACTTTCTGGGCTTGACCT 
 
A qPCR master mix was prepared as defined in Table 2.5. A 7µl volume of 
master mix was dispensed into each well of a 96-well plate followed by 3µl of 
the respective cDNA to produce a 10µl total reaction volume. The plates were 
sealed, centrifuged at 1,000rpm for 1 minute and then placed in the real-time 
cycler to commence the cycling program as described in Table 2.6. 
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Table 2.5 qPCR master mix components for quantification of CCND1, c-
MYC and SFRP1. 
Component Volume per reaction (µl) 
ImmoMix™ (2x) (Bioline, UK) 5.00 
MgCl2 (50mm) (Bioline, UK) 0.10 
BSA (10mg/ml) (Ambion, UK) 1.00 
ROX Reference Dye (50x) (Invitrogen, UK) 0.20 
SYBR Green (100x) (Invitrogen, UK) 0.06 
RNase-free water 0.60 
Forward primer (100µM) 0.02 
Reverse primer (100µM) 0.02 
 
Table 2.6 Cycling programme used for quantification of CCND1, c-MYC 
and SFRP1 using the Applied Biosystems® StepOnePlus™ System. 
Step Time Temperature 
Number of 
cycles 
PCR initial 
activation step 
10 minutes 95°C 1 
3-step cycling: 
Denaturation 
Annealing 
Extension 
 
30 seconds 
30 seconds 
30 seconds 
 
95°C 
60°C 
72°C 
40 
 
 
Data collection 
2.2.1.3.2 Quantification of APC, AXIN2, CTNNB1, FOSL1, GSK3β, c-JUN, 
SFRP2, WNT5A and WNT11 
Quantification of APC, AXIN2, CTNNB1, FOSL1, GSK3β, c-JUN, SFRP2, 
WNT5A and WNT11 alongside the two reference genes 18S and 2M was 
performed using the QuantiTect® SYBR® Green PCR Kit (Qiagen, UK) and the 
QuantiTect® Primer Assays (please see Table 2.7). Lyophilised QuantiTect® 
Primer Assays were reconstituted in 1.1ml Tris EDTA (TE), pH 8.0 and kept at -
20°C. 
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Table 2.7 QuantiTect® Primer Assays for quantification of WNT pathway-
related gene expression by qPCR. 
Gene QuantiTect® Primer Assay name 
18S Hs_RRN18S_1_SG 
2M Hs_B2M_1_SG 
APC Hs_APC_2_SG 
AXIN2 Hs_AXIN2_1_SG 
CTNNB1 Hs_CTNNB1_1_SG 
FOSL1 Hs_FOSL1_1_SF  
GSK3β Hs_GSK3B_1_SG 
c-JUN Hs_JUN_1_SG 
SFRP2 Hs_SFRP2_1_SG 
WNT5A Hs_WNT5A_1_SG 
WNT11 Hs_WNT11_1_SG 
 
A qPCR master mix was prepared as defined in Table 2.8 and 15µl of master 
mix were dispensed into each well of a 96-well plate followed by 5µl of the 
respective cDNA to produce a 20µl total reaction volume. The plates were 
sealed, centrifuged at 1,000rpm for 1 minute and then placed in the real-time 
cycler to commence the cycling program as described in Table 2.9. 
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Table 2.8 Reaction components for gene expression analyses using 
QuantiTect primer assays by qPCR. 
Component 
Volume per reaction 
(µl) 
QuantiTect SYBR Green PCR Master Mix (2x) 10 
QuantiTect Primer Assay (10x) 4 
RNase-free water 1 
 
Table 2.9 Cycling conditions for gene expression analyses using 
QuantiTect primer assays by qPCR. 
Step Time Temperature 
Number of 
cycles 
PCR initial 
activation step 
15 minutes 95°C 1 
3-step cycling: 
Denaturation 
Annealing 
Extension 
 
15 seconds 
30 seconds 
30 seconds 
 
94°C 
55°C 
72°C 
40 
 
 
Data collection 
2.2.1.4 Gene expression data processing 
Prior to analysis of the qPCR data, the melt curves were checked for a single 
peak as multiple peaks can be indicators of lack of specificity or the formation of 
primer-dimers. A constant threshold value was set for each gene separately for 
all samples as described in Table 2.10. This was calculated by taking the 
average of the set thresholds for each gene for every plate.  
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Table 2.10 Set thresholds for gene expression analyses. 
Gene Set Threshold 
18S 1.451 
β2M 1.384 
APC 1.336 
AXIN2 1.804 
CCND1 2.066 
c-MYC 1.800 
CTNNB1 1.706 
FOSL1 0.960 
GSK3β 1.820 
c-JUN 1.748 
SFRP1 2.060 
SFRP2 1.481 
WNT5A 1.805 
WNT11 1.272 
 
Two reference genes were quantified on each plate alongside the target genes 
for each sample. The geometric mean of 18S and β2M housekeeping genes 
was calculated for each sample and used for the normalisation of the 
expression of each gene as described by Vandesompele et al. (Vandesompele 
et al., 2002). 
The delta Ct (∆Ct) value was calculated for each gene for each sample by 
subtracting the mean Ct value of the geometric mean of the reference genes 
from the mean Ct value of duplicates for the gene of interest: 
∆Ct = Ct (target gene) – Ct (geometric mean of 18S and β2M) 
The relative copies for each gene were then calculated using the formula: 
Relative copies = 2-∆Ct 
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The adjusted copies were calculated by multiplying the relative copies by a 
constant factor, in this case 10,000.  
Adjusted copies = relative copies x 10,000  
The standard deviation (SD) was calculated for each gene for each sample and 
any samples with SD >0.5 were repeated or excluded from statistical analysis.  
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2.2.2 MicroRNA expression analyses 
2.2.2.1 Total RNA including miRNA extraction from rectal mucosal 
biopsies 
Total RNA was extracted using Qiagen’s miRNeasy Mini Kit (Qiagen, UK) 
following the manufacturer’s instructions. OCT-embedded samples were 
removed from storage at -80°C. Whole biopsies were cut in half using a new, 
sterile scalpel blade for each sample and RNA was extracted from half a biopsy. 
The remaining half not used was immediately placed back into its tube and 
returned to storage at -80°C. Tissue disruption and homogenisation were 
performed using glass beads (VWR, UK) followed by QiaShredders (Qiagen, 
UK). Tissue was disrupted in 2ml tubes containing five 3mm glass beads and 
700µl QIAzol Lysis Reagent and shaken for 1 minute using an amalgamator.  
The lysate and beads were poured into the QiaShredder column and 
centrifuged for 2 minutes at maximum speed. The homogenate was left at room 
temperature for 5 minutes to promote dissociation of nucleoprotein complexes. 
A 140µl volume of chloroform (Sigma-Aldrich) was added to the homogenate 
and shaken vigorously for 15 seconds using the amalgamator. After incubation 
at room temperature for 2 minutes, the sample was centrifuged for 15 minutes 
at 12,000g at 4°C. The upper aqueous phase, approximately 330µl in volume, 
was transferred to a new 2ml collection tube and 495µl of 100% RNase-free 
ethanol were added and mixed thoroughly. Up to 700µl of the sample were 
pipetted into a RNeasy Mini spin column in a 2ml collection tube and 
centrifuged at 10,000rpm for 15 seconds at room temperature. The flow-through 
was discarded and the step was repeated with the remainder of the sample.  
The spin column membrane was washed with 700µl of Buffer RWT and 
centrifuged at 10,000rpm for 15 seconds. The flow-through was discarded and 
500µl Buffer RPE were added to the column. The tube was centrifuged at 
10,000rpm for 15 seconds at room temperature to wash the column and the 
flow-through was discarded. Another 500µl of Buffer RPE was added and 
centrifuged at 10,000 rpm for 2 minutes at room temperature to dry the column 
membrane and ensure that no ethanol was carried over during the elution step. 
A final centrifugation step was performed in a new 2ml collection tube at 
maximum speed for 1 minute to eliminate any possible carryover of Buffer RPE.  
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The RNeasy Mini spin column was then transferred to a new 1.5ml tube and 
30µl of RNase-free water were pipetted directly onto the column membrane. 
The tube was centrifuged at 10,000rpm for 1 minute at room temperature to 
elute the RNA.   
2.2.2.2 cDNA synthesis 
cDNA was synthesised from 0.8µg of RNA using the miScript II RT Kit (Qiagen) 
as described in the manufacturer’s manual. The miScript HiSpec Buffer (5x) 
was used during reverse transcription to enable subsequent quantification of 
mature miRNAs. 
The reverse transcription master mix was prepared as described in Table 2.11 
and template RNA (variable volumes, equal to 0.8µg) was added to the 
respective tubes.  
Table 2.11 miScript II RT Kit reverse transcription master mix. 
Component Volume per reaction (µl) 
miScript HiSpec Buffer (5x) 4 
miScript Nucleics Mix (10x) 2 
miScript Reverse Transcriptase Mix 2 
RNase-free water Variable 
 
Alongside the samples, two negative controls were included to determine the 
presence of any contaminants. These were: 
1. A NTC containing all the reaction components except the template RNA, 
which was replaced with RNase-free water (12µl).  
2. A RTC containing all the reaction components except the reverse 
transcriptase enzyme, which was replaced with 2µl of RNase-free water. 
The tubes were mixed, centrifuged briefly and incubated for 60 minutes at 37°C 
followed by 5 minutes at 95°C to inactivate the miScript Reverse Transcriptase 
Mix. All incubation steps were performed using the Sensoquest lab cycler 
(Göttingen, Germany). The cDNA was stored at -20°C. Prior to running the 
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qPCRs, the cDNA samples were diluted to a total volume of 200µl with RNase-
free water.  
2.2.2.3 cDNA quality control prior to profiling mature miRNAs 
The miScript miRNA Quality Control (QC) PCR Array (Qiagen) was run to 
assess the quality of a random selection of eight cDNA samples obtained from 
all three participant groups prior to the analyses of the selected miRNAs by 
qPCR. 
QuantiTect SYBR Green PCR Master Mix, miScript Universal Primer, template 
cDNA and RNase-free water were thawed at room temperature and mixed. A 
PCR master mix was prepared as described in Table 2.12 for each of the eight 
cDNA samples. 
Table 2.12 qPCR master mix for miScript miRNA QC PCR Array. 
Component Volume (µl) 
QuantiTect SYBR Green PCR Master 
Mix (2x) 
175 
RNase-free water 135 
miScript Universal Primer (10x) 35 
Template cDNA 5 
 
The miScript miRNA QC PCR Array was carefully removed from storage at -
80°C and 25µl of master mix were dispensed into the respective wells. The 
plate was sealed and centrifuged for 1 minute at 1,000rpm at room temperature. 
The real-time cycler was programmed and run as described in Table 2.13. 
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Table 2.13 Cycling programme used to quantify miRNAs using the Applied 
Biosystems® StepOnePlus™ System. 
Step Time Temperature Number of cycles 
PCR initial 
activation step 
15 minutes 95°C 1 
3-step cycling: 
Denaturation 
Annealing 
Extension 
 
15 seconds 
30 seconds 
30 seconds 
 
94°C 
55°C 
70°C 
40 
 
 
Data collection 
2.2.2.4 miRNA quantification by qPCR 
Quantification of the selected miRNAs and two reference controls, the small 
nucleolar RNA (snoRNA) SNORD68 and the small nuclear RNA (snRNA) 
RNU6, were performed using the miScript SYBR® Green PCR Kit (Qiagen, UK) 
and the miScript Primer Assays (please see Table 2.14 and Table 2.15). 
Lyophilised miScript Primer Assays were reconstituted in 550µl TE Buffer, pH 
8.0 and kept at -20°C. 
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Table 2.14 Primer assays used for quantification of selected miRNAs for 
Intervention participants. 
miRNA 
miScript Primer 
Assay 
Mature miRNA sequence 
SNORD68 
control 
Hs_SNORD68_11  
RNU6 control Hs_RNU6-2_11  
miR-17 Hs_miR-17_2 5' CAAAGUGCUUACAGUGCAGGUAG 
miR-19a Hs_miR-19a_1 5' UGUGCAAAUCUAUGCAAAACUGA 
miR-19b Hs_miR-19b_2 5' UGUGCAAAUCCAUGCAAAACUGA 
miR-20a Hs_miR-20a_1 5' UAAAGUGCUUAUAGUGCAGGUAG 
miR-25 Hs_miR-25_1 5' CAUUGCACUUGUCUCGGUCUGA 
miR-93 Hs_miR-93_1 5' CAAAGUGCUGUUCGUGCAGGUAG 
miR-106b Hs_miR-106b_1 5' UAAAGUGCUGACAGUGCAGAU 
miR-424 Hs_miR-424_1 5' CAGCAGCAAUUCAUGUUUUGAA 
Table 2.15 Primer assays used for quantification of selected miRNAs in 
participants at differential risk of CRC. 
miRNA 
miScript Primer 
Assay 
Mature miRNA sequence 
miR-101 Hs_miR-101_3 5' UACAGUACUGUGAUAACUGAA 
miR-122a Hs_miR-122a_1 5' UGGAGUGUGACAAUGGUGUUUG 
miR-135b Hs_miR-135b_1 5' UAUGGCUUUUCAUUCCUAUGUGA 
miR-145 Hs_miR-145_1 5' GUCCAGUUUUCCCAGGAAUCCCU 
miR-335 Hs_miR-335_1 5' UCAAGAGCAAUAACGAAAAAUGU 
 
A qPCR master mix was prepared as defined in Table 2.16 and 18µl of master 
mix were dispensed into each well of a 96-well plate followed by 2µl of the 
respective cDNA to produce a 20µl total reaction volume. The plates were 
sealed, centrifuged at 1,000 rpm for 1 minute at room temperature and then 
placed in the real-time cycler to commence the cycling program as described in 
Table 2.13. 
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Table 2.16 Reaction components for miRNA expression analyses by 
qPCR. 
Component 
Volume per reaction 
(µl) 
QuantiTect SYBR Green PCR Master Mix (2x) 10 
RNase-free water 4 
miScript Universal Primer (10x) 2 
miScript Primer Assay (10x) 2 
2.2.2.5 miRNA expression data processing 
Prior to analysis of the qPCR data, the melt curves were checked for a single 
peak as multiple peaks can be indicators of lack of specificity or the formation of 
primer dimers (Figure 2.5). A constant threshold value was set for each miRNA 
separately for all of the samples as described in Table 2.17 (for the miRNAs 
selected for intervention analyses) and in Table 2.18 (for the miRNAs selected 
for analysis in participants at differential risk of CRC). This was calculated by 
taking the average of the set thresholds for each miRNA for every plate.  
Figure 2.5 qPCR melt curve analysis of miR-25. 
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Table 2.17 Set thresholds for analyses of miRNAs selected for 
quantification in intervention participants. 
miRNA  Set Threshold 
RNU6 1.72 
SNORD68 1.11 
miR-17 1.74 
miR-19a 1.23 
miR-19b 1.31 
miR-20a 1.50 
miR-25 1.83 
miR-93 1.81 
miR-106b 1.64 
miR-424 1.91 
Table 2.18 Set thresholds for analyses of miRNAs selected for 
quantification in participants at differential risk of CRC. 
miRNA  Set Threshold 
RNU6 1.72 
SNORD68 1.11 
miR-101 2.11 
miR-122a 1.40 
miR-135 1.19 
miR-145 2.05 
miR-335 1.26 
 
Two control RNAs, RNU6 and SNORD68, were quantified for each sample 
alongside the target miRNAs. The geometric means of RNU6 and SNORD68 
controls were calculated and used for the normalisation of the expression of 
each miRNA.  
The delta Ct (∆Ct) value was calculated for each miRNA for each sample by 
subtracting the geometric mean of the control RNAs from the mean Ct value of 
duplicates for the target miRNA: 
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∆Ct = Ct (target miRNA) – Ct (geometric mean of RNU6 and SNORD68)  
The relative copies for each miRNA were then calculated using the formula: 
Relative copies = 2-∆Ct 
The adjusted copies were calculated by multiplying the relative copies by a 
factor, in this case 1,000.  
Adjusted copies = relative copies x 1,000  
The standard deviation for the duplicates was calculated and any samples with 
a standard deviation >0.5 were repeated or excluded from statistical analysis.  
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2.2.3 Methylation analyses 
DNA methylation analyses were performed using the bisulphite modification 
protocol developed by Frommer and colleagues (Frommer et al., 1992). This 
method involves bisulphite modification, which is the conversion of 
unmethylated, but not methylated (5-methylcytosine), cytosine residues to uracil 
by deamination.  This provides a robust method which allows for the distinction 
between methylated and unmethylated DNA. Sequencing primers for a region 
of interest, commonly CpG islands known to contain several CpG sites, are 
designed and used to amplify the region of interest by PCR of the bisulphite-
modified (BM) DNA. 
Following amplification of the BM DNA, DNA methylation was quantified at 
specific CpG sites by pyrosequencing, a ‘sequencing by synthesis’ technique 
regarded as the gold standard (Migheli et al., 2013). Pyrosequencing involves 
the quantification of methylation at individual cytosine residues within a specific 
region of interest, expressed as percentage methylation. Methylation analyses 
were performed using commercially-available, optimised Qiagen assays, which 
include both the PCR primer and sequencing primer. Details about the 
sequences analysed and primers can be found in sections 3.5 and 5.4.3). 
Firstly, the denatured single-stranded PCR product sequence is hybridised by 
the sequencing primer and is elongated by DNA polymerase with the addition 
and incorporation of nucleotides. When a deoxynucleotide triphosphate (dNTP) 
is added, a molecule of pyrophosphate (PPi) is released (Figure 2.6 (A)). This 
pyrophosphate is then converted into adenosine triphosphate (ATP) by 
sulfurylase. Luciferin is oxidised by luciferase using the generated ATP (Figure 
2.6 (B)), and this produces a light signal that is detected by the pyrosequencer 
and expressed as a peak for the incorporated nucleotide on the Pyrogram® 
(Figure 2.6 (C)). If the nucleotide was not incorporated, it is degraded by 
apyrase and there is no subsequent generation of ATP or resultant peak. The 
heights of the resultant peaks for each dNTP on the Pyrogram are proportional 
to the number of nucleotides added.  
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Figure 2.6 Steps involved in the quantification of DNA methylation by 
pyrosequencing.  
 
Adapted with permission from Qiagen (Qiagen, 2014). 
2.2.3.1 DNA extraction 
DNA was extracted from half a rectal mucosal biopsy using a phenol-chloroform 
protocol. OCT-embedded samples were removed from storage at -80°C and 
excess OCT compound was removed. Whole biopsies were cut in half using a 
new, sterile scalpel blade for each sample and the remaining half not used was 
immediately placed back into its tube and returned to storage at -80°C.  
Samples were homogenised on a shaker set to 900rpm for 8 hours at 55°C in 
500μl of SET-sodium dodecyl sulphate solution (25ml Tris (50mM), 12.5Mm 
EDTA, 0.5% sodium dodecyl sulphate (SDS)) with the addition of 16μl of 
Proteinase K (Fermentas). The homogenised samples were centrifuged at 
13,000rpm for 3 minutes. DNA was precipitated using 600μl of 
chloroform:isoamyl alcohol 24:1 (Fermentas). Phase lock gel (5 Prime, 
Hamburg, Germany) was utilised to separate the DNA by centrifuging at 
10,000rpm for 5 minutes at room temperature. The upper phase was poured 
into a new tube and 16μl of RNase A/T1 (Fermentas) were added. After 
incubating at 37°C for 30 minutes, 42μl of sodium acetate solution (3M, pH 5.2) 
were added. The tubes were inverted several times and 400μl of isopropanol 
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and 2.5μl of glycogen (Fermentas) were added. The tubes were inverted 
several times and then centrifuged at 13,000rpm for 5 minutes at room 
temperature. The supernatant was discarded and the DNA pellet was washed 
twice by adding 500μl of 70% ethanol and centrifuging at 13,000rpm for 2 
minutes at room temperature, discarding the ethanol in-between washes. The 
DNA pellet was left to air dry for an hour, re-suspended in 50μl of 2mM Tris and 
left to dissolve overnight at 4°C on the shaker. 
The DNA purity and concentration were measured using the NanoDrop 1000 
spectrophotometer, similarly to that described for RNA in Section 2.2.1.1.1.  
DNA extraction from the Intervention, ‘UC’ and ‘Polyp’ biopsy samples was 
performed by Mr. Iain McCallum, Dr. Naomi Willis and Dr. Long Xie. 
2.2.3.2 Bisulphite modification of DNA 
Bisulphite modification of DNA was performed using the EZ DNA Methylation- 
Gold™ Kit (Zymo Research). A total of 250ng of DNA made up to a volume of 
20μl with water was prepared and 130μl of CT Conversion Reagent (900μl 
water, 300μl M-Dilution Buffer and 50μl M-Dissolving Buffer) were added. The 
samples were mixed by pipetting up and down, centrifuged and placed in the 
Sensoquest lab cycler programmed to perform the following steps for DNA 
denaturation followed by CT-conversion reaction: 
1. 98°C for 10 minutes 
2. 64°C for 2.5 hours 
3. Hold at 4°C for storage 
DNA samples were loaded into Zymo-Spin™ IC Columns containing 600μl of 
M-Binding Buffer placed in a collection tube. These were centrifuged at 
maximum speed and the flow-through discarded. Samples were washed by 
adding 100μl of M-Wash Buffer and centrifuging at maximum speed for 30 
seconds. The samples were then incubated at room temperature with 200μl of 
M-Desulphonation Buffer for 20 minutes. After the incubation, samples were 
centrifuged at maximum speed for 30 seconds. Two further wash steps were 
performed by adding 200μl of M-Wash Buffer, centrifuging at maximum speed 
for 30 seconds and repeating. The columns were placed into 1.5ml 
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microcentrifuge tubes, and to elute the BM DNA 10μl of M-Elution Buffer were 
added followed by a centrifugation step for 30 seconds at maximum speed. 
DNA bisulphite modification reactions of the Intervention samples were 
performed Dr. Naomi Willis and Dr. Long Xie as part of the DISC Study.  
2.2.3.3 Amplification of bisulphite-modified DNA 
A PCR master mix was prepared as described in Table 2.19 and 24μl were 
dispensed into 0.5ml tubes. BM DNA (1μl) was added to each tube, with each 
sample performed in duplicate, with the exception of the negative controls which 
included 1μl of Epitect human control DNA (Qiagen) or 1μl of water. All PCR 
reactions were performed on the S1000™ (Bio-Rad) PCR machine under the 
conditions described in Table 2.20. 
Table 2.19 Pyrosequencing PCR reaction components. 
Component Volume per reaction (µl) 
HotStarTaq Master Mix (2x) 12.5 
H2O 9.5 
PCR primer 2 
 
Table 2.20 Cycling conditions for pyrosequencing PCR. 
Step Time Temperature Number of cycles 
Initialization 15 minutes 95°C 1 
3-step cycling: 
Denaturation 
Annealing 
Extension 
 
20 seconds 
40 seconds 
20 seconds 
 
95°C 
55°C 
72°C 
40 
 
 
 
Final elongation 5 minutes 72°C 1 
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2.2.3.3.1 Agarose gel electrophoresis of PCR products for methylation 
analyses 
PCR products and negative controls were run on a 1% agarose gel stained with 
SafeView (NBS Biologicals Ltd, Cambridgeshire, UK) by loading 4μl of PCR 
products with 1μl of loading dye alongside 3μl of 100bp DNA ladder. Samples 
were electrophoresed at 120mV, 300mA for 35 minutes to check that the 
correct sequence was amplified and that there was no contamination in the 
negative controls (H2O and gDNA) (Figure 2.7).  
Figure 2.7 Agarose gel electrophoresis image of SFRP1 assay PCR 
product. 
 
Agarose gel electrophoresis was used to check the PCR products prior to analysis by 
pyrosequencing. There were no bands present in the negative controls (H2O and 
gDNA) indicating that there was no contamination. Bands of the correct product size 
(257bp) were observed for all sample and control PCR products. 
2.2.3.4 Pyrosequencing 
Pyrosequencing was performed using the Pyromark Q96 ID (Qiagen) 
Pyrosequencer and Pyromark Gold Q96 reagents (Qiagen). A master mix for 
the 96-well PCR plate was prepared as described in Table 2.21, and 70μl of 
master mix were added to each well followed by 5μl of PCR product. The PCR 
plate was sealed and shaken for 10 minutes at 15rpm to prevent sedimentation 
of the beads. 
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Table 2.21 Pyrosequencing master mix for PCR plate. 
Component 
Volume per reaction 
(µl) 
Binding Buffer (Qiagen) 38 
Nuclease-free water (Qiagen) 30 
Streptavidin Sepharose High Performance 
Beads (GE Healthcare, Uppsala, Sweden) 
2 
 
In a pyrosequencing plate (Qiagen), 9μl of annealing buffer (Qiagen) and 3μl of 
sequencing primer (Qiagen) were added to each well. The PyroMark Q96 
Vacuum Workstation (Qiagen) was used to aspirate the samples from the PCR 
plate using the vacuum. The vacuum probes were then washed in 70% ethanol 
for 5 seconds, denatured in denaturing buffer (0.8% NaOH solution) for 5 
seconds and washed in Pyromark wash buffer (Qiagen) for 5 seconds. The 
vacuum was switched off and the samples were transferred to the 
pyrosequencing plate and heated at 80°C for at least 2 minutes to bind the 
sequencing primer. The enzyme, substrate mixtures and nucleotides were 
dispensed into their respective reagent and nucleotide tips as determined by the 
PyroMark CpG Software 1.0.11. The cartridge and plate were inserted and, 
after successful tip dispensation testing, run on the pyrosequencer. 
All samples were run in duplicate using duplicates from two individual PCR 
amplification reactions. Participant sample order was randomised so that 
comparable numbers of each gender and endoscopy procedure, and 
intervention group as appropriate, were present on each pyrosequencing run 
plate. Pre- and post-intervention samples were run on the same 
pyrosequencing plate for the intervention samples. On each pyrosequencing 
plate, two negative controls to check for any contamination and 0% and 100% 
methylation controls were run alongside the samples. 
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2.2.3.5 Bisulphite modification quality control 
Quantification of methylation by pyrosequencing included an internal control 
that confirmed full bisulphite conversion i.e. that all templates show conversion 
to thymine where unmethylated cytosines are not followed by guanine. Any 
samples indicating an incomplete bisulphite conversion were flagged by the 
Pyromark software (highlighted in yellow) at the analysis stage and would be 
consequently excluded from subsequent analyses. I did not encounter this 
problem during my analyses.  
As, in a minority of cases, previously bisulphite-modified and stored DNA 
samples were utilised for quantification of methylation by pyrosequencing, 
methylation was quantified and compared in newly bisulphite-modified and 
previously bisulphite-modified samples. The results from this analysis showed 
there were no differences in the amplification of BM DNA by PCR and that 
methylation levels of SFRP1 at each CpG site were highly comparable between 
both newly- and previously- bisulphite-modified samples (see Table 2.22).  
Figure 2.8 Agarose gel electrophoresis image for comparison of SFRP1 
assay PCR products amplified from 091 pre-intervention newly bisulphite-
modified samples and previously bisulphite-modified samples. 
 
Agarose gel electrophoresis was used to check the PCR products prior to analysis by 
pyrosequencing. In this image, PCR products from newly bisulphite-modified (N) and 
previously bisulphite-modified (P) DNA from sample 091 pre-intervention are 
compared. Bands of the correct product size (257bp) were observed for both samples 
and were of comparable intensity. 
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Table 2.22 Comparison of 091 pre-intervention SFRP1 methylation levels 
using newly bisulphite-modified samples and previously bisulphite-
modified samples. 
 
SFRP1 methylation (%) 
Mean (SD) 
CpG site 091 pre N 091 pre P 
1 27.3 (3.2) 26.2 (0.6) 
2 21.6 (1.8) 21.5 (2.3) 
3 22.0 (2.9) 18.9 (0.6) 
4 29.2 (0.2) 24.8 (4.3) 
5 19.4 (1.3) 19.4 (1.4) 
6 26.1 (3.2) 24.5 (2.4) 
7 25.6 (2.4) 24.9 (1.7) 
Mean 24.4 (3.5) 22.9 (2.9) 
SFRP1 methylation levels (%) at each CpG site and the mean methylation across all 
seven CpG sites expressed as mean and standard deviation for newly bisulphite-
modified (N) and previously bisulphite-modified (P) samples for 091 pre-intervention.  
2.2.3.6 Methylation data processing 
The means of the duplicates of the pyrosequencing data, expressed as 
percentage methylation (%), were taken and used for statistical analyses. 
Duplicate data were checked for a difference of no greater than 5%. Samples 
with a discordance between duplicates of >5% were repeated, and 
subsequently excluded from analyses if a difference of ≤5% was not achieved.   
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2.2.4 Assessment of colonic crypt cell kinetics 
Colonic crypt cell kinetics, particularly the colonic crypt cell proliferative state 
(CCPS), were assessed by counting the number of mitotic figures following 
histochemical staining and whole crypt microdissection of rectal biopsies.  
Schiff reagent was utilised for staining using the DNA-specific Feulgen 
technique, or nucleal reaction, which was first described in 1914 by Robert 
Feulgen (Feulgen, 1914). The DNA is first hydrolysed in warm, weak 
hydrochloric acid (HCl), resulting in removal of the purine bases and formation 
of aldehyde groups on deoxyribose sugars (Ross and Pawlina, 2011).  Schiff 
reagent then reacts with the formed aldehyde residues via a condensation 
reaction to produce a magenta colour (Mescher, 2010), which is visible under a 
light microscope. 
The whole crypt microdissection method was first validated in 1991 by Goodlad 
et al. who compared mitoses counts and crypt cell mass data derived from the 
microdissection technique with an autoradiography-based technique in a study 
in dogs (Goodlad et al., 1991).  The authors concluded that the microdissection 
technique had resulted in comparable data but was significantly less time-
consuming.  
Whole crypt microdissection is now the preferred method for the assessment of 
GI cell proliferation in human studies compared with in vitro methods, such as 
immunohistochemical staining, which may not yield as reliable data and are 
more time-consuming and labour intensive (Wong and Wright, 1999). 
Compared with autoradiography techniques that label DNA synthesising cells, 
an advantage of using microdissected crypts is that, although the numbers of 
mitotic figures counted are significantly lower, data are produced for entire 
crypts (Wong and Wright, 1999).   
Mills et al. have established the reliability and reproducibility of mitosis counting 
using Schiff reagent-stained microdissected crypts taken from healthy 
participants and participants with adenoma, carcinoma or FAP for the 
assessment of human colonic crypt cell proliferation (Mills et al., 2001). They 
found that, within an individual, mitotic counts were consistent in three biopsies 
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from the same site (the rectum), suggesting that data counted in a single biopsy 
may be used to represent mitosis at that site. 
2.2.4.1 Tissue hydrolysis and staining 
Carnoy’s-fixed biopsies were removed from storage and halved using a sterile 
scalpel blade. Half a biopsy was transferred into new tubes containing 1ml of 
50% ethanol, and the remaining half was returned to storage. Samples were left 
to hydrate for 10 minutes at room temperature followed by another 10 minute 
hydration step in 25% ethanol. The biopsies were transferred into new tubes 
containing 1ml of 1M HCl for 10 minutes at 60°C in a water bath to be 
hydrolysed. The samples were then stained in Schiff reagent (Surgipath™) for 1 
hour at room temperature. The Schiff reagent was removed and replaced with 
1ml of 45% acetic acid. Stained samples were microdissected immediately. 
2.2.4.2 Whole crypt microdissection 
The stained crypts were microdissected using the Olympus SZ40 dissecting 
microscope and Leica CLS 150X light source. A clean microscope slide 
(Surgipath™, Leica Microsystems, UK) was placed on the base of the 
dissecting microscope and a drop of 45% acetic acid was added to the centre of 
the slide. The stained biopsy was placed in the acetic acid and arranged so that 
the bases of the crypts were facing upwards. Using 25G x 5/8” fine gauge 
hypodermic needles (Terumo®, Belgium) attached to 2ml syringes (Terumo®, 
Belgium), rows of crypts were carefully teased apart by separating the serosa 
and muscularis mucosa and spreading over the acetic acid. Any connective 
tissue or Peyer’s patches were removed. The crypts were covered with a cover 
slip (Surgipath® Premier Cover glass 22 x 22 #1.5 Leica, UK) and slight 
pressure was applied using the rubber-end of a pencil to spread out the crypts. 
Sufficient pressure was applied so that the crypts were in focus but not enough 
to burst the cells. Prepared samples were counted immediately to prevent the 
samples from drying out.  
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2.2.4.3 Crypt dimension measurement and mitosis counting 
A light microscope was used to examine the microdissected crypts under 40x 
magnification to allow visualisation of individual cells in single crypts. Ten intact 
crypts to be analysed were selected randomly. The length of the crypt was 
measured by placing the graticule (reticle eyepiece) at the middle of the base of 
the crypt in the middle plane of focus. The width of the crypt was measured by 
placing the graticule at the widest part of the crypt in the middle plane of focus 
and measuring from one edge to the opposite edge. Using the length 
measurement, the crypt was divided into ten equal compartments i.e. if the crypt 
length is 140 graticule marks, the compartments were 1-14, 15-28, 29-42, etc. 
Graticule marks were converted into micrometres (µm) by multiplying the 
number of graticule marks by 2.47 as calculated following calibration of the 
graticule with a stage micrometre. 
To analyse colonic crypt cell mitosis and apoptosis, the number of cells in 
mitosis or apoptosis in each compartment were counted by focusing up and 
down through the crypt, commencing with the first compartment at the base of 
the crypt. Cells in prophase, metaphase, anaphase or telophase were 
characterised as mitotic. The ten compartments were counted per crypt, and a 
total of ten crypts were analysed per tissue sample.  
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2.2.5 Quantification of BAX and BCL-2 expression as markers of 
apoptosis 
Although the assessment of colonic crypt cell kinetics following whole crypt 
microdissection allowed for the successful quantification of proliferating cells, it 
was uncommon to count an apoptotic cell within the crypts. Because of this, the 
expression of the pro-apoptotic gene Bcl-2 associated X protein (BAX) and the 
anti-apoptotic gene B-cell lymphoma 2 (BCL-2) were quantified by qPCR as 
markers of apoptosis within the crypts.  
The RNA utilised for this analysis was the total RNA extracted for the miRNA 
analyses as described in Section 2.2.2.1. cDNA was synthesised from 0.5µg of 
RNA by reverse transcription using the QuantiTect Reverse Transcription Kit as 
described in Section 2.2.1.2. cDNA was diluted 10x with RNase-free water to 
yield a total volume of 200µl. 
Quantification of BAX and BCL-2 alongside 18S and 2M was carried out 
utilising the QuantiFast SYBR® Green PCR Kit (Qiagen, UK) and the 
QuantiTect® Primer Assays (please see Table 2.23). 
Table 2.23 QuantiTect® primer assays for quantification BAX and BCL-2. 
Gene QuantiTect® Primer Assay  
18S Hs_RRN18S_1_SG 
2M Hs_B2M_1_SG 
BAX Hs_BAX_1_SG 
BCL-2 Hs_BCL2_1_SG 
 
A qPCR master mix was prepared as described in Table 2.24 and 12µl were 
dispensed into the appropriate wells of a 96-well PCR plate followed by 8µl 
(20ng) of the respective cDNA samples. The plate was sealed and centrifuged 
at 1,000rpm for 1 minute. 
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Table 2.24 Reaction components for BAX and BCL-2 gene expression 
analyses by qPCR. 
Component 
Volume per reaction 
(µl) 
QuantiFast SYBR Green PCR Master Mix (2x) 10 
QuantiTect Primer Assay (10x) 2 
 
Samples, alongside negative controls, were run in duplicate using the fast 
protocol on the Applied Biosystems® StepOnePlus™ System as described in 
Table 2.25. 
Table 2.25 Fast cycling programme used to quantify BAX and BCL-2 
mRNA using the Applied Biosystems® StepOnePlus™ System. 
Step Time Temperature 
Number of 
cycles 
PCR initial 
activation step 
5 minutes 95°C 1 
2-step cycling: 
Denaturation 
Annealing 
 
10 seconds 
30 seconds 
 
95°C 
60°C 
40 
 
Data collection 
 
qPCR data were processed as previously described in Section 2.2.1.3. 
Thresholds were calculated as described in Section 2.2.1.4 and are described 
in Table 2.26. 
Table 2.26 Set thresholds for analyses of BAX and BCL-2. 
Gene Set Threshold 
18S housekeeping gene 1.43 
β2M housekeeping gene 1.54 
BAX 1.35 
BCL-2 1.42 
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2.2.6 Statistical analyses 
Prior to statistical analyses, the data were checked for normal distribution using 
the Kolmogorov-Smirnov normality test and producing a normality plot. Data not 
normally distributed, where p<0.05, were transformed using an appropriate 
transformation (usually log10 or taking the square root). All statistical analyses 
were conducted on Minitab® 16.1.0 and graphs were produced using the 
SigmaPlot™ 12.5 software. 
2.2.6.1 Statistical analyses of intervention participants 
For normally distributed data, the analysis of variance (ANOVA) general linear 
model (GLM) was used to investigate post-intervention differences in the 
analysed outcomes (gene expression, miRNA expression, methylation and 
colonic crypt cell kinetics) between the intervention groups by using the pre-
intervention measurement as a covariate. The ANOVA GLM uses a least 
squares regression approach and analyses the relationship between factors, as 
well as covariates, and the response outcome. Other covariates included in the 
ANOVA GLM were age, gender, endoscopy procedure, BMI and smoking 
status. Where data were not normally distributed despite transformation, the 
Kruskal-Wallis one-way analysis of variance test was used. Kruskal-Wallis is the 
non-parametric equivalent of the ANOVA GLM. 
To investigate the effects of each dietary agent (RS or PD) individually and a 
potential interaction effect, the ANOVA GLM was used to examine the effects of 
“Treatment 1” and “Treatment 2” (referring to the RS and PS) on the analysed 
outcomes post-intervention, with the pre-intervention measurement, age, 
gender, endoscopy procedure, BMI and smoking status included as covariates. 
Where data were not normally distributed, the Kruskal-Wallis non-parametric 
test was used, inserting the analysed outcome as the response and “Treatment 
1” and “Treatment 2” as the factors (individually). In this case, pre-intervention 
differences in the outcome measurement (gene expression, methylation or 
proliferation) between the intervention groups were investigated to check that 
there were no differences at baseline that could have effects on the post-
intervention analysis outcomes. The Bonferroni method was applied to correct 
   
 103 
for multiple comparisons. An example of the analyses outcomes using the 
ANOVA GLM can be found in Appendix G. 
2.2.6.2 Statistical analyses of participants at differential risk of CRC 
To compare differences in the analysed outcomes between the ‘Normal’ and 
higher-risk (‘UC’ and ‘Polyp’) groups, the ANOVA GLM was used with age, 
gender, endoscopy procedure, BMI and smoking status including as covariates. 
Dunnett’s test was applied to correct for multiple comparisons and the 
Bonferroni method was used for pairwise comparisons. Where data were not 
normally distributed, the Kruskal-Wallis non-parametric test was used. 
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Chapter 3 Selection of WNT pathway-related genes and 
microRNAs for expression and methylation analyses  
3.1 Introduction to Chapter 3 
The aim of this chapter is to describe the processes behind the selection of the 
genes and miRNAs that were quantified and the methylation assays that were 
used for analyses in this Ph.D. The primary outcome measurement of this Ph.D. 
was the quantification of expression of WNT pathway-related genes as an 
indicator of WNT pathway activity. A total of 12 genes were selected by 
reviewing the literature to find genes that are altered in CRC and/or modified by 
butyrate and by conducting a pilot study to investigate differences in expression 
of WNT pathway-related genes in people at higher risk of CRC, with a prior 
history of adenomatous polyps. The selected 12 WNT pathway-related genes 
were quantified both in intervention participants (section 4.2) and in people at 
differential risk of CRC (‘Normal’, ‘UC’ and ‘Polyp’ participants) (section 5.2).  
A similar selection process was applied for the selection of miRNAs to be 
quantified in the intervention participants (section 3.4.1). miRNAs reported to be 
aberrantly expressed in CRC and modulated by butyrate were identified from 
the literature. In addition, as effects of RS and PD were observed on expression 
of SFRP1, miRNAs predicted to target this gene were included. The eight 
selected miRNAs were also quantified in people at differential risk of CRC with 
the addition of five miRNAs reported to be abnormally expressed in CRC and 
involved in the regulation of the WNT signalling pathway (section 3.4.2). 
Lastly, this chapter describes the selection of the assay used for the analysis of 
SFRP1 methylation in both intervention participants (section 4.4) and in people 
at differential risk of CRC (section 5.5) by pyrosequencing. 
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3.2 Pilot Study: WNT pathway-related gene expression in the 
macroscopically-normal colorectal epithelium of people at higher 
risk of CRC 
3.2.1 Introduction 
A pilot study was performed to investigate differences in expression of a panel 
of WNT pathway-related genes in the macroscopically-normal mucosa of 
people at normal and higher risk of developing CRC. Analysis of the ‘Normal’ 
participants used pre-intervention samples from the DISC Study intervention 
arm and the higher-risk group comprised participants with a prior history of 
adenomatous polyps.   
3.2.2 Hypotheses, Aims and Objectives 
3.2.2.1 Hypotheses 
The hypothesis for this pilot study was that participants at higher risk of CRC, 
i.e. those with a prior history of adenomatous polyps, would have differential 
expression of WNT pathway-related genes compared with ‘Normal’ participants. 
In particular, it was hypothesised that ‘Polyp’ participants would have increased 
expression of genes that indicate an increase in WNT activity, such as WNT 
ligands and target genes, and reduced expression of genes that would suggest 
a decrease in WNT activity, such as WNT inhibitors, compared with ‘Normal’ 
participants.  
3.2.2.2 Aims 
This pilot study aimed to test this hypothesis by quantifying expression of a 
panel of WNT-pathway related genes in the macroscopically-normal mucosa of 
people at differential CRC risk i.e. those at normal risk of developing CRC and 
those with a prior history of adenomatous polyps, at higher risk of developing 
CRC. The ultimate aim of this pilot study was to identify a subset of WNT genes 
which are differentially expressed in the macroscopically-normal mucosa of 
people at higher CRC risk that could be used as possible markers of increased 
CRC risk to test the effects of the dietary intervention supplementing healthy 
participants with RS and PD. 
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3.2.2.3 Objectives 
 To obtain colorectal biopsies from the macroscopically-normal mucosa of 
two groups of DISC Study participants at differential risk of CRC i.e. 
‘Normal’ participants and ‘Polyp’ participants; 
 To identify matched pairs of ‘Normal’ and ‘Polyp’ participants in the DISC 
Study; 
 To optimise isolation of RNA from OCT-embedded rectal mucosal 
biopsies; 
 To extract an adequate amount of high-quality RNA from OCT-
embedded rectal mucosal biopsies; 
 To synthesise cDNA by reverse transcription; 
 To quantify expression of a panel of 70 WNT pathway-related genes by 
qPCR; 
 To compare gene expression in the ‘Normal’ and ‘Polyp’ participants. 
3.2.3 Methods 
3.2.3.1 Selected participants 
Eleven ‘Normal’ and nine ‘Polyp’ participants were selected. ‘Normal’ 
participants were selected from the dietary intervention arm of the DISC Study 
and baseline (pre-intervention) samples were used for analyses. The ‘Normal’ 
and ‘Polyp’ participants were age and gender-matched where possible. There 
were similar numbers of male and female participants in each risk group, with 
the exception of the ‘Polyp’ group which consisted of five males and four 
females. Additionally, it was ensured that mean ages for the normal and higher-
risk participants were comparable within a gender. The selected participants 
were all non-smokers to avoid smoking habit as a potential confounder. The 
BMI was also determined for each participant and the mean BMIs for each 
gender were compared between risk groups.  
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3.2.3.2 Total RNA extraction from OCT-embedded rectal mucosal biopsies  
Total RNA was extracted using Qiagen’s RNeasy Mini Kit (Qiagen, UK) 
following the manufacturer’s instructions. This was performed as described in 
the methods section 2.2.1.1, with the exception of tissue disruption, which was 
achieved by grinding the tissue in lysis buffer (600µL Buffer RLT) using a sterile 
plastic pestle (Starlab). Tissue disruption was further optimised after completion 
of this pilot study to that described in the methods chapter.  
3.2.3.2.1 RNA Quantification 
The total RNA yield and purity (A260/280 ratio) were quantified using the 
NanoDrop 1000 spectrophotometer (Thermo Scientific) and the NanoDrop 1000 
software version 3.7.1.  
The quality and integrity of the RNA were assessed by agarose gel 
electrophoresis. A 1% agarose gel was prepared using agarose powder 
(Fermentas) and 1x Tris-borate-ethylenediaminetetraacetic acid (EDTA) (TBE) 
buffer and heated until the agarose had dissolved. The gel was stained with 2µL 
ethidium bromide (Invitrogen™) and the cooled mixture was poured into the 
electrophoresis tray and left to set for 30 minutes. A 3µl volume of 6x loading 
dye (Fermentas) was added to a 4µL aliquot of each RNA sample and made up 
to 12µl with nuclease-free water. The samples and a DNA molecular weight 
marker ladder (Fermentas) were loaded onto the gel and run at 120V for 
approximately 30 minutes. RNA was visualised under UV light using the Uvitec 
Gel Doc and the UVIPhotoMW Software version 11.01.   
3.2.3.3 cDNA synthesis 
cDNA was synthesised from 1µg of template RNA by reverse transcription using 
the QuantiTect Reverse Transcription Kit (Qiagen, UK) as described in the 
methods section 2.2.1.2.  
3.2.3.4 Quantification of WNT pathway-related gene expression 
The expression of 70 WNT pathway-related genes (see Table 3.1) were 
quantified by qPCR using primers developed by Dr. Nigel Belshaw and Dr. 
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Wing Leung at the Institute of Food research (IFR), Norwich. Expression levels 
(described as highly, moderately or weakly expressed in Table 3.1) had been 
previously determined at the IFR following quantification by qPCR. In addition, 
expression of two housekeeping genes, 18S rRNA (18S) and beta-2-
microglobulin (β2M), was quantified. Samples were analysed on a gene by gene 
basis by running all of the samples in duplicate on a 96-well plate. In addition, 
each plate contained a no template control (NTC) and a reverse transcriptase 
negative control (RTC) to detect any possible contamination.  
The 20µl of cDNA was first diluted to a total volume of 500µl using elution 
buffer. A PCR master mix was prepared in excess as described in the methods 
section 2.2.1.3.1, and kept on ice. A volume of 3µl of cDNA was added to 7µl of 
PCR master mix to yield a total reaction volume of 10µl. A 10 minute start step 
was performed at 95°C followed by 40 cycles of denaturing at 95°C for 30 
seconds, annealing at 60°C for 30 seconds and extending at 72°C for 30 
seconds using the ABI 7300 real-time PCR machine (Applied Biosystems). For 
quantification of weakly expressed genes (see Table 3.1), the number of cycles 
was increased to 50 cycles. Data were expressed as deltaCT (ΔCt) relative to 
the geometric mean of 18S and β2M and the adjusted copies were calculated 
using the formula adjusted copies = 2-ΔCt x 1,000. 
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Table 3.1 Pilot study WNT pathway-related genes analysed by qPCR. 
Highly expressed Moderately expressed Weakly expressed 
AES 
CCND1 
CCND2 
CCND3 
CSNK1A1 
CSNK1D 
CSNK2A1 
CTBP1 
CTBP2 
CTNNB1 
DAAM1 
DVL1 
EP300 
FBXW2 
FBXW4 
FBXW11 
FRZB 
FZD5 
GSK3A 
GSK3B 
c-JUN 
KREMEN 
LRP5 
LRP6 
MYC 
NLK 
PPP2R1A 
RHOU 
SENP2 
SLC9A3R1 
TLE1 
TLE2 
AXIN1 
BCL9 
CTNNB1P1 
DIXDC1 
FOSL1 
FRAT1 
FZD1 
FZD2 
FZD6 
FZD7 
FZD8 
PORCN 
PPP2CA 
SFRP1 
TCF7 
WNT2B 
WNT3 
WNT5B 
WNT6 
WNT11 
 
APC 
CSNK1G1 
DKK1 
FOXN1 
FZD4 
LEF1 
LGR5 
NKD1 
PITX2 
PYGO1 
SFRP4 
SOX17 
TCF7L1 
WIF1 
WISP1 
WNT1 
WNT2 
WNT5A 
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3.2.3.5 Statistical analyses 
Statistical analyses were performed using the Minitab 16 Statistical Software. 
Prior to analyses, the distribution of each dataset was examined and, where 
necessary, data were transformed to achieve normally-distributed data. The 
ANOVA GLM was used to examine differences in gene expression between the 
two risk groups on a gene-by-gene basis. All analyses were adjusted for the 
effect of age and gender as covariates and the Bonferroni method was used to 
correct for multiple testing. A p value of <0.05 was considered statistically 
significant.  
3.2.4 Results 
3.2.4.1 Participant characteristics 
A total of 20 volunteers (11 ‘Normal’ and 9 ‘Polyp’ participants) were used in this 
pilot study. Participants were age- and gender-matched, where possible, and 
mean ages for ‘Normal’ and ‘Polyp’ participants were comparable within a 
gender (Table 3.2). All participants were Caucasian and non-smokers to avoid 
these as possible confounders.  
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Table 3.2 Characteristics of selected ‘Normal’ and ‘Polyp’ participants for 
the pilot study. 
Characteristics ‘Normal’ group ‘Polyp’ group 
Number of participants 11 9 
Age (mean years)  
Range (years) 
62.6 
47 – 78 
61.6 
48 – 79 
Gender  
Male (%) 
Female (%) 
 
5 (46%) 
6 (54%) 
 
5 (56%) 
4 (44%) 
BMI (kg/m2) (mean) 
Range (kg/m2) 
30.5 
22.9 – 41.7 
28.4 
20.6 – 40.3  
3.2.4.2 Total RNA quantity and quality 
Total RNA was isolated from OCT-embedded rectal mucosal biopsies using the 
RNeasy Kit (Qiagen) as described in Section 3.2.3.2. The RNA quantity and 
quality were analysed to determine the RNA yield and purity (indicated by the 
absorbance at 260/280 ratio).  
The average concentration of the extracted RNA was 98ng/µl (109ng/µl and 
86ng/µl for the ‘Normal’ and ‘Polyp’ samples respectively) (Figure 3.1 (A)). 
However, this yield ranged from 55ng/µl to 182ng/µl due to the large inter-
participant variability in biopsy size and quality. The average 260/280 ratio was 
2.08 (2.09 and 2.07 for ‘Normal’ and ‘Polyp’ samples respectively) (Figure 3.1 
(B)), indicating good purity of the RNA.  
   
 112 
Figure 3.1 RNA concentrations and absorbance at 260/280 ratios for 
‘Normal’ and ‘Polyp’ participants in the pilot study. 
 
Data are presented as means and error bars represent SEM. N=20 
3.2.4.3 WNT pathway-related gene expression in people at higher risk of 
CRC 
Expression of a total of 70 WNT pathway-related genes was quantified in this 
pilot study. Significant differences in expression of three WNT pathway-related 
genes were observed, with lower expression of CSNK1D, CTBP1 and CTNNB1 
in ‘Polyp’ participants compared with ‘Normal’ participants (Figure 3.2).  
Expression of CSNK1D was almost two-fold lower in ‘Polyp’ compared with 
‘Normal’ participants (Figure 3.2 (A)). Similarly, CTPB1 expression was greater 
than two-fold lower in the ‘Polyp’ group (Figure 3.2 (B)). Expression of β-
catenin, encoded by CTNNB1, was reduced by one-and-a-half times in 
participants with a prior history of polyps compared with ‘Normal’ participants 
(Figure 3.2 (C)).  
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Figure 3.2 Expression of (A) CSNK1D (B) CTPB1 and (C) CTNNB1 in the 
macroscopically-normal rectal mucosa of ‘Normal’ and ‘Polyp’ 
participants in the pilot study. 
 
Data are expressed as adjusted copies (2-ΔCt x 1,000 relative to the geometric mean of 
18S and β2M) and presented as least squares means (LSMs). Error bars represent 
SEMs. N= 20. 
The gene expression data were also expressed as fold difference (‘Polyp’ 
compared with ‘Normal’ participants) and the 15 genes showing the largest 
positive difference (Table 3.3) and 15 genes showing the largest negative 
difference (Table 3.4) were determined, however the majority of these 
differences were not statistically significant.  
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Table 3.3 WNT pathway-related genes showing the 15 largest positive fold 
differences when comparing ‘Polyp’ with ‘Normal’ participants in the pilot 
study. 
Gene Fold difference P value 
TCF7 1.68 0.254 
SFRP4 1.54 0.408 
NKD1 1.37 0.337 
c-JUN 1.36 0.295 
AES 1.21 0.444 
WNT5A 1.20 0.530 
WNT3 1.16 0.751 
PORCN 1.15 0.507 
SOX17 1.14 0.701 
SLC9AR1 1.14 0.555 
KREMEN 1.13 0.703 
TCF7L1 1.11 0.630 
WNT11 1.10 0.689 
CCND2 1.08 0.803 
FBXW4 1.07 0.769 
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Table 3.4 WNT pathway-related genes showing the 15 largest negative fold 
differences when comparing ‘Polyp’ with ‘Normal’ participants in the pilot 
study. 
Gene Fold change P value 
FOXN1 -18.03 0.056 
WNT6 -3.18 0.625 
WNT2 -2.86 0.166 
TLE1 -2.30 0.057 
CTBP1 -2.21 0.003 
WISP1 -2.02 0.060 
CSNK1D -1.91 0.039 
LGR5 -1.76 0.385 
GSK3A -1.61 0.095 
RHOU -1.56 0.258 
CTNNB1 -1.53 0.026 
CCND3 -1.51 0.166 
AXIN1 -1.49 0.129 
FOSL1 -1.47 0.549 
CSNK1A1 -1.46 0.180 
Statistically significant p-values are shown in bold.  
3.2.5 Discussion 
This pilot study aimed to quantify expression of a panel of 70 WNT pathway-
related genes in the macroscopically-normal mucosa of people at normal and at 
higher risk (with a prior history of adenomatous polyps) of CRC. The results 
from this study demonstrated that expression of CSNK1D, CTBP1 and CTNNB1 
was significantly reduced in ‘Polyp’ compared with ‘Normal’ participants. 
CSNK1D encodes casein kinase 1 delta (CK1δ), a member of the casein kinase 
1 family (McKay et al., 2001). CK1δ is a positive regulator of the canonical WNT 
signalling pathway (Peters et al., 1999), therefore a reduction in CSNK1D 
expression in ‘Polyp’ participants suggests a decrease in WNT activity. To my 
knowledge, altered CSNK1D expression has not been reported previously in 
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CRC. A germline missense mutation in CSNK1D, CSNK1D(R324H), was 
discovered in a patient with multiple adenomatous polyps and with a high 
familial incidence rate of CRC (Tsai et al., 2007). This individual developed 
larger and a greater number of polyps at a much earlier age than both his 
affected siblings, suggesting that the mutation may affect polyp formation and 
therefore the risk of developing CRC. The mutant form was more active and 
promoted colony formation in a colon cancer cell line, however these effects 
were found to be independent of WNT signalling as WNT pathway activity did 
not increase when stimulated by the mutant compared with the wildtype 
CSNK1D.  
CTBP1 encodes C-terminal binding protein 1, a nuclear protein that activates 
WNT signalling via a positive feedback loop following stimulation of the WNT 
pathway by WNT ligands. However, in the absence of WNT pathway activation 
by WNT ligands, CTBP1 acts as a repressor. Phelps et al. have suggested that 
CTBP1 plays a role in tumour initiation following the loss of APC and observed 
upregulation of CTBP1 at the protein level in both adenoma samples from FAP 
patients and adenocarcinoma samples (Phelps et al., 2009). CTBP1 has 
previously been found to be overexpressed in tissue samples taken from all four 
different stages of CRC compared with normal tissue (Gujral and MacBeath, 
2010). In addition, greater expression of CTBP1 was noted in colon cancer cells 
with activated WNT signalling compared with normal cells and that CTBP1 
expression levels correlated positively with cell proliferation and migration. 
These findings were confirmed at the protein level, where increased CTBP1 
expression was observed in tumour compared with normal tissue. Based on 
these findings, the authors concluded that CTBP1 may be a potential marker of 
CRC progression with CTBP1 upregulation following WNT pathway activation 
occurring at all four stages of CRC. The findings from both studies suggest a 
role for CTBP1 at the stage of adenoma formation, progression and early 
events in colorectal carcinogenesis.  
A reduction in expression of CTNNB1, encoding β-catenin, a key component of 
canonical WNT signalling that induces the transcription of WNT target genes 
following activation of this pathway, in people with a prior history of 
adenomatous polyps, at higher risk of developing CRC, suggests that WNT 
signalling pathway activity is reduced in these participants. This observation is 
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contrary to previous studies that have reported increased β-catenin expression, 
predominantly at the protein level, in tissue from adenomatous polyps 
compared with normal tissue. Iwamoto et al. quantified β-catenin protein levels 
in the normal mucosa, hyperplastic polyps, adenomas and carcinomas and 
observed an increase in β-catenin, particularly within the nucleus, in 
adenomatous polyps and carcinomas compared with normal tissue and 
hyperplastic polyps (Iwamoto et al., 2000). In a case control study, Ahearn et al. 
also observed 3% greater β-catenin protein levels in sporadic colorectal 
adenoma cases compared with controls, however this was not statistically 
significant. In a recent study, β-catenin expression, again at the protein level, 
was assessed specifically in hyperplastic polyps, sessile serrated adenomas, 
traditional serrated adenomas, CRCs and in the normal colon (Fang et al., 
2014). A correlation between the abnormal expression of β-catenin and 
increasing severity of the colorectal lesion was observed, with all 14 CRCs 
analysed showing abnormal β-catenin expression. As the present study used 
macroscopically-normal tissue from patients with a prior history of polyps, this 
could explain the differences in the findings from my study compared with the 
literature, which used samples from the polyp tissues themselves.  
In conclusion, expression of three genes (CSNK1D, CTBP1 and CTNNB1) 
differed significantly between normal and higher-risk participants. In all cases, 
participants with a prior history of polyps had reduced expression of these 
genes. A total of 30 WNT pathway-related genes (15 with the largest positive 
fold-difference and 15 with the largest negative fold-difference) were taken 
forward to be used for the selection of genes to be quantified in the intervention 
participants and in the larger study of participants at differential risk of CRC, as 
described in section 3.3. These included the three genes, CSNK1D, CTBP1 and 
CTNNB1 that differed significantly between the two participant groups.  
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3.3 Selection of WNT pathway-related genes for expression analyses in 
intervention and higher-risk participants 
One of the aims of this Ph.D. study was to investigate changes in WNT 
pathway-related gene expression following supplementation with NDCs (RS 
and PD) and to compare expression in people at differential risk of CRC 
(‘Normal’, ‘UC’ and ‘Polyp’ participants). Therefore, the following criteria were 
applied in the process of WNT pathway-related gene selection: 
a) Genes whose expression is altered in patients with CRC 
b) Genes whose expression is modified by butyrate treatment (butyrate is 
an anti-neoplastic SCFA produced when NDCs are fermented in the 
large bowel) 
c) Genes that showed a significant difference and/or the largest fold 
difference in expression when comparing normal-risk participants with 
those at higher risk of CRC (‘Polyp’ participants in the pilot study) 
(Section 3.2) 
A total of 12 WNT pathway-related genes were selected for quantification by 
qPCR. The WNT gene selection process is illustrated in a Venn diagram in 
Figure 3.3. Firstly, the literature was reviewed to investigate WNT genes that 
were a) implicated in colorectal carcinogenesis (selection criterion 1) and b) 
whose expression is modified by butyrate (selection criterion 2). The literature 
search was conducted on PubMed and the date on which the last search was 
performed was March 2013. The keywords used in this literature search are 
detailed in Table 3.5. 
Table 3.5 Keywords used for the literature search on PubMed for WNT 
pathway-related gene selection. 
Search Keywords 
Expression change in CRC 
‘WNT’,‘WNT signalling’, ‘WNT pathway’, ‘colon’, 
‘large bowel’, ‘colon cancer’, ‘colorectal cancer’, 
‘rectal cancer’ 
Effect of butyrate 
‘WNT’,‘WNT signalling’, ‘WNT pathway’, 
‘butyrate’, ‘short-chain fatty acids’, ‘SCFA’, 
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A pilot study was also conducted to investigate c) WNT genes with altered 
expression in participants with a prior history of adenomatous polyps and, 
therefore, at higher risk of CRC (section 3.2). The genes showing the largest 
differences in expression (15 with the largest positive fold-difference and 15 
with the largest negative fold-difference) between normal and higher-risk 
participants were included in the selection criterion 3 set. 
The WNT pathway-related genes that belonged in the intersection of all three 
selection criteria were prioritised for gene expression analyses, followed by 
those whose expression is altered in CRC and modified by butyrate (Table 3.6). 
This yielded a total of eleven genes that were (i) reported to be altered in CRC 
and in response to butyrate and showed the largest differences in expression 
between normal and higher-risk participants in the polyp study or that were (ii) 
altered in CRC and modulated by butyrate. In addition, APC (found in the ‘WNT 
genes altered in CRC’ set) was selected due to its key role in the WNT 
signalling pathway and in CRC.  
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Figure 3.3 Venn diagram illustrating the criteria for the selection of WNT 
pathway-related genes to be quantified in intervention participants and in 
participants at differential risk of CRC. 
 
The three Venn diagram sets show the selection criteria used for the selection of WNT 
pathway-related genes to be quantified by qPCR: (i) altered expression in CRC (results 
from the literature search), (ii) modified by butyrate (results from the literature search) 
and (iii) differentially expressed in the macroscopically-normal mucosa of people at 
higher risk of CRC with a prior history of adenomatous polyps (results from the pilot 
study). The 12 selected genes are shown in red boxes and either belonged in all three 
sets or were reported to be altered in CRC and modified by butyrate. In addition, APC 
was also selected due to its role in both sporadic and inherited forms of CRC.  
   
   
  
Table 3.6 Evidence from the literature on changes in expression of WNT pathway-related genes in CRC and in response to 
butyrate treatment. 
Gene 
Selection 
criterion 1: 
Expression 
change in CRC 
References 
Selection 
criterion 2: 
Effect of butyrate 
on expression 
References 
AXIN2 Increased 
(Wu et al., 2012b), (Metcalfe et 
al., 2010), (Lustig et al., 2002) 
Increased (Daly et al., 2005) 
CCND1 Increased (Nakashima et al., 2002) Decreased 
(Daroqui and Augenlicht, 2010), (Maier et al., 
2009), (Germann et al., 2003), (Lallemand et 
al., 1996) 
CTNNB1 Increased (Wang et al., 2011a) Decreased (Kucerova et al., 1999) 
FOSL1 Increased 
(Zhang et al., 2005), (Tice et al., 
2002) 
Decreased (Germann et al., 2003) 
GSK3β Increased (Wang et al., 2011a) Decreased (Vincan et al., 2000) 
c-JUN Increased 
(Wang et al., 2000), (Zhang et al., 
2005) 
Increased 
Increased 
(Tsai et al., 2000), (Velazquez et al., 1996) 
 
1
2
1
 
   
  
Gene 
Selection 
criterion 1: 
Expression 
change in CRC 
References 
Selection 
criterion 2: 
Effect of butyrate 
on expression 
References 
c-MYC Increased 
(Sikora et al., 1987), (Smith et al., 
1993) 
Decreased 
(Daroqui and Augenlicht, 2010), (Tsai et al., 
2000), (Souleimani and Asselin, 1993) 
SFRP1 Decreased 
(Caldwell et al., 2006), (Qi et al., 
2006), (Caldwell et al., 2004) 
Increased (Shin et al., 2012) 
SFRP2 Decreased (Qi et al., 2006) Increased (Shin et al., 2012) 
WNT5A Decreased 
(Cao et al., 2012), (Li and Chen, 
2012), (Ying et al., 2008) 
Increased (Li and Chen, 2012), (Bordonaro et al., 2011) 
WNT11 Increased (Nishioka et al., 2013) Increased (Bordonaro et al., 2011) 
 
1
2
2
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3.4 Selection of microRNAs for expression analyses in intervention and 
in higher-risk participants 
Another aim of this Ph.D. study was to investigate changes in expression of 
miRNAs, to test the hypothesis that gene expression is regulated by epigenetic 
mechanisms, such as expression of miRNAs, following supplementation with 
NDCs (RS and PD) and to compare miRNA expression in people at differential 
risk of CRC (‘Normal’, ‘UC’ and ‘Polyp’ participants).  
Therefore, eight miRNAs that fit the following selection criteria were selected for 
quantification in intervention participants: 
 miRNAs whose expression is altered in patients with CRC 
 miRNAs whose expression is modified by butyrate treatment  
 miRNAs that are predicted to target SFRP1, that was differentially 
expressed following supplementation with RS and PD  
In addition, five miRNAs whose expression is altered in patients with CRC and 
that are implicated in the regulation of the WNT signalling pathway were 
selected to be quantified in people at differential risk of CRC (‘Normal’, ‘UC’ and 
‘Polyp’ participants). The eight miRNAs selected as part of the intervention 
study were also quantified in these participants. 
3.4.1 Selection of microRNAs for quantification in intervention 
participants 
In preparation for investigation of the effects of supplementation with NDCs (RS 
and PD) on miRNA expression in biopsies from the intervention study 
participants, a rigorous miRNA selection process was applied and is outlined in 
Figure 3.4. This involved a literature search conducted on PubMed. The last 
search was performed in December 2013. 
The first step of the miRNA selection process was to review the literature for 
miRNAs whose expression was reported to be altered by butyrate treatment 
either in healthy or cancerous colorectal tissue or cells. The keywords used in 
this literature search were: ‘microRNA’, ‘microRNAs’, ‘miRNA’, ‘miRNAs’, 
‘butyrate’, ‘short-chain fatty acids’ and ‘SCFAs’. This first investigation yielded a 
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total of 45 miRNAs previously reported to be altered by butyrate treatment 
(please refer to Appendix H). 
The next step was to investigate whether members of this subset of miRNAs 
were reported to be abnormally expressed in colon, rectal or colorectal cancer. 
The keywords used in this literature search were: ‘microRNA’, ‘microRNAs’, 
‘miRNA’, ‘miRNAs’, ‘colon’, ‘large bowel’, ‘colorectal cancer’, ‘colon cancer’ and 
‘rectal cancer’. In addition each of the 45 miRNAs were searched for individually 
with the addition of the keywords ‘colon’, ‘large bowel’, ‘colorectal cancer’, 
‘colon cancer’ and ‘rectal cancer’. Of the 45 miRNAs altered by butyrate 
treatment, 31 have been previously observed to be abnormally expressed in 
CRCs (please refer to Appendix H). 
SFRP1 was selected as a potentially important target gene because it showed 
statistically significant differences in expression between intervention groups 
post-intervention (section 4.2.4.2). In the next stage of the miRNA selection 
process, I reviewed the literature to identify those miRNAs that may regulate 
SFRP1 expression. The keywords used in this literature search were: 
‘microRNA’, ‘microRNAs’, ‘miRNA’, ‘miRNAs’, ‘secreted Frizzled-related protein’ 
and ‘SFPR1’. 
Fu and colleagues observed an inverse correlation between 26 CRC-specific 
miRNAs and SFRP1 following analysis by microarray (Fu et al., 2012). Of these 
26 miRNAs, the authors found that only one (miR-27a) was predicted to target 
SFRP1 by two miRNA databases (TargetSCAN Human and miRanda). 
However, despite not being predicted to target SFRP1 by both the TargetSCAN 
Human and miRanda miRNA databases, the inverse correlations between both 
miR-21 and miR-29a and SFRP1 observed during microarray analyses were 
confirmed by qPCR. Of the 31 miRNAs abnormally expressed in CRC and 
altered by butyrate treatment, 11 were reported to show a significant inverse 
correlation with SFRP1 and therefore have been predicted to target SFRP1 (Fu 
et al., 2012).  
The remaining 11 miRNAs were examined and those for which expression was 
reported to be affected by butyrate treatment on both papers by Hu et al. and 
Humphreys et al. were shortlisted (Hu et al., 2011; Humphreys et al., 2013). 
These were miR-17, miR-19a, miR-19b and miR-20a.  
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A further four miRNAs for which altered expression following butyrate treatment 
was confirmed by qPCR analysis (miR-25, miR-93, miR-106b and miR-424) in 
the study by Hu et al. (2011) were also selected, yielding a total of eight 
miRNAs for quantification by qPCR (Table 3.7). 
Figure 3.4 Selection process used to identify eight miRNAs that are 
differentially expressed in CRC, responsive to butyrate treatment and 
predicted (or known) to target SFRP1 for analysis in participants in the 
intervention study. 
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Table 3.7 Eight selected miRNAs for analysis by qPCR in intervention 
participants - relationship with SFRP1 and effects of butyrate treatment. 
Study Hu et al. (2011) 
Humphreys 
et al. (2013) 
Fu et al. (2012) 
miRNA 
Effect of 
butyrate 
(microarray 
data) 
(fold 
change) 
Effect of 
butyrate 
(qPCR 
data) 
(fold 
change) 
Effect of 
butyrate 
(microarray 
analysis, 
confirmed 
by qPCR) 
CRC vs. 
normal 
tissue 
(fold 
change) 
Correlation 
with SFRP1 
(Pearson’s 
R) 
miR-17 -1.25 -1.50 ↓ +2.59 -0.781 
miR-19a -1.25 X ↓ +2.66 -0.579 
miR-19b -1.20 -1.50 ↓ +2.57 -0.675 
miR-20a -1.25 -2.00 ↓ +2.58 -0.785 
miR-25 -1.20 -1.90  +1.59 -0.776 
miR-93 -1.20 -1.70  +1.76 -0.827 
miR-106b -1.20 -2.00  +2.16 -0.703 
miR-424 +1.50 +1.50  +4.60 -0.758 
3.4.2 Selection of microRNAs for analysis in people at differential risk of 
colorectal cancer 
In addition to the eight miRNAs selected for analysis in the intervention 
participants, that were also quantified in participants at differential risk of CRC 
(‘Normal’, ‘UC’ and ‘Polyp’), five miRNAs were selected to be analysed 
specifically in ‘Normal’, ‘UC’ and ‘Polyp’ participants. 
As this Ph.D. investigated differences in the WNT signalling pathway in 
participants at differential risk of CRC, the following criteria were applied for the 
selection of miRNAs to be analysed in ‘Normal’, ‘UC’ and ‘Polyp’ participants: 
a) miRNAs whose expression is altered in CRC 
b) miRNAs involved in the regulation of the WNT signalling pathway 
A similar literature search-based process was used as in the selection of 
miRNAs for quantification in the intervention participants. The literature search 
   
 127 
was performed on PubMed and the last search was performed in December 
2013. The keywords used in this literature search are described in Table 3.8. 
Table 3.8 Keywords used for the literature search on PubMed for the 
selection of miRNAs to be quantified in people at differential risk of CRC. 
Search Keywords 
Expression change in CRC 
‘microRNA’, ‘microRNAs’, ‘miRNA’, 
‘miRNAs’, ‘colon’, ‘large bowel’, ‘colon 
cancer’, ‘colorectal cancer’, ‘rectal cancer’ 
Regulation of the WNT signalling 
pathway 
‘microRNA’, ‘microRNAs’, ‘miRNA’, 
‘miRNAs’, ‘WNT’, ‘WNT signalling’, ‘WNT 
pathway’ 
 
A total of five miRNAs were selected for quantification by qPCR that fulfilled the 
two criteria above (see Table 3.9). These were miR-101, miR-122a, miR-135b, 
miR-145 and miR-335. 
   
  
Table 3.9 Evidence from the literature identifying five miRNAs whose expression is altered in CRC and involved in the 
regulation of the WNT signalling pathway. 
miRNA 
Implicated in 
CRC 
References 
Involvement in the regulation of the WNT 
signalling pathway 
References 
miR-101 Downregulated (Schee et al., 2012) 
- WNT activation induces miR-101 repression 
- miR-101 re-expression impairs β-catenin 
nuclear translocation and subsequent 
transcription 
(Strillacci et al., 2013) 
miR-122a Downregulated (Wang et al., 2009b) 
Aberrant WNT activation mediates miR-122a 
downregulation 
(Wang et al., 2009b) 
miR-135b Upregulated 
(Wang et al., 2010) 
(Bandres et al., 2006) 
Suppresses APC expression and induces WNT 
activity 
(Nagel et al., 2008) 
miR-145 Downregulated 
(Schee et al., 2012) 
(Wang et al., 2009a) 
(Bandres et al., 2006) 
(Michael et al., 2003) 
Impairs β-catenin nuclear translocation and 
subsequent transcription 
(Yamada et al., 2013b) 
miR-335 Upregulated (Wang et al., 2010) 
Activates WNT signalling and downregulates 
DDK1 
(Yan et al., 2012) 
(Zhang et al., 2011) 
1
2
8
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3.5 Pyrosequencing bioinformatic analysis and SFRP1 assay selection 
Since expression of SFRP1 differed between the intervention groups (section 
4.2.4.2), it was hypothesised that this may have been due to epigenetic factors 
such as DNA methylation. Therefore, the methylation status of key regulatory 
domains within the promoter region of the SFRP1 gene was analysed to 
determine whether these differences in gene expression could be attributed to 
differences in DNA methylation.  
Promoter sequences of SFRP1 were identified using the Genomatix Software. 
Two promoter sequences were identified at 41166172 – 41167556 and 
41164408 – 41165009. The NCBI Nucleotide database was used to obtain the 
nucleotide sequence for a region encompassing both promoter sequences, i.e. 
between 41164300 – 41167700. MethPrimer (Li and Dahiya, 2002) was then 
used to find CpG islands within this region employing the following criteria: 
island size >100 bases, GC ratio >0.5 and observed to expected ratio >0.6. The 
sequences of the two available PyroMark CpG assays (Qiagen) for SFRP1 
were identified within the DNA sequence. Both promoter sequences, CpG 
islands and the two possible assay sequences are illustrated in Figure 3.5. Both 
assay sequences, in red, are located within the second promoter region and in 
the first CpG island identified. 
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Figure 3.5 SFRP1 nucleotide sequence illustrating promoter sequences 
and CpG islands.  
 
Promoter sequences are in bold and underlined, CpG islands are highlighted in yellow 
and sequences identified as potential targets for methylation quantification using the 
two available PyroMark CpG assays (Qiagen) are in red. 
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The Genomatix Software Suite v3.2 (Genomatix, 2014) was used to identify 
transcription factor binding sites identified in cells from the digestive system 
tissue within the SFRP1 promoter sequence. The transcription factor binding 
sites (shown in brackets) within close proximity of the two SFRP1 PyroMark 
CpG assays were identified (Figure 3.6). 
Figure 3.6 Transcription factor binding sites within, or close to, domains 
in the two PyroMark CpG assay sequences within the second promoter of 
SFRP1. 
 
CpG islands are highlighted in yellow. Coloured brackets represent transcription factor 
binding sites. Primer assays 1 and 2 are shown by circled numbers. 
Primer assay 1 was selected to be used for analysis of SFRP1 methylation 
because it a) contained more CpG sites (seven CpG sites compared with six) 
and b) contained or was close to more transcription factor binding sites than 
primer assay 2 (four transcription factor bindings sites compared with three). 
The seven CpG sites which were analysed are highlighted in yellow in the 
sequence below: 
Primer assay 1: CGGCTCGCACGAGTCGCGCACGGCCTCG
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Chapter 4 The effects of non-digestible carbohydrates on the 
WNT signalling pathway and its functional outcomes 
4.1 The DISC Study intervention participants 
Over 1,500 potential participants were invited to take part in the DISC Study, of 
whom 1,401 were excluded, primarily because they did not meet the inclusion 
criteria or were not willing to participate. Eighty-eight healthy participants were 
recruited by the DISC Team and randomised for the intervention arm of the 
study. Following randomisation, 11 participants (12.5%), equally distributed 
amongst the four intervention groups, were lost to follow up. Eight participants 
withdrew consent, two could no longer be contacted and one no longer met the 
inclusion criteria.  
A total of 77 participants completed the dietary intervention successfully, 
however two participants from intervention group C were excluded at the 
analysis stage. One of these was excluded as their family history was uncertain 
and they could not be contacted for this to be verified. The other participant was 
administering Orlistat, an inhibitor of fat digestion, which could be associated 
with effects on the microbiota as dietary fat has been shown to alter the 
microflora. The flow of participants throughout the DISC study is presented in a 
CONSORT diagram (Figure 4.1). 
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Figure 4.1 CONSORT diagram: flow of participants throughout the DISC 
Study RCT. 
 
4.1.1 Baseline characteristics of intervention participants 
A total of 75 participants completed the DISC Study dietary intervention arm 
and were included in the analyses. Table 4.1 describes the baseline (pre-
intervention) characteristics for all of the intervention participants by intervention 
group. The ANOVA GLM was used to analyse mean age and mean BMI (kg/m2) 
and Chi-square tests were used for the analysis of intervention group 
differences in other participant characteristics at baseline. 
The majority of the participants were Caucasian. All variables, with the 
exception of age, were comparable between the four intervention groups. 
Participants in group B (mean age 58.3 years) were significantly older than 
participants in the other groups (p=0.041). The mean participant age across all 
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groups was 52.4 years, with the youngest and oldest participants being 30 and 
84 years old respectively. A large proportion of participants were overweight 
(36%) or obese (47%) with only 17% of the intervention participants having a 
normal BMI (18.5-25kg/m2). Furthermore, 12 participants had a BMI greater 
than 35kg/m2. To avoid any confounding effects of intervention group 
differences in age, gender, endoscopy procedure, BMI or smoking status on the 
measured outcomes, these variables were included as covariates during 
statistical analyses using the ANOVA GLM.  
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Table 4.1 Baseline characteristics of intervention participants in the DISC 
Study. 
Intervention group All A B C D 
P 
value 
 RS - - + +  
 PD - + - +  
Number of 
participants 
75 20 20 17 18  
Ethnicity 
Caucasian (%) 
Black African (%) 
Mixed race (%) 
 
73 (97) 
1 (1.33) 
1 (1.33) 
 
19 (95) 
1 (5) 
0 (0) 
 
19 (95) 
0 (0) 
1 (5) 
 
17 (100) 
 
 
 
18 (100) 
 
 
 
Gender 
Female (%) 
Male (%) 
 
40 (53) 
35 (47) 
 
10 (50) 
10 (50) 
 
11 (55) 
9 (45) 
 
13 (76) 
4 (24) 
 
6 (33) 
12 (67) 
0.084 
Age 
Mean (years) 
Range 
 
52.4 
30-80 
 
48.0 
30-70 
 
58.3 
33-80 
 
53.4 
42-67 
 
50.1 
36-74 
0.041 
Smoking status 
Never (%) 
Former (%) 
Current (%) 
 
38 (51) 
21 (28) 
16 (21) 
 
12 (60) 
4 (20) 
4 (20) 
 
12 (60) 
5 (25) 
3 (15) 
 
8 (47) 
6 (35) 
3 (18) 
 
6 (33) 
6 (33) 
6 (33) 
0.604 
BMI 
Mean (kg/m2) 
Range 
 
30.0 
23.0 – 
49.3 
 
29.8 
23.2 - 
37.1 
 
29.7 
23.2 - 
49.3 
 
30.9 
23.0 - 
43.1 
 
29.9 
23.4 - 
41.8 
0.901 
Procedure 
Colonoscopy (%) 
Flexible    
Sigmoidoscopy (%) 
 
23 (31) 
 
52 (69) 
 
6 (30) 
 
14 (70) 
 
6 (30) 
 
14 (70) 
 
6 (35) 
 
11 (65) 
 
5 (28) 
 
13 (72) 
0.969 
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4.2 The effects of supplementation with RS and PD on WNT pathway-
related gene expression in the human colorectal mucosa 
4.2.1 Introduction 
The WNT signalling pathway is an important regulator of physiological 
processes, including cell proliferation, differentiation and apoptosis, that 
maintain a homeostatic environment within the colorectal epithelium. However, 
aberrant WNT signalling is implicated in colorectal carcinogenesis, including 
both sporadic and inherited forms of this cancer, resulting in inappropriate 
activation of the WNT pathway. Due to its role in CRC, and because of 
speculations that NDCs and butyrate may be protective against CRC via 
positive modulation of this pathway, the effects of the dietary intervention on 
WNT signalling were investigated. Here, I report the results of quantification of 
the expression of WNT pathway-related genes in biopsies of colorectal mucosa 
as an indicator of WNT pathway activity.  
4.2.1.1 Effects of non-digestible carbohydrates on WNT pathway-related 
gene expression 
To date, there is only one study which has investigated the effects of RS on 
WNT pathway-related gene expression in the colon and no studies on the 
effects of PD. In addition, the single published study is based on work in rats 
(see below) so that, to my knowledge, my study is the first to have been carried 
out in humans. 
The effects of RS on the expression of eight WNT pathway-related genes have 
been investigated in both normal (untreated) and carcinogen-treated rats (Cray, 
2013). Three corn maize varieties were tested: Argentinian (AR), Guatemalan 
(GUAT) and the AR x GUAT hybrid and fed for ten weeks. The highest RS 
content was found in the GUAT diet (18.6%) and the lowest in the AR diet 
(5.4%). In normal rats, there was a significant increase in β-catenin expression 
in rats fed the GUAT diet compared with the hybrid diet. However, in 
carcinogen-treated rats, significantly lower β-catenin expression was observed 
in rats fed the hybrid diet compared with the AR diet, which had a lower RS 
content. AXIN2 expression was significantly lower in rats fed the higher RS 
GUAT diet compared with the lower RS AR diet in both normal and carcinogen-
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treated rats. Expression of WISP1, an inhibitor of WNT signalling, was also 
significantly lower in rats fed the two diets with highest RS content compared 
with the AR diet. In carcinogen-treated rats, the investigators also observed 
significantly higher SFRP4 expression in the GUAT diet compared with the two 
diets of lower RS content.  
4.2.1.2 Effects of butyrate on WNT pathway-related gene expression 
The effects of butyrate on the WNT signalling pathway were first investigated in 
vitro by Bordonaro and colleagues in 1999 (Bordonaro et al., 1999). Prior to that 
study, the induction of cell cycle arrest, differentiation and apoptosis in colonic 
carcinoma cell lines by butyrate treatment was already well established 
(Williams et al., 2003) but the pathways involved in the regulation of these 
processes in the colorectal epithelium were relatively unknown. Bordonaro et al. 
(1999) aimed to investigate the effects of butyrate on the canonical WNT 
signalling pathway, due to its role in colon cancer aetiology, in colonic epithelial 
cells. Treatment of SW620 colonic carcinoma cells with 5mM butyrate (a 
physiologically relevant concentration) resulted in a five-fold increase in TCF 
activity at 24 hours. TCF is a transcription factor that activates transcription of 
WNT target genes when bound to β-catenin following β-catenin translocation to 
the nucleus. Butyrate treatment also increased the formation of β-catenin/TCF 
complexes. Furthermore, during the 24 hours after exposure to butyrate, 
apoptosis was induced as indicated by several markers including G0-G1 cell 
cycle arrest, caspase-3 activation and DNA fragmentation. The authors 
concluded that the induction of apoptosis by butyrate was linked to the increase 
in TCF activity (Bordonaro et al., 1999). Following this finding, the authors were 
interested in investigating the mechanism by which butyrate is able to modulate 
the WNT pathway in different colon carcinoma cell lines. It was observed that 
the modulation of WNT signalling by butyrate was both promoter- and cell-type 
dependent (Bordonaro et al., 2002). 
A recent study by the Bordonaro group continued their investigations into the 
modulation of the WNT pathway by butyrate using a total human genome 
microarray (Lazarova et al., 2014b). These authors treated HCT-116 CRC cells 
with a physiologically-relevant concentration of butyrate (5mM) and observed 
significantly altered expression of 1587 genes, including both direct and indirect 
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targets of WNT signalling (p<0.05). These included upregulation of the 
expression of AXIN2, DKK1, WNT5B and c-JUN and downregulation of FOSL1 
and c-MYC. A similar earlier study by the group compared the effects of 5mM 
butyrate treatment on LT97 colon microadenoma and on SW620 colorectal 
adenocarcinoma cell lines. Their results showed a significant effect of butyrate 
on the expression of genes including downregulation of c-MYC in both cell lines 
(Lazarova et al., 2014a).  
Another group used oligonucleotide microarrays to investigate the effects of 
butyrate treatment on the expression of 12 WNT target genes in the CC531 rat 
colon carcinoma cell line (Germann et al., 2003). In response to butyrate, the 
expression of four target genes normally induced by activated WNT pathway 
viz. CCND1, c-MYC, FOSL1 and FST all decreased. Importantly, c-MYC, 
CCND1 and FOSL1 have been reported to be overexpressed in colorectal 
carcinomas (Wong and Pignatelli, 2002) .  
4.2.2 Hypotheses, Aims and Objectives  
4.2.2.1 Hypotheses 
The hypothesis for this study was that NDCs modulate the WNT pathway 
positively by altering the expression of WNT signalling genes. Specifically, it 
was hypothesised that the expression of genes that resulted in reduced WNT 
pathway activity, such as WNT inhibitors, would be increased, and that genes 
associated with enhanced WNT pathway activity, such as WNT ligands and 
target genes, would be decreased.  
4.2.2.2 Aims 
This study aimed to test this hypothesis by investigating the effects of 
supplementing healthy human participants with NDCs on the expression of 12 
selected WNT pathway-related genes.  
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4.2.2.3 Objectives 
 To select a subset of WNT pathway-related genes for analysis; 
 To obtain colorectal mucosal biopsies from DISC Study participants 
before and after 50 days supplementation with NDCs; 
 To extract an adequate amount of high-quality RNA from OCT-embedded 
rectal mucosal biopsies; 
 To synthesise cDNA by reverse transcription of RNA; 
 To quantify the expression of the selected WNT genes by qPCR; 
 To investigate the effects of the supplementation with NDCs on the 
expression of the selected WNT genes; 
 To explore the effects of key epidemiological factors including age and 
gender on WNT pathway-related gene expression. 
4.2.3 Methods 
The methods utilised for this study can be found in section 2.2.1. The analyses 
were performed using RNA extracted from OCT-embedded rectal biopsies, 
which was then reverse transcribed to cDNA. The synthesised cDNA was used 
for the quantification of the 12 selected WNT pathway-related genes by qPCR.  
The effects of the interventions were determined by analysis of post-intervention 
expression data using the ANOVA GLM, with the corresponding pre-
intervention value as a covariate. Other covariates in the analyses were age, 
gender, endoscopy procedure, BMI and smoking status. The Bonferroni 
correction was used to adjust for multiple comparisons. 
4.2.4 Results 
4.2.4.1 Reproducibility analysis 
As quantification of the selected genes for each participant was performed 
using two separate PCR plates, the housekeeping genes 18S and β2M were 
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analysed twice (once on each PCR plate). The data from both qPCR runs were 
utilised for a reproducibility analysis.  
To examine the correlation between the two qPCR runs, Spearman’s rank 
correlation was used to analyse the Ct values for 18S and β2M as well as the 
geometric mean of the housekeeping genes using SigmaPlot v.12.5. Strong, 
positive correlations between qPCR runs were observed for 18S, β2M and the 
geometric mean of the two (Figure 4.2). The Spearman correlation coefficients 
were 0.813 and 0.931 for 18S and β2M respectively (p<0.001) (Figure 4.2 (A) 
and (B)). Consequently, a strong correlation between the geometric means of 
the two housekeeping genes was also achieved, with a Spearman correlation 
coefficient of 0.887 (p<0.001) (Figure 4.2 (C)). 
Figure 4.2 Positive correlation of (A) 18S expression, (B) β2M expression 
and (C) geometric mean data between plate 1 and plate 2.  
 
Data are expressed as Ct values. (A) N=113, (B) N=108 and (C) N=100. 
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4.2.4.2 Effects of RS and PD on WNT pathway-related gene expression 
Expression of each of the 12 WNT pathway-related genes in the rectal mucosa 
of healthy participants in the DISC Study was quantified by qPCR. Expression 
levels for each of the 12 genes in the rectal mucosa were characteristically 
different, with the most abundantly expressed gene being CCND1, and the 
gene with lowest expression being SFPR2. From the 12 WNT pathway-related 
genes quantified, significant effects of the intervention agents on the expression 
of CTNNB1, c-MYC, SFRP1 and SFRP2 were observed (Table 4.2).  
Expression of CTNNB1 (which encodes β-catenin) was significantly lower 
(reduced by 25%) in participants supplemented with RS (p=0.045).There was 
no effect of PD supplementation on CTNNB1 expression. 
Participants supplemented with RS also had significantly lower c-MYC 
expression (p=0.037) but, again, there was no effect of PD. c-MYC expression 
following RS supplementation was approximately half that observed in the 
placebo group.  
Supplementation with each of the intervention agents lowered SFRP1 
expression, which was reduced by approximately two thirds following RS 
(p=0.005) and PD (p=0.053) supplementation. PD supplementation had a 
similar effect on SFRP2 expression (p=0.01), but there were no detectable 
effects of RS on expression of this gene. 
When applying Bonferroni’s correction for multiple testing, the set p-value is 
lowered to 0.004 and so the statistically significant effects of RS and PD on 
expression of CTNNB1, c-MYC, SFRP1 and SFRP2 are no longer present. 
Whilst there was no evidence of significant effects of RS and PD, there 
appeared to be interactions between RS and PD on expression of both FOSL1 
(p=0.055) and c-JUN (p=0.08). Supplementation with RS increased expression 
of FOSL1 when given with the PD placebo, but reduced FOSL1 expression 
when given with PD (Figure 4.3 (A)). On the contrary, expression of c-JUN 
reduced when RS was given with the PD placebo, but increased when 
administered with PD (Figure 4.3 (B)). 
   
  
Table 4.2 Effects of supplementation with RS and PD on expression of 12 WNT pathway-related genes in the human rectal 
mucosa. 
 
RS allocation 
LSM (95% CI) 
 
PD allocation 
LSM (95% CI) 
 
Interaction 
between RS 
and PD 
Gene 
Placebo 
(Amioca) 
RS 
(Hi-Maize® 260) 
P value 
Placebo 
(Maltodextrin) 
PD 
(Litesse® Ultra™) 
P 
value 
P value 
APC 
N=35 
1.83 
(1.48 – 2.22) 
1.49 
(1.17 – 1.85) 
0.227 
1.55 
(1.24 – 1.89) 
1.77 
(1.43 – 2.17) 
0.410 0.873 
AXIN2 
N=66 
2.15 
(1.81 – 2.50) 
2.22 
(1.89 – 2.55) 
0.230 
2.31 
(1.98 – 2.65) 
2.42 
(2.07 – 2.77) 
0.682 0.188 
CCND1 
N=35 
66.5 
(45.9 – 96.3) 
45.2 
(30.6 – 66.7) 
0.171 
50.9 
(33.4 – 77.6) 
59.0 
(37.7 – 92.4) 
0.678 0.352 
CTNNB1 
N=63 
14.9 
(12.3 – 17.7) 
11.1 
(9.0 – 13.5) 
0.045 
12.5 
(10.3 – 15.1) 
13.3 
(10.8 – 16.0) 
0.679 0.484 
FOSL1 
N=16 
0.02312 
(0.00534 – 
0.10010) 
0.01172 
(0.00536 – 
0.02565) 
0.474 
0.00887 
(0.00384 – 
0.02050) 
0.03055 
(0.00565 – 
0.16521) 
0.303 0.055 
 
1
4
2
 
   
  
Gene 
Placebo 
(Amioca) 
RS 
(Hi-Maize® 260) 
P value 
Placebo 
(Maltodextrin) 
PD 
(Litesse® Ultra™) 
P 
value 
P value 
GSK3β 
N=64 
5.31 
(4.56 – 6.07) 
4.08 
(4.08 – 5.53) 
0.351 
4.92 
(4.18 – 5.65) 
5.20 
(4.44 – 5.96) 
0.615 0.843 
c-JUN 
N=64 
8.20 
(6.54 – 10.04) 
7.23 
(5.73 – 8.91) 
0.436 
6.96 
(5.48 – 8.63) 
8.48 
(6.78 – 10.37) 
0.230 0.080 
c-MYC 
N=37 
10.18 
(6.97 – 14.85) 
5.41 
(3.58 – 8.19) 
0.037 
8.06 
(5.01 – 12.59) 
6.84 
(4.37 – 10.73) 
0.668 0.925 
SFRP1 
N=39 
6.19 
(3.63 – 10.57) 
1.78 
(1.00 – 3.18) 
0.005 
5.49 
(2.97 – 10.14) 
2.01 
(1.07 – 3.76) 
0.053 0.320 
SFRP2 
N=49 
0.00695 
(0.00397 – 
0.01216) 
0.00685 
(0.00378 – 
0.01243) 
0.980 
0.01242 
(0.00705 – 
0.02188) 
0.00383 
(0.00210 – 
0.00699) 
0.010 0.233 
WNT5A 
N=63 
0.133 
(0.097 – 0.183) 
0.103 
(0.076 – 0.140 ) 
0.267 
0.104 
(0.075 – 0.144) 
0.132 
(0.095 – 0.184) 
0.332 0.843 
WNT11 
N=42 
0.1174 
(0.0918 – 0.1463) 
0.0889 
(0.0666 – 0.1143) 
0.145 
0.1038 
(0.0785 – 0.1327) 
0.1015 
(0.0777 – 0.1285) 
0.910 0.684 
Data are expressed as Least Square Means (LSMs) and 95% confidence intervals for adjusted values (2-ΔCt x 10,000) relative to the 18S and β2M 
housekeeping genes 
1
4
3
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Figure 4.3 Interaction between RS and PD supplementation on FOSL1 (A) 
and c-JUN (B) expression.  
 
Data are expressed as adjusted copies and presented as LSMs. (A) N=16 and (B) 
N=64. 
4.2.4.3 Exploration of additional factors influencing WNT pathway-related 
gene expression 
Expression of the gene of interest plus the variables age, gender, endoscopy 
procedure, BMI and smoking status were included as covariates in statistical 
analyses. Gender, endoscopy procedure, BMI and smoking status did not affect 
the expression of any of the 12 genes quantified. However, there were 
significant positive effects of pre-intervention expression levels on post-
intervention expression for six of the genes (Table 4.3). Age was also a 
determinant of post-intervention expression levels for APC (p=0.035) and 
FOSL1 (p=0.012).  
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Table 4.3 P values for the effects of pre-intervention expression, age, 
gender, endoscopy procedure, BMI and smoking status on post-
intervention WNT pathway-related gene expression. 
Gene 
Pre-
intervention 
expression 
Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
APC 0.607 0.035 0.743 0.671 0.119 0.860 
AXIN2 0.001 0.990 0.896 0.716 0.294 0.503 
CCND1 0.001 0.885 0.207 0.235 0.225 0.619 
CTNNB1 0.005 0.589 0.448 0.795 0.203 0.310 
FOSL1 0.287 0.012 0.230 0.175 0.142 0.418 
GSK3β 0.001 0.724 0.601 0.782 0.962 0.061 
c-JUN 0.284 0.861 0.969 0.805 0.144 0.409 
c-MYC <0.001 0.955 0.751 0.264 0.603 0.365 
SFRP1 0.828 0.883 0.625 0.441 0.700 0.460 
SFRP2 0.399 0.866 0.258 0.388 0.676 0.056 
WNT5A <0.001 0.186 0.766 0.706 0.943 0.178 
WNT11 0.104 0.317 0.334 0.620 0.664 0.635 
 
Spearman correlation analyses revealed inverse correlations between age and 
post-intervention expression of both APC (Spearman correlation coefficient -
0.371, p=0.016) (Figure 4.4 (A)) and FOSL1 (Spearman correlation coefficient -
0.513, p=0.005) (Figure 4.4 (B)). 
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Figure 4.4 Inverse correlations between age and post-intervention 
expression of (A) APC and (B) FOSL1 in the human rectal mucosa.  
 
Expression data are expressed as adjusted copies. (A) N=35 and (B) N=16. 
4.2.5 Discussion 
To investigate the effects of supplementation with RS and PD on WNT activity 
in the human colorectal epithelium, 12 WNT pathway-related genes were 
selected to be quantified by qPCR. These were selected by reviewing the 
literature to identify WNT pathway-related genes implicated in colorectal 
carcinogenesis and whose expression had been reported to be modulated by 
butyrate as described in section 3.3. A pilot study (section 3.2) was also 
conducted to compare the expression of a panel of 70 WNT pathway genes in 
the macroscopically-normal mucosa of people at higher risk of CRC, with a prior 
history of adenomatous polyps. 
Supplementation with RS lowered CTNNB1 expression by approximately 25% 
(p=0.045) but PD supplementation had no effect on CTNNB1 expression 
(Figure 4.5 (A)). CTNNB1 encodes β-catenin, a central component of the 
canonical WNT signalling pathway which, when WNT signalling is activated, 
accumulates in the cytoplasm and translocates to the nucleus. In the nucleus, 
β-catenin acts as a co-activator and is recruited by the transcription factor family 
TCF/LEF which binds to DNA in enhancer elements of genes and switches on 
expression of oncogenes. A reduction in CTNNB1 expression at the mRNA 
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level may result in a decrease in the β-catenin protein and is suggestive of 
reduced WNT pathway activity. To my knowledge, there are no similar studies 
of RS or PD on CTNNB1 expression in the human colorectum. However, in 
AOM-treated rats, Cray et al. did not observe significant differences in β-catenin 
expression in the colonic epithelium when the rats were fed a low or a high RS 
diet for eight weeks (Cray, 2013). 
Previously, Bordonaro and colleagues did not observe any effect of sodium 
butyrate on total β-catenin levels in colon carcinoma cells (Bordonaro et al., 
2002). However, further investigation of the effects of 5mM sodium butyrate 
exposure for up to 24 hours produced significantly increased levels of active, 
dephosphorylated β-catenin, measured by Western Blot, in eight of ten CRC 
cell lines (Bordonaro et al., 2007). In addition, significantly increased 
concentrations of dephosphorylated β-catenin in the nucleus were confirmed in 
SW620 and HCT-116 cell lines.  
RS, but not PD, also lowered c-MYC expression significantly (p=0.037) so that 
post-intervention c-MYC expression in participants given RS was approximately 
half of that in participants given placebo (Figure 4.5 (B)). c-MYC is a target of 
the WNT pathway, whose expression is increased in response to WNT pathway 
activation (van de Wetering et al., 2002) (He et al., 1998). c-MYC is an 
oncogene considered to be a “master regulator” which controls many aspects of 
both cellular growth regulation and cellular metabolism (Miller et al., 2012). It is 
frequently overexpressed in CRCs (Stewart et al., 1986). 
The findings from my study are consistent with results from a very recent study 
by the Bordonaro group, where they reported a 50% reduction in c-MYC 
expression (p<0.05) following treatment with 5mM butyrate (Lazarova et al., 
2014b). An earlier study by this group found that 5mM butyrate treatment 
significantly reduced the expression of c-MYC in both LT97 and SW620 cell 
lines, with butyrate:control ratios for c-MYC being 0.04 and 0.052 respectively 
(Lazarova et al., 2014a). The authors argued that butyrate treatment would lead 
to an increase in WNT activity and that, although this would lead to an increase 
in c-MYC transcription, butyrate also inhibits transcriptional elongation (Wilson 
et al., 2002), consequently leading to a reduction in c-MYC expression overall.  
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The reduction of c-MYC expression by butyrate was first observed by Herold 
and Rothberg in 1988. They found that treatment of SW837 rectal carcinoma 
cells with butyric acid, with maximal reduction observed at a 1mM 
concentration, decreased mRNA levels of c-MYC in a dose-dependent manner 
(Herold and Rothberg, 1988). The Rothberg group further explored the 
attenuation of c-MYC transcription by butyrate. They observed a reduction in c-
MYC expression following treatment of SW837 with 2mM butyrate. A follow-up 
study by this group later identified that this reduction in expression resulted from 
prevention of transcriptional elongation as opposed to a reduction in the 
initiation of transcription or induction of RNA degradation (Heruth et al., 1993). 
The effects of butyrate on protein levels of c-MYC have been investigated in six 
human colon tumour cell lines and the investigators found that a similar 
reduction in c-MYC was achieved by butyrate in all six cell lines (Taylor et al., 
1992).  
Both RS and PD supplementation reduced expression of SFRP1 (Figure 4.5 
(C)). This was statistically significant for RS (p=0.005) and close to reaching 
statistical significance for PD (p=0.053), with expression levels which were only 
one third or less of expression levels compared with their placebos. In addition, 
PD, but not RS, significantly reduced SFRP2 expression (p=0.01) to a similar 
degree (Figure 4.5 (D)). SFRP1 and SFRP2 encode proteins which are 
members of the WNT antagonist family of SFRPs. SFRPs have a N-terminal 
cysteine-rich domain similar to that of Frizzled receptors and inhibit the WNT 
pathway competitively by competing with the Frizzled receptors for WNT ligand 
binding (Bafico et al., 1999). 
To my knowledge, this is the first study which has investigated the effects of 
NDCs or of butyrate on SFRP1 or SFPR2 expression in the colon. However, 
work in two gastric cancer cell lines, AGS and MKN45, showed that treatment 
with 2µM sodium butyrate restored SFRP1 and SFRP2 protein levels, which are 
diminished in cancer (Shin et al., 2012). 
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Figure 4.5 Significant effects of supplementation with RS and PD on 
expression of (A) CTNNB1, (B) c-MYC, (C) SFRP1 and (D) SFRP2 in the 
human rectal mucosa. 
 
 
Data are expressed as LSMs for adjusted copies relative to the geometric mean of 18S 
and β2M housekeeping genes. Error bars represent 95% CIs. *p<0.05 for effect of 
active agent versus placebo.(A) N=63, (B) N=37, (C) N=39 and (D) N=49. 
As shown in Figure 4.4, there were significant inverse relationships between 
age and expression of both APC (p=0.035) and FOSL1 (p=0.012). This is the 
first report of correlations between age and APC and FOSL1 expression in the 
colon. However, using bone marrow mesenchymal stem cells from cardiac 
patients, Brunt and colleagues have previously reported positive correlations 
between age and FOSL1 expression (Brunt et al., 2012).  
APC is a key component of the WNT signalling pathway and loss of APC 
through mutation or epigenetic silencing results in failure to degrade β-catenin 
and its accumulation in the cytoplasm. A reduction in APC expression with age 
suggests a decrease in APC protein levels, which would lead to reduced β-
catenin degradation by the destruction complex (which includes APC and 
GSK3β) and therefore to an increase in WNT activity. This could be one of the 
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possible mechanisms that contribute to the increasing risk of CRC with age. 
Conversely, FOSL1 is a target gene of the WNT pathway and therefore a 
reduction in FOSL1 expression with age could be an indication of reduced WNT 
pathway activation.  
In conclusion, RS and/or PD significantly modulated the expression of four of 
the 12 selected WNT pathway-related genes. RS significantly reduced the post-
intervention expressions of CTNNB1 and c-MYC compared with placebo. 
CTNNB1 encodes β-catenin, perhaps the key component of the canonical WNT 
pathway, that drives transcription of WNT target genes when the pathway is 
activated, and c-MYC is a target of the WNT pathway. A decrease in their 
expression would therefore be suggestive of a reduction in WNT signalling.  
On the contrary, both RS and PD reduced the expression of SFPR1 and PD 
reduced the expression of SFRP2 post-intervention. SFRP1 and SFRP2 are 
both inhibitors of the WNT signalling pathway and therefore a decrease in their 
expression, if paralleled at the protein level, would lead to reduced inhibition of 
the WNT pathway and subsequently an increase in WNT activity.  
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4.3 The effects of supplementation with RS and PD on microRNA 
expression in the human colorectal mucosa 
4.3.1 Introduction 
miRNAs are small, non-coding RNAs that are able to regulate gene expression 
epigenetically. As described in section 1.2.6.3, several miRNAs are aberrantly 
expressed in CRC, particularly members of the miR-17-92 cluster, leading to 
altered expression of their target genes.  
As an effect of both RS and PD was observed on SFRP1 expression, the 
effects of the intervention on the expression of miRNAs that may target SFRP1 
were investigated. A total of eight miRNAs were selected as described in 
section 3.4.1. These comprised miRNAs reported to be altered in colorectal 
carcinogenesis, modified by butyrate and predicted to target SFRP1.  
4.3.1.1 Effects of non-digestible carbohydrates on miRNA expression in 
the colon 
Very few studies have investigated the effects of NDCs or butyrate on 
expression of miRNAs that target the WNT signalling pathway in the colon. 
A very recent paper published by Humphreys et al. was the first study to 
investigate the effects of RS, and butyrate, on miRNA expression in colorectal 
cells in vivo (Humphreys et al., 2014). Healthy participants consumed a high red 
meat (HRM) diet, which is associated with increasing CRC risk, and a HRM diet 
plus butyrylated RS for four weeks in a cross-over design. The HRM diet 
increased expression of miR-17-92 cluster miRNAs. However, the authors 
observed lower expression of miR-17-92 cluster miRNAs following the HRM 
plus butyrylated RS diet compared with the HRM diet alone, suggesting that RS 
was able to reverse the detrimental effects of HRM on miRNA expression. This 
was statistically significant for miR-17, miR-19a, miR-19b, miR-20a and miR-92.  
4.3.1.2 Effects of butyrate on miRNA expression in the colon 
Hu et al. explored the effects of butyrate treatment of HCT-116 colon cancer 
cells on expression of miRNAs using a miRNA microarray (Hu et al., 2011). 
They found that butyrate significantly altered expression of 44 miRNAs, 
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including reduced expression of members of the miR-17-92 cluster.  
Interestingly, the authors found that miR-17, miR-20a, miR-20b, miR-93, mi-
106a and miR-106b, that were downregulated in butyrate-treated cells, were 
significantly overexpressed in colon tumour tissue compared with normal tissue. 
This suggested that one of the mechanisms by which butyrate is protective 
against CRC may be through the positive modulation of miRNAs that are 
abnormally overexpressed in CRC.  
As miRNAs from the miR-17-92 cluster have been reported to be 
overexpressed in CRC, Humphreys et al. investigated the effects of butyrate 
treatment on miRNA expression, particularly from this cluster, in HT-29 
colorectal adenocarcinoma and HCT-116 colorectal carcinoma cells 
(Humphreys et al., 2013). They assessed the effects of 48-hour treatment of 
HT-29 cells with 5mM butyrate on miRNA expression by microarray analysis 
and found that butyrate reduced and increased expression of 30 and 39 
miRNAs respectively. To validate the observed effects, miRNA expression in 
both HT-29 and HCT-116 cells treated with 1, 5 and 10mM butyrate were 
quantified by qPCR. Treatment with 5mM butyrate significantly downregulated 
miRNAs belonging to the miR-17-92 cluster (miR-18a, miR-19a, miR-19b, miR-
20a and miR-92a) in both cell lines. Furthermore, the authors observed 
decreased proliferation with 48-hour butyrate treatment of HT-29 and HT-116 
cells, and this was statistically significant with the physiologically-relevant 
concentration of 5mM. 
4.3.2 Hypotheses, Aims and Objectives  
4.3.2.1 Hypotheses 
The hypothesis for this study was that changes in the expression of SFRP1 
observed following supplementation with RS and PD resulted from altered 
expression of miRNAs predicted to target SFRP1.  
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4.3.2.2 Aims 
This study aimed to test this hypothesis by investigating the effects of 
supplementing healthy human participants with NDCs on the expression of 
eight selected miRNAs that may target SFRP1.  
4.3.2.3 Objectives 
 To select a subset of miRNAs for analysis; 
 To extract an adequate amount of high-quality total RNA, including small 
RNAs such as miRNAs, from OCT-embedded rectal mucosal biopsies; 
 To synthesise cDNA by reverse transcription of RNA; 
 To conduct a quality control PCR array experiment; 
 To quantify the expression of the selected miRNAs by qPCR; 
 To investigate the effects of supplementation with NDCs on expression of 
the selected miRNAs; 
 To explore the effects of key epidemiological factors including age and 
gender on expression of the selected miRNAs. 
4.3.3 Methods  
The methods for this study can be found in section 2.2.2. Total RNA, including 
small RNAs such as miRNAs, was extracted from OCT-embedded rectal 
biopsies and reverse transcribed to cDNA. A quality control (QC) PCR array 
was run prior to quantification of the selected miRNAs by qPCR.  
The effects of the interventions were determined by analysis of post-intervention 
expression data using the ANOVA GLM, with the corresponding pre-
intervention value as a covariate. Other covariates in the analyses were age, 
gender, endoscopy procedure, BMI and smoking status. For data that were not 
normally-distributed, the Kruskal-Wallis non-parametric test was utilised. 
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4.3.4 Results 
Expression of the eight selected miRNAs was quantified to investigate the 
effects of the dietary intervention. Prior to quantification, a QC PCR array was 
run to ensure that cDNA quality was suitable for subsequent analyses by qPCR. 
4.3.4.1 cDNA quality control prior to profiling mature miRNAs 
Prior to profiling the expression of the selected miRNAs, a cDNA QC PCR Array 
was run as described in section 2.2.2.3. This array included primers for the 
detection of C. elegans miR-39, three ubiquitously expressed miRNAs (miR-16, 
miR-21 and miR-191), three snoRNA controls (SNORD61, SNORD95 and 
SNORD96A) and two controls (PPC and RTC).  
The positive PCR control (PPC) assessed PCR performance and detected any 
inhibition of the PCR reaction. Ct values 19 ± 2 are indicative of high quality 
RNA. This was achieved for all samples run on the array, with a mean PPC Ct 
value of 18.7 for the eight cDNA samples. Likewise, the miRNA reverse 
transcription control (miRTC) assessed the reverse transcription reaction 
performance and detected any inhibition of reverse transcription by quantifying 
the template synthesised from a control RNA integrated in the miScript II RT Kit. 
The ΔCt was calculated from the PPC and miRTC duplicate mean values and 
should be less than 7. As shown in Table 4.4, the ΔCt values for all eight 
samples were less than 7, with a mean value of 2.52, indicating that there was 
no inhibition of reverse transcription.  
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Table 4.4 miScript QC PCR Array PPC and miRTC data.  
Sample PPC Ct mean miRTC Ct mean ΔCt 
011 pre 18.9 20.8 0.42 
032 pre 18.6 23.9 3.82 
066 pre 18.7 26.3 6.13 
079 post 18.7 22.5 2.34 
082 pre 18.6 20.6 0.52 
093 post 18.7 22.9 2.71 
109 18.7 20.4 0.21 
211 18.8 24.3 4.01 
Data are presented as duplicate mean Ct values for PPC and miRTC. ΔCt = CtmiRTC – 
CtPPC – 1.5. N=8. 
The C. elegans miR-39 should only be detectable when the Syn-cel-miR-39 
miScript miRNA Mimic has been spiked into the samples. All eight cDNA 
samples correctly resulted in undetectable (UD) levels of C. elegans miR-39 as 
shown in Table 4.5.  
Three miRNAs that are ubiquitously expressed across a variety of cell, tissue 
and fluid types, miR-16, miR-21 and miR-191, were detected and showed 
adequate Ct values for all eight samples analysed (Table 4.5). 
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Table 4.5 miScript QC PCR Array C. elegans miR-39, miR-16, miR-21 and 
miR-191 data.  
Sample 
C. elegans 
miR-39 
miR-16 miR-21 miR-191 
011 pre UD 16.7 14.0 18.5 
032 pre UD 19.2 14.7 20.3 
066 pre UD 20.9 15.0 21.1 
079 post UD 17.6 14.2 18.9 
082 pre UD 16.4 13.8 18.7 
093 post UD 18.0 13.7 19.4 
109 UD 16.0 13.3 18.2 
211 UD 19.4 14.5 20.4 
Data are presented as Ct values. N=8 
Three snoRNAs, SNORD61, SNORD95 and SNORD96A, that may be utilised 
as endogenous controls were quantified. The expression of these controls has 
been shown to be relatively stable across different tissue and cell types. This is 
reflected in the QC array data from the analysed samples (Table 4.6). 
Table 4.6 miScript QC PCR Array control snoRNA data for SNORD61, 
SNORD95 and SNORD96A.  
Sample SNORD61 SNORD95 SNORD96A 
011 pre 19.0 19.7 19.1 
032 pre 21.8 22.4 22.4 
066 pre 23.4 22.9 22.1 
079 post 20.2 20.2 20.0 
082 pre 19.7 19.5 19.6 
093 post 20.7 19.9 19.9 
109 18.0 18.7 18.7 
211 22.3 21.6 21.6 
Data are presented as Ct values. N=8 
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4.3.4.2 Reproducibility analysis 
As for 25 of the ‘Normal’ (pre-intervention) participants and the ‘Polyp’ and ‘UC’ 
groups the control RNAs RNU6 and SNORD68 were analysed twice (once on 
the plate analysing the miRNAs selected for the intervention and once on the 
plate analysing the miRNAs selected analysis of participants at differential risk 
of CRC), the data from both qPCR runs were utilised for a reproducibility 
analysis.  
To examine the correlation between the two qPCR runs, Spearman’s rank order 
correlation test was run on the Ct values for RNU6 and SNORD68 as well as 
the geometric mean of the two control RNAs using SigmaPlot v.12.5. Strong, 
positive correlations between qPCR runs were observed for both RNU6 and 
SNORD68. For RNU6, Spearman’s correlation coefficient was 0.968 (p<0.001) 
and the linear regression graph had a R2 value of 0.961 (Figure 4.6 (A)). For 
SNORD68, Spearman’s correlation coefficient was 0.899 (p<0.001) with an R2 
value of 0.884 (Figure 4.6 (B)). Consequently, a strong correlation between the 
geometric means was also achieved, with a Spearman’s correlation coefficient 
of 0.963 (p<0.001) and an R2 value of 0.958 (Figure 4.6 (C)).  
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Figure 4.6 Positive correlation of (A) RNU6 expression, (B) SNORD68 
expression and (C) geometric mean data between plate 1 and plate 2. 
 
Data are expressed as Ct values. N=63. 
4.3.4.3 Effects of the non-digestible carbohydrates on miRNA expression  
For three of the selected miRNAs, miR-17, miR-19b and miR-424, the ANOVA 
GLM was used to analyse for an effect of RS and PD. The effects of the 
intervention agents on the expression of the remaining five miRNAs were 
analysed using the non-parametric test Kruskal-Wallis as it was not possible to 
achieve normally-distributed data for these miRNAs despite transformation. RS 
and PD did not have an effect on expression of the eight miRNAs quantified. A 
series of trends, however, were observed, with participants supplemented with 
RS appearing to have reduced expression of miR-17, miR-19a, miR-19b, miR-
20a and miR-25 (Table 4.7).  
   
 
Table 4.7 Effects of supplementation with RS and PD on miR-17, miR-19b and miR-424 expression in the human rectal mucosa.  
 
RS allocation 
LSM (95% CI) 
 
PD  allocation 
LSM (95% CI) 
 
Interaction 
between RS 
and PD 
miRNA 
Placebo 
(Amioca) 
RS 
(Hi-Maize® 260) 
P value 
Placebo 
(Maltodextrin) 
PD 
(Litesse® Ultra™) 
P value P value 
miR-17 
153 
(133 – 178) 
136 
(119 – 157) 
0.279 
140 
(122 – 163) 
148 
(128 – 173) 
0.631 0.261 
miR-19b 
187 
(128 – 280) 
139 
(97 – 203) 
0.290 
150 
(105 – 219) 
172 
(118 – 258) 
0.625 0.307 
miR-424 
27.3 
(22.0 – 34.7) 
24.9 
(20.3 – 31.3) 
0.581 
23.4 
(19.1 – 29.3) 
29.2 
(23.1 – 38.0) 
0.205 0.202 
Data are expressed LSMs and 95% confidence intervals for adjusted values (2-ΔCt x 1,000) relative to the reference RNAs RNU6 and SNORD68 
(ANOVA GLM). N=56. 
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Table 4.8 Effects of supplementation with RS and PD on expression of miR-19a, miR-20a, miR-25, miR-93 and miR-106b in the 
human rectal mucosa. 
 
RS allocation 
Median (lower and upper quartiles) 
 
PD allocation 
Median (lower and upper quartiles) 
 
miRNA 
Amioca 
(placebo) 
Hi-Maize® 260 
(RS) 
P value 
Maltodextrin 
(placebo) 
Litesse® Ultra™ 
(PD) 
P value 
miR-19a 
283 
(82 – 532) 
211 
(102 – 429) 
0.870 
245 
(93 – 473) 
273 
(98 – 548) 
0.762 
miR-20a 
366 
(295 – 474) 
338 
(294 – 456) 
0.987 
357 
(287 – 470) 
355 
(316 – 419) 
0.889 
miR-25 
75.5 
(60.4 – 200.7) 
70.6 
(50.0 – 127.0) 
0.394 
70.1 
(55.8 – 178.2) 
74.3 
(58.0 – 132.0) 
0.762 
miR-93 
69.2 
(58.5 – 109.2) 
76.8 
(59.7 – 87.6) 
0.935 
72.5 
(57.4 – 104.5) 
71.8 
(59.9 – 92.4) 
0.700 
miR-106b 
172 
(158 – 255) 
173 
(141 - 213) 
0.724 
174 
(148 - 211) 
171 
(158 - 255) 
0.853 
Data are expressed median and lower and upper quartiles for adjusted values (2-ΔCt x 1,000) relative to the reference RNAs RNU6 and SNORD68 
(Kruskal-Wallis test). N= 56, with the exception of miR-106 where N=55. 
1
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4.3.4.4 Exploration of additional factors influencing miRNA expression 
Expression of the eight selected miRNAs plus the variables age, gender, 
endoscopy procedure, BMI and smoking status were included as covariates in 
statistical analyses (Table 4.9). A significant effect of pre-intervention 
expression was observed on post-intervention miR-19b (p<0.001) and miR-424 
(p<0.001) expression. Post-intervention miR-19b expression was significantly 
affected by age (p=0.012), and smoking status was a determinant of post-
intervention miR-93 expression (p=0.017) (Figure 4.7). 
Table 4.9 P values for the effects of pre-intervention expression, age, 
gender, endoscopy procedure, BMI and smoking status on post-
intervention miRNA expression. 
miRNA 
Pre-
intervention 
expression 
Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
miR-171 0.325 0.255 0.170 0.959 0.066 0.202 
miR-19a2 0.475 0.617 0.543 0.256 0.475 0.136 
miR-19b1 <0.001 0.012 0.355 0.703 0.144 0.055 
miR-20a2 0.475 0.738 0.430 0.233 0.475 0.091 
miR-252 0.475 0.330 0.384 0.691 0.475 0.231 
miR-932 0.475 0.717 0.543 0.621 0.475 0.017 
miR-106b2 0.474 0.510 0.866 0.118 0.474 0.070 
miR-4241 <0.001 0.406 0.513 0.074 0.837 0.649 
 
Spearman correlation analyses revealed a positive correlation between age and 
post-intervention miR-19b expression (Spearman correlation coefficient of 
0.179). Figure 4.7 (B) shows the correlation between the two following the 
removal of three outliers with very high post-intervention miR-19b expression. 
The Spearman correlation coefficient following the removal of the three outliers 
was 0.156. 
Smokers, comprising both current and former smokers, had higher post-
intervention miR-93 expression by approximately 25% compared with 
participants who had never smoked Figure 4.7 (B).  
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Figure 4.7 Significant effects of age and smoking status on miR-19b and 
miR-93 expression.  
 
(A) Positive correlation between age and miR-19b expression. (B) miR-93 expression 
by smoking status. Expression data are expressed as adjusted copies. Data are 
presented as median values following analysis using the Kruskal-Wallis test. Error bars 
represent lower and upper quartiles. N=56. 
4.3.5 Discussion 
miRNAs are small, non-coding RNAs that regulate gene expression at a post-
transcriptional level, by resulting in either RNA degradation or by blocking 
translation into proteins. The expression of eight selected miRNAs was 
quantified by qPCR to investigate the effects of supplementation with RS and 
PD and to test the hypothesis that changes in gene expression may result from 
epigenetic regulation, such as by miRNAs. As SFRP1 expression was 
downregulated by both RS and PD, miRNAs predicted to target SFRP1 were 
selected.  
Neither RS nor PD had effects on expression of the selected eight miRNAs. 
However, a trend for reduced expression of miR-19a and miR-19b by 
approximately 25% in participants supplemented with RS was observed. RS 
also appeared to reduce miR-17 expression by approximately 11% compared 
with placebo. 
Humphreys et al. have previously observed downregulation of miRNAs from the 
miR-17-92 cluster with butyrate treatment, including miR-19a and miR-19b that 
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were upregulated in HT-29 and HCT-116 CRC cells (Humphreys et al., 2013). 
An in vivo study by this group also observed a significant reduction in miR-17, 
miR-19a and miR-19b by approximately 20% with a HRM diet supplemented 
with butyrylated RS compared with the HRM diet alone (Humphreys et al., 
2014).  
In contrast, the opposite effect was observed for PD, with a trend for an 
increase in miR-424 and miR-19b expression by approximately 20% and 13% 
respectively compared with placebo. Both miR-19b (Tsuchida et al., 2011) and 
miR-424 (Wang et al., 2010) have been reported to be upregulated in colonic 
cancer tissue compared with adjacent normal tissue.  
A significant effect of age was observed on the post-intervention expression of 
miR-19b in the rectal mucosa. This finding is consistent with results from a 
study by Hackl and colleagues where a reduction in miR-19b expression was 
observed in six cell ageing models (Hackl et al., 2010). The post-intervention 
expression of miR-93 was significantly lower in smokers compared with 
participants who had never smoked. This has not been reported previously.   
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4.4 The effects of supplementation with RS and PD on SFRP1 DNA 
methylation in the human colorectal mucosa 
4.4.1 Introduction 
Another epigenetic mechanism that regulates gene expression is DNA 
methylation. DNA methylation is the addition of a methyl group to the carbon-5 
position within a cytosine residue (Smith and Meissner, 2013). A 
hypermethylated state is associated with inhibition of transcription and 
consequently gene silencing. As both RS and PD reduced expression of 
SFRP1, the DNA methylation state of SFRP1 was assessed to test the 
hypothesis that changes in gene expression may have resulted from alterations 
in SFRP1 methylation. Furthermore, SFRP1 is frequently downregulated in 
CRC due to DNA hypermethylation. 
4.4.1.1 SFRP1  
SFRP1, encoding secreted-Frizzled-related protein 1, is one of five members of 
the SFRP family of WNT pathway antagonists (Mao et al., 2010). SFRP1 is 
located at the human chromosome 8, p12-11.1 and encodes the 35.4kDA 
protein (Mao et al., 2010). It inhibits WNT pathway activation by competing with 
the Frizzled receptor for binding to WNT ligands (Bafico et al., 1999). In 
addition, SFRP1 can also directly bind to Frizzled receptors, thus inhibiting 
ligands from binding and preventing WNT pathway activation (Mao et al., 2010).  
4.4.1.2 SFRP1 methylation state in colorectal carcinogenesis 
SFRP1 expression has been observed to be reduced in CRC and SFRP1 has 
been identified as a tumour suppressor (Caldwell et al., 2004). A reduction in 
SFRP1 expression has correlated with, and is believed to result from, DNA 
hypermethylation (Rawson et al., 2011). Increased SFRP1 methylation has 
been observed in ACF, colorectal adenomas and carcinomas compared with 
normal tissue, resulting in reduced SFRP1 expression in these samples (Qi et 
al., 2006). Epigenetic silencing of SFRP1 results in increased WNT activity and 
has been proposed to be a contributing phenomenon in early colorectal 
tumourigenesis (Suzuki et al., 2004).  
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A very recent meta-analysis investigated the role of SFRP1 promoter 
methylation in colorectal carcinogenesis using eight cohort studies comprising a 
total of 942 CRC patients (Chen et al., 2014b). Results from this meta-analysis 
revealed that SFRP1 promoter methylation was significantly higher in cancer 
tissue compared with both adjacent and normal tissues.  
SFRP1 hypermethylation has also been observed in the DNA isolated from 
stool samples of CRC patients (Salehi et al., 2012). Consequently, Salehi et al. 
have proposed the use of SFRP1 promoter methylation state as an epigenetic 
biomarker for the diagnosis of CRC.  
A recent study by Lyu et al. in China investigated methylation levels of the 
SFRP1 promoter region in serum samples collected from patients with sporadic 
CRC by methylation-specific PCR (Lyu et al., 2014). Similar to findings from 
studies performed in colorectal tissue and stool samples, SFRP1 methylation 
was significantly higher, by 30.5%, in the sera from cancer patients compared 
with healthy participants.  
4.4.1.3 Effect of NDCs and butyrate on SFRP1 methylation  
To date, only one study has reported an effect of butyrate on the methylation 
state of SFRP1. This study was conducted by Shin et al. and investigated the 
epigenetic mechanisms by which sodium butyrate altered SFRP1 expression in 
human gastric cancer cells (Shin et al., 2012). Expression of SFRP1, and 
SFRP2, was quantified in nine gastric cancer cell lines by qPCR. None of the 
nine cell lines showed SFRP1 expression, however, treatment of the cells with 
an inhibitor of DNA methyltransferase, 5’-Aza-dC, resulted in restored SFRP1 
expression, suggesting that SFRP1 silencing resulted from hypermethylation.   
The authors then investigated the effects of treatment with 2µM sodium butyrate 
in two gastric cancer cell lines: AGS and MKN45. They observed SFRP1 
promoter demethylation following sodium butyrate treatment and this correlated 
with restored SFRP1 expression. 
In humans, a double-blind, placebo-controlled, crossover trial by Worthley et al. 
published in 2009 did not report an effect of a four-week RS diet, or of probiotic 
or symbiotic supplementation, on SFRP1 methylation in rectal mucosal biopsies 
(Worthley et al., 2009).  
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4.4.2 Hypotheses, Aims and Objectives 
4.4.2.1 Hypothesis 
The hypothesis for this study was that reduced expression of SFRP1 in 
participants supplemented with RS and with PD may be explained by alterations 
in SFRP1 DNA methylation. More specifically, reduced expression of SFRP1 in 
participants supplemented with RS and with PD may have resulted from SFRP1 
hypermethylation. 
4.4.2.2 Aims 
This study aimed to test this hypothesis by investigating the effects of 
supplementing healthy human participants with NDCs on the methylation state 
of SFRP1 in the colorectum.  
4.4.2.3 Objectives 
 To select a primer assay, within the promoter region and encompassing 
as many CpG sites as possible, to be used for the assessment of SFRP1 
methylation by pyrosequencing; 
 To bisulphite-modify rectal mucosal DNA previously extracted by 
members of the DISC Study team; 
 To amplify the specific region to be sequenced by PCR; 
 To perform a validation pyrosequencing experiment using standard 
curves to test the quality of the primer; 
 To quantify the methylation of SFRP1 at seven CpG sites by 
pyrosequencing; 
 To investigate the effects of the supplementation with NDCs on SFRP1 
methylation at each CpG site and on the mean methylation across all 
sites; 
 To explore the effects of key epidemiological factors including age and 
gender on SFRP1 methylation. 
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4.4.3 Methods 
The methods used for the quantification of SFRP1 methylation can be found in 
section 2.2.3. DNA, extracted by members of the DISC Study team, was first 
bisulphite modified. PCR was utilised to amplify the specific region to be 
analysed by PCR. SFRP1 methylation was quantified at each CpG site by 
pyrosequencing.  
The effects of the interventions were determined by analysis of post-intervention 
methylation data using the ANOVA GLM, with the corresponding pre-
intervention value as a covariate. Other covariates included in the analyses 
were age, gender, endoscopy procedure, BMI and smoking status. 
4.4.4 Results 
Quantification of SFRP1 methylation was performed at seven CpG sites within 
the promoter region by pyrosequencing. Prior to this, an assay validation 
experiment was performed using standard curves.  
4.4.4.1 Assay Validation 
SFRP1 assay validation was performed using both pre- and post-PCR dilutions. 
SigmaPlot 11.0 was used to plot the results with a line of best fit and to 
determine the coefficient of determination (R2). The R2 values for all of the 
regression analyses comparing expected and observed methylation values 
were >0.98 (Figure 4.8 and Figure 4.9).  
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Figure 4.8 Pre-PCR standard curves for the SFRP1 pyrosequencing assay 
validation at all seven CpG sites. 
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Figure 4.9 Post-PCR standard curves for the SFRP1 pyrosequencing 
assay validation at all seven CpG sites. 
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4.4.4.2 Effects of non-digestible carbohydrates on SFRP1 Methylation 
SFRP1 DNA methylation, quantified at the seven CpG sites within the promoter 
region, was moderate, with a mean pre and post-methylation of 26.3% and 
29.6% respectively across all groups. Mean pre-intervention methylation across 
all groups was lowest at CpG site 1 (29.8%) and highest at site 7 (29.9%). 
Mean post-intervention methylation across all groups was lowest at CpG site 5 
(25.6%) and highest at CpG site 2 (33.3%). Across all seven CpG sites and all 
four intervention groups, pre-intervention methylation ranged from 13.6% to 
44.9% and post-intervention methylation ranged from 13.2% to 56.1%. 
There were no statistically significant effects of RS or PD on SFRP1 methylation 
at any of the CpG sites or on the mean methylation (Table 4.10). Participants 
supplemented with PD appeared to have reduced SFRP1 methylation at CpG 
sites 4, 5, 6 and 7 and a close to significant effect of PD was observed on the 
mean methylation across all CpG sites (p=0.055).  
   
 
Table 4.10 Effects of supplementation with RS and PD on SFRP1 methylation in the human rectal mucosa. 
 
RS allocation 
LSM (95% CIs) 
 
PD allocation 
LSM (95% CIs) 
 
Interaction between 
RS and PD 
CpG site 
Amioca 
(placebo) 
Hi-Maize® 260 
(RS) 
P value 
Maltodextrin 
(placebo) 
Litesse® Ultra™ 
(PD) 
P value P value 
1 
N=66 
31.7 
(30.1 – 33.5) 
32.6 
(30.7 – 34.6 
0.526 
33.4 
(31.5 – 35.4) 
31.0 
(29.4 – 32.7) 
0.075 0.811 
2 
N=66 
25.2 
(23.9 – 26.5) 
25.9 
(24.6 – 27.3) 
0.456 
26.0 
(24.7 – 27.4) 
25.1 
(23.8 – 26.4) 
0.348 0.601 
3 
N=66 
23.9 
(22.4 – 25.7) 
24.4 
(22.8 – 26.3) 
0.705 
25.2 
(23.5 – 27.0) 
23.2 
(21.7 – 25.0) 
0.129 0.646 
4 
N=67 
31.9 
(30.3 – 33.6) 
33.0 
(19.5 – 57.0) 
0.417 
33.3 
(31.6 – 35.1) 
31.5 
(29.8 – 33.2) 
0.149 0.520 
5 
N=63 
23.8 
(22.4 – 25.4) 
24.7 
(23.0 – 26.4) 
0.500 
25.1 
(23.4 – 26.9) 
23.5 
(22.0 – 25.1) 
0.181 0.514 
6 
N=62 
30.1 
(28.5 – 31.7) 
30.5 
(28.8 – 32.2) 
0.714 
31.3 
(29.7 – 33.1) 
29.3 
(27.7 – 31.0) 
0.097 0.453 
 
1
7
1
 
   
 
 
RS allocation 
LSM (95% CIs) 
 
PD allocation 
LSM (95% CIs) 
 
Interaction between 
RS and PD 
CpG site 
Amioca 
(placebo) 
Hi-Maize® 260 
(RS) 
P value 
Maltodextrin 
(placebo) 
Litesse® Ultra™ 
(PD) 
P value P value 
7 
N=58 
31.1 
(29.1 – 33.1) 
32.4 
(30.4 – 34.4) 
0.404 
32.8 
(30.8 – 34.8) 
30.7 
(28.6 – 32.7) 
0.152 0.605 
Mean 
N=63 
29.0 
(27.3 – 30.7) 
28.8 
(27.1 – 30.7) 
0.954 
30.2 
(28.5 – 32.0) 
27.7 
(26.0 – 29.4) 
0.055 0.777 
Data are expressed LSMs and 95% CIs for percentage methylation (%) at each CpG site and the mean across all seven sites. 
 
1
7
2
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4.4.4.3 Exploration of additional factors influencing SFRP1 methylation 
The effect of pre-intervention SFRP1 methylation, age, gender, endoscopy 
procedure, BMI and smoking status on post-intervention methylation as 
covariates were analysed for each CpG site and mean SFRP1 methylation 
using the ANOVA GLM. Gender, endoscopy procedure, BMI and smoking 
status did not affect post-intervention SFRP1 methylation.  
Post-intervention SFRP1 methylation was significantly affected by pre-
intervention levels at all sites and for the mean methylation across all sites 
(p<0.001) (Table 4.11). Age was also a determinant of post-intervention 
methylation at CpG sites 1 (p=0.037), 4 (p=0.022) and 7 (p=0.041) but did not 
affect the mean methylation.  
Table 4.11 P values for the effects of pre-intervention methylation, age, 
gender, endoscopy procedure, BMI and smoking status on post-
intervention SFRP1 methylation. 
CpG Site 
Pre-
intervention 
methylation 
Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
1 <0.001 0.037 0.447 0.116 0.557 0.300 
2 <0.001 0.110 0.341 0.310 0.251 0.170 
3 <0.001 0.352 0.745 0.354 0.275 0.341 
4 <0.001 0.022 0.709 0.171 0.179 0.949 
5 <0.001 0.062 0.597 0.523 0.194 0.208 
6 <0.001 0.070 0.499 0.225 0.146 0.542 
7 <0.001 0.041 0.535 0.084 0.336 0.879 
Mean <0.001 0.119 0.602 0.553 0.155 0.535 
 
Spearman correlation analyses revealed positive correlations between age and 
post-intervention SFRP1 methylation at CpG sites 1, 4 and 7, with Spearman 
correlation coefficients of 0.596 (p<0.001), 0.555 (p<0.001) and 0.606 (p<0.001) 
respectively (Figure 4.10).  
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Figure 4.10 Positive correlations between age and SFRP1 methylation for 
CpG sites 1, 4 and 7.  
 
Correlation between age and post-intervention methylation. (A) N=66, (B) N=67 
and (C) N=58. 
4.4.4.4 Correlation of SFRP1 methylation between CpG sites 
Spearman correlation analyses were used to investigate the correlation 
between levels of SFRP1 methylation between the seven CpG sites. Both pre- 
and post-intervention, SFRP1 methylation was strongly correlated between the 
seven CpG sites (Figure 4.11). 
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Figure 4.11 Correlation of SFRP1 methylation between CpG sites. 
 
Values represent Spearman correlation coefficients (ρ) pre- (A) (N=69) and post-
intervention (B) (N=64). P<0.001. 
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4.4.4.5 Correlation between SFRP1 methylation and expression 
Spearman correlation analyses were used to investigate whether levels of DNA 
methylation correlated with SFRP1 expression. Inverse correlations between 
pre-intervention SFRP1 methylation and expression were observed at each 
CpG site and the overall mean (Table 4.12). Although this was not statistically 
significant, a close to significant p value was observed at CpG sites 4 and 5. 
Interestingly, the opposite trend was observed for the post-intervention data, 
where DNA methylation correlated positively with SFRP1 expression. This was 
statistically significant at CpG sites 1 (p=0.033), 3 (p=0.008), 6 (p=0.030) and 7 
(p=0.030) (Table 4.12).  
Table 4.12 Correlation between pre- and post-intervention SFRP1 
methylation and gene expression at each CpG site and for the mean 
across all sites. 
 Pre-intervention Post-intervention 
CpG site 
Spearman 
correlation 
coefficient 
P value 
Spearman 
correlation 
coefficient 
P value 
1 -0.189 0.260 0.357 0.033 
2 -0.294 0.073 0.309 0.071 
3 -0.284 0.087 0.427 0.008 
4 -0.304 0.063 0.300 0.071 
5 -0.308 0.063 0.328 0.051 
6 -0.282 0.095 0.367 0.030 
7 -0.226 0.190 0.383 0.030 
Mean -0.200 0.240 0.313 0.067 
Spearman correlation coefficients and corresponding p values for the correlation 
between SFRP1 methylation and expression pre- and post-intervention. N=37. 
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4.4.5 Discussion 
Gene expression may be regulated by epigenetic mechanisms such as DNA 
methylation. DNA hypermethylation is associated with reduced transcription and 
therefore a reduction in gene expression. To test the hypothesis that the 
observed effects of RS and PD on SFRP1 expression may have resulted from 
effects on the methylation state of SFPR1, DNA methylation was quantified at 
seven CpG sites within the promoter region of SFRP1. 
RS and PD did not have a significant effect on SFRP1 methylation at any of the 
seven CpG sites or on the mean methylation across all sites. This suggests that 
changes in SFRP1 gene expression resulted from mechanisms other than DNA 
methylation. However, a close to significant effect of PD was observed on the 
mean SFRP1 methylation across all seven CpG sites (p=0.055). Mean SFRP1 
methylation appeared to be lower in participants supplemented with PD, which 
would be associated with an increase in gene expression. However, this is the 
opposite to findings from the analyses on SFRP1 expression, where PD 
supplementation downregulated SFRP1.  
Methylation at the seven CpG sites analysed correlated strongly, as 
investigated using the Spearman correlation analysis. Despite this, the effects 
of the intervention on SFRP1 methylation were analysed at each CpG site as 
previous studies have shown that differences in methylation at specific, but not 
all, CpG sites may be observed between treatment groups. For example, 
Weaver et al. showed that nerve growth factor-inducible protein A methylation 
at CpG site 16 was increased in the offspring of high pup licking and grooming 
and arched-back nursing rat mothers whereas this is rarely methylated in rats 
with low levels of pup licking and grooming (Weaver et al., 2004). In contrast, 
methylation at CpG site 17 does not differ with differences in maternal care. In 
addition, the biological relevance of methylation at each CpG site may vary due 
to differences in the proximity to transcription factor binding sites. 
To further investigate the correlation between DNA methylation and expression 
levels, the Spearman correlation analysis was run on both pre and post-
intervention data. A trend for an inverse correlation between SFRP1 methylation 
and gene expression was observed for the pre-intervention data. However, the 
opposite was apparent for the post-intervention data, where a positive 
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correlation between post-intervention methylation at CpG sites 1, 3, 6 and 7 and 
SFRP1 expression was observed. This is contrary to reports in the literature 
that show a reduction in gene expression with increased DNA methylation.  
The effects of age, gender, endoscopy procedure, BMI and smoking status on 
post-intervention SFRP1 methylation were also explored. Post-intervention 
methylation was significantly affected by pre-intervention methylation levels at 
each site and the mean methylation across all sites. In addition, positive 
correlations between age and post-intervention SFRP1 methylation at CpG 
sites 1, 4, and 7 were observed. These findings are consistent with results from 
previous studies where SFRP1 promoter methylation was observed to be more 
common in CRC patients aged over 50 years (Rawson et al., 2011). A 
significant correlation between age and SFRP1 methylation has also been 
reported in the distal, but not proximal, normal-appearing mucosa (An et al., 
2010).  
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4.5 The effects of supplementation with RS and PD on colonic crypt cell 
proliferative state in the human colorectal mucosa 
4.5.1 Introduction 
Regulation of cell proliferation within the crypt is imperative for the maintenance 
of homeostasis within the colon. Importantly, altered cell proliferation can lead 
to an imbalance in cell proliferation and apoptosis leading to a hyperproliferative 
state that may promote colorectal tumourigenesis. Here I report the results of 
the effects of supplementation with RS and PD on the colonic crypt cell 
proliferative state (CCPS) in microdissected, Schiff reagent-stained human 
rectal biopsies. 
4.5.1.1 Effects of resistant starch on crypt cell proliferation in the healthy 
colon 
To date, the majority of studies exploring the effects of supplementation with RS 
on cell proliferation in the healthy colon have reported an increase in cell 
proliferation or have not observed any effects. On the contrary, a very early 
study reported a reduction in cell proliferation in 14 healthy participants 
supplemented with 45g of native amylomaize, equivalent to 28g of type 2 RS, 
for two weeks (van Munster et al., 1994).   
Mentschel and colleagues have investigated the effects of supplementation with 
resistant potato starch, a type 2 RS, for 19 days in 12 male pigs (Mentschel and 
Claus, 2003). Faecal butyrate concentrations were significantly higher in pigs 
fed the RS diet compared with the control group. Although the crypt length was 
significantly longer with RS supplementation, there was no effect observed on 
overall total mitosis, determined by histocytochemical analysis of Ki-67. 
However, when dividing the crypt into thirds and determining levels of mitosis in 
each compartment, the investigators found that pigs fed RS had increased cell 
proliferation in the middle and luminal compartments. On the contrary, cell 
proliferation was reduced in the lower stem cell compartment in pigs fed RS. 
In a small human study, 12 healthy participants consumed a control diet 
supplemented with corn starch (low RS) for four weeks, followed by a six-week 
washout period and another four weeks of control diet supplemented with up to 
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59.7g of highly resistant amylomaize starch per day (Wacker et al., 2002). 
There were no significant differences in rectal colonic crypt cell proliferation 
levels, measured by bromodeoxyuridine labelling, observed between the low 
and high RS diet periods.  
A randomised, double-blind, placebo-controlled, four-week crossover trial 
supplemented 20 healthy participants with RS, in the form of 25g/day of high-
amylose maize starch (HAMS), and/or 5g/day of Bifidobacterium lactis 
(Worthley et al., 2009). Again, the investigators did not observe an effect of 
either intervention on colonic crypt cell proliferation, assessed by 
immunohistochemical analysis of Ki-67. 
4.5.1.2 Effects of resistant starch on crypt cell proliferation in the 
diseased colon 
The majority of studies that have investigated the effects of RS on cell 
proliferation in the diseased colon used animal models of CRC, such as 
carcinogen-treated rats. Most of these studies have reported a reduction in 
crypt cell proliferation with RS administration.  
An in vivo study investigated the effects of RS administration, in the form of 
HAMS, on AOM-induced colorectal carcinogenesis in rats (Le Leu et al., 2007). 
Rats supplemented with both doses of RS (10% and 20%) showed significantly 
reduced proliferation in the distal colon, as indicated by a decrease in 
proliferating cell nuclear antigen labelling. SCFA analyses revealed that RS 
increased butyrate concentrations in the caecum, proximal colon, distal colon 
and in faeces and that this was statistically significant for the higher dose of RS 
(20% HAMS).  
A more recent study, using the AOM-induced rat model of colorectal 
carcinogenesis, compared levels of colonic proliferation and apoptosis in rats 
fed a low RS diet, a low RS diet plus tributyrin, a HAMS diet or a 10% 
butyrylated HAMS (HAMSB) diet (Clarke et al., 2012). The HAMSB diet yielded 
the highest colonic butyrate concentrations compared with the other three diet 
groups. Results from this study showed a trend for a reduction in cell 
proliferation, measured by immunohistochemical staining of Ki-67, in the distal 
colon of rats on the HAMS and HAMSB diets. Rats on the low RS diet 
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supplemented with tributyrin, a pro-drug of butyrate, also appeared to have 
lower levels of proliferation. 
Another study investigated the effects of a RS type 3 in a chemically-induced rat 
model of colon carcinogenesis (Bauer-Marinovic et al., 2006). Proliferation was 
assessed by immunohistochemical staining of Ki-67. The investigators 
observed a significant reduction in the number of proliferating cells, the size of 
the proliferative compartment and the crypt length in the distal, but not proximal, 
colon of rats fed the RS compared with standard diet. 
In another model of colorectal tumourigenesis, Young et al. compared the 
effects of a control diet, a raw potato starch (type 2 RS) diet and a diet with both 
potato starch and wheat bran (a non-starch polysaccharide) in DMH-treated rats 
(Young et al., 1996). Crypt depth was 15% longer in rats fed both potato starch 
diets compared with the control diet and this was associated with a significant 
increase in the number of cells entering metaphase during a three hour period, 
assessed histologically by haematoxylin and eosin staining.  
Winter et al. investigated the effects of RS in a Western diet model of 
spontaneous CRC, where mice were given a control diet or a diet containing 
heme, RS or heme plus RS (Winter et al., 2014). The diets containing RS 
significantly increased the faecal concentrations of butyrate, acetate and 
propionate both after four weeks and 18 months on the diet. Short-term data, 
after four weeks, indicated that mice fed the heme-rich diet had significantly 
increased cell proliferation in the colon. The investigators did not observe an 
effect of short-term supplementation with RS on cell proliferation in the colon. 
However, they found that RS significantly increased crypt height. Long-term 
analyses, following 18 months on the respective diets, showed that mice on the 
RS diets had both significantly increased colonic cell proliferation and increased 
crypt height. 
A two part, randomised and blinded study in rats was designed by Perrin and 
colleagues to mimic a human prospective study (Perrin et al., 2001). Mucosal 
proliferation was assessed after 44 days on the control diet or one of the 
following three high fibre diets: starch-free wheat bran, short-chain fructo-
oligosaccharides or RS type 3. There were no differences in proliferation 
observed between the low and higher fibre diets, or between the high (RS and 
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short-chain fructo-oligosaccharides) and low (control and starch-free wheat 
bran) butyrate-producing diets.  
Studies investigating the effects of RS in the diseased colon in humans with 
colorectal illnesses, however, have yielded conflicting results. Although a couple 
of studies have shown that RS consumption in humans resulted in reduced 
colonic crypt cell proliferation, many have not observed an effect of RS on 
proliferation.  
In a RCT undertaken in 65 patients with CRC or symptoms of CRC, Dronamraju 
and colleagues investigated the effects of RS supplementation for up to four 
weeks on cell proliferation, assessed by whole-crypt microdissection of Schiff 
reagent-strained crypts (Dronamraju et al., 2009). The trial comprised two 
separate studies, and there were no effects of RS observed on post-intervention 
total mitoses or crypt measurements in either study. However, supplementation 
with RS reduced the proportion of mitotic cells in the top half of the crypt, and 
this was statistically significant in Study 1 (p=0.028). When data from both 
studies were pooled, the authors observed a 44% reduction in the proportion of 
mitotic cells in the top half of the crypt in participants supplemented with RS 
compared with ordinary starch (p=0.07).  
A more recent study by Burn et al. randomised 206 FAP patients from 12 
international centres to one of the four following intervention groups: aspirin plus 
RS, aspirin plus RS placebo, aspirin placebo plus RS or aspirin placebo plus 
RS placebo (Burn et al., 2011a). The investigators assessed proliferation by 
direct counting of mitotic cells in microdissected crypts and 
immunohistochemical analysis of Ki-67. A trend for an increased number of 
mitotic cells in participants given RS compared with the non-RS groups was 
observed (p=0.12), but this was not reflected in the data from the 
immunohistochemical analysis. There were no effects of RS on colonic crypt 
dimensions, although the authors did observe a significant reduction in mean 
crypt length over time in participants given RS compared with those given RS 
placebo (p<0.001).   
A study by Grubben et al. investigated the effects of RS on cell proliferation in 
23 patients with recently removed adenomas (Grubben et al., 2001). 
Participants were stratified by gender and randomised to the control group or 
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the RS group, where they were supplemented with 45g of high amylomaize 
starch, equating to 28g of RS type 2, for four weeks. However, the investigators 
did not observe significant differences in cell proliferation between the two 
groups.  
A similar finding was observed in a randomised, double-blind, placebo-
controlled trial that recruited 111 patients with sporadic adenomas (van Gorkom 
et al., 2002). Participants were randomised to the control group (two placebos), 
the calcium group (1g calcium plus RS placebo) or the RS group (30g 
amylomaize, equating to 19g of RS, plus calcium placebo) for two months. The 
investigators did not observe any differences in total or luminal proliferation, 
measured by bromodeoxyuridine incorporation, between the three intervention 
groups at any of the four sites (caecum, transverse colon, sigmoid colon or 
rectum).  
4.5.1.3 Effects of polydextrose on colonic crypt cell proliferation in the 
colon 
To date, studies investigating the effects of PD on colonic crypt cell proliferation 
are limited. In vitro, Putaala and colleagues used Enteromix®, an in vitro semi-
continuous colon simulator comprising four vessels that mimic the human 
proximal, ascending, transverse and distal colon, to simulate the fermentation of 
PD and produce the PD metabolome (Putaala et al., 2011).  The latter was then 
used to treat Caco-2 human colonic adenocarcinoma cells to investigate the 
effects of the fermented PD, as well as 5mM butyrate and 100mM NaCl, on 
Caco-2 cells. After 24 hours, treatment with the fermentation metabolome from 
2% PD retrieved from the proximal, ascending and distal colon vessels resulted 
in significantly reduced levels of proliferation compared with 0% PD.  
In vivo, an animal study investigated the effects of PD in the large intestine of 
Sprague-Dawley rats (Yoshioka et al., 1994). The first experiment divided 62 
rats into six groups which administered three different doses of PD, cellulose or 
galatomannan. The second experiment further investigated the effects of 
different doses (5, 10 and 20%) of PD or a fibre-free diet in 35 rats. The authors 
used haematoxylin and eosin staining of caecal and colonic samples to assess 
crypt depth and muscular layer thickness but did not measure cell proliferation 
directly. Results from the first experiment did not report a significant difference 
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in caecal or colonic crypt lengths between the six groups. However, in the 
second experiment, the investigators observed significantly longer crypts in the 
caecum of rats given the highest PD dose (20%) compared with the lowest PD 
dose (5%) and the fibre-free diet.  
A Chinese randomised, double-blind, placebo-controlled human study explored 
the effects of supplementation with three doses of PD (4g PD/day, 8g PD/day or 
12g PD/day) or control for 28 days in 120 healthy participants (Jie et al., 2000). 
Proliferation in the caecum was assessed using light microscopy following 
staining of samples with Schiff reagent. PD increased post-intervention caecal 
butyrate concentrations compared with pre-intervention levels and compared 
with the control group, and this was statistically significant for the two highest 
PD doses. All three PD doses resulted in significantly higher post-intervention 
total whole crypt proliferation compared with pre-intervention levels and the 
control group.  
4.5.1.4 Effects of butyrate on crypt cell proliferation in the healthy colon 
In the healthy colon, or in in vitro studies using normal cells, butyrate has either 
produced no effect on proliferation or has resulted in increased cell proliferation. 
In vivo, a study in piglets investigated the effects of colon-delivered butyrate on 
colonic cell proliferation (Kien et al., 2007). Twenty-four piglets were 
randomised to either the control group, the caecal butyrate infusion group, the 
inulin supplementation group or the caecal butyrate infusion plus inulin 
supplementation group. Cell proliferation was assessed by bromodeoxyuridine 
labelling and crypt measurements were taken. The proliferative index in piglets 
in the caecal butyrate infusion group was significantly higher in the caecum and 
distal colon compared to the control group.  
In humans, Mortensen et al. investigated the effects of butyrate administered 
directly to the rectum via Hartmann’s procedure in eight patients (Mortensen et 
al., 1999).  Participants were given 100ml of placebo for 14 days followed by 
100ml of SCFAs for 14 days in a blinded manner. Cell proliferation was 
determined by immunohistochemical analysis of Ki-67 in rectal biopsies. A 
significant increase in proliferation following Hartmann’s procedure was 
observed in the rectal mucosa post-SCFA treatment compared with baseline 
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and post-placebo levels. Furthermore, the majority of the increase in 
proliferating cells was observed in the upper two thirds of the crypt.  
Another study investigated the effects of three SCFAs at physiological 
concentrations utilising caecal biopsies taken from 45 healthy participants 
(Scheppach et al., 1992). Tissues were incubated for three hours with acetate, 
propionate and butyrate, both in combination and individually. Caecal 
proliferation was assessed autoradiographically by thymidine incorporation 
analyses and was increased by all SCFAs both individually and in combination. 
Butyrate (10mmol/L) significantly increased cell proliferation by 89%, which was 
comparable to the increase achieved following combined incubation with all 
three SCFAs. When the crypts were divided into five compartments of equal 
size, the observed increase in proliferation was restricted to the basal three 
compartments.  
4.5.1.5 Effects of butyrate on crypt cell proliferation in the diseased colon 
In the diseased colon however, butyrate results in the opposite effect and has 
been reported to reduce cell proliferation. This has been named ‘the butyrate 
paradox’. 
In a study by Hodin and colleagues, cell proliferation following butyrate 
treatment was assessed in HT-29 cells by both cell counts and thymidine 
incorporation analyses (Hodin et al., 1996). Significantly reduced cell 
proliferation, as demonstrated by a 32% decrease in total cell number, was 
observed in HT-29 cells treated with 5mM butyrate for 48 hours compared with 
the control.   
In vivo, Clarke et al. investigated the effects of increasing colonic butyrate 
concentrations through the delivery of butyrylated starch on colonic rates of 
apoptosis and proliferation in AOM-treated rats (Clarke et al., 2012). The rats 
fed a 10% HAMSB diet had higher colonic digesta and plasma SCFA 
concentrations compared with the other three groups that were not given 
butyrate. Furthermore, the authors observed a correlation between luminal 
butyrate concentrations and an increase in apoptosis in the distal colon of the 
HAMSB rats. In addition, this increase in apoptotic rates occurred 
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predominantly in the lower, normally proliferative, crypt compartments. 
However, there were no effects of butyrate on the rates of proliferation.  
To try and explain the contradictory outcomes observed by butyrate, Comalada 
et al. investigated the effects of butyrate treatment in foetal human normal colon 
cells and in colon adenocarcinoma HT-29 cells (Comalada et al., 2006). An 
inhibitory effect of butyrate was observed on the proliferation of HT-29 cells. 
However, in the normal, healthy cells, the authors did not observe an effect of 
butyrate, or the other tested SCFAs, on cell proliferation at any of the tested 
concentrations.   
4.5.2 Hypotheses, Aims and Objectives  
4.5.2.1 Hypotheses 
The hypothesis for this study was that NDCs would reduce CCPS and, in 
particular, decrease the proportion of mitotic cells in the top half of the crypt. 
4.5.2.2 Aims 
This study aimed to test this hypothesis by investigating the effects of 
supplementing healthy participants with NDCs on CCPS and crypt dimensions.  
4.5.2.3 Objectives 
 To stain, using Schiff reagent, and microdissect whole crypts from 
Carnoy’s-fixed rectal biopsies; 
 To count the number of mitotic cells in ten intact crypts from each 
participant; 
 To record crypt measurements (length and width) from ten intact crypts 
from each participant; 
 To calculate the proportion of mitotic cells in the top half of the crypts; 
 To assess the effects of the intervention on CCPS and crypt dimensions; 
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 To explore the effects of key epidemiological factors including age and 
gender on CCPS and crypt dimensions. 
4.5.3 Methods 
The methods used for the assessment of CCPS can be found in section 2.2.4. 
Briefly, Carnoy’s-fixed biopsies were hydrated, hydrolysed and stained in Schiff 
reagent prior to microdissection. CCPS was analysed in 38 participants, with 
ten intact crypts analysed per participant by light microscopy. The number of 
mitotic cells as well as crypt measurements were recorded.  
4.5.4 Results 
4.5.4.1 Baseline characteristics of intervention participants analysed for 
analysis of colonic crypt cell proliferation 
Colonic crypt cell proliferation was analysed in a total of 38 participants 
comprising comparable numbers in each intervention group (Table 4.13). The 
characteristics of the participants in terms of age, gender, BMI, smoking status 
and endoscopy within each group were also representative of that observed in 
the complete set of 75 intervention participants.  
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Table 4.13 Baseline characteristics of intervention participants analysed 
for analysis of colonic crypt cell proliferation. 
Intervention group A B C D 
RS - - + + 
PD - + - + 
Number of 
participants 
10 10 9 9 
Ethnicity 
Caucasian (%) 
Black African (%) 
Mixed race (%) 
 
9 (90) 
1 (10) 
0 (0) 
 
9 (90) 
0 (0) 
1 (10) 
 
9 (100) 
0 (0) 
0 (0) 
 
9 (100) 
0 (0) 
0 (0) 
Gender 
Female (%) 
Male (%) 
 
5 (50) 
5 (50) 
 
5 (50) 
5 (50) 
 
7 (78) 
2 (22) 
 
3 (33) 
6 (67) 
Age 
Mean (years) 
Range 
 
47.6 
30 – 68 
 
62.3 
42 – 80 
 
53.6 
42 – 67 
 
52.6 
37 – 74 
Smoking status 
Never (%) 
Former (%) 
Current (%) 
 
8 (80) 
1 (10) 
1 (10) 
 
6 (60) 
2 (20) 
2 (20) 
 
6 (67) 
2 (22) 
1 (11) 
 
4 (45) 
3 (33) 
2 (22) 
BMI 
Mean (kg/m2) 
Range 
 
28.2 
23.2 – 36.2 
 
28.9 
23.2 – 38.4 
 
30.5 
26.3 – 34.6 
 
30.4 
23.4 – 41.8 
Procedure 
Colonoscopy (%) 
Flexible    
Sigmoidoscopy (%) 
3 (30) 
7 (70) 
3 (30) 
7 (70) 
3 (33) 
6 (67) 
3 (33) 
6 (67) 
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4.5.4.2 Effects of non-digestible carbohydrates on colonic crypt cell 
proliferative state 
The colonic CCPS was analysed in ten crypts per participant using whole crypt 
microdissected Schiff reagent-stained rectal biopsies. Proliferation was 
assessed by counting the number of mitotic cells in ten equally-sized 
compartments per crypt and calculating the mean total number of mitotic cells 
per crypt and the percentage of mitotic cells in the top half of the crypts.  
The data for the effects of supplementation with RS and PD on CCPS and crypt 
measurements are summarised in (Table 4.14). A significant effect of RS 
supplementation on the mean total number of mitotic cells per crypt (p=0.03) 
was observed. Participants supplemented with RS had significantly higher 
mean total mitoses counts, with a mean of 8 mitotic cells per crypt compared 
with 6 mitotic cells per crypt in participants given placebo. However, there was 
no significant effect of either RS or PD on the percentage of mitotic cells in the 
top half of the crypt. 
When applying Bonferroni’s correction for multiple testing, the set p-value is 
lowered to 0.01 and so the statistically significant effects of RS on the mean 
total number of mitotic cells per crypt (p=0.03) is lost. 
In addition to mitotic counts, crypt measurements were also recorded in the 
form of crypt width and length, and the crypt volume was calculated. There were 
no effects of RS or PD observed on the crypt measurements. 
   
 
Table 4.14 Effects of supplementation with RS and PD on CCPS and crypt dimensions. N=36.  
 
RS allocation 
LSM (95% CI) 
 
PD allocation 
LSM (95% CI) 
 
Interaction 
between RS 
and PD 
 
Placebo 
(Amioca) 
RS 
(Hi-Maize® 260) 
P value 
Placebo 
(Maltodextrin) 
PD 
(Litesse® Ultra™) 
P value P value 
Total 
mitoses 
6.20 
(4.99 – 7.41) 
8.33 
(7.05 – 9.61) 
0.030 
7.37 
(6.10 – 8.65) 
7.15 
(5.89 – 8.42) 
0.821 0.685 
Mitoses in 
top half of 
crypt (%) 
4.44 
(2.26 – 7.35) 
4.54 
(2.22 – 7.68) 
0.960 
4.29 
(2.05 – 7.36) 
4.69 
(2.33 – 7.85) 
0.848 0.270 
Crypt length 
(µm) 
540 
(508 – 573) 
532 
(498 – 567) 
0.765 
538 
(503 – 572) 
535 
(501 – 570) 
0.930 0.612 
Crypt width 
(µm) 
117 
(109 – 125) 
120 
(111 – 129) 
0.648 
115 
(106 – 123) 
122 
(114 – 131) 
0.268 0.958 
Crypt 
volume 
(µm3) 
5.81 x 106 
(4.85  x 106 – 
6.86 x 106) 
6.13 x 106 
(5.09 x 106 –   
7.27 x 106) 
0.685 
5.65 x 106 
(4.66  x 106 – 
6.74  x 106) 
6.30 x 106 
(5.25 x 106 – 7.45 
x 106) 
0.432 0.918 
1
9
0
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4.5.4.3 Exploration of additional factors influencing colonic crypt cell 
proliferative state 
The effects of the pre-intervention measurement, age, gender, endoscopy 
procedure, BMI and smoking status were analysed as covariates using the 
ANOVA GLM. 
There were no effects of any of the covariates observed on any of the outcome 
measurements of CCPS, with the exception of the total number of mitotic cells 
per crypt (Table 4.15). The post-intervention total number of mitotic cells per 
crypt was significantly affected by the pre-intervention measurement (p=0.006). 
Table 4.15 P values for the effects of pre-intervention measurement, age, 
gender, endoscopy procedure, BMI and smoking status on CCPS 
measured outcomes. 
 
Pre-
intervention 
measurement 
Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
Total 
mitoses 
0.006 0.147 0.847 0.537 0.930 0.726 
Mitoses in 
top half of 
crypt (%) 
0.085 0.721 0.531 0.570 0.244 0.125 
Crypt 
length 
0.053 0.697 0.309 0.263 0.784 0.902 
Crypt 
width 
0.139 0.238 0.543 0.965 0.323 0.895 
Crypt 
volume 
0.146 0.452 0.363 0.746 0.470 0.827 
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4.5.5 Discussion  
Studies investigating the effects of RS, PD and butyrate on colonic crypt cell 
proliferation have yielded inconsistent results. In the normal colon, in vitro and 
in vivo studies have suggested that NDCs and butyrate may induce proliferation 
and others have reported no effect. This could be explained by the fact that 
butyrate is the main energy source for colonocytes and therefore may have 
trophic effects in the colon. However, in the diseased colon, the opposite has 
been observed, with a reduction in proliferation following NDC or butyrate 
administration in vitro in colorectal carcinoma cell lines and in vivo, both in 
animal models of CRC and in patients with CRC or other colonic diseases. This 
controversy is particularly true in studies investigating the effects of butyrate, 
where this phenomenon has been named the ‘butyrate paradox’.  
To test the effects of supplementation with RS and PD on the CCPS in the 
healthy colorectal mucosa, rectal biopsies were stained with Schiff reagent and 
microdissected. Ten intact crypts were analysed and divided into ten equal-
sized compartments in which the number of proliferating cells were counted and 
crypt measurements were recorded.  
An effect of RS, but not PD, was observed on the mean total number of mitotic 
cells per crypt (Figure 4.12). Total mitoses were significantly greater in 
participants supplemented with RS compared with placebo (p=0.030). As the 
distribution of mitotic cells may be more significant than the total number of 
proliferating cells themselves, with the majority of mitotic cells being localised to 
the basal half of the crypt, the proportion of mitotic cells in the lower and upper 
halves of the crypts were calculated. The percentage of mitotic cells in the top 
half of the crypt were comparable in all four intervention groups, suggesting 
that, although RS increased the total number of mitotic cells, RS did not have 
an adverse effect through alterations to the proportion of mitotic cells in the 
upper half of the crypts. There were no significant effects of either RS or PD on 
the additional measured outcomes.  
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Figure 4.12 Significant effect of supplementation with RS on the mean 
total number of mitotic cells per crypt.  
 
Data are expressed as LSMs and error bars represent 95% CIs. *p<0.05 for effect of 
active agent versus placebo. N=36. 
In conclusion, the findings from my study are consistent with findings from 
studies in the healthy colon where an increase in colonic crypt cell proliferation 
has been reported with RS or butyrate supplementation.  
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4.6 The effects of supplementation with RS and PD on expression of 
BAX and BCL-2 apoptotic genes in the human colorectal mucosa 
4.6.1 Introduction 
The method utilised for the assessment of CCPS, whole crypt microdissection 
of Schiff reagent-stained biopsies, did not allow for the analysis of apoptosis as 
the recording of cells undergoing apoptosis was rare. Because of this, the 
effects of supplementation with RS and PD on apoptosis in the human 
colorectal mucosa were assessed by quantifying the expression of two 
apoptotic genes: Bcl-2-associated X (BAX), a pro-apoptotic gene, and B-cell 
lymphoma 2 (BCL-2), an anti-apoptotic gene.  
4.6.1.1 BAX and BCL-2-mediated apoptosis 
BAX and BCL-2 are members of the Bcl-2 family of proteins that regulate 
apoptosis. BCL-2 was the first member of the family discovered and has been 
identified as a proto-oncogene (Gross et al., 1999).  
BAX is normally localised to the cytoplasm and, in the presence of a death 
stimulus, BAX forms a homodimer and translocates to the mitochondria where it 
acts as an integral membrane protein (Wolter et al., 1997). On the other hand, 
BCL-2 is permanently located as an integral membrane protein in the 
mitochondria and, in the healthy colon, BCL-2 is found at the base of the crypts 
(Biden et al., 1999). In the presence of BCL-2, activation of BAX is inhibited and 
BAX and BLC-2 are able to form heterodimers. More important than the 
expression of BAX or BCL-2 individually in determining cell fate is the ratio of 
the two (Oltvai et al., 1993). 
4.6.1.2 The role of BAX and BCL-2 in colorectal carcinogenesis 
Altered rates of apoptosis, leading to an imbalance in proliferation and 
apoptosis that favours tumour growth, have been associated with colorectal 
carcinogenesis. This can result from aberrant expression of genes involved in 
the regulation of apoptosis. Due to its role in inhibiting apoptosis and promoting 
cell survival, BCL-2 has been defined as an oncogene (Hockenbery, 1992). 
Aberrant BCL-2 expression has been described as an early event in colorectal 
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carcinogenesis and is abnormally expressed in up to 75% of carcinomas (Biden 
et al., 1999). This has also been reported in normal tissue adjacent to colorectal 
tumours (Bronner et al., 1995) Expression of BCL-2 may prevent the removal of 
cells containing DNA damage and can confer a growth advantage to cancerous 
cells.   
On the contrary, expression of pro-apoptotic BAX has been reported to be 
reduced in CRC. BAX is also frequently mutated in CRC (Ouyang et al., 1998), 
leading to gene inactivation. Progression of cancer stage has been associated 
with further reduction of BAX expression (Tsamandas et al., 2007).  
4.6.1.3 Effects of non-digestible carbohydrates on BAX and BCL-2 
expression 
A study investigated the protective effects of polysaccharide of Larimichthys 
crocea swimming bladder (PLCSB) in a mouse model of colon carcinogenesis 
(Chen et al., 2014a). The authors observed a significant reduction in anti-
apoptotic BCL-2 and an increase in pro-apoptotic BAX protein expression, 
determined by Western Blot, in the mice in the PLCSB group and found that this 
effect was enhanced in the group of mice given PLCSB plus RS type 3 
microspheres. 
To date, there have not been any previous studies investigating the effect of PD 
on BAX and BCL-2 expression. To my knowledge, the present study is the first 
study to investigate the effects of supplementation with PD on expression of 
BAX and BCL-2 in the healthy colorectal mucosa.  
Furthermore, only one study has investigated the effects of PD on apoptosis in 
the colon. Putaala and colleagues used a semi-continuous colon simulator 
model, Enteromix®, to investigate the effects of 1% and 2% PD on apoptosis in 
the human adenocarcinoma cell line Caco-2 (Putaala et al., 2011). The effects 
of PD on apoptosis were analysed by enzyme-linked immunosorbent assay 
(ELISA) and by analysis of caspase activation. The authors found a significant 
increase in apoptosis and in caspase-3 activation, suggesting that like RS, PD 
may also positively modulate the regulation of apoptosis in models of colorectal 
carcinogenesis by inducing apoptosis.  
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4.6.1.4 Effects of butyrate on BAX and BCL-2 expression 
Similar to the butyrate paradox used to describe the conflicting effects of 
butyrate on cell proliferation, effects on apoptosis differ between healthy and 
diseased colon models. In the healthy colon, butyrate has been reported to 
reduce apoptosis, whereas in the diseased colon it has been observed to 
induce apoptosis.  
In a model of the healthy colon, although Mentschel et al. did not observe an 
effect of butyrate on colonic crypt cell proliferation in pigs, they reported 
significantly lower levels of apoptosis, determined using the terminal 
deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) assay, in the 
pigs fed a raw potato starch diet, as a source of butyrate, compared with the 
control group (Mentschel and Claus, 2003). In addition, histocytochemical 
analyses revealed significantly higher expression of BCL-2 by two-fold in the 
butyrate group.  
Incubation of guinea pig colon tissue sheets with 10mmol/L butyrate has been 
observed to result in a more sparse population of apoptotic cells compared with 
control, where a substantial amount of apoptotic cells were detected on the 
mucosal surface (Hass et al., 1997). The effects of incubation with butyrate on 
BAX and BCL-2 protein levels were assessed by Western Blot. There were no 
differences observed in BCL-2 protein expression between control and butyrate-
treated tissues. However, expression of BAX was three-fold higher in control 
tissue compared with tissue incubated with butyrate. These effects were 
confirmed by immunohistochemical analyses where more intense staining of 
BAX was observed in control tissue. Results from this study suggest that the 
reduction in apoptosis observed with butyrate may result from reduced 
expression of the pro-apoptotic protein BAX.  
However, in models of colorectal carcinogenesis, studies have reported an 
induction of apoptosis by butyrate. An in vitro study investigated the effects of 
butyrate treatment of primary invasive human colonocytes on BAX and BCL-2 
protein levels by immunofluorescent confocal microscopy (Emenaker et al., 
2001). Butyrate treatment (0.01mol/L) significantly increased BCL-2 expression 
by 187% (p<0.001) and reduced BAX expression by 15% (p<0.001).  
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Another in vitro study investigated the effects of the fermentation product of RS 
type 3 on proliferation and apoptosis in the human colon cancer cell line HCT-
116 (Purwani et al., 2012). Apoptosis was detected semi-quantitatively by 
fluorescence microscopy. Butyrate treatment at concentrations of 2.6mM and 
5.3mM resulted in seven and nine-fold greater BAX expression respectively 
compared with untreated cells. However, there were no significant effects 
observed on BCL-2 expression. These findings suggest that there was an 
increase in the BAX:BCL-2 ratio, with an increase in pro-apoptotic BAX, thus 
promoting apoptosis. Indeed, the authors also observed an increase in levels of 
caspase-3, an activator of apoptosis, assessed by ELISA, with butyrate 
treatment of HCT-116 cells.  
A study by Ruemmele et al. reported that butyrate induced apoptosis by up to 
79% in a time- and dose-dependent manner in Caco-2 cells, but did not observe 
any effects on the expression of the BCL-2 protein (Ruemmele et al., 1999). A 
later study by the same group also did not observe effects of butyrate treatment, 
with concentrations up to 100mM, on the expression of BAX or BCL-2 proteins 
analysed by Western Blotting (Ruemmele et al., 2003). However, the authors 
reported an effect of butyrate on the expression of another protein from the Bcl-
2 family: BAK.  
4.6.2 Hypotheses, Aims and Objectives 
4.6.2.1 Hypotheses 
The hypothesis for this study was that NDCs would induce apoptosis by 
increasing the expression of pro-apoptotic genes i.e. BAX and reducing the 
expression of anti-apoptotic genes i.e. BCL-2.  
4.6.2.2 Aims 
This study aimed to test this hypothesis by investigating the effects of 
supplementing healthy human participants with NDCs on the expression of two 
apoptosis-related genes: BAX (pro-apoptotic) and BCL-2 (anti-apoptotic) in the 
colorectum.  
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4.6.2.3 Objectives 
 To quantify expression of BAX and BCL-2 by qPCR using cDNA already 
prepared for quantification of WNT pathway-related gene expression; 
 To investigate the effects of the supplementation with NDCs on 
expression of BAX and BCL-2 and on the ratio of BAX to BCL-2; 
 To explore the effects of key epidemiological factors including age and 
gender on expression of BAX and BCL-2 and on the ratio of BAX to BCL-
2. 
4.6.3 Methods 
The methods for this study can be found in section 2.2.5. cDNA was 
synthesised from RNA previously extracted for the quantification of WNT 
pathway-related gene expression. The expression of BAX and BLC-2, as well 
as the two housekeeping genes 18S and β2M, was quantified by qPCR. 
Reverse transcription and the quantification of BAX and BCL-2 were undertaken 
under my supervision by Idoia Ibero, an Erasmus Project student, to whom I am 
very grateful. 
4.6.4 Results 
As assessment of CCPS following microdissection of Schiff reagent-stained 
rectal biopsies did not allow for the successful analysis of apoptosis, the effects 
of the intervention on the expression of two genes, BAX (pro-apoptotic) and 
BCL-2 (anti-apoptotic), were investigated by qPCR. 
4.6.4.1 Effects of non-digestible carbohydrates on the expression of BAX 
and BCL-2 
Supplementation with RS and PD did not have an effect on expression of BAX 
or BCL-2 (Table 4.16). As regulation of apoptosis results from a balance 
between pro- and anti-apoptotic genes, BAX and BCL-2 expression data were 
expressed as a ratio (BAX/BCL-2). However, there were no significant effects of 
RS or PD on the ratio of BAX to BCL-2 (Table 4.16). 
   
 
Table 4.16 Effects of supplementation with RS and PD on expression of BAX and BCL-2 in the human rectal mucosa.  
 RS allocation  PD allocation  
Interaction 
between RS 
and PD 
Gene 
Placebo 
(Amioca) 
RS 
(Hi-Maize® 260) 
P value 
Placebo 
(Maltodextrin) 
PD 
(Litesse® Ultra™) 
P value P value 
BAX1 
2.61 
(1.51 – 3.64) 
1.97 
(1.13 – 3.31) 
0.390 
2.10 
(1.46 – 3.66) 
2.61 
(1.02 – 3.33) 
0.888 - 
BCL-21 
0.266 
(0.177 – 0.652) 
0.231 
(0.160 – 0.340) 
0.538 
0.266 
(0.201 – 0.359) 
0.220 
(0.123 – 0.704) 
0.375 - 
BAX/BCL-22 
0.808 
(0.778 – 0.838) 
0.826 
(0.765 – 0.585) 
0.425 
0.819 
(0.791 – 0.847) 
0.816 
(0.791 – 0.782) 
0.871 0.524 
1Data for BAX (N=49) and BCL-2 (N=46) expression are expressed as median and lower and upper quartiles for adjusted values (2-ΔCt x 10,000) 
relative to 18S and β2M housekeeping genes (Kruskal-Wallis test). 2Data for the BAX/BCL-2 ratios represent BAX ΔCt value to BCL-2 ΔCt value, 
relative to 18S and β2M housekeeping genes (N=43). Data are presented as LSMs and 95% CIs (ANOVA GLM). 
 
1
9
9
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4.6.4.2 Exploration of additional factors influencing BAX and BCL-2 
expression 
The effects of pre-intervention expression, age, gender, endoscopy procedure, 
BMI and smoking status on BAX, BCL-2 and the ratio of BAX/BCL-2 were 
assessed. There were no effects of any of the covariates observed for any of 
the outcomes with the exception of age. Age was a determinant of the post-
intervention ratio of BAX/BCL-2 (p=0.037). 
Table 4.17 P values for the effects of pre-intervention expression, age, 
gender, endoscopy procedure, BMI and smoking status on post-
intervention BAX and BCL-2 expression and on the BAX-BCL-2 ratio. 
Gene 
Pre-
intervention 
expression 
Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
BAX2 0.473 0.699 0.400 0.766 0.473 0.416 
BCL-22 0.471 0.331 0.272 0.608 0.472 0.524 
BAX/BCL-2 
(ΔCt)1 
0.151 0.037 0.407 0.684 0.135 0.955 
 
Analyses using Spearman’s correlation test revealed an inverse correlation 
between age and the post-intervention BAX/BCL-2 ratio (Spearman correlation 
coefficient of -0.300 (p=0.046)) (Figure 4.13). 
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Figure 4.13 Inverse correlation between age and post-intervention 
BAX/BCL-2 ratio. 
 
Data for the BAX/BCL-2 ratio represent BAX ΔCt value to BCL-2 ΔCt value, relative to 
18S and β2M housekeeping genes. N=43. 
4.6.5 Discussion 
The effects of supplementation with RS and PD on apoptotic rates in the colonic 
crypt were first assessed by light microscopy following whole crypt 
microdissection of Schiff reagent-stained crypts. However, this was not an 
appropriate indicator of apoptosis as the numbers of apoptotic cells observed by 
this method were negligible. An alternative method was utilised as an indicator 
of apoptosis: the quantification of two genes involved in the regulation of 
apoptosis: BAX, a pro-apoptotic gene, and BCL-2, an anti-apoptotic gene.  
Supplementation with RS or PD did not affect expression of BAX or BCL-2. As 
the regulation of apoptosis is achieved through a balance of pro- and anti-
apoptotic genes, the ratio of BAX to BCL-2 was calculated. Similar to that 
observed when the genes were expressed individually, there were no effects of 
RS or PD on BAX/BCL-2. However, an inverse correlation was observed 
between age and the post-intervention BAX/BCL-2 ratio.  
A small number of studies have specifically looked at the effects of NDCs on 
apoptosis via the quantification of BAX and BCL-2 expression. One study 
reported a greater reduction in BCL-2 and an increase in BAX proteins with the 
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addition of RS type 3 to PLCSB in a mouse model of colon carcinogenesis 
(Chen et al., 2014a). However, the results from this study showed no effect of 
either NDC on BAX or BCL-2 expression or on the ratio of these regulators of 
apoptosis in the rectal mucosa of healthy participants. 
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Chapter 5 The WNT signalling pathway and its functional 
outcomes in the macroscopically-normal mucosa of people 
at differential risk of colorectal cancer 
5.1 The DISC Study participants at differential risk of CRC 
For this study, I used samples and data from a total of 91 normal-risk 
participants. This included baseline samples and data from the 75 participants 
who took part in the dietary intervention study within the DISC Study plus 16 
dropout participants, i.e. those who did not complete the intervention or who 
were excluded for various reasons. The higher-risk groups consisted of two 
participant groups: the ‘UC’ group with 12 participants and the ‘Polyp’ group 
with 26 participants. The majority of participants in the ‘Normal’ group 
underwent endoscopic examination by flexible sigmoidoscopy, whereas almost 
all of the higher-risk participants had a colonoscopy. 
The participant characteristics of each group are detailed in Table 5.1. The 
majority of the participants were Caucasian. Within the ‘Normal’ group, the 
proportion of females and males were comparable, but in both ‘UC’ and ‘Polyp’ 
groups the majority of participants (approximately 75%) were male. The 
participants in the ‘Polyp’ group were approximately 10 years older than those 
in the ‘Normal’ group (p=0.001), with the mean age of the ‘UC’ participants 
being midway between the other two groups.  
There were no significant differences between groups in the mean BMI of the 
participants (p=0.503). The mean BMIs were high in all three participant groups. 
In the ‘Normal’ group, 13 participants had a normal BMI, 31 were classified as 
being overweight and 40 were classified as being obese. In the ‘UC’ group, 
three participants had a normal BMI, four were classified as being overweight 
and four were obese. In the ‘Polyp’ group, five participants had a normal BMI, 
eleven were overweight and ten were obese. 
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Table 5.1 Characteristics of participants in ‘Normal’, ‘UC’ and ‘Polyp’ 
groups.  
Risk group Normal UC Polyp P value 
Number of 
participants 
91 12 26  
Ethnicity 
Caucasian (%) 
Black African (%) 
Mixed race (%) 
 
89 (98) 
1 (1) 
1 (1) 
 
12 (100) 
0 (0) 
0 (0) 
 
26 (100) 
0 (0) 
0 (0) 
0.848 
Gender 
Female (%) 
Male (%) 
 
50 (55) 
41 (45) 
 
3 (25) 
9 (75) 
 
6 (23) 
20 (77) 
0.005 
Age 
Mean (years) 
Range 
 
51.8 
26 – 80 
 
56.5 
38 – 71 
 
61.9 
44 – 79 
0.001 
Smoking status 
Never (%) 
Former (%) 
Current (%) 
 
43 (47) 
22 (24) 
17 (19) 
 
3 (25) 
8 (67) 
1 (8) 
 
8 (31) 
11 (42) 
5 (19) 
0.051 
BMI (kg/m2) 
Mean 
Range 
 
30.1 
23.0 – 49.3 
 
29.3 
22.2 – 37.6 
 
28.8 
19.8 – 40.3 
0.503 
Procedure 
Colonoscopy (%) 
Flexi Sigmoidoscopy 
(%) 
 
25 (27) 
66 (73) 
 
 
12 (100) 
0 (0) 
 
 
24 (92) 
2 (8) 
 
<0.001 
Data on smoking status were not available for nine ‘Normal’ and two ‘Polyp’ 
participants and anthropometric data for seven ‘Normal’ and one ‘UC’ participants.  
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5.2 WNT pathway-related gene expression in the macroscopically-
normal mucosa of people at differential risk of CRC 
5.2.1 Introduction 
As WNT signalling is frequently aberrantly activated in CRC, this study aimed to 
investigate the expression of a panel of WNT pathway-related genes in the 
macroscopically-normal mucosa of people at “normal” risk of CRC and in those 
at higher CRC risk because of quiescent UC or a prior history of adenomatous 
polyps. 
5.2.1.1 Expression of WNT pathway components in the colorectum of 
people with ulcerative colitis 
Due to its role in maintaining homeostasis and in regulating several processes 
including cell proliferation and apoptosis within the colon, several studies have 
been interested in investigating differences in WNT signalling in patients with 
UC. When analysing the expression of WNT components, the majority of 
studies have focussed on quantifying expression at the protein level.  
A WNT array was used to investigate the expression of WNT pathway-related 
genes in uninflamed and inflamed tissue from six UC patients (You et al., 2008). 
Seven WNT ligands (WNT2B, WNT3A, WNT5B, WNT6, WNT7A, WNT9A and 
WNT11) and two receptors from the Frizzled family (FZD3 and FZD4) showed 
significantly higher expression in uninflamed tissue from UC patients compared 
with six healthy participants, which could be indicative of an increase in WNT 
pathway activity. However, expression of FZD1 and FZD5 was significantly 
reduced in UC patients. Within the UC patients, a significant increase in the 
expression of COL1A1, DKK4, DVL2, SOX17 and a decrease in CCND3, 
SFRP2, WISP3, WNT3A was observed in inflamed compared with uninflamed 
mucosa, demonstrating differences in WNT activity between active and inactive 
disease. Increased expression of members of the Frizzled receptor family and 
DVL have also been observed in the inflamed mucosa of UC patients compared 
with healthy participants (Uthoff et al., 2001).  
Differences in the expression of WNT pathway components have also been 
observed in myofibroblasts isolated from colonic tissue from normal participants 
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and UC patients. These included a greater than three-fold reduction in the 
expression of SFRP1, an antagonist of WNT signalling, in UC (Hughes et al., 
2011). Similar to the findings by You et al. (2008), downregulation of SFRP1 
would consequently result in reduced inhibition of the WNT pathway and 
therefore increased WNT activity. 
Van Dekken et al. investigated changes in the WNT signalling pathway in a 
cross-sectional study of the progression from dysplasia to carcinoma in 21 
patients with UC (van Dekken et al., 2007). The expression of four WNT 
pathway proteins, β-catenin, E-cadherin, cyclin D1 and c-MYC, was determined 
by immunohistochemical analysis in 18 adenocarcinomas and 17 dysplastic 
lesions. β-catenin abundance, particularly within the nucleus, was significantly 
increased in both dysplasia and adenocarcinoma compared with normal tissue. 
Significantly reduced E-cadherin expression was observed in cancerous 
compared with normal tissue. Nuclear cyclin D1 expression was significantly 
higher in cancerous tissue compared with normal tissue and there was a trend 
towards higher c-MYC expression in both dysplastic and cancerous tissues. 
Overall, the results from this study suggested that, in the progression to 
carcinoma in UC patients, WNT activity is increased, as demonstrated by 
enhanced β-catenin expression alongside an upregulation of cyclin D1 and c-
MYC and reduced expression of E-cadherin.  
More recently, Shenoy and colleagues also evaluated WNT pathway activity 
during the progression from colitis to cancer (Shenoy et al., 2012). They 
showed significantly higher β-catenin expression in tissue from UC patients and 
sporadic CRC, increased by 2.5-fold and 4.5-fold respectively, compared with 
healthy controls. The authors concluded that the activity of WNT signalling in 
UC was intermediate between that in the healthy colon and in CRC.  
The expression of cyclin D1, a target of WNT signalling which is involved in  
regulation of the cell cycle and is overexpressed in CRC (Maeda et al., 1998) 
has been compared in patients with quiescent UC, active UC, dysplasia and 
UC-related cancer (Wong et al., 2003). Whilst cyclin D1 expression in the 
mucosa from patients with quiescent UC was similar to that in healthy 
participants, significantly higher cyclin D1 expression was observed in patients 
with active UC or dysplasia, where expression levels were comparable. Based 
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on these results, Wong et al. (2003) suggested that cyclin D1 expression may 
be increased early during the progression from UC-associated inflammation to 
dysplasia and ultimately carcinoma. This is in contrast with Xie and Itzkowitz, 
who suggested that aberrant WNT signalling is observed at later stages in the 
progression from colitis to cancer (Xie and Itzkowitz, 2008). 
A study by Aust et al. was the first to investigate the altered expression of WNT 
related proteins, β-catenin, E-cadherin and APC, in UC-related cancer using 
tissue from 33 UC-related cancer and 42 sporadic CRC patients (Aust et al., 
2001). Immunohistochemical analyses revealed that both cancer types were 
associated with an increase in cytoplasmic and nuclear β-catenin, as opposed 
to membrane-associated, whereas abnormal staining of nuclear β-catenin was 
significantly higher in sporadic cases. Reduced APC expression was observed 
in both cancer types compared with normal tissue, however there was no 
difference between the two cancers themselves. E-cadherin expression was 
also significantly lower in cancerous compared with normal tissue. Abnormal 
levels of membrane-associated E-cadherin were greater in UC-related cancers, 
however the opposite was found for nuclear E-cadherin. The authors reported a 
stronger association between abnormal levels of membrane-associated E-
cadherin and abnormal levels of cytoplasmic β-catenin in UC-related cancers 
compared with sporadic cases. In sporadic cancers, they observed an 
association between abnormal APC levels and nuclear β-catenin expression. 
This demonstrated that, although abnormal expression of WNT proteins was 
observed in both UC-related and sporadic cancers of the colon, β-catenin 
expression in UC-related cancers was regulated by E-cadherin expression 
whereas APC had a more significant role in sporadic cancers.  
5.2.1.2 Expression of WNT pathway components in the colorectum of 
people with polyps 
Similar to studies examining the expression of WNT pathway components in the 
tissue of patients with UC, studies in patients with polyps have also primarily 
assessed protein levels. Furthermore, studies have also investigated 
differences in expression between different polyp types, such as hyperplastic 
polyps and tubular adenomas.  
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Dai et al. (2007) assessed levels of APC, β-catenin, c-MYC and cyclin D1 
proteins in normal mucosa, adenomas and carcinomas (Dai et al., 2007). APC 
expression was lower in colorectal carcinomas and malignant adenomas 
compared with non-malignant adenomas and the normal mucosa. Abnormal 
expression of β-catenin was observed significantly more in tissues from both 
non-malignant and malignant adenomas and carcinomas compared with the 
normal mucosa. In addition, an inverse correlation between the expression of 
APC and β-catenin was found. c-MYC and cyclin D1, two targets of WNT 
signalling, were also upregulated in carcinomas and both adenoma types 
compared with healthy tissue. Furthermore, c-MYC and cyclin D1 expression 
correlated positively with abnormal β-catenin expression. Altogether, the 
findings from this study demonstrate that abnormal expression of WNT proteins, 
resulting in reduced inhibition of β-catenin and increased WNT pathway activity, 
is not only observed in colorectal carcinomas but may be apparent early in the 
progression to CRC in non-malignant adenomas. 
The sub-cellular localisation as well as the expression of the WNT pathway 
components APC, AXIN, AXIN2 and β-catenin have also been compared in 
healthy colonic crypts, adenomatous polyps and adenocarcinomas (Anderson 
et al., 2002). An increase in nuclear β-catenin was found in adenocarcinoma 
tissue compared with healthy and polyp tissues, where the majority of β-catenin 
was localised to cell-cell junctions. In polyp tissue, levels of nuclear AXIN were 
reduced and levels of cytoplasmic AXIN were increased compared with healthy 
tissue. Levels of AXIN2 were comparable between the three tissues and were 
predominantly observed within the nuclei. In healthy tissue, expression of APC, 
AXIN and AXIN2 was representative of inhibition of WNT signalling and, 
consequently, a lack of nuclear β-catenin. However, in adenomatous polyps and 
adenocarcinomas, abnormal expression of APC, AXIN and β-catenin were 
observed.  
β-catenin expression has also been investigated specifically in a variety of 
colorectal lesions including hyperplastic polyps, sessile serrated adenomas and 
traditional serrated adenomas (Fang et al., 2014). Abnormal β-catenin was 
observed more frequently in all lesions compared with the normal mucosa. 
Furthermore, both sessile and traditional serrated adenomas showed an 
increased incidence of abnormal β-catenin expression compared with 
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hyperplastic polyps, and therefore the investigators concluded that the WNT 
pathway may play a more important role in the development of serrated lesions. 
Iwamoto et al. investigated the expression of the two key components of the 
canonical WNT signalling pathway, APC and β-catenin, in the normal mucosa, 
hyperplastic polyps, adenomas and carcinomas (Iwamoto et al., 2000). In the 
normal mucosa and in hyperplastic polyps, expression of APC and β-catenin 
was comparable. However, almost a third of the adenomas and more than 
three-quarters of the carcinomas analysed showed complete loss of APC. 
Furthermore, abnormal β-catenin expression, particularly that within the 
nucleus, was also observed in adenomas and carcinomas.  
FAP is an inherited disease, usually resulting from a mutation in and loss of the 
APC gene, where patients characteristically develop hundreds of intestinal 
polyps (De Queiroz Rossanese et al., 2013).  Gaspar et al. have analysed gene 
expression in adenomatous polyps from patients with FAP and in polyps from a 
mouse model of FAP (Gaspar et al., 2008). The investigators applied stringent 
criteria to select a total of 166 genes that were both differentially expressed in 
polyps from FAP patients compared with healthy mucosa and in polyps from 
C57BL6J Apc+/1638N compared with control mice. These genes included several 
WNT pathway-related genes such as CCND1 and CD44, two target genes of 
WNT signalling that are upregulated early during colorectal carcinogenesis 
(Abbasi et al., 1993).  
Wang et al. also investigated expression of β-catenin and cyclin D1, encoded by 
CCND1, in the normal mucosa and in adenomas and carcinomas from FAP 
patients (Wang et al., 2013a). Both β-catenin and cyclin D1 were significantly 
increased in low and high-grade adenomas and carcinomas compared with 
normal mucosa. Furthermore, nuclear β-catenin was significantly enhanced in 
adenomas and carcinomas. These findings demonstrate that abnormal β-
catenin expression observed in colorectal adenomas and carcinomas is not only 
limited to sporadic cases but may also be observed in low-grade adenomas and 
later stages in patients with FAP.  
An earlier study investigated the expression of two target genes of the WNT 
pathway, c-MYC and NKD1, and SFRP1, a WNT antagonist, at the mRNA level 
in patients with FAP and sporadic adenomas (Caldwell et al., 2010). SFRP1 
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was downregulated in adenomas of both FAP and sporadic patients compared 
with the normal mucosa, however this was more pronounced in sporadic 
adenomas. An increase in c-MYC and NKD1 expression was observed in 
adenomas from FAP patients and sporadic cases compared with the normal 
mucosa and, again, this was enhanced in sporadic cases. The results from this 
study demonstrate that similarities exist between adenomas occurring 
sporadically and those resulting from an inherited disease, FAP.  
5.2.2 Hypotheses, aims and objectives 
5.2.2.1 Hypotheses 
The hypothesis for this study was that participants at higher risk of CRC, i.e. 
those with quiescent UC or a prior history of adenomatous polyps, would have 
aberrant expression of WNT pathway-related genes. In particular, it was 
hypothesised that higher-risk participants would have increased expression of 
genes that indicate an increase in WNT activity, such as WNT target genes, and 
reduced expression of those that suggest reduced activity, such as WNT 
inhibitors, compared with normal participants.  
5.2.2.2 Aims 
This study aimed to test the hypothesis by quantifying expression of the 
selected WNT-pathway related genes in the macroscopically-normal mucosa of 
people at differential CRC risk i.e. those with quiescent UC, those with a prior 
history of adenomatous polyps and those at normal risk of developing CRC.  
5.2.2.3 Objectives 
 To obtain colorectal biopsies from the macroscopically-normal mucosa of 
three groups of DISC Study participants at differential risk of CRC i.e. 
those with quiescent UC, those with a prior history of adenomatous 
polyps and “normal” participants; 
 To extract an adequate amount of high-quality RNA from OCT-
embedded rectal mucosal biopsies; 
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 To synthesise cDNA by reverse transcription; 
 To quantify the expression of the 12 selected WNT genes by qPCR; 
 To compare gene expression in the ‘Normal’ participants and in the two 
higher-risk groups (‘UC’ and ‘Polyp’ participants); 
 To investigate the effects of key epidemiological factors including age 
and gender on WNT pathway-related gene expression. 
5.2.3 Methods 
A total of 12 WNT pathway-related genes were selected as described in section 
3.3. Their expression was quantified by qPCR using cDNA synthesised from 
RNA extracted from rectal mucosal biopsies as detailed in section 2.2.1.  
The ANOVA GLM was used to investigate differences in expression between 
the three participant groups, with age, gender, endoscopy procedure, BMI and 
smoking status incorporated as covariates. Dunnett’s test was used to correct 
for multiple comparison testing and pairwise comparisons were analysed using 
the Bonferroni method. When data were not normally-distributed, the non-
parametric test Kruskal-Wallis was applied. 
5.2.4 Results 
The expression of the 12 selected WNT pathway-related genes was quantified 
in rectal biopsies from the macroscopically-normal mucosa of the three groups 
of participants at differential risk of CRC. Data for the expression of three of 
these genes is not included in this thesis (CCND1, c-MYC and SFRP1) because 
of technical difficulties with the assays, evident from the melt curves observed 
during qPCR, in the samples from ‘UC’ and ‘Polyp’ participants.  
5.2.4.1 WNT pathway-related gene expression in the macroscopically-
normal epithelium of ‘Normal’, ‘UC’ and ‘Polyp’ participants 
Levels of expression differed considerably (by greater than three orders of 
magnitude) between each of the nine WNT pathway-related genes (Table 5.2). 
Across all three participant groups, the gene with the greatest expression in the 
rectal mucosa was CTNNB1, with a mean expression of 16.3 (adjusted copies) 
   
 212 
whilst the gene with the lowest expression was SFRP2, with a mean expression 
of 0.06 (adjusted copies).  
With the exception of c-JUN (p=0.046) and WNT11 (p=0.040), expression of 
most of the genes was similar in all three groups. c-JUN expression was lowest 
in the ‘Normal’ group, a little higher in the ‘UC’ group and highest in the ‘Polyp’ 
group, where expression levels were 76% greater than those seen in the 
‘Normal’ group. Similarly, WNT11 expression was highest in the ‘Polyp’ group, 
where it was 56% higher than in the ‘Normal’ group.  
When applying Bonferroni’s correction for multiple testing, the set p-value is 
lowered to 0.004 and so the statistically significant differences in c-JUN 
(p=0.046) and WNT11 (p=0.040) expression between the three participant 
groups are lost. 
Although not statistically significant, there was evidence for apparent between 
group differences in expression for four other genes. Whilst mean expression of 
FOSL1 was approximately five-fold greater in the ‘Normal’ group compared with 
that in the two higher-risk groups, this substantial difference was not statistically 
significant because of the large range in individual expression values within 
each group.  In addition, expression of APC, AXIN2 and CTNNB1 appeared to 
be reduced in the ‘UC’ group compared with both the ‘Normal’ and ‘Polyp’ 
groups.  
   
 213 
Table 5.2 Expression of WNT pathway-related genes in the 
macroscopically-normal mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ 
participants.  
Gene Normal UC Polyp P value 
APC1 
N=108 
1.86 
(1.33 – 2.44) 
1.04 
(0.73 – 2.37) 
1.69 
(1.09 – 2.13) 
0.080 
AXIN22 
N=108 
2.41 
(2.06 – 2.82) 
1.76 
(1.18 – 2.64) 
2.51 
(1.86 – 3.37) 
0.293 
CTNNB12 
N=108 
14.6 
(11.9 – 17.5) 
11.0 
(5.8 – 17.8) 
15.9 
(11.0 – 21.6) 
0.432 
FOSL11 
N=82 
0.1647 
(0.0228 – 0.4785) 
0.0293 
(0.0138 – 0.4003) 
0.0309 
(0.0144 – 0.2626) 
0.325 
GSK3β2 
N=108 
4.84 
(4.06 – 5.69) 
4.47 
(2.73 – 6.65) 
5.81 
(4.31 – 7.54) 
0.450 
c-JUN1 
N=116 
6.28 
(4.31 – 10.30) 
7.39 
(3.50 – 14.43) 
11.05 
(5.72 – 21.17) 
0.046 
SFRP22 
N=89 
0.0231 
(0.015 – 0.034) 
0.0383 
(0.013 – 0.109) 
0.0322 
(0.015 – 0.069) 
0.679 
WTN5A2 
N=106 
0.151 
(0.116 – 0.198) 
0.150 
(0.078 – 0.291) 
0.190 
(0.117 – 0.306) 
0.712 
WNT112 
N=88 
0.0905 
(0.0706 – 0.1139) 
0.0725 
(0.0381 – 0.1230) 
0.1454 
(0.0999 – 0.2028) 
0.040 
Data are expressed as adjusted copies. 1Data are presented as median (lower and 
upper quartiles). The non-parametric Kruskal-Wallis test was used to compare gene 
expression between the three groups. 2Data are presented as LSMs (95% CIs). The 
ANOVA GLM was used to compare gene expression between the three groups and 
Dunnett’s post-hoc test was used for multiple comparisons with the control group and 
the Bonferroni method was used for pairwise comparisons. 
5.2.4.2 Exploration of additional factors influencing WNT pathway-related 
gene expression 
Given the evidence from epidemiological studies that age, gender and lifestyle 
factors are major determinants of CRC risk, the effects of age, gender, BMI and 
smoking status on the expression of the selected gene panel were investigated. 
In addition, I examined the effect of the two endoscopy procedures (flexible 
   
 214 
sigmoidoscopy and colonoscopy) used to collect colorectal biopsies since it was 
not known whether these procedures per se (or the different bowel preparations 
which preceded them) influenced gene expression in the colorectal mucosa. 
Potential effects of these factors were determined by their inclusion as 
covariates in the ANOVA GLM. However, as the data for APC, FOSL1 and c-
JUN expression were not normally-distributed despite transformation, the non-
parametric Kruskal-Wallis test was utilised. The p values from the results of 
these analyses are shown in Table 5.3. 
Table 5.3 P values for the effects of age, gender, endoscopy procedure, 
BMI and smoking status on WNT pathway-related gene expression. 
Gene Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
APC 0.296 0.069 0.142 0.413 0.079 
AXIN2 0.463 0.711 0.057 0.340 0.148 
CTNNB1 0.998 0.325 0.061 0.167 0.465 
FOSL1 0.539 0.422 <0.001 0.446 0.008 
GSK3β 0.254 0.763 0.037 0.441 0.768 
c-JUN 0.149 0.893 0.011 0.505 0.104 
SFRP2 0.572 0.103 0.823 0.244 0.295 
WTN5A 0.283 0.390 0.020 0.436 0.134 
WNT11 0.967 0.228 0.277 0.728 0.024 
For these analyses, data from all three participants were pooled.  
Despite the epidemiological evidence of their role in determining CRC risk, 
there was no evidence that age, gender or BMI were associated with 
expression of any of the selected WNT pathway-related genes. However, for 
four of the nine genes (FOSL1, GSK3β, c-JUN and WNT5A) there were 
statistically significant differences in expression between the two endoscopy 
procedures. Expressions of FOSL1, GSK3β and WNT5A were significantly 
lower in participants who had endoscopic examination by colonoscopy 
compared with flexible sigmoidoscopy (Figure 5.1 (A, B and D)) whereas the 
opposite effect was observed for c-JUN (Figure 5.1 (C)).  
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Figure 5.1 Effect of endoscopy procedure on expression of FOSL1, 
GSK3β, c-JUN and WNT5A. 
 
 
Data are expressed as adjusted copies. Data for the expression of FOSL1 (A) (N=82) 
and c-JUN (C) (N=116) are presented as medians and error bars represent lower and 
upper quartiles (Kruskal-Wallis). Data for the expression of GSK3β (B) (N=108) and 
WNT5A (D) (N=106) are presented as LSMs and error bars represent 95% CIs 
(ANOVA GLM). 
The expression of FOSL1, as well as WNT11, was significantly affected by 
smoking status. Interestingly, FOSL1 expression was significantly reduced in 
participants who were former smokers, compared with both those who had 
never smoked and those who were current smokers (Figure 5.2 (A)). In 
contrast, the expression of WNT11 appeared to increase with cigarette 
exposure, and was significantly higher in current smokers than in those who 
never smoked (Figure 5.2 (B)).  
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Figure 5.2 Effect of smoking status on expression of FOSL1 and WNT11.  
 
Data are expressed as adjusted copies. Data for the expression of FOSL1 (A) are 
presented as medians and error bars represent lower and upper quartiles (Kruskal-
Wallis) (N=82). Data for the expression of WNT11 (B) are presented as LSMs and error 
bars represent 95% CIs (ANOVA GLM) (N=88). 
5.2.5 Discussion 
The expression of 12 WNT pathway-related genes that are implicated in CRC 
were quantified in the macroscopically-normal mucosa of participants with 
quiescent UC and a prior history of polyps by qPCR, however, for higher-risk 
participants, data for 9 of the genes were analysed. There were significant 
differences in the expression of c-JUN and WNT11 between the three 
participant groups (Figure 5.3).  
The expression of c-JUN increased with increasing CRC risk, and was 
significantly upregulated in the ‘Polyp’ compared with the ‘Normal’ group (Figure 
5.3 (A)). c-JUN is a member of the JUN family of proto-oncogenes and is a 
stimulator of cell proliferation (Wang et al., 2000). It is also a target gene of the 
WNT signalling pathway that is transcribed following the activation of the WNT 
pathway and consequent induction of transcription by β-catenin within the 
nucleus (Mann et al., 1999). Therefore, an increase in c-JUN expression would 
suggest an increase in WNT signalling activity. Furthermore, at the protein level, 
c-JUN expression has been shown to be increased in colorectal carcinomas 
compared with the healthy mucosa (Pandey et al., 1995) and to be higher in 
large tubulovillous adenomas, as well as in adenocarcinomas (Magrisso et al., 
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1993). The present study is the first to observe increased expression of c-JUN 
in UC patients.  
I also observed higher expression of WNT11 in the macroscopically-normal 
mucosa of participants with a prior history of polyps compared with both 
‘Normal’ and ‘UC’ participants (Figure 5.3 (B)). WNT11 is a WNT ligand that, 
although originally believed to target only the non-canonical WNT signalling 
pathway (Rao and Kuhl, 2010), may also inhibit or activate the canonical WNT 
pathway (Maye et al., 2004; Tao et al., 2005). Increased expression of WNT11 
has been observed previously in colorectal adenocarcinomas (Kirikoshi et al., 
2001) and it is thought to contribute to cancer progression through the 
stimulation of proliferation, migration and invasion (Nishioka et al., 2013). In a 
mouse model of Peutz-Jegher’s syndrome (where patients develop polyps 
throughout the digestive tract), WNT11 expression was approximately two-fold 
greater in gastric polyp tissue compared with healthy mucosa (Lai et al., 2011). 
WNT11 expression has been investigated in only one previous study where the 
authors reported significantly greater WNT11 expression in the uninflamed 
mucosa of UC patients compared with healthy controls (You et al., 2008). Their 
observation is contrary to my observation in the present study where WNT11 
expression was slightly lower in participants in the ‘UC’ group than in the 
‘Normal’ group. The reason for this divergence between studies is not known 
but may relate to choice of “normal” (control) patients or other confounding 
factors.  
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Figure 5.3 Expression of c-JUN and WNT11 in the macroscopically-normal 
mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ participants.  
 
Data are expressed as adjusted copies. Data for c-JUN expression are presented as 
medians and error bars represent lower and upper quartiles (Kruskal-Wallis) (N=116). 
Data for WNT11 expression are presents as LSMs and error bars represent 95% CIs 
(ANOVA GLM) (N=88). 
Interestingly, WNT11 expression increased with increasing exposure to 
tobacco, and was significantly increased in participants who were current 
smokers compared with those who had never smoked. This effect has not been 
reported previously. Another novel finding from the present study was a 
significant effect of endoscopy procedure on expression of FOSL1, GSK3β, c-
JUN and WNT5A. 
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5.3 microRNA expression in the macroscopically-normal mucosa of 
people at differential risk of CRC 
5.3.1 Introduction 
This study aimed to investigate the expression of miRNAs implicated in 
colorectal carcinogenesis and involved in the regulation of the WNT signalling 
pathway in the macroscopically-normal mucosa of people at “normal” risk of 
CRC and in those at higher CRC risk because of quiescent UC or a prior history 
of adenomatous polyps. The criteria for the selection of the miRNAs quantified 
in this study can be found in section 3.4.2. In addition, the miRNAs selected to 
be quantified in the intervention arm of this Ph.D. were also quantified in this 
study. 
5.3.1.1 microRNAs 
miRNAs are short (approximately 22 nucleotides long), non-coding, single-
stranded RNAs that are able to regulate gene expression both by degrading 
mRNA or inhibiting transcription (Chen and Rajewsky, 2007). Each miRNA can 
target hundreds of genes (Thomas et al., 2010) and therefore regulate a variety 
of cellular processes including apoptosis, differentiation and proliferation 
(Kloosterman and Plasterk, 2006). 
5.3.1.2 microRNA expression in the colorectum of people ulcerative 
colitis 
A number of studies investigating miRNA expression in UC exist, the majority of 
which are human studies. Wu and colleagues were the first to investigate 
differences in expression of miRNAs involved in the regulation of inflammation 
in the colonic mucosa of IBD patients (Wu et al., 2008). The study recruited 15 
patients with inactive UC and 15 with active UC as well as additional healthy 
participants and those with other colonic diseases. Microarray analyses 
revealed that 18 miRNAs, out of the 554 miRNAs quantified, were differentially 
expressed in tissue from active UC patients compared with normal participants. 
Of these, 12 were also differentially expressed in inactive UC samples 
compared with normal tissue. Analysis by qPCR confirmed the downregulation 
of three miRNAs (miR-192, miR-375 and miR-422b) and upregulation of eight 
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miRNAs (miR-16, miR-21, miR-23a, miR-24, miR-29a, miR-126, miR-195 and 
Let-7f) in active UC tissue compared with normal tissue.  
A later study investigated differences in miRNA expression in the mucosa of 
patients with active UC and healthy controls by analysing a greater number of 
miRNAs (710) by microarray (Takagi et al., 2010). Twenty-seven were 
differentially expressed in tissue from UC patients compared with healthy 
controls and two of these miRNAs, miR-21 and miR-150, were confirmed to be 
significantly upregulated in active UC tissue by qPCR.  
More recently, studies have also compared miRNA expression between inactive 
and active forms of UC. In a study which compared miRNA expression in 
patients with UC (active and quiescent), Crohn’s disease or healthy participants, 
Coskun et al. identified five miRNAs that were upregulated in active UC and two 
miRNAs that were upregulated in quiescent UC compared with healthy controls 
(Coskun et al., 2013). These findings demonstrate that miRNAs do not only 
have the potential to be used as biomarkers for the diagnosis of UC, but they 
could also be used to distinguish between disease activity.   
Furthermore, studies have also coupled investigations into the expression of 
miRNAs in people with UC with explorations into their possible gene targets. 
For example, Pekow et al. showed a significant inverse correlation between 
miR-143 and miR-145, that were downregulated in UC patients, with their 
targets IRS-1, K-RAS, API5 and MEK-2 (Pekow et al., 2012). Koukos et al. also 
observed significantly increased STAT3 expression in paediatric patients with 
UC and concluded that this may be explained by reduced miR-124 expression 
that may regulate STAT3 expression (Koukos et al., 2013). TNF-α has also 
been described to be a target of a miRNA, miR-19a, found to be significantly 
downregulated in colon tissue from patients with UC (Chen et al., 2013). 
5.3.1.3 microRNA expression in the colorectum of people with polyps 
Tsikitis et al. recently investigated expression of miR-145, miR-192 and miR-
320a, three miRNAs implicated in colorectal carcinogenesis, in 113 adenomas 
that varied histologically and in tumour grade (Tsikitis et al., 2014). Analysis by 
microarray revealed that miR-320 expression increased with histologic 
progression, from normal mucosa to tubular, sessile serrated and traditional 
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serrated adenomas and to, ultimately, high grade dysplasia. This finding 
disagrees with previous reports in the literature that have observed reduced 
miR-320 expression in CRC (Sun et al., 2012). Interestingly, one of the targets 
of miR-320 is β-catenin, and it has previously been shown that miR-320 
inhibited β-catenin expression in CRC cells, resulting in reduced cell 
proliferation (Sun et al., 2012). On the contrary, expression of both miR-145 and 
miR-192 decreased with histologic progression. miR-192 expression has been 
reported to be downregulated in CRCs (Chiang et al., 2012), and so findings 
from this study suggest that altered miR-192 expression may be observed early 
during carcinogenesis. The results from this study, where a reduction in miR-
145 was observed with progression towards carcinoma, are in agreement with 
previous studies that have shown reduced miR-145 expression in CRC and 
have identified it as a tumour suppressor (Slaby et al., 2007).  
Oberg and colleagues quantified expression of 735 miRNAs by microarray in 
normal colonic mucosa, tubulovillous adenomas and in adenocarcinomas in an 
attempt to further examine changes in miRNA expression in the progression 
from the normal mucosa to carcinoma (Oberg et al., 2011). The differences in 
global miRNA expression patterns clearly distinguished the three tissue types 
and further analyses revealed a total of 31 miRNAs that were significantly up- or 
downregulated in adenomas compared with normal tissue. These included miR-
135b, miR137, miR-552 and miR-99a. Interestingly, Nagel et al. have previously 
shown that miR-135b, which was increased in both adenomas and carcinomas, 
targets APC, consequently resulting in an induction of the WNT signalling 
pathway (Nagel et al., 2008). 
A miRNA cluster that has been implicated in CRC, and more recently in pre-
neoplastic lesions, is the miR-17-92 cluster, encoding miR-17, miR-18a, miR-
19a, miR-19b, miR-20a and miR-92. Tsuchida et al. quantified expression of the 
six mature miRNAs encoded by this cluster in colorectal adenoma and 
carcinoma tissues by qPCR (Tsuchida et al., 2011). All six miRNAs were 
upregulated in adenoma and carcinoma tissues compared with healthy controls, 
however this was only statistically significant for the carcinoma versus normal 
tissue comparison. Diosdado et al. conducted a similar study and also 
quantified expression of the six miRNAs encoded by the miR-17-92 cluster in 
healthy controls and patients with adenomas and adenocarcinomas (Diosdado 
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et al., 2009). The results from this study were consistent with the findings from 
the study by Tsuchida et al. (2011) and found that expression of all six miRNAs 
was increased in both adenoma and carcinoma tissues. In addition, they 
observed significantly higher expression of the miRNAs in carcinoma compared 
with adenoma tissues.  
Studies that have investigated miRNA expression in polyps have not been 
limited to the colorectal mucosa. A study investigated differences in miRNA 
expression in the plasma of patients with adenomas with the aim of identifying 
potential biomarkers (Kanaan et al., 2013). A total of 380 miRNAs were 
quantified and eight miRNAs (miR-15b, miR-17, miR-142-3p, miR-195, miR-
331, miR-532, miR-532-3p and miR-652) were differentially expressed in the 
plasma of polyp patients compared with healthy controls. The authors 
concluded that, after further validation, the differentially expressed miRNAs 
could potentially be used as future biomarkers of colorectal adenomas and that 
their measurement in plasma provides a non-invasive and inexpensive method.  
In stool, differences in miRNA expression in patients with polyps have also been 
detected. Wu and colleagues examined expression of miR-21 and miR-92a, two 
miRNAs upregulated in the tissue (Schetter et al., 2008) and plasma (Ng et al., 
2009) of CRC patients (Wu et al., 2012a), and found significantly upregulated 
miR-92a expression in the stool of patients with polyps compared with healthy 
controls. However, there were no differences observed in expression of miR-21. 
These findings support the use of stool samples for the detection of miRNAs 
differentially expressed in pre-neoplastic lesions that may be used as 
biomarkers.  
A later study by the group further investigated the use of miRNAs detected in 
stool samples as biomarkers of adenomas and carcinomas (Wu et al., 2014). 
Expression of 667 miRNAs was quantified by microarray analysis in both stool 
and tissue samples collected from healthy participants and patients with 
advanced adenomas and carcinomas. miR-31 and miR-135b, which were both 
upregulated, showed the largest difference between adenoma or carcinoma 
tissues and the normal mucosa. Similar analysis of stool samples agreed that 
miR-135b, but not miR-31, was significantly increased in patients with 
adenomas or carcinomas compared with healthy controls. The investigators 
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therefore identified another potential miRNA, miR-135b, which could be used as 
a biomarker of pre-cancerous lesions or carcinomas in stool samples. 
5.3.2 Hypotheses, aims and objectives 
5.3.2.1 Hypotheses 
The hypothesis for this investigation was that participants at higher risk of CRC, 
i.e. those with quiescent UC or a prior history of adenomatous polyps, would 
exhibit differential expression of miRNAs implicated in CRC and involved in the 
regulation of the WNT signalling pathway.  
5.3.2.2 Aims 
This study aimed to test this hypothesis by investigating the differences in 
miRNA expression in the macroscopically-normal mucosa of people at 
differential CRC risk, i.e. those with quiescent UC, those with a prior history of 
adenomatous polyps and those at normal risk of developing CRC.   
5.3.2.3 Objectives 
 To obtain colorectal biopsies from the macroscopically-normal mucosa of 
three groups of DISC Study participants at differential rick of CRC i.e. 
those with quiescent UC, those with a prior history of adenomatous polyps 
and “normal” participants; 
 To review the literature to select miRNAs to be quantified in participants at 
higher risk of CRC; 
 To extract an adequate amount of high-quality RNA, including small RNAs 
such as miRNAs, from OCT-embedded rectal mucosal biopsies;  
 To reverse transcribe RNA for the synthesis of cDNA; 
 To utilise cDNA to quantify the expression of the selected miRNAs using 
qPCR; 
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 To compare miRNA expression in the ‘Normal’ participants and in the two 
higher-risk groups (‘UC’ and ‘Polyp’ participants); 
 To investigate the effects of key epidemiological factors, including age 
and gender, and endoscopy procedure on miRNA expression. 
5.3.3 Methods 
The expression of miRNAs was quantified by qPCR as described in section 
2.2.2. The ANOVA GLM was used to investigate differences in expression 
between the three participant groups, with age, gender, endoscopy procedure, 
BMI and smoking status incorporated as covariates. Dunnett’s test was used to 
correct for multiple comparison testing and pairwise comparisons were 
analysed using the Bonferroni method. Where data were not normally-
distributed despite transformation, the non-parametric Kruskal-Wallis test was 
used.   
5.3.4 Results 
A total of five miRNAs were selected to be quantified in the ‘UC’ and ‘Polyp’ 
participants as part of the analyses in participants at differential CRC risk. 
These were miR-101, miR-122a, miR-135b, miR-145 and miR-335. In addition, 
the eight miRNAs selected to be quantified in the dietary intervention arm of the 
study were also analysed in the higher-risk groups. The data for the intervention 
eight miRNAs from the higher-risk groups were compared with the pre-
intervention data from the intervention study, which represented the ‘Normal’ 
group.  
5.3.4.1 Expression of miR-101, miR-122a, miR-135, miR-145 and miR-335 
in the macroscopically-normal mucosa of ‘Normal’, ‘UC’ and 
‘Polyp’ participants 
miR-101, miR-122a, miR-135b, miR-145 and miR-335 were selected to be 
quantified in participants at higher risk of CRC. A total of 63 participants, 
comprising 25 ‘Normal’, 12 ‘UC’ and 26 ‘Polyp’ participants, were used in the 
analysis of the five selected miRNAs in participants at differential risk of CRC 
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(Table 5.4). These were age and gender-matched as best possible as well as 
attempting to match for BMI and smoking status.  
Table 5.4 Participant characteristics for the quantification of miRNAs in 
participants at differential risk of CRC. 
  Higher-risk 
Risk group Normal  UC Polyp 
Number of participants 25 12 26 
Ethnicity 
Caucasian (%) 
25 (100) 12 (100) 26 (100) 
Gender 
Female (%) 
Male (%) 
 
6 (24) 
19 (76) 
 
3 (25) 
9 (75) 
 
6 (23) 
20 (77) 
Age 
Mean (years) 
Range 
 
60.8 
43 – 78 
 
56.5 
38 – 71 
 
61.9 
44 – 79 
Smoking status 
Never (%) 
Former (%) 
Current (%) 
 
12 (48) 
10 (40) 
3 (12) 
 
3 (25) 
8 (67) 
1 (8) 
 
8 (31) 
11 (42) 
5 (19) 
BMI 
Mean (kg/m2) 
Range 
 
28.5 
23.2 – 35.5 
 
29.3 
22.2 – 37.6 
 
28.8 
19.8 – 40.3 
Procedure 
Colonoscopy (%) 
Flexi Sigmoidoscopy (%) 
 
5 (20) 
20 (80) 
 
12 (100) 
0 (0) 
 
24 (92) 
2 (8) 
 
Differences in expression of miR-101, miR-122, miR-135b and miR-335 were 
analysed using the ANOVA GLM. Expression data for miR-145 were not 
normally-distributed, despite transformation, and consequently the non-
parametric test Kruskal-Wallis was utilised to investigate differences between 
the participant groups. There were no statistically significant differences in 
expression of the quantified miRNAs observed between the three participant 
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groups (Table 5.5). Differential expression of miR-135b between the three 
participant groups was close to reaching statistical significance (p=0.076), with 
expression being approximately two-fold higher in the ‘UC’ group compared with 
‘Normal’ and ‘Polyp’ participants who had comparable expression levels.  
Table 5.5 Expression of miRNAs selected for quantification in participants 
at differential risk of CRC in the macroscopically-normal mucosa of 
‘Normal’, ‘UC’ and ‘Polyp’ participants.  
miRNA Normal UC Polyp P value 
miR-1011 
N=60 
38.8 
(23.9 – 63.1) 
26.1 
(13.9 – 48.8) 
36.5 
(24.1 – 55.2) 
0.588 
miR-1221 
N=54 
0.0244 
(0.0170 – 0.0349) 
0.0163 
(0.0101 – 0.0261) 
0.0165 
(0.0122 – 0.0223) 
0.355 
miR-135b1 
N=60 
5.37 
(3.64 – 7.92) 
10.06 
(6.10 – 16.60) 
5.38 
(3.87 – 7.50) 
0.076 
miR-1452 
N=63 
1140 
(880 - 1919) 
767 
(322 - 1545) 
1040 
(745 - 1479) 
0.264 
miR-3351 
N=60 
5.14 
(3.72 – 7.08) 
3.87 
(2.56 – 5.85) 
3.30 
(4.35) 
0.201 
Data are presented as adjusted copies. 1Data are presented as LSMs (95% CIs). The 
ANOVA GLM was used to compare miRNA expression between the three groups and 
Dunnett’s post-hoc test was used for multiple comparisons with the control group and 
the Bonferroni method was used for pairwise comparisons. 2Data are presented as 
median (lower and upper quartiles). The non-parametric Kruskal-Wallis test was used 
to compare miRNA expression between the three groups. 
5.3.4.2 Expression of miR-17, miR-19a, miR-19b, miR-20a, miR-25, miR-93, 
miR-106b and miR-424 in the macroscopically-normal mucosa of 
‘Normal’, ‘UC’ and ‘Polyp’ participants 
Differences in expression of miR-17, miR-19b and miR-25 between participant 
groups were analysed using the ANOVA GLM. However, it was not possible to 
achieve normally-distributed data, despite transformation, for expression of 
miR-19a, miR-20a, miR-93, miR-106b and miR-424 and, consequently, the non-
parametric test Kruskal-Wallis was used.  
Expression of miR-424 differed significantly between the three participant 
groups (p<0.01) (Table 5.6). miR-424 expression was greater than two-fold 
   
 227 
higher in participants in the ‘UC’ group compared with the ‘Normal’ group and 
almost three-fold higher when compared with the ‘Polyp’ group. Furthermore, 
miR-424 expression was significantly lower in ‘Polyp’ compared with ‘Normal’ 
participants.  
When applying Bonferroni’s correction for multiple testing and adjusting the p-
value threshold to 0.006, the differences in miR-424 expression between the 
three participant groups remain statistically significant (p<0.001). 
A close to significant effect of risk group was observed for miR-20a expression, 
with reduced miR-20a expression in both higher-risk groups compared with the 
‘Normal’ group (p=0.055). There were no significant differences observed for 
any of the other miRNAs analysed. However, although not statistically 
significant, there was evidence for apparent between group differences in 
expression of miR-19a and miR-19b. miR-19a expression appeared to be 50% 
greater in participants in the ‘Polyp’ group compared with those in the ‘Normal’ 
and ‘UC’ groups. Participants in the higher-risk groups appeared to have 
increased miR-19b expression compared with the ‘Normal’ group by just under 
two-fold. Interestingly, miR-19b expression was highly comparable in the ‘UC’ 
and ‘Polyp’ participants.  
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Table 5.6 Expression of miRNAs selected for the intervention arm of the 
study in the macroscopically-normal mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ 
participants.  
miRNA Normal UC Polyp P value 
miR-171 
120 
(109 – 132) 
128 
(110 – 151) 
127 
(109 – 149) 
0.823 
miR-19a2 
96.9 
(36.8 – 268.8) 
89.4 
(64.1 – 356.3) 
155.5 
(61.3 – 373.0) 
0.465 
miR-19b1 
61.7 
(46.7 – 83.2) 
118.3 
(61.0 – 262.2) 
117.9 
(72.0 – 206.7) 
0.120 
miR-20a2 
333 
(258 – 424) 
279 
(238 – 311) 
308 
(251 – 374) 
0.055 
miR-251 
98.4 
(81.6 – 121.0) 
86.2 
(60.4 – 133.1) 
66.3 
(52.4 – 86.5) 
0.097 
miR-932 
77.2 
(59.0 – 97.5) 
67.7 
(60.7 – 78.3) 
69.5 
(62.2 – 75.2) 
0.277 
miR-106b2 
164 
(138 - 222) 
144 
(119 – 174) 
162 
(120 – 193) 
0.296 
miR-4242 
32.5 
(19.2 – 43.8) 
68.6 
(32.7 – 89.7) 
23.9 
(16.0 – 30.9) 
<0.001 
Data are expressed as adjusted copies. 1Data are presented as LSMs (95% CIs). The 
ANOVA GLM was used to compare miRNA expression between the three groups and 
Dunnett’s post-hoc test was used for multiple comparisons with the control group and 
the Bonferroni method was used for pairwise comparisons (N=91). 2Data are presented 
as median (lower and upper quartiles). The non-parametric Kruskal-Wallis test was 
used to compare miRNA expression between the three groups (N=94). 
5.3.4.3 Exploration of additional factors influencing microRNA expression 
For the miRNAs selected to be analysed specifically in participants at 
differential risk of CRC, a significant effect of endoscopy procedure was 
observed on miR-145 expression (p=0.016). There were no effects of any other 
the covariates observed on the other miRNAs (Table 5.7).  
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Table 5.7 P values for the effects of covariates on the expression of 
miRNAs selected for quantification in participants at differential risk of 
CRC. 
miRNA Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
miR-101 0.237 0.436 0.610 0.325 0.230 
miR-122a 0.835 0.846 0.519 0.545 0.074 
miR-135b 0.283 0.881 0.825 0.440 0.549 
miR-145 0.739 0.699 0.016 0.416 0.546 
miR-335 0.723 0.799 0.865 0.662 0.540 
 
miR-145 expression was significantly higher, by greater than one and a half-
fold, in participants who underwent examination by flexible sigmoidoscopy 
compared with those who had a colonoscopy (Figure 5.4).  
Figure 5.4 Effect of endoscopy procedure on expression of miR-145. 
 
Data are expressed as adjusted copies and presented as medians. Error bars 
represent low and upper quartiles (Kruskal-Wallis). N=63. 
For the miRNAs selected for the intervention analyses, that were also quantified 
in participants at differential risk of CRC, a number of associations between the 
analysed additional factors and expression of the miRNAs were observed 
(Table 5.8). An effect of endoscopy procedure was observed on all but three of 
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the miRNAs quantified. Smoking status was a determinant of miR-19a and miR-
19b expression. Significant effects of BMI on expression of miR-17 and miR-
19b and of age on miR-25 expression were also found.  
Table 5.8 P values for the effects of covariates on the expression of 
miRNAs selected for the intervention arm of the study. 
miRNA Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
miR-17 0.159 0.050 0.003 0.039 0.081 
miR-19a 0.517 0.799 0.753 0.438 0.023 
miR-19b 0.969 0.294 0.009 0.002 0.011 
miR-20a 0.600 0.239 0.001 0.432 0.068 
miR-25 0.015 0.092 0.688 0.579 0.421 
miR-93 0.233 0.060 0.031 0.422 0.207 
miR-106b 0.365 0.113 0.027 0.424 0.165 
miR-424 0.213 0.581 0.139 0.444 0.398 
 
Analysis using the Spearman rank order correlation test revealed a positive, but 
weak, correlation between participant age and miR-25 expression (Spearman 
correlation coefficient 0.062) (Figure 5.5).  
Figure 5.5 Positive correlation between age and miR-25 expression. 
 
N=91.  
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Interestingly, expression of miR-17, miR-19b, miR-20a, miR-93 and miR-106b 
was significantly lower in participants who underwent endoscopic examination 
by colonoscopy compared with those who had a flexible sigmoidoscopy (Figure 
5.6). 
Figure 5.6 Effect of endoscopy procedure on miRNA expression.  
 
 
 
Data are expressed as adjusted copies. Data for miR-17 (A) and miR-19b (B) are 
presented as LSMs and error bars represent 95% CIs (ANOVA GLM) (N=91). Data for 
miR-20a (C), miR-93 (D) and miR-106b (E) are presented as medians and error bars 
represent lower and upper quartiles (Kruskal-Wallis) (N=94). 
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In addition, expression of miR-17 and miR-19b was also significantly affected by 
BMI. In both cases, an inverse correlation between BMI and miRNA expression 
was observed (Figure 5.7). 
Figure 5.7 Inverse correlation between BMI and miR-17 (A) and miR-19b 
(B) expression.  
 
Data are expressed as adjusted copies and presented as LSMs (ANOVA GLM). N=91. 
A significant association between smoking status and expression of miR-19a 
and miR-19b was found. Current smokers had significantly increased 
expression of both miR-19a and miR-19b compared with participants who had 
never smoked and former smokers (Figure 5.8). In both cases, miRNA 
expression was approximately two-fold greater in current smokers compared 
with non-smokers.  
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Figure 5.8 Effect of smoking status on miR-19a and miR-19b expression.  
 
Data are expressed as adjusted copies. Data for miR-19a (A) are presented as 
medians and error bars represent the lower and upper quartiles (Kruskal-Wallis) 
(N=94). Data for miR-19b (B) are presented as LSMs and error bars represent 95% CIs 
(ANOVA GLM) (N=91). 
5.3.5 Discussion 
This study quantified miRNA expression in the macroscopically-normal mucosa 
of people at differential risk of CRC. The literature was reviewed to select 
miRNAs reported to be aberrantly expressed in CRC and involved in the 
regulation of the WNT signalling pathway.  
Previous studies have observed differential expression of miRNAs in the active 
and uninflamed mucosa of patients with UC compared with the normal mucosa 
(Wu et al., 2008; Takagi et al., 2010; Bian et al., 2011; Coskun et al., 2013). 
Differences in expression of miRNAs, particularly the miR-17-92 cluster 
(Diosdado et al., 2009; Tsuchida et al., 2011), have also been observed in the 
mucosa, plasma and stool of patients with polyps (Wu et al., 2012a; Kanaan et 
al., 2013). Furthermore, one study identified an increase in a miRNA that 
targets and inhibits β-catenin (Sun et al., 2012), miR-320, in the histological 
progression from the normal mucosa to adenomas and ultimately high-grade 
dysplasia (Tsikitis et al., 2014). 
In the present study, there were no differences in expression of miR-101, miR-
122, miR-135b, miR-145 or miR-335, selected specifically for quantification in 
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the macroscopically-normal mucosa of participants at differential risk of CRC, 
between the three participant groups. Reduced miR-145 expression has been 
reported in both the mucosa of patients with UC (Pekow et al., 2012) and in the 
progression from normal mucosa to adenomas and dysplasia (Tsikitis et al., 
2014). On the other hand, miR-135b expression has previously been observed 
to be increased in the stool of patients with colorectal adenomas (Wu et al., 
2014).  To date, altered expression of miR-101, miR-122 or miR-335 in UC or 
polyps have not been reported previously. 
In addition, the eight miRNAs selected to be quantified in the intervention arm of 
the DISC Study, that are also implicated in colorectal carcinogenesis, were also 
quantified in the two higher-risk groups. From the eight miRNAs analysed, a 
significant difference between participant groups was discovered for the 
expression of miR-424. Participants with quiescent UC had greater miR-424 
expression compared with ‘Normal’ and ‘Polyp’ participants (Figure 5.9). This is 
consistent with findings from a study by Lin et al. where increased miR-424 
expression was observed in colonic tissue samples collected from IBD patients, 
comprising both UC and Crohn’s disease patients (Lin et al., 2014). 
Interestingly, an increase in expression of miR-424 has also been previously 
observed in colonic cancer tissue compared with adjacent normal tissue in CRC 
without lymph node metastasis (Wang et al., 2010). I also observed that miR-
424 expression was significantly lower in participants with a prior history of 
polyps compared with ‘Normal’ participants. This has not been reported 
previously. 
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Figure 5.9 Expression of miR-424 in the macroscopically-normal mucosa 
of ‘Normal’, ‘UC’ and ‘Polyp’ participants.  
 
Data are presented as adjusted copies and expressed as medians (Kruskal-Wallis). 
Error bars represent lower and upper quartiles. N=94. 
Previous studies have reported an increase in miR-17, miR-19a, miR-19b and 
miR-20a expression in adenomas (Diosdado et al., 2009; Tsuchida et al., 2011). 
In the present study, although not statistically significant, an increase in miR-
19a was observed in the ‘Polyp’ group and upregulated miR-19b was found in 
both higher-risk groups compared with the ‘Normal’ group.  
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5.4 WNT11 DNA methylation in the macroscopically-normal mucosa of 
people at differential risk of CRC 
5.4.1 Introduction 
As differences in WNT11 expression at the mRNA level were observed between 
the three participant groups, WNT11 methylation was assessed to test the 
hypothesis that changes in gene expression may result from alterations in DNA 
methylation. To my knowledge, this is the first study to investigate WNT11 
methylation in the human colorectal mucosa.   
5.4.1.1 The role of WNT11 in the WNT signalling pathway 
WNT11 encodes a 45kD glycoprotein that acts as a ligand in the WNT 
signalling pathway and binds to Frizzled receptors, particularly Fzd7 (Uysal-
Onganer and Kypta, 2012). WNT11 is a member of the WNT5A family of WNT 
proteins that comprises WNT4, WNT5A and WNT11 (Du et al., 1995). Unlike 
the WNT1 family, the WNT5A family are not potent activators of the canonical 
WNT signalling pathway (Maye et al., 2004).  
Although WNT11 has been observed to act principally via the non-canonical 
WNT signalling pathway (Rao and Kuhl, 2010), it has also been suggested that 
WNT proteins may activate both canonical and non-canonical pathways (Maye 
et al., 2004). In the canonical pathway, WNT11 has been shown to activate 
(Tao et al., 2005) and inhibit WNT signalling (Maye et al., 2004). 
5.4.1.2 WNT11 in the healthy colon and in carcinogenesis 
In the colon, Liu et al. have investigated the role of WNT11 in the inflammatory 
response to Salmonella infection (Liu et al., 2011). An increased risk of IBD has 
been reported in people previously infected with Salmonella (Gradel et al., 
2009). In small intestinal epithelial cells and in the mouse intestine, an increase 
in WNT11 expression at both the mRNA and protein level was observed 
following Salmonella infection. Further investigations revealed that increased 
WNT11 reduced the number of Salmonella bacteria in HCT-116 cells and 
inhibited the inflammatory response, suggesting that WNT11 plays a role in 
protecting against bacterial infections and in the regulation of inflammation.  
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WNT11 has been implicated in colorectal carcinogenesis and has been 
proposed to be involved in cancer progression through the induction of 
proliferation, migration and invasion (Nishioka et al., 2013). In addition, in 
mouse intestinal epithelial cells, WNT11 stimulates proliferation and migration 
(Ouko et al., 2004). Furthermore, a reduction in cell migration has been 
reported in HCT-116 cells with abolished WNT11 expression (Dwyer et al., 
2010). Kirikoshi and colleagues have proposed that upregulation of WNT11 in 
colorectal adenocarcinomas may play an important role in colorectal 
tumourigenesis through the stimulation of WNT signalling (Kirikoshi et al., 
2001). 
5.4.1.3 WNT11 in the colorectum of people with ulcerative colitis 
Differential expression of WNT11 in the mucosa of people with UC has only 
been reported in one study. WNT11 expression, assessed by microarray 
analysis, was eleven-fold higher in the uninflamed mucosa of patients with UC 
compared with healthy controls (You et al., 2008).  
An earlier study investigated expression of WNT11, amongst other WNT ligands 
and receptors, in myofibroblasts isolated from patients with UC but found that 
WNT11 expression was too low to be analysed (Hughes et al., 2011).  
5.4.1.4 WNT11 in the colorectum of people with polyps 
Similar to investigations in patients with UC, the number of studies investigating 
WNT11 expression in patients with polyps are limited and WNT11 methylation 
in these patients has not been analysed previously.   
Lai et al. investigated expression of WNT11, amongst other genes, in a mouse 
model of Peutz-Jegher’s syndrome, an inherited disease characterised by the 
development of polyps in the digestive tract (Lai et al., 2011). Peutz-Jegher’s 
patients are at increased risk of developing cancers of the GI tract, amongst 
others. Expression of a number of WNT pathway-related genes differed 
significantly in gastric polyp tissue compared with the healthy mucosa, including 
WNT5A, WNT11 and FZD4. WNT11 expression was more than two-fold greater 
in gastric polyps compared with the healthy mucosa. 
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5.4.2 Hypotheses, aims and objectives 
5.4.2.1 Hypotheses 
The hypothesis for this investigation was that the differential expression of 
WNT11 observed in ‘Polyp’ participants, who are at higher risk of CRC, may be 
a consequence of differences in WNT11 methylation. In particular, it was 
hypothesised that the increased expression of WNT11 in these participants may 
have resulted from a reduction in WNT11 methylation. 
5.4.2.2 Aims 
This study aimed to test this hypothesis by investigating the differences in 
WNT11 methylation levels in the macroscopically-normal mucosa of people at 
differential CRC risk, i.e. those with quiescent UC, those with a prior history of 
adenomatous polyps and those at normal risk of developing CRC.  
5.4.2.3 Objectives 
 To obtain colorectal biopsies from the macroscopically-normal mucosa of 
three groups of DISC Study participants at differential risk of CRC, i.e. 
those with quiescent UC, those with a prior history of adenomatous polyps 
and “normal” participants; 
 To select an adequate primer to be used to quantify WNT11 methylation; 
 To bisulphite modify DNA previously extracted by the DISC Study Team; 
 To amplify the region to be analysed by PCR; 
 To perform an assay validation analysis; 
 To quantify WNT11 methylation at each CpG site by pyrosequencing; 
 To compare WNT11 methylation at each CpG site and the mean across 
all sites in the ‘Normal’ participants and in the two higher-risk groups (‘UC’ 
and ‘Polyp’ participants); 
 To investigate the effects of key epidemiological factors including age and 
gender on WNT11 methylation. 
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5.4.3 Methods 
The methods for this study are described in section 2.2.3. Amplification of BM-
DNA by PCR and subsequent quantification of WNT11 methylation by 
pyrosequencing was undertaken under my supervision by Idoia Ibero, an 
Erasmus Project student, to whom I am very grateful. A commercially-available 
primer assay was used for the methylation analysis of WNT11. The sequence 
analysed (please see below) comprised five CpG sites (highlighted in yellow), 
was within a CpG island and was located 1,436bp away from the promoter 
region (Figure 5.10).  
GGAGACGGGGTCCTCGGGGGACGCACGGCGA 
The ANOVA GLM was used to investigate differences in WNT11 mean 
methylation and methylation at each CpG site with the exception of site 4, 
where the data were not normally-distributed and consequently the non-
parametric test Kruskal-Wallis was used. The Dunnett post-hoc test was used 
for multiple comparisons with the control (‘Normal’) group and the Bonferroni 
method was used for pairwise comparisons. 
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Figure 5.10 WNT11 nucleotide sequence (-) illustrating promoter 
sequences, CpG islands and sequence analysed by pyrosequencing. 
 
CpG islands are highlighted in yellow and the promoter sequence is in bold and 
underlined. The sequence analysed by the PyroMark WNT11 assay (Qiagen) is in red 
and underlined.  
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5.4.4 Results 
DNA methylation was quantified at five CpG sites within a CpG island by 
pyrosequencing. Differences between the three participant groups were 
analysed at each of the five CpG sites as well as for the mean methylation 
across all five sites.  
WNT11 methylation was quantified in a total of 58 participants, comprising 20 
‘Normal’ participants, 12 ‘UC’ participants and 26 ‘Polyp’ participants. The 
participant characteristics are described in Table 5.9. Participants were 
matched for age, gender, BMI, smoking status and endoscopy procedure as 
best as possible and the participants were all Caucasian.  
Table 5.9 Participant characteristics for WNT11 methylation analysis. 
  Higher-risk 
Risk group Normal UC Polyp 
Number of participants 20 12 26 
Gender 
Female (%) 
Male (%) 
 
5 (25) 
15 (75) 
 
3 (25) 
9 (75) 
 
6 (23) 
20 (77) 
Age 
Mean (years) 
Range 
 
59.6 
41-78 
 
56.50 
38 – 71 
 
61.88 
44 – 79 
Smoking status 
Never (%) 
Former (%) 
Current (%) 
 
10 (50) 
7 (35) 
3 (15) 
 
3 (25) 
8 (67) 
1 (8) 
 
8 (31) 
11 (42) 
5 (19) 
BMI 
Mean (kg/m2) 
Range 
 
28.9 
23.2 – 35.7 
 
29.3 
22.2 – 37.6 
 
28.8 
19.8 – 40.3 
Procedure 
Colonoscopy (%) 
Flexi Sigmoidoscopy (%) 
 
4 (20) 
16 (80) 
 
12 (100) 
0 (0) 
 
24 (92) 
2 (8) 
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5.4.4.1 WNT11 pyrosequencing assay validation 
Similarly to that performed prior to quantification of SFRP1, standard curves 
were run to validate the commercially-available WNT11 pyrosequencing assay. 
The correlations between expected and observed methylation were optimal, 
with R2 values greater than 0.96 achieved for all five CpG sites (Figure 5.11). 
Figure 5.11 Standard curves for WNT11 pyrosequencing assay validation 
at all five CpG sites. 
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5.4.4.2 WNT11 methylation in the macroscopically-normal mucosa of 
‘Normal’, ‘UC’ and ‘Polyp’ participants 
WNT11 methylation was low across all three participant groups at all five CpG 
sites, ranging from 0% to 13%, (‘Normal’ 0% - 3.4%, ‘Polyp’ 0% - 13.0% and 
‘UC’ 0.6% - 3.3%). The CpG site with the greatest methylation was CpG site 2 
(mean methylation 2.1%) and the site with lowest methylation was CpG site 3 
(mean methylation 1.5%). 
Table 5.10 Mean WNT11 methylation in the macroscopically-normal 
mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ participants at each CpG site and the 
mean methylation across all five sites.  
CpG site Normal UC Polyp P value 
11 
N=50 
1.37 
(0.80 – 1.94) 
1.58 
(0.94 – 2.21) 
2.18 
(1.70 – 2.66) 
0.184 
21 
N=47 
1.51 
(0.98 – 2.33) 
1.05 
(0.69 – 1.59) 
2.12 
(1.54 – 2.92) 
0.016 
31 
N=47 
1.18 
(0.80 – 1.71) 
1.36 
(0.11 – 0.82) 
1.53 
(1.10 – 2.13) 
0.660 
42 
N=53 
1.88 
(0.85 – 2.23) 
1.97 
(1.69 – 2.63) 
1.98 
(1.40 – 2.66) 
0.325 
51 
N=47 
1.77 
(1.15 – 2.72) 
1.86 
(1.13 – 3.08) 
1.49 
(1.02 – 2.18) 
0.694 
Mean1 
N=51 
1.20 
(0.82 – 1.74) 
1.73 
(1.15 – 2.59) 
2.01 
(1.50 – 2.69) 
0.225 
Data are expressed as percentage methylation. 1Data are presented as LSMs (95% 
CIs). The ANOVA GLM was used to compare methylation between the three 
participant groups. Dunnett’s post-hoc test was used for multiple comparisons with the 
control group and the Bonferroni method was used for pairwise comparisons. 2Data are 
presented as medians (lower and upper quartiles). The non-parametric Kruskal-Wallis 
test was used to compare methylation between the three participant groups. 
WNT11 methylation differed significantly between the three participant groups 
at CpG site 2 (p=0.016). WNT11 methylation at CpG site 2 was approximately 
two-fold greater in ‘Polyp’ participants compared with those in the ‘UC’ group. In 
addition, WNT11 methylation at CpG site 2 also appeared to be increased in the 
‘Polyp’ group compared with the ‘Normal’ group. However, when applying 
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Bonferroni’s correction for multiple testing and adjusting the p-value threshold to 
0.008, the differences in WNT11 methylation at CpG site 2 (p=0.016) lose 
statistical significance. 
5.4.4.3 Exploration of additional factors influencing WNT11 methylation 
The effects of age, gender, endoscopy procedure, BMI and smoking status on 
WNT11 methylation at each CpG site and on the mean methylation across all 
five sites were also explored. With the exception of endoscopy procedure, there 
were no effects of any these additional factors on WNT11 methylation (Table 
5.11).  
Table 5.11 P values for the effects of age, gender, endoscopy procedure, 
BMI and smoking status on WNT11 methylation at each CpG site and on 
the mean methylation across all sites. 
CpG site Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
11 0.776 0.895 0.259 0.543 0.082 
21 0.529 0.510 0.027 0.916 0.525 
31 0.978 0.642 0.457 0.749 0.259 
42 0.249 0.508 0.114 0.445 0.078 
51 0.616 0.660 0.367 0.718 0.886 
Mean1 0.175 0.846 0.405 0.571 0.429 
1Analysed as covariates in the ANOVA GLM. 2Analysed using the non-parametric 
Kruskal-Wallis test. 
WNT11 methylation at CpG site 2 was more than three-fold higher in 
participants who had a colonoscopy compared with a flexible sigmoidoscopy 
(p=0.027) (Figure 5.12).  
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Figure 5.12 Effect of endoscopy procedure on WNT11 methylation at CpG 
site 2.  
 
Data are expressed as LSMs and error bars represent 95% CIs (ANOVA GLM). N=47. 
5.4.4.4 Correlation of WNT11 methylation between CpG sites 
Spearman’s correlation analysis was applied to investigate the correlation of 
WNT11 methylation levels between the five CpG sites. Correlation between 
CpG sites ranged from moderate, for example between CpG site 3 and 1, 2, 4 
and 5, to low, such as that observed between CpG site 5 and sites 2 and 4 
(Figure 5.13). 
Figure 5.13 Correlation of WNT11 methylation between CpG sites. 
  
Values represent Spearman correlation coefficients (ρ). (N=47). P<0.05. 
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5.4.4.5 Correlation between WNT11 methylation and expression 
To investigate whether WNT11 expression at the mRNA level was associated 
with WNT11 methylation, Spearman rank order correlation analysis was run on 
methylation at each CpG site and the mean methylation across all five CpG 
sites. The results from these analyses are shown in Table 5.6. 
There were no statistically significant correlations between WNT11 methylation 
and expression at any of the CpG sites or the mean methylation across all five 
CpG sites. For two of the sites (CpG sites 1 and 5), WNT11 methylation and 
expression were inversely correlated. However, for the mean methylation and 
the remainder of the CpG sites, a positive correlation was observed. 
Interestingly, at CpG site 2, where significant differences in methylation were 
found between the three participant groups, a close to significant positive 
correlation between WNT11 methylation and expression was observed 
(p=0.071). 
Table 5.12 Correlation between WNT11 methylation and expression.  
CpG site 
Spearman Correlation 
Coefficient 
P value 
1 -0.0237 0.876 
2 0.2740 0.071 
3 0.0246 0.875 
4 0.0208 0.891 
5 -0.2050 0.186 
Mean 0.0170 0.912 
Spearman correlation coefficients and corresponding p values for correlation between 
WNT11 methylation and expression. N=46. 
5.4.5 Discussion 
WNT11 is a WNT ligand that binds Frizzled receptors, however its effects on 
the WNT signalling pathway are not certain. Some studies have reported that it 
is only involved in activation of the non-canonical WNT pathway (Rao and Kuhl, 
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2010), whilst others have suggested that it is also able to activate or inhibit the 
canonical WNT signalling pathway (Maye et al., 2004; Tao et al., 2005). 
Few studies have investigated the role of WNT11 in colorectal carcinogenesis 
and a small number of studies have reported upregulation of WNT11 in CRC 
(Kirikoshi et al., 2001; Nishioka et al., 2013). Furthermore, WNT11 expression is 
increased in the uninflamed tissue of patients with UC (You et al., 2008) and in 
polyps from a mouse model of Peutz-Jegher’s syndrome (Lai et al., 2011).  
However, these studies have not investigated differences in WNT11 methylation 
in these patients. 
In the present study, WNT11 methylation was assessed at five CpG sites in the 
macroscopically-normal mucosa of healthy participants, participants with 
quiescent UC and participants with a prior history of adenomatous polyps by 
pyrosequencing. A significant difference in WNT11 methylation at CpG site 2 
was observed, where WNT11 methylation was higher in ‘Polyp’ participants 
compared with ‘Normal’ and ‘UC’ participants (p=0.016) (Figure 5.14). At the 
remaining four CpG sites, WNT11 methylation was comparable between the 
three participant groups.  
Figure 5.14 WNT11 methylation at CpG site 2 in the macroscopically-
normal mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ participants.  
 
Data are expressed as percentage methylation. Data are presented as LSMs (95% 
CIs). The ANOVA GLM was used to compare methylation between the three groups. 
Dunnett’s post-hoc test was used for multiple comparisons with the control group and 
the Bonferroni method for pairwise comparisons.N=47. 
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Contrary to findings from a previous study where an increase in WNT11 
expression was reported (Lai et al., 2011), an increase in methylation in ‘Polyp’ 
participants would be indicative of a reduction in WNT11 expression. 
Interestingly, the results from the analysis of WNT11 expression in the higher-
risk participants (Section 5.2.4.1) showed that WNT11 was significantly 
increased in ‘Polyp’ participants compared with the ‘Normal’ group. This 
suggests that the differences in WNT11 expression in participants with a prior 
history of adenomatous polyps result from genetic or epigenetic mechanisms 
other than DNA methylation.   
In addition, to test the hypothesis that WNT11 expression is regulated by DNA 
methylation, the correlation between WNT11 methylation and expression was 
investigated using Spearman’s rank order correlation test. There were no 
significant correlations observed between methylation and expression at any of 
the CpG sites or the mean methylation. However, a close to significant 
correlation was observed for methylation at CpG site 2, where WNT11 
methylation correlated positively with expression. This is contradictory to the 
normal association of an increase in methylation resulting a reduction in gene 
expression. 
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5.5 SFRP1 DNA methylation in the macroscopically-normal mucosa of 
people at differential risk of CRC 
5.5.1 Introduction 
SFRP1 encodes a member of the SFRP family that antagonises WNT signalling 
through competitive inhibition of Frizzled receptors (Bafico et al., 1999). SFRP1 
is a tumour suppressor (Caldwell et al., 2004) that is downregulated in CRCs as 
a result of DNA hypermethylation (Chen et al., 2014b). Furthermore, an 
increase in SFRP1 methylation, resulting in epigenetic silencing of SFRP1, has 
been proposed to be an early event in the adenoma-carcinoma sequence 
(Suzuki et al., 2004). 
5.5.1.1 SFRP1 methylation in the colorectum of ulcerative colitis 
In inflamed rectal tissue from 36 UC patients, Kim et al. investigated the 
methylation levels of four genes, including SFRP1, as markers of CRC risk (Kim 
et al., 2013). Methylation-specific PCR revealed that SFRP1 was frequently 
methylated in the inflamed tissue from UC patients. Furthermore, SFRP1 
methylation was significantly higher in participants aged over 40 years old 
compared with those younger than 20 years old. When comparing SFRP1 
methylation in the tissue from UC and CRC patients, SFRP1 methylation was 
approximately three-fold lower in UC patients compared with CRC patients. 
However, this study did not examine SFRP1 methylation in healthy controls and 
therefore did not compare SFRP1 methylation between UC and normal tissue.  
Within UC patients, SFRP1 methylation levels have also been reported to be 
increased in inflamed tissue compared with adjacent normal tissue (Wang et al., 
2013b). Furthermore, Wang et al. (2013) reported that this increase was greater 
than 50% in a quarter of the UC patients analysed. 
An increase in SFRP1 methylation, by over 60%, has also been found in IBD-
associated neoplasia compared with tissue from UC patients, and this was 
increased in older compared with younger study participants (Dhir et al., 2008). 
Similar to the findings from the study by Kim et al. (2013) where SFRP1 
methylation was lower in tissue from UC patients compared with that from CRC 
patients, SFRP1 methylation in UC-related neoplasia has been observed to be 
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significantly lower than that in sporadic CRC tissue by almost two-fold (Konishi 
et al., 2007).  
5.5.1.2 SFRP1 methylation in the colorectum of people with polyps 
Shao et al. have reported higher SFRP1 methylation in patients with 
adenomatous polyps (55% methylation) compared with healthy controls, where 
they did not observe any methylation of SFRP1 (Shao et al., 2012). SFRP1 
methylation was significantly increased in CRC tissue (68.9% methylation) 
compared with that in adenomatous polyps. Belshaw et al. have also observed 
a two-fold increase in SFRP1 methylation in tissue from patients with 
adenomatous polyps compared with healthy participants, however this 
difference was not statistically significant (Belshaw et al., 2008). Similar to the 
findings from other studies, a positive correlation between age and SFRP1 
methylation was found.   
An increase in SFRP1 methylation has been observed in both sporadic 
adenomas and those occurring in patients with FAP, compared with matched 
healthy tissue (Caldwell et al., 2010). When the authors compared sporadic 
adenomas with those arising in FAP patients, they observed significantly higher 
SFRP1 methylation in sporadic cases. As well as quantifying SFRP1 
methylation, the study also examined SFRP1 expression at the mRNA level to 
investigate any associations between the two. Indeed, SFRP1 expression was 
reduced in both sporadic and FAP-related adenomas, where an increase in 
SFRP1 methylation was observed, compared with healthy tissue. This was 
more pronounced in sporadic adenomas compared with FAP-related 
adenomas. 
Caldwell et al. have also reported reduced SFRP1 expression by approximately 
ten-fold in adenoma tissue compared with healthy controls (Caldwell et al., 
2006). Protein levels of SFRP1, assessed by immunohistochemistry, were also 
lower in adenomas compared with normal-adjacent tissue, and in the normal-
adjacent tissue compared with healthy controls. They further investigated this 
finding by quantifying DNA methylation by combined bisulphite restriction 
analysis (COBRA) and observed significantly higher SFRP1 methylation by 
approximately two-fold in adenoma tissue compared with healthy controls.  
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SFRP1 methylation has been observed in 88% of sporadic adenoma cases 
compared with 53% of healthy and normal-adjacent tissues (Qi et al., 2006). 
Significantly increased SFRP1 methylation was found in adenoma tissue 
compared with both normal-adjacent tissues and healthy controls, however 
there were no differences in SFRP1 methylation observed between adenomas 
and carcinomas. Gene silencing or a significant reduction in SFRP1 expression 
were observed in 76% of sporadic adenoma cases, and this was significantly 
higher when compared with that observed in healthy controls. These findings 
suggest that the loss of or reduction in SFRP1 expression is observed early in 
the progression from normal tissue to adenoma and ultimately carcinoma and 
results from hypermethylation of SFRP1. 
5.5.2 Hypotheses, aims and objectives 
5.5.2.1 Hypotheses 
The hypothesis for this study was that participants at higher risk of CRC, i.e. 
those with quiescent UC or a prior history of adenomatous polyps, would have 
increased SFRP1 methylation. 
5.5.2.2 Aims 
This study aimed to test this hypothesis by quantifying SFRP1 methylation 
levels in the macroscopically-normal mucosa of people at differential CRC risk 
i.e. those with quiescent UC, those with a prior history of adenomatous polyps 
and those at normal risk of developing CRC. 
5.5.2.3 Objectives 
 To obtain colorectal biopsies from the macroscopically-normal mucosa of 
three groups of DISC Study participants at differential risk of CRC i.e. 
those with quiescent UC, those with a prior history of adenomatous polyps 
and “normal” participants; 
 To select an adequate primer within the promoter region of SFRP1 and 
encompassing as many CpG sites as possible to quantify SFRP1 
methylation; 
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 To bisulphite modify DNA previously extracted by the DISC Study Team; 
 To amplify the region to be analysed by PCR; 
 To perform an assay validation analysis; 
 To quantify SFRP1 methylation at each CpG site by pyrosequencing; 
 To compare SFRP1 methylation at each CpG site and the mean across 
all sites in the ‘Normal’ participants and in the two higher-risk groups (‘UC’ 
and ‘Polyp’ participants); 
 To investigate the effects of key epidemiological factors including age and 
gender on SFRP1 methylation. 
5.5.3 Methods 
SFRP1 methylation was quantified at seven CpG sites by pyrosequencing using 
a commercially-available, optimised Qiagen assay (please see section 3.5). The 
methods for this study can be found in section 2.2.3. 
Differences in SFRP1 methylation between the three participant groups were 
analysed at each CpG site and for the mean methylation across all seven CpG 
sites using the ANOVA GLM with the inclusion of age, gender, endoscopy 
procedure, BMI and smoking status as covariates. Dunnett’s post-hoc test was 
used for multiple comparisons with the control group and the Bonferroni method 
was used for pairwise comparisons. 
5.5.4 Results 
SFRP1 methylation was moderate at all seven CpG sites, but the inter-
participant variability was large, with methylation ranging from 7.3% to 70.9% 
across all risk groups (‘Normal’ 13.6% - 45.9%, ‘UC’ 7.3% - 54.2% and ‘Polyp’ 
13.6% - 70.9%). Methylation across all three participant groups was lowest at 
CpG site 5 (mean methylation 24.9%) and highest at CpG site 4 (mean 
methylation 32.4%).   
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5.5.4.1 SFRP1 methylation in the macroscopically-normal mucosa of 
‘Normal’, ‘UC’ and ‘Polyp’ participants 
A significant difference in SFRP1 methylation between the three participant 
groups was observed for the majority of the CpG sites (bar CpG site 1) and for 
the mean methylation across the seven sites (p<0.05) (Table 5.13). However, 
differences in SFRP1 methylation at CpG site 1 between the three participants 
was close to reaching statistical significance (p=0.055). Dunnett’s post-hoc test 
revealed that, in all cases, SFRP1 methylation was significantly higher in the 
‘Polyp’ compared with the ‘Normal’ group.  
Mean SFRP1 methylation across all seven CpG sites increased with increasing 
CRC risk, from ‘Normal’ participants to that observed in participants with 
quiescent UC and ultimately in those with a prior history of adenomatous 
polyps. Mean SFRP1 methylation was 1.2-times higher in the ‘Polyp’ group 
compared with the ‘Normal’ group. A similar pattern was observed at each CpG 
site. 
When applying Bonferroni’s correction for multiple testing and adjusting the p-
value threshold to 0.006, the differences in SFRP1 methylation observed at 
CpG sites 2 to 7 and on the mean methylation across all sites is lost.  
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Table 5.13 Mean SFRP1 methylation in the macroscopically-normal 
mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ participants at each CpG site and the 
mean across all sites. 
CpG site Normal UC Polyp P value 
1 
N=103 
29.8 
(28.3 – 31.5) 
31.4 
(27.5 – 25.8) 
34.8 
(31.4 – 38.6) 
0.055 
2 
N=104 
23.9 
(22.4 – 25.4) 
27.0 
(23.1 – 31.5) 
30.1 
(26.7 – 34.0) 
0.011 
3 
N=102 
22.3 
(20.9 – 23.9) 
25.1 
(21.1 – 29.7) 
28.2 
(24.6 – 32.3) 
0.025 
4 
N=105 
30.4 
(28.8 – 30.9) 
34.7 
(30.6 – 38.8) 
36.4 
(33.3 – 39.5) 
0.010 
5 
N=103 
22.4 
(21.1 – 23.8) 
25.8 
(22.2 – 30.0) 
27.5 
(24.6 – 30.9) 
0.014 
6 
N=100 
28.13 
(26.2 – 30.0) 
32.0 
(27.3 – 36.7) 
34.9 
(31.2 – 38.6) 
0.016 
7 
N=101 
29.1 
(27.1 – 31.1) 
32.3 
(27.4 – 37.2) 
36.1 
(32.2 – 39.9) 
0.018 
Mean 
N=103 
26.4 
(24.9 – 27.9) 
28.9 
(26.1 – 32.0) 
31.8 
(27.6 – 36.6) 
0.027 
 
5.5.4.2 Exploration of additional factors influencing SFRP1 methylation 
The effects of age, gender, endoscopy procedure, BMI and smoking status on 
SFRP1 methylation at each CpG site and on the mean across all sites were 
analysed using the ANOVA GLM. There were no associations between gender, 
endoscopy procedure, BMI or smoking status and SFRP1 methylation at any of 
the CpG sites or the mean across all sites (Table 5.14). Age was a determinant 
of SFRP1 methylation at all seven CpG sites and the mean methylation across 
all seven CpG sites (p<0.001). 
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Table 5.14 P values for the effects of age, gender, endoscopy procedure, 
BMI and smoking status on SFRP1 methylation at each CpG site and on 
the mean methylation across all sites. 
CpG site Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
1 <0.001 0.578 0.752 0.404 0.666 
2 <0.001 0.551 0.610 0.451 0.906 
3 <0.001 0.839 0.801 0.580 0.952 
4 <0.001 0.787 0.766 0.263 0.802 
5 <0.001 0.826 0.661 0.646 0.674 
6 <0.001 0.971 0.822 0.310 0.659 
7 <0.001 0.931 0.802 0.259 0.782 
Mean <0.001 0.802 0.694 0.418 0.664 
 
A positive correlation was found between age and SFRP1 methylation at each 
CpG site and for the mean SFRP1 methylation (Table 5.15). A Spearman 
correlation coefficient of 0.614 and a R2 value of 0.313 were found for the 
correlation between age and mean SFRP1 methylation (Figure 5.15). 
   
 256 
Table 5.15 Correlation between age and SFRP1 methylation.  
CpG site 
Spearman Correlation 
Coefficient 
P value 
1 0.590 <0.001 
2 0.596 <0.001 
3 0.584 <0.001 
4 0.608 <0.001 
5 0.588 <0.001 
6 0.605 <0.001 
7 0.553 <0.001 
Mean 0.614 <0.001 
 
Figure 5.15 Positive correlation between age and mean SFRP1 
methylation across all seven CpG sites. N=101. 
 
5.5.4.3 Correlation of SFRP1 methylation between CpG sites 
Spearman correlation analyses were used to investigate the correlation 
between levels of SFRP1 methylation between the seven CpG sites in all three 
groups. A strong correlation in SFRP1 methylation levels was found between all 
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seven CpG sites, as indicated by Spearman correlation coefficients >0.900 
(Figure 5.16). 
Figure 5.16 Correlation of SFRP1 methylation between CpG sites. 
 
Values represent Spearman correlation coefficients (ρ). (N=100). P<0.001. 
5.5.5 Discussion 
SFRP1, as a consequence of DNA hypermethylation, is frequently 
downregulated in CRCs (Chen et al., 2014b). Increased SFRP1 methylation has 
also been reported in the inflamed colorectal tissue of patients with UC (Kim et 
al., 2013) and in UC-associated cancers (Konishi et al., 2007). Several studies 
have also observed hypermethylation of SFRP1 in adenomas (Caldwell et al., 
2006; Qi et al., 2006; Belshaw et al., 2008; Shao et al., 2012), including those in 
patients with FAP (Caldwell et al., 2010), suggesting that this is an early event 
in the adenoma-carcinoma sequence. 
In the present study, SFRP1 methylation was quantified in the macroscopically-
normal mucosa of healthy participants, participants with quiescent UC and 
participants with a prior history of adenomatous polyps at seven CpG sites 
within the SFRP1 promoter region by pyrosequencing. At all seven CpG sites, 
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an increase in SFRP1 methylation was observed with increasing CRC risk, from 
‘Normal’ to ‘UC’ and, ultimately, to ‘Polyp’ groups (Figure 5.17). These 
differences were statistically significant at all CpG sites with the exception of 
CpG site 1, where a close to significant difference was observed (p=0.055), and 
for the mean methylation across all seven CpG sites. 
Figure 5.17 SFRP1 methylation in the macroscopically-normal mucosa of 
‘Normal’, ‘UC’ and ‘Polyp’ participants. 
 
Data are expressed as percentage methylation. Data are presented as LSMs (95% 
CIs). The ANOVA GLM was used to compare methylation between the three groups 
and Dunnett’s post-hoc test was used for multiple comparisons with the control group 
and the Bonferroni method was used for pairwise comparisons. * p<0.05, ** p<0.10. 
The effects of age, gender, endoscopy procedure, BMI and smoking status on 
SFRP1 methylation were assessed as covariates using the ANOVA GLM. An 
association between age and SFRP1 methylation was observed at all seven 
CpG sites and on the mean methylation across all sites. In all cases, age and 
SFRP1 methylation correlated positively. This is consistent with findings from 
previous studies where a significant increase in SFRP1 methylation has been 
reported with increasing age in healthy, UC and adenoma tissues (Belshaw et 
al., 2008; An et al., 2010; Rawson et al., 2011; Kim et al., 2013). Furthermore, 
this finding is consistent with that observed in the results from similar analyses 
in the intervention arm of the DISC Study (section 4.4.4.3). An increase in 
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SFRP1 methylation with age suggests a reduction in SFRP1 expression, 
resulting in reduced inhibition and therefore an increase in WNT signalling 
activity. This could be one of the mechanisms contributing to an increase in 
CRC incidence with age.   
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5.6 Colonic crypt cell proliferative state in the macroscopically-normal 
mucosa of people at differential risk of CRC 
5.6.1 Introduction 
In this study, differences in cell proliferation, a functional outcome of the WNT 
pathway that is dysregulated in CRC, in the macroscopically-normal mucosa of 
people at differential risk of CRC were assessed following whole crypt 
microdissection of Schiff reagent-stained biopsies.  
5.6.1.1 Cell proliferation in the colorectum of people with ulcerative colitis 
Studies investigating cell proliferation in patients with UC, predominantly human 
studies, have been consistent in finding an increase in colonic crypt cell 
proliferation with UC and have also observed an altered distribution of 
proliferating cells. 
In a rat model of induced colitis, which structurally resembles UC in humans, 
the cell proliferation index, assessed by Ki-67 immunoreactivity, was 40 to 60-
fold higher in the colonic mucosa of colitis rats compared with controls (Vetuschi 
et al., 2002). The authors concluded that the hyperproliferative state observed 
with UC may contribute to the frequent development of cancers in these 
patients. 
One of the earliest studies investigating cell kinetics in patients with UC 
reported an increase in the proportion of mitotic cells in the upper compartments 
of the crypt in rectal biopsies from patients with active UC compared with 
healthy controls (Serafini et al., 1981). The proliferating index in patients in 
remission was also significantly higher than that in healthy controls but 
comparable to that observed in patients with active UC. 
A later study utilised autoradiography to compare proliferation between healthy 
controls, patients with UC, patients with adenomas and CRC patients 
(Kanemitsu et al., 1985). The number of proliferating cells was approximately 
double in patients with UC, who also had a larger proliferative compartment, 
which is normally found in the basal half of the colonic crypt, compared with 
healthy controls. That same year, Franklin et al. also investigated differences in 
colonic crypt kinetics in patients with quiescent and active UC using 
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immunohistochemical techniques (Franklin et al., 1985). A significantly higher 
proportion of proliferating cells was observed in the proliferative compartment 
(the lower two-thirds of the crypt) and the upper quarter of the crypt in patients 
with active UC compared with those with quiescent UC and healthy controls. In 
addition, a greater proportion of proliferating cells in the proliferative 
compartment were found in patients with quiescent UC compared with healthy 
controls.  
In the rectum of patients with UC, although Biasco et al. did not observe a 
significant difference in the total number of proliferating cells, a four-fold 
increase in proliferation was observed in the upper 40% of the crypt compared 
with healthy controls (Biasco et al., 1990). A similar later study also reported a 
shift in the proliferative compartment towards the mouth of the crypt in patients 
with UC compared with healthy controls (Paganelli et al., 1993).  
Sipos et al. have shown increasing cell proliferation with increasing 
inflammation in IBD, including patients with UC, compared with healthy controls, 
suggesting that stimulation of proliferation is a consequence of the inflammation 
associated with this disease (Sipos et al., 2005). The group also reported 
differences in cell proliferation in patients with varying degrees of UC (Sipos et 
al., 2002). Proliferation, assessed by PCNA staining, was significantly higher in 
all degrees of UC compared with healthy controls. Furthermore, proliferation 
was greater in moderate compared with mild UC, and higher in severe UC 
compared with both moderate and mild UC. In UC patients in remission, cell 
proliferation has also been found to be increased. The proliferation index of 23 
patients with UC (mean 42%) exceeded that observed in the healthy epithelium 
(Buczynski et al., 2012).  
5.6.1.2 Cell proliferation in the colorectum of people with polyps 
A very early study by Kanemitsu et al., whose study was described previously, 
found that, similar to findings observed in UC patients, cell proliferation was 
approximately two-fold higher in patients with adenomas compared with healthy 
controls (Kanemitsu et al., 1985). Furthermore, proliferating cells were counted 
in all parts of the crypt and there was no longer a defined proliferative 
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compartment. The investigators also observed a positive correlation between 
tumour grade and cell proliferation.  
A similar finding in the alteration of the distribution of mitotic cells within the 
crypts of patients with adenomas has been shown by Biasco and colleagues 
(Biasco et al., 1990). Although a significant difference was not observed in the 
total number of proliferating cells, cell proliferation in the upper 40% of the crypt 
was more than two-fold greater in the rectum of patients with adenomas 
compared with healthy controls.  
Microradiography has also been used to investigate changes in proliferative 
activity in patients with adenomatous polyps and carcinomas in the colon (Ponz 
de Leon et al., 1988). The number of mitotic cells within the crypts was greater 
in patients with polyps and carcinomas compared with healthy controls. Polyp 
and carcinoma patients also had a significantly greater number of proliferating 
cells in the upper sections of the crypt (top three fifths) compared with healthy 
controls. These findings demonstrated that differences in proliferation in the 
progression of normal colonic tissue to carcinoma may be detected in 
adenomatous polyps. Furthermore, it was not only the levels of proliferation that 
differed but also the distribution of mitotic cells, with the proliferative 
compartment enlarging towards the mouth of the crypt in both adenomatous 
polyps and carcinomas.  
A later study also investigated levels of proliferation in patients with colonic 
polyps using immunohistochemical assessment of bromodeoxyuridine 
incorporation (Wilson et al., 1990). However, in this study the analysed tissue 
was removed from a minimum of five centimetres away from the adenoma(s). It 
was observed that proliferation in these tissues was significantly higher than 
that observed in healthy controls and, consistent with findings from the study by 
Ponz de Leon et al. (1988), the proliferative compartment extended towards the 
mouth of the crypt.  
Roncucci and colleagues evaluated cell proliferation in the normal mucosa of 
patients with different types of colonic polyps, including tubular and tubulovillous 
polyps, as well as evaluating whether differences could be observed between 
different clinical characteristics or outcomes (Roncucci et al., 1991). 
Proliferation was significantly higher in the normal tissue from all of the polyp 
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participants compared with healthy controls, but the authors did not observe 
differences between clinical characteristics or outcomes, such as adenoma size 
or number. These findings demonstrated that the increase in cell proliferation 
and enlargement of the proliferative compartment towards the mouth of the 
crypts in adenoma patients may be observed in normal-appearing tissue and is 
detectable regardless of adenoma type or size.  
Proliferation in lesions of the colorectum, including hyperplastic polyps, 
adenomas and carcinomas, has been assessed by Ki-67 labelling (Kikuchi et 
al., 1997). In hyperplastic polyps, proliferation levels and distribution were 
comparable to that in the crypt base of the healthy colon but was increased in 
adenomas. A similar study compared cell proliferation between three different 
polyp types: serrated, hyperplastic and tubular adenomas, in an attempt to 
distinguish between characteristics of the three (Kang et al., 1997). Proliferation 
in the middle and upper sections of the crypt increased from hyperplastic polyps 
to serrated adenomas and was ultimately greatest in tubular adenomas. A more 
recent study also assessed proliferation in different polyp types by measuring 
phospho-histone H3, which specifically detects mitosis (Endo et al., 2013). An 
altered distribution of mitotic cells was observed in all three diseased tissue 
types when compared with the normal crypt, where proliferating cells were 
predominantly found in the lower third of the crypt. Proliferating cells in sessile 
serrated and in microvesicular hyperplastic polyps were also found in the middle 
and upper half of the crypt, and those in tubular adenomas were recorded in all 
areas of the crypt. Mitotic indices in sessile serrated polyps and tubular 
adenomas were significantly higher than those in both normal tissue and in 
microvesicular hyperplastic polyps.  
Shpitz and colleagues have assessed cell proliferation at each sequential stage 
of colorectal carcinogenesis: ACF, hyperplastic polyps, dysplastic polyps and 
carcinomas (Shpitz et al., 1997). When the crypts were divided into thirds, an 
increase in cell proliferation at each compartment was observed with increasing 
stage of carcinogenesis (i.e. from ACF to carcinomas), with the exception of 
hyperplastic polyps. 
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5.6.2 Hypotheses, aims and objectives 
5.6.2.1 Hypotheses 
The hypothesis for this investigation was that participants at higher risk of CRC, 
i.e. those with quiescent UC or a prior history of adenomatous polyps, would 
have increased colonic crypt cell proliferation and that a greater proportion of 
mitotic cells would be observed in the upper half of the crypts. 
5.6.2.2 Aims 
This study aimed to test this hypothesis by quantifying colonic crypt cell 
proliferation in the macroscopically-normal mucosa of people at differential CRC 
risk i.e. those with quiescent UC, those with a prior history of adenomatous 
polyps and those at normal risk of developing CRC.  
5.6.2.3 Objectives 
 To obtain colorectal biopsies from the macroscopically-normal mucosa of 
three groups of DISC Study participants at differential risk of CRC i.e. 
those with quiescent UC, those with a prior history of adenomatous polyps 
and “normal” participants; 
 To compare colonic crypt cell proliferation in the ‘Normal’ participants and 
in the two higher-risk groups (‘UC’ and ‘Polyp’ participants); 
 To assess differences in crypt measurements (length, width and volume) 
in ‘Normal’ participants and in the two higher-risk groups (‘UC’ and ‘Polyp’ 
participants); 
 To investigate the effects of key epidemiological factors including age and 
gender on colonic crypt cell proliferation. 
5.6.3 Methods 
Assessment of colonic crypt cell kinetics was performed as described in section 
2.2.4. Briefly, rectal biopsies were hydrated, hydrolysed and stained in Schiff 
reagent prior to crypt microdissection. Crypts were divided into ten equal-sized 
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compartments and the number of mitotic cells were counted in each 
compartment in addition to the recording of crypt measurements. Ten intact 
crypts were analysed per participant. 
The ANOVA GLM was used to investigate differences in the measured 
outcomes between the three groups, with the inclusion of age, gender, 
endoscopy procedure, BMI and smoking status as covariates. The Dunnett 
post-hoc test was used for multiple comparisons with the control group and the 
Bonferroni method was used for pairwise comparisons. 
5.6.4 Results 
Using rectal mucosal biopsies from the macroscopically-normal mucosa of 
participants from the ‘Normal’, ‘UC’ and ‘Polyp’ groups, colonic crypt cell 
proliferation was assessed following whole crypt microdissection of Schiff 
reagent-stained biopsies. The mean total number of mitotic cells per crypt and 
the mean percentage of mitotic cells in the top half of the crypt were calculated 
by calculating the average across the 10 crypts for each participant. In addition, 
the crypt volumes were calculated by assuming that crypts resembled the 
shape of a cylinder. 
5.6.4.1 Colonic crypt cell proliferation in the macroscopically-normal 
mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ participants 
Significant differences between the three participant groups were observed for 
the mean total number of mitotic cells (p=0.009) and all three crypt 
measurements (length, width and volume) (Table 5.16). The total number of 
mitotic cells was approximately two-fold lower in ‘Polyp’ participants compared 
with ‘Normal’ participants. Participants with quiescent UC also appeared to have 
a reduced total number of mitotic cells compared with the ‘Normal’ group.  
Although ‘Normal’ participants had a higher total number of mitotic cells per 
crypt compared with ‘Polyp’ participants, the opposite was observed for the 
percentage of mitotic cells in the top half of the crypt. The latter appeared to be 
highest in the two higher-risk groups, however this was not statistically 
significant. 
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Significant differences in all three crypt measurements (length, width and 
volume) were observed between the three participant groups. The crypts were 
significantly longer in ‘UC’ participants, who had a mean crypt length of 630µm 
compared with 557µm and 545µm in the ‘Polyp’ and ‘Normal’ groups 
respectively. ‘UC’ participants also had significantly wider crypts than the other 
two groups, with a mean crypt width of 139µm compared with 121µm and 
113µm in the ‘Normal’ and ‘Polyp’ groups respectively. Furthermore, the crypt 
volume, calculated by assuming the shape of a cylinder, was also significantly 
greater in the ‘UC’ group compared with participants in the ‘Normal’ and ‘Polyp’ 
groups. 
When applying Bonferroni’s correction for multiple testing and adjusting the p-
value threshold to 0.01, the differences in total mitoses, crypt width and crypt 
volume between the three participant groups remain statistically significant. 
However, this is lost for the differences in crypt length between groups, but 
remains close to reaching statistical significance (p=0.014). 
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Table 5.16 Colonic crypt cell proliferation and crypt measurements in the 
macroscopically-normal mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ 
participants. 
 Normal UC Polyp P value 
Total 
mitoses 
7.69 
(6.22 – 9.51) 
5.09 
(3.50 – 7.42) 
4.20 
(3.27 – 5.41) 
0.009 
Mitoses in 
top half of 
crypt 
4.85 
(3.27 – 7.91) 
9.21 
(4.58 – 18.52) 
5.71 
(3.57 – 9.13) 
0.338 
Crypt 
length 
(µm) 
545 
(518 – 572) 
630 
(598 – 663) 
557 
(509 – 605) 
0.014 
Crypt 
width (µm) 
121 
(115 – 127) 
139 
(128 – 152) 
113 
(107 – 120) 
<0.001 
Crypt 
volume 
(µm3) 
6.04 x 106 
(6.80 – 5.40 x 
106) 
8.81 x 106 
(7.53 x 106 – 
1.04 x 107) 
5.48 x 106 
(4.60 – 6.65 x 
106) 
0.001 
Data are presented as LSMs (95% CIs). The ANOVA GLM was used to compare 
methylation between the three groups. Dunnett’s and Bonferroni post-hoc tests were 
used for multiple comparisons. N=71. 
5.6.4.2 Exploration of additional factors influencing colonic crypt cell 
proliferation 
The effects of age, gender, endoscopy procedure, BMI and smoking status on 
the measured outcomes were also explored. Age, gender, endoscopy 
procedure and BMI did not have an effect on colonic crypt cell proliferation or 
crypt measurements (Table 5.17). However, a significant effect of smoking 
status was observed for the total number of mitotic cells per crypt, crypt width 
and crypt volume. 
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Table 5.17 P values for the effects of age, gender, endoscopy procedure, 
BMI and smoking status on colonic crypt cell proliferation and crypt 
measurements. 
 Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
Total 
mitoses 
0.934 0.748 0.363 0.964 0.022 
Mitoses in 
top half of 
crypt 
0.990 0.244 0.249 0.192 0.408 
Crypt 
length 
0.212 0.111 0.328 0.729 0.534 
Crypt 
width 
0.352 0.637 0.324 0.685 0.002 
Crypt 
volume 
0.384 0.931 0.263 0.923 0.005 
 
The mean number of mitotic cells was almost two-fold higher in former smokers 
compared with participants who never smoked (Figure 5.18 (A)). Both former 
and current smokers had significantly wider and larger crypts compared with 
participants who had never smoked (Figure 5.18 (B) and (C)).  
   
 269 
Figure 5.18 Effect of smoking on the total number of mitotic cells per crypt 
(A), crypt width (B) and crypt volume (C).  
 
Data are presented as LSMs and error bars represent 95% CIs (ANOVA GLM). N=71. 
5.6.5 Discussion 
Differences in the CCPS in the macroscopically-normal mucosa of people at 
differential risk of CRC were assessed following whole crypt microdissection of 
Schiff reagent-stained crypts. In ten crypts per participant, the total number of 
mitotic cells per crypt were counted and the proportion of mitotic cells in the 
upper half of the crypt were calculated as an indicator of crypt health. 
Furthermore, crypt measurements in the form of length and width were 
recorded and the crypt volume was calculated.  
Unexpectedly, a reduction in the total number of mitotic cells per crypt was 
observed in higher-risk participants, and this was statistically significant for the 
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comparison between the ‘Polyp’ and ‘Normal’ groups (Figure 5.19). This finding 
is contrary to previous reports in the literature, where an increase in cell 
proliferation has been observed in both UC (Sipos et al., 2005; Buczynski et al., 
2012) and polyp patients (Ponz de Leon et al., 1988; Wilson et al., 1990).  
However, in the present study, the proportion of mitotic cells in the top half of 
the crypt appeared to be greater in higher-risk participants, particularly those 
with quiescent UC. The latter is a better indicator of crypt health as proliferation 
is normally observed in the proliferative compartment in the lower half of the 
crypt in the healthy colon. This observation is consistent with previous findings 
that have reported an altered distribution of mitotic cells within the crypt, with an 
enlargement of the proliferative compartment and an increase in the number of 
mitotic cells found towards the mouth of the crypt, in both UC (Serafini et al., 
1981; Biasco et al., 1990; Paganelli et al., 1993) and polyp patients (Kanemitsu 
et al., 1985; Roncucci et al., 1991). Furthermore, an altered distribution of 
mitotic cells is one of the earliest detectable alterations in the apparently-normal 
mucosa prior to the development of malignancies (Roncucci et al., 1991).  
Figure 5.19 Total number of mitotic cells per crypt in the macroscopically-
normal mucosa of ‘Normal, ‘UC’ and ‘Polyp’ participants. 
 
Data are presented as LSMs (95% CIs). The ANOVA GLM was used to compare the 
number of mitotic cells per crypt between the three groups and Dunnett’s post-hoc test 
was used for multiple comparisons with the control group and the Bonferroni method 
was used for pairwise comparisons. N=71. 
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To my knowledge, this is the first study to report that crypts in people with 
quiescent UC are longer, wider and larger in volume compared with ‘Normal’ 
and ‘Polyp’ participants (Figure 5.20). 
Figure 5.20 Crypt measurements and volumes in the macroscopically-
normal mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ participants. 
 
Data are expressed as µm for crypt length and width and as µm3 for crypt volume. Data 
are presented as LSMs (95% CIs). The ANOVA GLM was used to compare 
methylation between the three groups and Dunnett’s post-hoc test was used for 
multiple comparisons with the control group and the Bonferroni method for pairwise 
comparisons. N=71. 
Exploration of additional factors influencing colonic crypt cell proliferation and 
crypt dimensions revealed a significant effect of smoking status on the total 
number of mitotic cells and crypt width and volume. Smokers, particularly 
former smokers, had a greater number of proliferating cells. They also had 
wider crypts that were greater in volume which, although this was not paralleled 
   
 272 
by an increase in the total number of mitotic cells, could be a consequence of 
the increased proportion of mitotic cells in the top half of the crypt. This would 
be consistent with findings from a previous study that reported stimulation of 
proliferation by nicotine in Caco-2 and HCT-8 CRC cell lines (Cucina et al., 
2012). 
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5.7 Expression of BAX and BCL-2 apoptotic genes in the 
macroscopically-normal mucosa of people at differential risk of CRC 
5.7.1 Introduction 
As the technique utilised to assess the colonic CCPS was not adequate for the 
assessment of apoptosis, the expression of BAX, a pro-apoptotic gene, and 
BCL-2, an anti-apoptotic gene, were quantified as markers of apoptosis. These 
genes are described in more detail in section 4.6.1.  
5.7.1.1 Apoptosis in the colorectum of people with ulcerative colitis 
Epithelial dysfunction in UC is thought to result mainly from aberrant levels of 
apoptosis (Seidelin and Nielsen, 2006). Studies investigating the rates of 
apoptosis in the colonic epithelium of patients with active UC have observed 
significantly increased levels of apoptosis in the inflamed tissue. Enhanced 
apoptosis has also been reported in the uninflamed tissue or in patients with 
quiescent UC. Furthermore, UC patients also have an altered distribution of 
apoptotic cells, with cells undergoing apoptosis being detected in all parts of the 
crypt in contrast to the healthy colon where apoptosis occurs mainly in the 
upper sections of the crypt. It has been suggested that the induction of 
apoptosis in UC results from the levels of inflammation in these patients 
(Seidelin and Nielsen, 2009) and that it jeopardises the function of the 
epithelium as a barrier and increases the possibility of infiltration of molecules 
such as enterotoxins and antigens (Vetuschi et al., 2002; Seidelin and Nielsen, 
2009).  
An increase in apoptosis has been observed in a DSS-induced rat model of 
colitis (Vetuschi et al., 2002). The apoptotic index, determined using the TUNEL 
assay, was up to 120-fold higher in colitis rats compared with controls. 
Furthermore, expression of pro-apoptotic BAX, assessed by 
immunohistochemical analysis, was also significantly increased. The authors 
concluded that the enhanced levels of apoptosis observed in UC could lead to a 
breakdown of the epithelial barrier function and consequently initiate mucosal 
invasion (Vetuschi et al., 2002). 
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Iwamoto and colleagues have investigated levels of apoptosis in both the 
inflamed and uninflamed tissue from patients with UC using various 
measurements such as the TUNEL assay to detect DNA breaks and IHC to 
quantify Fas and Fas-ligands (Iwamoto et al., 1996). A significantly greater 
number of TUNEL-positive cells were observed in the inflamed compared with 
uninflamed tissue of UC patients, and significantly more TUNEL-positive cells in 
UC patients compared with controls. Both uninflamed and inflamed tissues from 
UC patients were positive for markers indicative of apoptosis, such as Fas and 
DNA breaks, in the lower half of the crypts compared with normal controls, 
where apoptosis was mainly observed towards the mouth of the crypts.  
A correlation between apoptosis and increasing inflammation in patients with 
IBD, including UC patients, compared with healthy controls has been reported 
(Sipos et al., 2005). This group have also reported a correlation between levels 
of apoptosis and the severity of UC, where patients with severe UC had 
significantly higher levels of apoptosis compared with those with moderate UC 
and patients with moderate UC had greater levels of apoptosis compared with 
healthy controls (Sipos et al., 2002).  
A study by Seidelin and Nielsen was the first to investigate rates of apoptosis in 
UC patients with different disease characteristics (Seidelin and Nielsen, 2009). 
Flow cytometry was used to quantify apoptosis in 20 patients with UC, of whom 
12 had the active form of the disease, and 20 controls. Within the UC patients, 
the investigators observed significantly increased rates of apoptosis in the 
inflamed compared with uninflamed tissue, suggesting that the enhancement of 
apoptosis is driven by local inflammation. Consistent with the findings from the 
study by Sipos et al. (2005), a positive correlation between microscopic 
inflammation grade and apoptosis rates was found. However, contrary to 
previous findings, although rates of apoptosis were significantly higher in the 
inflamed tissue of UC patients, there were no differences observed in the 
uninflamed tissue compared with healthy controls. Overall, the authors did not 
observe relationships between any of the markers of disease characteristics or 
clinical outcomes and epithelial rates of apoptosis.  
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5.7.1.2 BAX and BCL-2 expression in the colorectum of people with 
ulcerative colitis 
Although numerous studies have reported an increase in apoptosis in patients 
with UC, studies suggest that this is mediated through alternative apoptotic 
pathways to the BAX/BCL-2 pathway.  
A study by Iimura et al. was the first to show that, unexpectedly, both BAX 
mRNA expression and protein levels were reduced in the inflamed colonic 
epithelium of UC patients, which would be indicative of a reduction in apoptosis 
(Iimura et al., 2000). BAX expression in the uninflamed tissue of UC patients 
was comparable to that measured in healthy controls. BCL-2 expression did not 
differ between healthy controls and UC patients. The authors concluded that the 
BAX/BCL-2 pathway was not involved in the regulation of the altered levels of 
apoptosis observed in UC. However, they suggested that, although altered 
expression of BAX did not contribute to the induction of apoptosis in UC, this 
could be one of the factors that results in dysregulated apoptosis in the colonic 
epithelium. 
A similar conclusion was drawn in a prospective study by Karamanolis and 
colleagues, who examined expression of BAX and BCL-2 by IHC and assessed 
apoptosis using the TUNEL method in 23 UC patients and 11 healthy controls 
(Karamanolis et al., 2007). The investigators concluded that apoptosis was not 
mediated through the BAX/BCL-2 pathway as they did not find a correlation 
between levels of apoptosis and the expression of either protein. However, an 
overall increase in expression of both BAX and BCL-2 proteins was observed.  
In a study described earlier, Buczynski et al. also assessed levels of apoptosis 
semi-quantitatively in UC patients in remission through immunohistochemical 
staining of BAX (Buczynski et al., 2012). The authors established that apoptosis 
in UC patients was between 2% - 75%, which was significantly higher than the 
0.5% - 11% normally observed in the healthy colon. In addition, staining of pro-
apoptotic BAX, which would normally be observed towards the mouth of the 
crypt, was found at the base of the crypt.  
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5.7.1.3 Apoptosis in people with polyps 
Polyps were previously thought to result primarily from a hyperproliferative state 
until it was suggested that dysregulation in apoptosis may also be implicated 
and that a balance between the two processes was important in determining the 
overall proliferative state of the crypt (Bedi et al., 1995).  
In the healthy crypt, the majority of the apoptotic cells are found in the mouth of 
the crypt (Hall et al., 1994), however, in adenomatous polyps the inverse has 
been observed, with apoptosis being reported at the base of the crypt (West et 
al., 2009). Controversially, the majority of studies have reported an increase in 
the levels of apoptosis in the progression of the normal mucosa to adenomas 
and ultimately carcinomas (Koornstra et al., 2003), with only a limited number of 
studies reporting a reduction in apoptosis in adenomas (Bedi et al., 1995; Moss 
et al., 1996a; Moss et al., 1996b). More recently, studies have focussed on 
comparing levels of apoptosis in different polyp types such as serrated or 
hyperplastic polyps. 
A reduction in apoptosis in adenomatous polyps was observed in a study by 
Moss et al., which assessed levels of apoptosis in surgically-resected tissues 
taken from 10 healthy participants and 22 patients with adenomatous polyps 
using the TUNEL method (Moss et al., 1996b). In the healthy mucosa, the 
majority of cells undergoing apoptosis were located in the base of the crypt but 
in tissue from adenomatous polyps a gradient with increasing apoptosis from 
the luminal surface towards the base of the crypt was observed. Overall, 
apoptosis levels in adenomatous polyps were approximately half that observed 
in healthy controls. A more recent, large prospective study observed similar 
findings in 226 adenoma patients and 493 healthy controls from the Diet and 
Health Study III (Martin et al., 2002). Patients with adenomas had lower 
apoptotic scores (mean 2.46 apoptotic cells per crypt) compared with healthy 
controls (mean 2.94 apoptotic cells per crypt).  
As concluded by Koornstra et al. (2003) in their review, the majority of studies 
have consistently reported an increase in apoptosis in patients with polyps.  
Sinicrop et al. examined apoptotic rates in tissue taken from normal 
participants, those with polyps (hyperplastic and adenomatous) and carcinomas 
using the TUNEL method and observed significantly greater levels of apoptosis 
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in the mucosa of patients with polyps (Sinicrope et al., 1996). Furthermore, the 
number of apoptotic cells in the base of the crypt was also significantly 
increased. The authors concluded that a progressive increase in apoptotic rates 
was found during the progression from the normal mucosa to adenomas and 
ultimately adenocarcinomas. An increase in apoptosis with colorectal tumour 
progression has also been reported by Hawkins et al., who used an in situ end-
labelling assay to detect apoptosis in samples from 26 adenomas and 83 
carcinomas (Hawkins et al., 1997).  
Several studies have also investigated apoptosis in the crypts of varying polyp 
types and the majority have reported an increase in apoptosis with increasing 
severity or grades of dysplasia of the polyps. The assessment of apoptosis in 
different types of polyps, including sessile serrated, microvesicular hyperplastic 
polyps and tubular adenomas, has been assessed through the detection of 
cleaved caspase 3, an effector caspase of apoptosis (Endo et al., 2013). Similar 
to that observed in healthy tissue, cells undergoing apoptosis in sessile serrated 
polyp and microvesicular hyperplastic polyp tissues were located at the mouth 
of the crypts. However, in tissue from tubular adenomas, apoptotic cells were 
observed in all parts of the crypts. Apoptotic indices were comparable and 
lowest in normal and microvesicular hyperplastic polyps tissue but were 
increased in sessile serrated polyps and in tubular adenomas. 
An increase in rates of apoptosis with progressing severity of polyp types has 
also been reported by Ladas et al., who detected apoptosis using the TUNEL 
method in 75 polyp patients, comprising patients with serrated polyps, 
hyperplastic polyps and tubulovillous adenomas (Ladas et al., 2005). Apoptosis 
was lowest in hyperplastic polyps and highest in tubulovillous adenomas.  
5.7.1.4 BAX and BCL-2 expression in people with polyps 
Studies investigating expression of BAX and BCL-2 proteins in polyps have 
predominantly used IHC. The results from these studies have yielded conflicting 
findings, with some reporting an increase in BCL-2 expression in adenomas 
compared with healthy tissue (Bosari et al., 1995; Nakamura et al., 1995; Flohil 
et al., 1996) and others have observed that expression of BAX and BCL-2 is 
dependent on polyp type (Ladas et al., 2005; Endo et al., 2013). 
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An early study by Nakamura et al. reported significantly higher expression of 
anti-apoptotic BCL-2 in colorectal polyps (adenomas) compared with adjacent 
normal tissue and healthy controls, suggesting that, in adenoma tissue, BCL-2 
is involved in the regulation of apoptosis (Nakamura et al., 1995). That year, 
another study also quantified BCL-2 expression in the healthy mucosa, 
hyperplastic polyps, adenomas and carcinomas (Bosari et al., 1995). The 
authors observed comparable levels of BCL-2 expression in the healthy mucosa 
and in hyperplastic polyps, but increased BCL-2 expression in adenomas 
compared with the latter two. The findings from a later study were consistent 
with that observed by Nakamura et al. (1995) and Bosari et al. (1995) where 
BCL-2 expression was greatest in carcinoma tissue and was also higher in 
adenoma tissue compared with hyperplastic polyps (Flohil et al., 1996). 
In addition to investigating apoptosis using the TUNEL method, Ladas et al. 
also quantified BAX and BCL-2 by IHC in patients with serrated polyps, 
hyperplastic polyps and adenomas (Ladas et al., 2005). Expression of the anti-
apoptotic BCL-2 protein was comparable in serrated and hyperplastic polyps, 
but significantly higher in tubulovillous adenomas. Expression of the pro-
apoptotic protein, BAX, was lowest in hyperplastic polyps and highest in 
tubulovillous adenomas. Endo et al. also examined expression of BAX and 
BCL-2 in sessile serrated polyps, hyperplastic polyps and tubular adenomas 
and, contrary to the previous literature, they observed significantly reduced 
expression of both BCL-2 and BAX in serrated and hyperplastic polyps (Endo et 
al., 2013). However, the expression of both proteins was significantly increased 
in tubular adenomas compared with healthy controls. A reduction in BAX 
expression in hyperplastic polyps has also been reported by Tateyama et al., 
who also observed an increase in BAX protein levels in serrated and tubular 
adenomas (Tateyama et al., 2002).  
Giarnieri et al. have investigated differences in BAX and BCL-2 expression in 
varying degrees of dysplasia in rectal adenomatous polyps (Giarnieri et al., 
2000). Reduced expression of anti-apoptotic BCL-2 was observed in dysplastic 
polyps of moderate and severe degree, compared with those of low degree and 
hyperplastic polyps. However, there were no differences in the expression of 
pro-apoptotic BAX observed. Similar findings were reported by Hawkins et al., 
who reported an inverse correlation between BCL-2 expression and the 
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increase in levels of apoptosis they observed in the progression of colorectal 
neoplasia (Hawkins et al., 1997). 
5.7.2 Hypotheses, aims and objectives 
5.7.2.1 Hypotheses 
The hypothesis for this study was that participants at higher risk of CRC, i.e. 
those with quiescent UC or a prior history of adenomatous polyps, would have 
greater levels of apoptosis, indicated by an increase in expression of BAX (pro-
apoptotic) and a decrease in expression of BCL-2 (anti-apoptotic) compared 
with normal participants. 
5.7.2.2 Aims 
This study aimed to test this hypothesis by quantifying expression of BAX and 
BCL-2 apoptotic genes in the macroscopically-normal mucosa of people at 
differential risk of CRC i.e. those with quiescent UC, those with a prior history of 
adenomatous polyps and “normal” participants.  
5.7.2.3 Objectives 
 To obtain colorectal biopsies from the macroscopically-normal mucosa of 
DISC Study participants at differential risk of CRC i.e. those with 
quiescent UC, those with a prior history of adenomatous polyps and 
“normal” participants; 
 To utilise previously extracted RNA to synthesise cDNA; 
 To quantify the expression of BAX and BCL-2 by qPCR; 
 To compare BAX and BCL-2 expression in the ‘Normal’ participants and 
in the two higher-risk groups (‘UC’ and ‘Polyp’ participants); 
 To investigate the effects of key epidemiological factors including age and 
gender on expression of BAX and BCL-2. 
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5.7.3 Methods 
RNA previously extracted for the quantification of WNT pathway-related gene 
expression was used to synthesise cDNA for the quantification of BAX and 
BCL-2 expression as described in section 2.2.5. Reverse transcription and 
quantification of BAX and BCL-2 expression by qPCR were undertaken under 
my supervision by Idoia Ibero, an Erasmus Project student, to whom I am very 
grateful.  
Differences in BAX and BCL-2 expression and in the ratio of BAX to BCL-2 
between the three participant groups were investigated using the ANOVA GLM, 
with the inclusion of age, gender, endoscopy procedure, BMI and smoking 
status as covariates. Dunnett’s post-hoc test was used for multiple comparisons 
with the control group and the Bonferroni method was used for pairwise 
comparisons. Data for BAX expression was not normally-distributed despite 
transformation and consequently the non-parametric Kruskal-Wallis test was 
used to investigate differences between the three groups. 
5.7.4 Results  
5.7.4.1 BAX and BCL-2 expression in the macroscopically-normal mucosa 
of ‘Normal’, ‘UC’ and ‘Polyp’ participants 
Expression of BAX and BCL-2 was low in the colorectal mucosa of all three 
participants groups. The results from this study showed that expression of both 
BAX and BCL-2 (p<0.001) and the ratio of BAX/BCL-2 (p=0.027) differed 
significantly between the three participant groups (Table 5.18). Expression of 
both BAX and BCL-2 was significantly higher in ‘Polyp’ participants compared 
with ‘Normal’ and ‘UC’ participants. ‘Normal’ participants had a significantly 
higher ratio of BAX to BCL-2 by approximately 10% compared with the two 
higher-risk groups. 
When applying Bonferroni’s correction for multiple testing and adjusting the p-
value threshold to 0.017, the differences in BAX and BCL-2 expression between 
the three participant groups remain statistically significant (p<0.001). However, 
statistical significance for differences in the ratio of BAX/BCL-2 is lost (p=0.027). 
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Table 5.18 BAX and BCL-2 expression in the macroscopically-normal 
mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ participants.   
 Normal UC Polyp 
P 
value 
BAX1 
N=81 
1.37 
(0.74 – 2.86) 
2.25 
(1.34 – 3.09) 
11.12 
(3.89 – 21.14) 
<0.001 
BCL-22 
N=70 
0.420 
(0.306 – 0.576) 
0.238 
(0.119 – 0.475) 
1.301 
(0.736 – 2.300) 
<0.001 
BAX/BCL-22 
N=68 
0.878 
(0.856 – 0.900) 
0.800 
(0.750 – 0.850) 
0.815 
(0.772 – 0.858) 
0.027 
BAX and BCL-2 expression data are expressed as adjusted copies. BAX/BCL-2 is 
expression as the ratio of BAX ΔCt to BCL-2 ΔCt. 1Data are presented as median 
(lower and upper quartiles). The non-parametric Kruskal-Wallis test was used to 
compare methylation between the three groups. 2Data are presented as LSMs (95% 
CIs). The ANOVA GLM was used to compare methylation between the three groups 
and Dunnett’s post-hoc test was used for multiple comparisons with the control group 
and the Bonferroni method was used for pairwise comparisons. 
5.7.4.2 Exploration of additional factors influencing BAX and BCL-2 
expression 
The effects of age, gender, endoscopy procedure, BMI and smoking status on 
BCL-2 expression and on the ratio of BAX to BCL-2 were assessed as 
covariates using the ANOVA GLM. As BAX expression was not normally-
distributed, the non-parametric Kruskal-Wallis test was used. There were no 
effects of age, gender, BMI or smoking status on expression of BAX or BCL-2. 
Endoscopy procedure was found to have a significant effect on BAX expression 
(Table 5.19).  
Table 5.19 P values for the effects of age, gender, endoscopy procedure, 
BMI and smoking status on BAX and BCL-2 expression.  
 Age Gender 
Endoscopy 
procedure 
BMI 
Smoking 
status 
BAX 0.812 0.891 0.002 0.437 0.494 
BCL-2 0.991 0.496 0.996 0.502 0.744 
BAX/BCL-2 0.864 0.191 0.795 0.217 0.924 
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Participants who underwent endoscopic examination by colonoscopy had 
significantly higher expression of pro-apoptotic BAX, by approximately two-fold, 
compared with those who had the flexible sigmoidoscopy procedure (Figure 
5.21).  
Figure 5.21 Effect of endoscopy procedure on BAX expression.  
 
Data are expressed as adjusted copies. Data are presented as medians and error bars 
represent lower and upper quartiles (Kruskal-Wallis). N=81. 
5.7.5 Discussion 
Induced apoptosis has been observed in the colorectum of patients with UC, 
however, studies suggest that this is not mediated by the BCL-2 family. Whilst 
one study observed a reduction in BAX expression in the inflamed tissue of UC 
patients (Iimura et al., 2000), other studies have found an increase in both BAX 
and BCL-2 expression with UC (Karamanolis et al., 2007). BAX expression was 
approximately eight-fold greater in participants with a prior history of polyps 
compared with ‘Normal’ participants, and five times greater than that quantified 
in participants with quiescent UC (Figure 5.22 (A)). Expression of BAX was also 
approximately two-fold greater in ‘UC’ participants compared with ‘Normal’ 
participants, but this was not statistically significant. An increase in expression 
of pro-apoptotic BAX in these higher-risk participants would suggest an 
increase in apoptosis, which is consistent with findings from the literature.  
Expression of anti-apoptotic BCL-2 was also highest in ‘Polyp’ participants 
compared with the other two groups (Figure 5.22(B)), which, contrary to that 
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insinuated by an increase in pro-apoptotic BAX, suggests a reduction in 
apoptosis in participants with a prior history of adenomatous polyps.  
Figure 5.22 Expression of BAX and BCL-2 in the macroscopically-normal 
mucosa of ‘Normal’, ‘UC’ and ‘Polyp’ participants. 
 
Expression of BAX (A) (N=81) and BLC-2 (B) (N=70) are expressed as adjusted 
copies. The BAX/BCL-2 ratios (C) (N=68) )were calculated using the ΔCt values for 
each gene.  Data for BAX (A) are presented as medians and error bars represent lower 
and upper quartiles (Kruskal-Wallis). Data for BCL-2 (B) and BAX/BCL-2 ratio (C) are 
presented as LSMs and error bars represent 95% CIs (ANOVA GLM). Dunnett’s post-
hoc test was used for multiple comparisons with the control group and the Bonferroni 
method for pairwise comparisons. 
Controversially, as reviewed by Koornstra et al. (2003), the majority of studies 
investigating apoptosis in polyps have observed an increase in apoptosis 
compared with the healthy mucosa (Koornstra et al., 2003), with only a limited 
number of studies reporting a reduction (Bedi et al., 1995; Moss et al., 1996a; 
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Moss et al., 1996b). However, several studies have reported an alteration in the 
distribution of apoptotic cells with an increase in the number of cells undergoing 
apoptosis at the base of the crypt (Hall et al., 1994).  
Previous studies investigating BAX and BCL-2 expression have primarily 
quantified protein levels by immunohistochemical analyses. BAX expression 
has been reported to be increased in adenomas, however differences between 
colorectal lesions have been observed with increasing expression associated 
with polyps of greater severity such as tubular adenomas (Ladas et al., 2005; 
Endo et al., 2013). Consistent with findings from the present study, several 
studies have suggested that BCL-2 expression is increased in adenomas 
(Nakamura et al., 1995), however a study that quantified BCL-2 in the rectum 
reported reduced expression in lesions of moderate and severe degrees 
(Giarnieri et al., 2000).  
The findings from the present study where expression of both pro-apoptotic 
BAX and BCL-2 was increased in the macroscopically-normal mucosa of 
participants with prior history of polyps is consistent with findings from previous 
studies (Giarnieri et al., 2000; Ladas et al., 2005; Endo et al., 2013). Although 
an increase in BAX suggests an increase in apoptosis, an increase in BCL-2 
expression is representative of the contrary. The finding that the BAX/BCL-2 
ratio was significantly lower in the ‘Polyp’ group compared with the ‘Normal’ 
group suggests that apoptosis is reduced in these participants (Figure 5.22 (C)). 
Altogether, the higher expression of pro-apoptotic BAX and reduced inhibition 
associated with lower expression of BCL-2 in participants with quiescent UC 
compared with ‘Normal’ participants is consistent with findings from previous 
studies that have reported increased apoptosis in these patients.  However, the 
observation that the BAX/BCL-2 ratio was significantly lower in participants with 
quiescent UC compared with ‘Normal’ participants contradicts this finding 
(Figure 5.22 (C)). 
   
 285 
Chapter 6 General Discussion 
6.1 Main findings 
This Ph.D. project was embedded within the DISC Study, which is the largest 
randomised, placebo-controlled dietary intervention investigating the effects of 
supplementing healthy participants with RS and/or PD on colorectal function. 
This Ph.D. project focused on testing the hypothesis that these NDCs modulate 
the WNT signalling pathway, primarily the expression of WNT pathway 
components, and two of its functional outcomes viz. cell proliferation and 
apoptosis. In addition, I tested the hypothesis that effects on WNT signalling 
resulted from altered epigenetic mechanisms specifically DNA methylation and 
miRNA expression. To determine the potential implications of these WNT 
signalling changes, I also investigated similar outcomes in the macroscopically-
normal mucosa of people at higher risk of CRC i.e. those with quiescent UC or 
with a prior history of adenomatous polyps. The main findings from both studies 
(the dietary intervention and investigations in people at differential risk of CRC) 
are summarised in Table 6.1. 
For these purposes, I quantified the expression of twelve WNT pathway-related 
genes which were selected because of their involvement in the WNT signalling 
pathway, evidence that they were dysregulated in CRC and that their 
expression is modulated by butyrate (see section 3.3). Furthermore, a pilot 
study was conducted to compare the expression of a larger panel of WNT 
pathway-related genes in people at normal CRC risk and in the 
macroscopically-normal mucosa of those with a prior history of adenomatous 
polyps, at higher risk of CRC. A subset of these genes showing the largest fold-
difference and/or statistically significant differences between the groups was 
chosen (see section 3.2). 
I observed that both RS and PD affected expression of WNT pathway 
components and/or target genes at the mRNA level and the main findings were 
the following:  
1. RS supplementation downregulated expression of β-catenin, encoded by 
CTNNB1, and the target gene c-MYC, suggesting that it reduced WNT 
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pathway activity. This is consistent with previous findings that treatment 
of SW837 and HCT-116 CRC cells with butyrate, a product of RS and 
NDC fermentation, decreased c-MYC expression at both the mRNA 
(Wilson et al., 2002; Lazarova et al., 2014b) and protein levels (Taylor et 
al., 1992). In contrast, other  studies have observed no effect of RS on 
CTNNB1 expression in a rat model of CRC (AOM-treated rats) (Cray et 
al., 2013) or of butyrate treatment on CTNNB1 expression in SW620 and 
HCT-116 CRC cells (Bordonaro et al., 2002) and one study reported 
increased levels of β-catenin protein in eight CRC cell lines (SW48, 
SW620, LS174T, HCT-116, DLD-1, COLO201, HT29 and LoVo) after 
5mM butyrate treatment (Bordonaro et al., 2007). 
2. I observed that expression of SFRP1, an antagonist of WNT signalling, 
was lower in participants who consumed RS compared with placebo. 
Less SFRP1 would suggest less repression of WNT signalling and, 
consequently, enhanced pathway activity. However, SFRP1 antagonises 
WNT signalling competitively either by binding to WNT ligands or to 
Frizzled receptors and so an increase in WNT ligands may overcome 
these effects of repressed activity. Interestingly, PD also reduced the 
expression of both SFRP1 (p=0.053) and SFRP2 (p=0.010). To my 
knowledge, the effects of RS or PD (or of butyrate) on SFRP1 and 
SFRP2 expression within the colorectal mucosa have not been 
investigated previously. However, a study using gastric cancer cell lines 
reported that butyrate increases the expression of SFRP1 and SFRP2 
proteins (Shin et al., 2012). 
3. At the mRNA level, I observed that expression of c-JUN (p=0.046), a 
target of the WNT pathway, and of WNT11 (p=0.040), a WNT ligand, was 
increased in those at higher CRC risk with the expression of both genes 
being greatest in ‘Polyp’ participants. These findings suggest that those 
at greater CRC risk experienced enhanced WNT pathway activity as 
WNT11 is an activator of WNT signalling and c-JUN is a target gene. 
Whilst it has been suggested that WNT11 can activate (Tao et al., 2005) 
or repress the WNT pathway (Maye et al., 2004), my observation of 
greater c-JUN expression in ‘Polyp’ participants suggests higher WNT 
pathway activity in higher-risk individuals. Both c-JUN and WNT11 are 
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upregulated in colorectal adenocarcinomas (Magrisso et al., 1993; 
Kirikoshi et al., 2001). Interestingly, although not statistically significant, 
RS supplementation lowered WNT11 expression, suggesting that RS 
may have the potential to reduce the aberrant expression of this gene in 
people at higher risk of CRC.  
4. To test the hypothesis that altered WNT gene expression may result from 
epigenetic mechanisms, I explored the epigenetic regulation of SFRP1, 
which was modified by both RS and PD, by quantifying by qPCR the 
expression of a panel of eight miRNAs implicated in CRC, modulated by 
butyrate and predicted to target SFRP1. Neither RS nor RS had 
significant effects on expression of miR-17, miR-19a, miR-19b, miR-20a, 
miR-25, miR-93, miR-106b or miR-424. However, there was a trend for 
lower expression of three miRNAs from the miR-17-92 oncogenic cluster, 
miR-17, miR-19a and miR-19b, with RS supplementation. This 
observation is consistent with the reports of down-regulated expression 
of these three miRNAs by butyrylated RS in humans (Humphreys et al., 
2014) and by butyrate in vitro in HT-29 and HCT-116 CRC cells 
(Humphreys et al., 2013). Additional miRNAs may be involved in the 
modulation of SFRP1 expression by RS or PD. The deciphering of 
miRNAs that target specific genes is complex because a single gene 
may be regulated by a large number of miRNAs and, likewise, a single 
miRNA may target numerous genes (Lewis et al., 2005). The panel of 
miRNAs quantified in this study were selected by reviewing findings from 
studies that used expression techniques and bioinformatic databases 
which, based on sequence homology, predicted those miRNAs which 
would target SFRP1. However, the fact that, to my knowledge, there are 
no studies that have investigated the regulation of SFRP1 expression by 
miRNAs directly is a limitation of the evidence base.  
5. In the analyses of the participants at differential risk of CRC, a panel of 
five miRNAs was selected based on evidence that the expression of 
each miRNA has been reported to be dysregulated in CRC and that the 
miRNA is involved in regulation of the WNT signalling pathway. I 
observed no significant differences in the expression of these miRNAs 
between ‘Normal’, ‘UC’ and ‘Polyp’ participants. In addition, in these 
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participants at differential CRC risk, I quantified the expression of the 
same panel of eight miRNAs selected for the RS and PD intervention 
study analyses. This showed that miR-424 expression was increased in 
participants with quiescent UC compared with both ‘Normal’ and ‘Polyp’ 
participants. This is consistent with findings from a study by Lin et al., 
who reported dysregulated expression of miR-424 in the colonic mucosa 
of both UC and Crohn’s disease patients (Lin et al., 2014). 
6. To investigate the potential regulation of SFRP1 by promoter 
methylation, I quantified DNA methylation at seven CpG sites within the 
promoter region of SFRP1 by pyrosequencing in both intervention 
participants and in the three groups of participants at differential risk of 
CRC. This investigation was built on evidence of lower SFRP1 
expression by promoter hypermethylation in CRCs (Chen et al., 2014b). I 
observed no significant effects of neither RS nor PD on methylation of 
SFRP1 at any of the seven CpG sites quantified or on the mean 
methylation across all 7 sites. In both the intervention and higher-risk 
participants, there was a strong correlation of SFRP1 methylation 
between the seven CpG sites. However, as effects may only be 
observed on methylation at a single CpG site (Weaver et al., 2004), 
effects of the intervention at each of the seven CpG sites as well as on 
the mean methylation across all sites were investigated. Moreover, in 
cross-section analysis, there was no evidence of a correlation between 
SFRP1 methylation and expression (see section 4.4.4.4). Because of the 
critical role played by promoters in regulation of gene expression, SFRP1 
methylation was examined at CpG site-rich regions known as CpG 
islands within the promoter region. Recent evidence suggests that 
methylation at additional genomic domains known as CpG shores, which 
are found up to 2kb upstream of the promoter region, may also be 
important in the regulation of gene expression and altered methylation of 
CpG island shores has been reported in colon cancer tissue (Irizarry et 
al., 2009). In addition, RS and PD may regulate SFRP1 by other 
epigenetic mechanisms with or without the involvement of DNA 
methylation. Butyrate is a well-established HDACi (Berni Canani et al., 
2012) and so altered histone acetylation may be an alternate mechanism 
through which RS and PD could have modulated SFRP1 expression. 
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7. Greater methylation of SFRP1 at all seven CpG sites investigated was 
observed in ‘UC’ and, even higher methylation, in ‘Polyp’ participants 
compared with normal controls. This is consistent with reports in the 
literature that SFRP1 methylation is increased in both UC and adenoma 
patients (Caldwell et al., 2006; Qi et al., 2006; Belshaw et al., 2008; Shao 
et al., 2012; Kim et al., 2013). Higher methylation implies lower SFRP1 
expression and, consequently, an increase in WNT pathway activity 
would be anticipated. However, a limitation of this study is that, due to 
unreliable data for expression of SFRP1 at the mRNA level, it was not 
possible to investigate the relationship between SFRP1 methylation and 
expression directly.  
8. Based on my observation of significant differences in expression of 
WNT11 in people at differential risk of CRC (see section 5.2.4.1), I 
undertook the first known study of the methylation state of WNT11 in the 
colorectum. Spearman correlation analyses revealed only a weak to 
moderate correlation between methylation levels at the different CpG 
sites, strengthening the rationale to analyse differences between risk 
groups both at each of the five CpG sites and on the methylation across 
all sites. This showed that methylation at CpG site 2 was significantly 
lower in participants with quiescent UC compared with ‘Normal’ and 
‘Polyp’ participants. However, mean methylation across all five CpG sites 
did not differ between participant groups. 
9. Dysregulation of the WNT pathway during colorectal carcinogenesis 
affects cell proliferation (which is usually increased (Risio et al., 1991; 
Bostick et al., 1997)). In the present study, I quantified colorectal crypt 
cell proliferation by whole crypt microdissection of Schiff reagent-stained 
biopsies as described and validated previously by Mills et al. (Mills et al., 
2001). This revealed that RS supplementation increased total crypt cell 
proliferation by approximately 33%. This agrees with the literature where 
a number of studies in healthy participants have shown an increase in 
cell proliferation in healthy tissue with RS supplementation (Mentschel 
and Claus, 2003), although others have not observed an effect of RS 
(Wacker et al., 2002; Worthley et al., 2009). However, there were no 
effects of either RS or PD on the proportion of mitotic cells observed in 
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the upper half of the crypt, suggesting that neither NDC had positive, or 
adverse, effects on a functional marker of CRC risk in these healthy 
participants. In contrast, Dronamraju et al. reported that RS 
supplementation for up to four weeks in patients prior to surgery for CRC 
removal reduced cell proliferation in the upper half of the crypt (p=0.028 
for Study 1) (Dronamraju et al., 2009). Taken together, these findings 
suggest that any “protective” effects of RS on crypt cell proliferation may 
be evident only in those with CRC. 
10. In the present study, cell proliferation was lower in ‘UC’ and ‘Polyp’ 
participants compared with ‘Normal’ participants. This is contrary to  
findings from previous studies which have reported consistently 
increased levels of cell proliferation in both UC and polyp patients 
(Serafini et al., 1981; Kanemitsu et al., 1985; Biasco et al., 1990; Wilson 
et al., 1990). However, although not statistically significant, the proportion 
of mitotic cells in the top half of the crypt appeared to be increased in 
higher-risk participants, particularly in those with quiescent UC (see 
section 5.6.4.1). This finding is consistent with those from the literature 
which show dysregulation of the distribution of mitotic cells in such 
patients (Franklin et al., 1985; Ponz de Leon et al., 1988; Biasco et al., 
1990).  The latter is a superior indicator of bowel health as altered 
distribution of mitotic cells within the crypt is one of the earliest 
detectable alterations in the mucosa prior to the development of 
malignancies (Roncucci et al., 1991).  
11. Attempts were made to use microdissected crypts for the assessment of 
apoptosis but very few apoptotic cells were detected so that this 
technique was insufficiently sensitive for investigating potential treatment 
differences in apoptosis. As an alternative approach, expression of BAX 
and BCL-2, (positive and negative regulators of the apoptotic response, 
respectively), was quantified by qPCR. In the intervention participants, 
there was no evidence that either RS or PD modulated expression of 
BAX or BCL-2 at the mRNA level. Since the protein products of these 
two genes have opposing effects on regulation of apoptosis, the ratio of 
pro-apoptotic BAX to anti-apoptotic BCL-2 was calculated as this may be 
more meaningful in the regulation of apoptosis than the expression of 
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either gene individually. Again, this showed no significant effects of RS 
nor PD and these findings suggest that neither RS nor PD affects the 
mitochondrial, or intrinsic, pathway of apoptosis which is mediated by the 
BCL-2 family of apoptotic genes. However, whether RS and/or PD 
affected levels of apoptosis overall remains to be discovered since there 
are additional apoptotic pathways such as the extrinsic pathway 
(Watson, 2004).  
12. Expression of both BAX and BCL-2 was greater in ‘Polyp’ participants 
compared with ‘Normal’ participants and with quiescent UC patients. 
Furthermore, both ‘Polyp’ and ‘UC’ participants had lower BAX/BCL-2 
ratios than that observed in healthy controls. A lower ratio of BAX/BCL-2 
suggests a reduction in apoptosis which is contrary to findings from the 
majority of previous studies showing increased levels of apoptosis in 
patients with polyps (Koornstra et al., 2003). Whilst there is evidence that 
apoptosis is increased in the tissue of UC patients (Iwamoto et al., 1996; 
Sipos et al., 2005), previous investigations of the expression of BAX and 
BCL-2 in UC patients have yielded conflicting results. Whilst some 
studies have reported downregulation of BAX in tissue from UC patients, 
others have observed upregulation of BAX and BCL-2 (Iimura et al., 
2000; Karamanolis et al., 2007).  
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Table 6.1 Summary of main findings from dietary intervention study and 
CRC differential risk study. 
 
Change in 
CRC 
Findings from 
dietary intervention 
study 
Findings from CRC 
differential risk study 
WNT pathway-related gene expression 
c-JUN Increased No effect 
Increased in ‘Polyp’ 
group 
c-MYC Increased Decreased with RS No differences 
CTNNB1 Increased Decreased with RS No differences 
SFRP1 Decreased 
Decreased with RS 
and trend for 
decrease with PD 
No differences 
SFRP2 Decreased Decreased with PD No differences 
WNT11 Increased No effect 
Increased in ‘Polyp’ 
group 
DNA methylation 
SFRP1 Increased No effect 
Increased in ‘Polyp’ 
group 
WNT11 
Not reported 
previously 
- 
Increased at CpG site 
2 in ‘Polyp’ group 
miRNA expression 
miR-424 Increased No effect 
Increased in ‘UC’ 
group 
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Change in 
CRC 
Findings from 
dietary intervention 
study 
Findings from CRC 
differential risk study 
Colonic crypt cell proliferative state 
Total 
proliferation 
Increased Increased with RS 
Decreased in ‘Polyp’ 
group 
Crypt 
dimensions 
Increased No effect 
Increased in ‘UC’ 
group 
Expression of regulators of apoptosis 
BAX Decreased No effect 
Increased in ‘Polyp’ 
group 
BCL-2 Increased No effect 
Increased in ‘Polyp’ 
group 
BAX/BCL-2 
ratio 
Decreased No effect 
Decreased in ‘UC’ and 
‘Polyp’ groups 
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6.2 Conclusions 
This Ph.D. study aimed to test the hypothesis that the NDCs RS and PD are 
protective against CRC through the genetic and epigenetic modulation of the 
WNT signalling pathway, which is frequently aberrantly expressed in CRC. I 
also hypothesised that two functional outcomes of this pathway, cell 
proliferation and apoptosis, would be modulated as a consequence of altered 
WNT signalling. In addition, I hypothesised that participants at higher risk of 
CRC, i.e. those with quiescent UC or a prior history of adenomatous polyps, 
would have aberrantly expressed WNT signalling and dysregulated proliferation 
and apoptosis. 
At first sight, my major findings on the effects of NDC supplementation on WNT 
pathway gene expression appear to be in conflict. The reduced expression of 
CTNNB1 and c-MYC following RS supplementation suggests a reduction in 
WNT pathway activity. However, the downregulation of two WNT antagonists, 
SFRP1 and SFRP2, by RS and/or PD suggests that NDC supplementation may 
have reduced a brake on WNT signalling activity. Given that RS induced cell 
proliferation but had no detectable effect on BCL-2-mediated apoptosis, it 
seems probable that the net effect of RS supplementation was increased WNT 
pathway activity. Bordonaro et al. have proposed that butyrate, a fermentation 
product of RS and other NDCs, stimulates the WNT signalling pathway and that 
moderate levels of WNT signalling pathway stimulation are associated with 
increased cell proliferation (Bordonaro et al., 2008a). We may therefore 
conclude that the observed increase in cell proliferation following RS 
supplementation may have resulted from stimulation of the WNT pathway, as 
indicated by a decrease in SFRP1 expression.  
Further exploration of these findings is warranted. For example, there is a need 
to confirm that the modulation in expression of WNT pathway-related genes at 
the mRNA level, reported here, is also evident at the levels of both protein 
concentration and activity. It would be useful to investigate other doses of these 
agents to determine the dose which maximised effects on WNT signalling and 
its associated functional outcomes. In addition, extending the duration of 
intervention with RS and/or PD would help to reveal whether the observed 
effects are i) increased with exposure time or ii) temporary and diminish with 
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time. The latter would be evidence that, in healthy  participants, changes in 
WNT signalling in the colorectal mucosa are part of a homeostatic response to 
increased intake of NDCs and, therefore, of limited relevance to longer-term 
CRC  risk. If the effects increased with time of exposure, this would suggest that 
RCTs with interventions lasting 50 days (as in the present study) may be 
inadequate to reveal the full effects of NDC supplementation. Longer-term 
interventions are more challenging in terms of logistical issues and in 
maintaining participant compliance. 
Furthermore, the relatively large inter-participant variability, particularly when 
examining gene and miRNA data, made it difficult to detect statistically 
significant effects of the interventions or of differences between CRC risk 
groups. Some of this inter-individual variation may be inevitable (a consequence 
of individual genotype or previous environmental exposures) but some variance 
may be within the experimenter’s control. For example, the DISC Study 
recruited both men and women over a wide range of ages and with 
considerable variation in adiposity, smoking behaviour and habitual diet. I 
attempted to control for the most obvious potential confounders e.g. age, sex, 
BMI and smoking behaviour by including these factors as covariates in my 
analyses but it is probable that other unmeasured, or unknown, factors 
contributed to inter-individual variation in WNT pathway gene expression. A 
better understanding of these factors would allow the design of future 
intervention studies which were more sensitive i.e. capable of detecting smaller 
treatment effects. 
In addition, some of the observed inter-individual variation may have been due 
to differences in the cellular composition of the colorectal mucosal biopsies 
collected in the DISC Study. We attempted to minimise inter-individual 
differences by ensuring that all biopsies were collected from the same 
anatomical site i.e. 10 centimetres from the ano-rectal margin. This is important 
because my earlier Masters’ project had shown differences in WNT gene 
expression when biopsies were collected from different, but defined, sites in the 
large bowel (Malcomson, 2011). In addition, previous work from the Mathers’ 
laboratory has shown that there are systematic gradients in crypt cell 
proliferation along the human large bowel (Mills et al., 2001). Visual inspection 
of the biopsies used in this study showed that they differed in size and this may 
   
 296 
reflect differences in the depth of the “bite” taken by the biopsy forceps. 
Different depths of biopsy “bite” may result in differences in the proportions of 
columnar epithelial cells and of the underlying stroma in different biopsies. Only 
a small number of studies have reported expression of WNT pathway 
components, predominantly WNT ligands such as WNT2 and WNT5A (Smith et 
al., 1999; Fodde and Brabletz, 2007; Najdi et al., 2011), in stromal 
compartments, suggesting that potential differences in the proportion of stromal 
tissue between samples may have implications on the estimates of expression 
of these genes.   
The results from this study suggest that WNT signalling is aberrantly expressed 
in participants at higher risk of CRC and that this is detectable even in the 
macroscopically-normal mucosa of these patients, suggesting a field effect 
within the colorectum. This is demonstrated by the upregulation of WNT11, a 
WNT ligand that can activate the WNT pathway, and c-JUN, a target of WNT 
signalling. However, these findings at the mRNA level require confirmation at 
the protein level. Unexpectedly, whilst both ‘UC’ and ‘Polyp’ participants had 
reduced total numbers of mitotic cells per crypt compared with ‘Normal’ 
participants, the proportion of mitotic cells in the upper (luminal) half of the crypt 
appeared to be increased, which suggests dysregulation in this process. The 
lower BAX/BCL-2 expression ratio which I observed is evidence that apoptosis 
mediated by the BCL-2 family was reduced in higher-risk participants. Lazarova 
et al. have previously shown a correlation between WNT pathway activity and 
levels of apoptosis (Lazarova et al., 2004), although others have reported the 
opposite (Groden et al., 1995; Morin et al., 1996; Zhang et al., 2001), 
underlining the importance of undertaking further studies of the WNT signalling 
pathway, and related functional outcomes, in the macroscopically-normal 
human colorectal mucosa.   
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6.3 Strengths and limitations of the study 
To date, the DISC Study is the largest double-blind, randomised-controlled 
dietary intervention investigating the effects of NDCs in healthy subjects. 
Previous studies such as the CAPP1 and CAPP2 studies have investigated the 
effects of RS in patients with FAP and HNPCC who are at much higher-risk of 
CRC because of inherited defects in the APC gene and in those encoding MMR 
genes respectively (Burn et al., 2011a; Mathers et al., 2012). Both CAPP1 (113 
participants) and CAPP2 (463 participants), were large, long-term studies that 
supplemented participants with 30g of RS daily for up to 12 and four years 
respectively. Another study supplemented 65 CRC patients with RS or ordinary 
starch for up to four weeks and investigated the effects of RS on colonic crypt 
cell kinetics and expression of cell cycle regulatory genes in both tumour and 
adjacent normal tissues from these participants (Dronamraju et al., 2009). Other 
trials in healthy subjects include a randomised, placebo-controlled, crossover 
study in which 20 participants were given 12.5g of RS and/or Bifidobacterium 
lactis for four weeks (Worthley et al., 2009) and a randomised, crossover trial 
supplementing 18 participants with 28g of RS for seven days (van Munster et 
al., 1994).  
I observed a significant effect of RS on some of the measured outcomes, with a 
25% difference being the smallest effect size for CTNNB1 expression and total 
mitoses for the comparison of RS and placebo. Consequently, I calculated the 
sample size which would be required to detect a similar-sized effect on other 
outcomes measured. For example, in my study there were no significant effects 
of RS or PD on miRNA expression. A sample size calculation (α 0.05 and power 
of the test 0.80) revealed that I would have needed at least 91 participants to 
detect a 25% difference in expression of miR-17, a miRNA with intermediate 
levels of variation between participants. However, for miR-19b, which showed 
the largest inter-participant variation in expression, a sample size of 2067 would 
have been required to detect a 25% difference in expression due to RS or PD. 
Finally, for the analysis of SFRP1 methylation, a post hoc power analysis 
revealed that the probability of correctly rejecting a false null hypothesis was 
only 0.20 and was consequently underpowered. 
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A strength of this project is that all of the participants in the DISC Study, 
including both those in the intervention and the higher-risk groups, were 
recruited from two hospitals in the North East of England and samples were 
collected, processed and stored using identical methods which minimises 
potential confounders. Stringent inclusion and exclusion criteria, such as the 
exclusion of people taking anti-inflammatories, minimised the effects of possible 
confounders on the analysed outcomes. Furthermore, where possible, 
participant characteristics, such as age, gender and BMI, were included as 
covariates during statistical analyses to prevent any effects on the measured 
outcomes. Randomisation of participants across the study groups aims to 
remove the effect of such confounders, however this did not apply for the 
investigations in the ‘UC’ and ‘Polyp’ participants. The double-blind nature of the 
DISC Study was maintained until the completion of all analyses (both laboratory 
and statistical), reported in this Ph.D., consequently preventing any bias.  
This Ph.D. utilised mucosal biopsies collected from the mid-rectum. The fact 
that changes were observed within the rectum, which is not as active in respect 
of bacterial fermentation of NDCs as more proximal areas in the large bowel, 
may suggest that the effects of treatments (and differences between CRC risk 
groups) may have been more pronounced in other sites, such as the caecum 
and transverse colon. On the other hand, because the majority of CRCs 
develop in the rectum, [between 2007 and 2009, 27% of CRC cases in the UK 
were rectal (CRUK, 2014a)], analyses performed at this site may be more 
relevant from a disease prevention perspective. With the notable exceptions of 
AES, CTNNB1 and FBXW4, previous work demonstrated that overall there 
were no differences in the expression of WNT pathway components in the 
caecum, transverse colon, sigmoid colon and rectum in a panel of 35 WNT 
pathway-related genes (Malcomson, 2011). In that study, I found that the 
expression of AES and CTNNB1 was significantly greater in the rectum and that 
FBXW4 expression was reduced in the rectum compared with the sigmoid 
colon, suggesting that WNT activity is enhanced in the rectum. It is important to 
note that CTNNB1 expression was altered by RS supplementation in the 
present study. These findings suggest that the effects on WNT signalling 
observed in this study may be representative of the whole colorectum but this 
remains to be demonstrated experimentally.  
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The fact that all the biopsies used in this study were collected from the same 
anatomical site is a strength since it implies that the data are likely to be directly 
comparable and not subject to confounding by (unknown) differences due to 
sample site. In addition, for the analyses in the higher-risk participants who had 
quiescent UC or a prior history of adenomatous polyps, all biopsies were of 
macroscopically-normal mucosa i.e. not tissue with active inflammation and not 
from the polyp tissues themselves. The majority of previous studies utilising 
patients with UC or polyps have analysed the diseased tissue i.e. the inflamed 
or polyp tissue itself. The present study facilitated detection of any field effects 
that may be present in the normal-appearing tissue in the mucosa of people at 
higher risk of CRC. It must be noted, however, that not all analyses were 
undertaken in the same biopsy sample from the individual. For example, gene 
expression and methylation analyses were performed in OCT-embedded 
biopsies whereas CCPS analyses were in Carnoy’s-fixed biopsies.  
The collection of rectal biopsies post-intervention by rigid sigmoidoscopy is a 
less invasive procedure than flexible sigmoidoscopy and colonoscopy and does 
not require bowel preparation. Logistically, it would not have been ideal to ask 
the participants to undergo another flexible sigmoidoscopy or colonoscopy 
procedure to retrieve biopsies from other sites within the colon post-intervention 
and, in any case, it would not have been possible to recruit the number of 
volunteers in the specified timeframe. However, the fact that bowel preparation 
was required prior to the collection of pre-intervention samples, or baseline 
samples for the higher-risk participants, but not post-intervention could have 
had an effect on some of the results. To minimise this possibility and to avoid 
any confounding effects of bowel preparation, participants were randomised to 
NDC intervention according to the endoscopy procedure used at baseline and 
the latter was included as a covariate during statistical analyses.  
With regard to analytical techniques, robust methodology was utilised in each 
aspect of the laboratory work undertaken in this study. Where applicable, 
technique optimisation and validation assays were run prior to the main 
analyses to test the accuracy, specificity and/or reproducibility of the 
procedures. For example, thorough optimisation of the method utilised to isolate 
RNA from rectal mucosal biopsies was performed which aimed to achieve the 
greatest yield and quality possible from these small samples. Other examples 
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showing the robustness of the methodological techniques used include the 
analysis of melt (dissociation) curves for each qPCR experiment to test the 
specificity of the experiment and the running of standard curves for each assay 
analysed by pyrosequencing prior to quantification. 
The quantification of gene and miRNA expression could have been improved by 
the use of TaqMan® assays, which provide greater detection specificity than is 
possible with DNA-binding dye-based methods such as SYBR® Green which 
was used in the present study. However, as noted above, the melt curves for 
each experiment were checked, and if they were found to be inadequate, the 
experiment was repeated and/or data were excluded from subsequent 
analyses. A limitation to the SFRP1 and WNT11 methylation analyses by 
pyrosequencing is that this is limited to a specific site, for example within the 
promoter region, and does not exclude effects or differences at additional sites 
within the gene.  
Furthermore, suitable methods were selected for statistical analyses following 
examination of the distribution of each dataset. When data were normally-
distributed, the parametric ANOVA GLM test was used and included age, 
gender, endoscopy procedure, BMI and smoking habit as covariates. Not only 
did this adjust for these factors as possible confounders, but it also allowed for 
the exploration of the effects of these factors on the measured outcomes. For 
the analyses of the intervention data, the pre-intervention measurement was 
also included as a covariate, which adjusted for any differences between the 
groups at baseline.  
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6.4 Future research 
Statistically significant differences in the expression of certain WNT pathway 
genes were observed following RS and PD supplementation in the intervention 
study and in the comparisons between ‘Normal’, ‘UC’ and ‘Polyp’ participants. 
Although there are correlations between expression at the mRNA level and the 
abundances of the corresponding proteins, this correlation can be as little as 
40%, suggesting that the remaining 60% may result from post-transcriptional 
regulation (Vogel and Marcotte, 2012). To confirm that the effects that I have 
observed at the mRNA level are mirrored phenotypically, protein levels should 
be quantified for example by immunohistochemical analyses or semi-
quantitatively using Western Blotting. This should include quantification of 
SFRP1 protein expression for which I observed significantly greater promoter 
methylation in higher-risk participants compared with normal-risk participants. 
A panel of 12 WNT pathway-related genes was selected carefully to be 
quantified in the intervention study and higher-risk participants. It would be very 
interesting to explore differences in a larger number of genes using microarray 
technology, in at least a smaller sample of the participants. WNT signalling 
pathway PCR arrays are available and allow for the quantification of 84 WNT 
pathway-related genes. Similarly, additional arrays could be used to investigate 
differences in other non-WNT pathway-related genes such as the Human 
Cancer Pathway Finder PCR array (Qiagen) that quantifies expression of genes 
encompassing nine pathways implicated in transformation and tumourigenesis. 
This approach could also be applied to quantify the expression of additional 
miRNAs implicated in carcinogenesis. 
To confirm the effects of the observed differences in the expression of WNT 
pathway-related genes on WNT signalling, measurements of active, 
dephosphorylated β-catenin by IHC could be used as an indicator of WNT 
activity. For example, I speculated that lower WNT pathway activity would be 
responsible for the observed reduction in c-MYC found in participants who were 
supplemented with RS, and I hypothesise that these participants would also 
show a reduction in β-catenin, particularly the dephosphorylated active form, at 
the protein level. In addition, it would be possible to detect the sub-cellular 
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location of β-catenin through IHC staining. More nuclear β-catenin staining 
would be indicative of greater WNT pathway activity.  
Levels of apoptosis were assessed by quantification of the expression of BAX 
and BCL-2, two members of the BCL-2 family of apoptosis-regulators. However, 
differences in the expression of BAX and BCL-2 only reflect effects on 
apoptosis mediated by the BCL-2 family of proteins and may not be a true 
indicator of apoptosis levels within the crypt. Furthermore, it is the BAX and 
BCL-2 proteins which are regulators of apoptosis and, therefore, it would be 
important to quantify expression of these at the protein level. In addition, 
apoptosis within the colon may be mediated via other pathways such as the 
extrinsic pathway (Watson, 2004). Consequently, further investigations into 
levels of apoptosis in the crypts of participants at higher-risk and those who 
underwent the intervention are merited.  For example, the TUNEL assay could 
be used to detect DNA fragmentation, a consequence of apoptosis, as an 
indicator of apoptosis. 
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Appendices 
Appendix A. Confirmation of ethical opinion 
Newcastle & North Tyneside 2 Research Ethics Committee 
Room 002 
TEDCO Business Centre 
Rolling Mill Road 
Jarrow 
NE32 4BW 
 
 Telephone: 0191 428 3565  
Facsimile: 0191 428 3432 
10 December 2009                                                               Email: gillian.mayer@sotw.nhs.uk 
 
Professor John Mathers 
Professor of Human Nutrition 
Institute of Ageing and Health 
William Leech Building 
Newcastle University 
Newcastle upon Tyne 
NE2 4HH 
 
Dear Professor Mathers 
 
Study Title: Diet related biomarker of colorectal cancer risk - the 
impact of non-digestible carbohydrates 
REC reference number: 09/H0907/77 
Protocol number: v 1 
 
Thank you for your letter of 4 December 2009, responding to the Committee’s request 
for further information on the above research and submitting revised documentation.   
 
The further information has been considered on behalf of the Committee by the Chair 
who noted that this is a good, thorough response.     
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a Favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation as revised, subject to the conditions specified below. 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the 
start of the study (see “Conditions of the favourable opinion” below). 
 
The Committee has not yet been notified of the outcome of any site-specific 
assessment (SSA) for the non-NHS research site(s) taking part in this study. The 
favourable opinion does not therefore apply to any non-NHS site at present. I will write 
to you again as soon as one Research Ethics Committee has notified the outcome of a 
SSA. In the meantime no study procedures should be initiated at non-NHS sites. 
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Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start 
of the study. 
 
Management permission or approval must be obtained from each host organisation 
prior to the start of the study at the site concerned. 
 
For NHS research sites only, management permission for research (“R&D approval”) 
should be obtained from the relevant care organisation(s) in accordance with NHS 
research governance arrangements.  Guidance on applying for NHS permission for 
research is available in the Integrated Research Application System or at 
http://www.rdforum.nhs.uk.  Where the only involvement of the NHS organisation is as 
a Participant Identification Centre, management permission for research is not required 
but the R&D office should be notified of the study. Guidance should be sought from the 
R&D office where necessary. 
 
Sponsors are not required to notify the Committee of approvals from host 
organisations. 
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site (as 
applicable). 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date      
Covering Letter  Iain McCallum  23 October 2009    
REC application  28026/70673/1
/201  
20 October 2009    
Protocol  v 1  21 October 2009    
Investigator CV  John Mathers  20 October 2009    
Referees or other scientific critique report  Ref 49395, 
49396, 49425  
12 December 2008    
Summary/Synopsis  v 1  16 October 2009    
CV for student/key investigator  Iain McCallum  20 October 2009    
CV for key investigator  Seamus Kelly  20 October 2009    
CV for key investigator  David 
Bradburn  
20 October 2009    
Letter of support from Danisco  Julian Stowell  30 March 2009    
Letter of support from SUERC  Tom Preston  19 March 2009    
Details of subcontractors  Danisco and 
SUERC  
     
Letter from Newcastle University re peer reviews  Helen Rodgers  12 December 2008    
Response to reviewers' comments  Seamus Kelly       
Response to Request for Further Information  John Mathers  04 December 2009    
Participant Information Sheet: Normals  v 2  21 November 2009    
Participant Information Sheet: Polyps  v 2  21 November 2009    
Participant Information Sheet: UC  v 2  21 November 2009  
Participant Consent Form  v 2  21 November 2009    
Letter of invitation to participant  (Normals) v 2  21 November 2009    
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Letter of invitation to participant  (Polyps) v 2  21 November 2009    
Letter of invitation to participant  (UC) v 2  21 November 2009    
GP/Consultant Information Sheets  (Normals) v 2  21 November 2009  
GP/Consultant Information Sheets  (UC) v 2   21 November 2009    
GP/Consultant Information Sheets  (Polyps) v 2  21 November 2009    
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National 
Research Ethics Service website > After Review 
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure.  If you wish to make 
your views known please use the feedback form available on the website. 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Progress and safety reports 
 Notifying the end of the study 
The NRES website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to improve 
our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk.  
 
09/H0907/77 Please quote this number on all correspondence 
 
Yours sincerely 
 
Professor Philip M Preshaw 
Chair 
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Appendix B. Letter sent to potential DISC Study participants 
Dept of Surgery 
North Tyneside General Hospital 
Rake Lane 
North Shields 
NE29 8NH 
 
Dear Mr./Mrs. X, 
 
We are writing to inform you about a study that we are conducting at North Tyneside 
General Hospital and Wansbeck General Hospital. We are writing to you because you 
have been booked for an endoscopy (a camera examination of the lower bowel). 
 
Our research aims to examine how diet can influence cells in the bowel wall and the 
changes they sometimes undergo to become a cancer. To conduct this study we require 
samples taken from the bowel wall from normal volunteers without a cancer.  
 
Please take your time reading the enclosed information. When you arrive for your 
endoscopy you will be seen by one of the research team who will be able to provide you 
with further information. If you decide to take part in the study you will have to sign a 
consent form. If you decide not to participate now, or at a later time within the study, it 
will not affect any other aspect of your treatment at the hospital. 
 
Thank you for your cooperation which is very much appreciated. 
 
Yours sincerely 
 
 
Naomi Willis 
Research Associate 
Newcastle University 
 
On behalf of the research team 
 
John Mathers    Iain McCallum  Naomi Willis 
Professor of Nutrition  Research Fellow  Research Associate 
Newcastle University  North Tyneside Hospital Newcastle University 
 
Seamus Kelly   Mike Bradburn   
Consultant Surgeon  Consultant Surgeon   
North Tyneside Hospital Wansbeck Hospital 
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Letter of invitation / research participant information sheet 
 
Dear Sir/Madam, 
 
You are being asked if you would be willing to participate in one of our research projects that is 
being conducted by Northumbria NHS Foundation Trust and Newcastle University.  
Before you decide to participate, please read the details below. Take the time to read the 
following information carefully and discuss it with friends, relatives and your GP if you wish. 
Ask us if there is anything that is not clear to you or if you would like more information. Your 
GP will be informed if you decide to participate in the study. Take time to decide whether or not 
you wish to take part. Deciding to take part or not to take part will not affect any other aspect of 
the care that you will receive. 
 
Why have I been offered entry to the study? 
You have been offered entry to the study because your doctor (GP or hospital doctor) has 
requested that we perform an endoscopy (camera examination of the lower bowel). For our 
research we require biopsy samples from patients’ colons to examine particular cells. 
Depending on the findings at your endoscopy, you may be asked to participate in the study 
where a food supplement is taken for 50 days and a repeat camera test is done with new biopsies 
taken. 
 
Why is this study being performed? 
One part of the study is designed to examine colon stem cells (stem cell study). Stem cells are 
present in all tissues of the body and are responsible for renewing all cells in the body. Cancers 
are thought to originate from stem cells by a process of genetic alterations. If no abnormality is 
present on your endoscopy we would like to take nine biopsies (tiny tissue samples) so that we 
can count the number of stem cells present in the tissue. We will be able to compare your 
samples with other peoples’ to see how the distribution of stem cells varies between people. We 
will also compare your samples with other people who have precancerous abnormalities to see 
how normal is different from them. 
 
In the colon we know that a substance thought to be protective against cancer (non-digestible 
carbohydrates) can reverse some very early precancerous changes at a microscopic level in 
tissue from people who have colon cancer. Two non-digestible carbohydrates are resistant 
starch and polydextrose. Non-digestible carbohydrates occur naturally in the diet. 
 
We believe that the changes in the cells in the bowel caused by non-digestible carbohydrates 
may be due to changes in the numbers of stem cells in the colon. To test this we would like you 
to take a food supplement which will be a type of non-digestible carbohydrate or a placebo (a 
substance that has no effect) for 50 days. We would then take further biopsy samples with a 
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different type of telescope that only examines the last 15cm of the bowel to see if the number of 
stem cells has changed. This procedure doesn’t require any medicines to cleanse the bowel 
beforehand.  
 
The other part of the study (marker study) aims to help us understand the molecular changes 
that put some people at risk of colon cancer. We know that diet and lifestyle choices can affect 
the risk of developing colon cancer. However definite answers that would tell us how colon 
cancer could be prevented are hard to come by as we have to conduct experiments over very 
long time periods as we need to wait and see who develops a cancer and this is a very slow 
process (tens of years). We need to understand some of the changes that we can measure much 
earlier, particularly expression of certain molecules and genes. To know whether these 
molecules are sensitive enough to show the very early changes we are looking for we need to 
test their response to dietary supplementation. These tests would be carried out on the same 
samples that you provided for the stem cell part of the study. 
 
What exactly would I have to do as a participant? 
If you decide to participate and there are no abnormalities seen in your colon we will ask if you 
would carry on with the study. This would involve taking a food supplement twice a day for 50 
days and then returning for a second endoscopy to look at the last 15cm of the bowel to collect 
further biopsies. 
 
We would ask all patients to answer some questions at the start of the study about their lifestyle 
(smoking, dietary and exercise habits). We would take height, weight, waist, hip and thigh 
measurements at the start and end of the study. We would also like to collect a blood sample as 
well as a urine, stool and cheek cell sample at the start and the end of the study. To allow the 
effects of the bowel preparation to wear off so that our measurements are accurate we would ask 
that you wait for one week after your first endoscopy before starting the food supplement. Just 
before starting the food supplement we would ask you to give a urine and stool sample. We will 
give you more details on this if you decide to participate. Deciding not to participate will not 
affect any other treatments or investigations that the hospital would provide for you. 
 
How often do I need to visit the hospital during the study? 
You would need to attend for the first endoscopy as you normally would. If you are asked to 
participate further the food supplement would be supplied to you and you would be asked to 
attend again for one further examination of the last 15cm of the bowel after 50 days of 
treatment. Before you start taking your supplement we would ask you to provide a urine and 
stool sample. This would be one week after the first endoscopy and we will provide you with 
equipment and instructions to collect this at home. We would pick up this sample from your 
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home at a time that suits you. You would then take your food supplement after this. Just before 
your second endoscopy we would ask you to provide a urine and stool sample in the same way 
which we would ask you to bring with you at the time of your second appointment. There may 
of course be other clinic appointments or tests required due to the results of tests that are 
unrelated to this study. These would not alter although we would do our best to fit your one 
repeat endoscopy test around any other appointments that you had to minimise your 
inconvenience. 
 
What food supplement would I be taking? 
You will not be told and we would not know what supplement you were taking. You would 
either be taking resistant starch, polydextrose or a substance called a placebo which is 
something that will have no effect on your cells. Both the patient and the study staff not 
knowing what supplement anyone is taking makes the experiment fairer when it comes to 
looking at the results. 
 
What do we know about non-digestible carbohydrates? 
Non-digestible carbohydrate is a term for any starch molecule in the diet that is not broken 
down by the intestine until it reaches the colon. In the colon natural bacteria break down the 
resistant starch into active chemicals. We know that these chemicals have the ability to interact 
with genes in cells and are able to switch on anti-cancer genes. We have shown that treatment 
with resistant starch can alter very early pre-cancerous changes in mature cells. This study aims 
to find the effects on the stem cells in the colon and the effects on molecules that could be tested 
for to show the earliest signs of cancer development. 
 
How is the supplement administered? 
We will ask you to take four sachets of the supplement each day for 50 days. The powder in 
these sachets can be put on cold food or sometimes dissolved in juice and does not have any 
taste. 
 
What side effects can I expect? 
Non-digestible carbohydrates are part of the normal diet although we are providing a 
supplement to exaggerate any effect that they have on colon cells. In larger amounts non-
digestible carbohydrates are known to sometimes cause: increased flatulence, bloating 
sensation, mild abdominal pain and mild laxative effects. These will all stop when the 
supplementation is stopped. No serious side-effects have ever been reported from non-digestible 
carbohydrates. 
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What are the risks of endoscopy examination and biopsies? 
All operations and procedures carry a small risk and it is important that you understand this 
before deciding whether or not to participate. There is a very small chance of a perforation (a 
hole made in the bowel) of the bowel (1 in 15 000). A perforation will almost always require an 
operation to fix it. Bleeding occurs more frequently (1 in 100-200) but is almost always minor 
and settles on its own. It is most common after removal of a polyp. Although you may require to 
have a polyp removed depending on what your consultant sees at your initial endoscopy this 
would not be a part of the study we are conducting. This risk of bleeding or perforation is 
obviously higher with each biopsy that is being taken. We plan to take nine biopsies at your first 
and second camera examinations. 
 
What happens if anything goes wrong? 
You are free to participate or not in the study and this will in no way affect your subsequent care 
in the hospital. There is no payment intended for patients or doctors. If you are harmed by 
taking part in this research project, there are no special compensation arrangements, but you will 
still be entitled to complain through your local NHS hospital procedure. If you are harmed due 
to someone’s negligence or wrong doing, then you may have grounds for a legal action but you 
may have to pay for it. You may withdraw from the study at any time without explaining why, 
this will not affect any future care that you may receive. 
 
Will the information be confidential? 
Yes. Only those involved will be able to look at any information records. Specific details which 
identify you will only be available to the study doctors. Your own doctor (GP) will be informed 
that you are taking part in this study.  
 
What will happen to the samples collected? 
The samples that are collected will be examined at laboratories in Newcastle University. All 
samples will be stored securely. We will perform tests to look for the stem cells and tests to look 
at the activity of the various markers we are looking into. After the study has finished the 
samples will be stored in our laboratory freezers in accordance with government regulations. 
Your name and details will no longer be associated with the samples. We keep the samples so 
that if new techniques or markers are discovered we can do further testing without having to 
collect new samples from other volunteers. 
 
What benefits may I get from the study? 
We do not believe that there will be any direct benefit to the health of those who participate in 
the study. The research may well help us to understand the development of bowel cancer and 
develop prevention or treatment strategies. 
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We will give all the patients who take part in the intervention phase (i.e. taking the food 
supplement) a shopping voucher for £50 as a thank you for the extra time that they will have 
given up for the project. Travel expenses for the additional trip to hospital will also be provided. 
 
Who is performing the research? 
The research team consists of five members: 
Mr Iain McCallum is a research fellow at Northumbria NHS Foundation Trust 
Dr Naomi Willis is a research associate at Newcastle University 
Professor John Mathers is the Professor of Human Nutrition at Newcastle University 
Mr Seamus Kelly is a consultant surgeon at North Tyneside General Hospital and a senior 
lecturer at Newcastle University 
Mr Mike Bradburn is a consultant surgeon at Wansbeck General Hospital 
 
We hope that you agree to participate, if you have any questions please ask. 
 
Study coordinator, Naomi Willis 
Research Associate 
Human Nutrition Research Centre 
Newcastle University 
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Appendix C. Patient screening 
Patient screening                                                 
 
Age <16      ○  Therapy with aspirin/other NSAID  ○ 
Age >85      ○ Familial polyposis syndrome ○ 
Lynch syndrome     ○ Known colorectal tumour  ○ 
Previous colorectal resection   ○ Pregnancy   ○ 
Chemotherapy in last 6 months   ○  Active colonic inflammation ○ 
Other immunosuppressive medication/steroid ○ Colorectal carcinoma found ○ 
Incomplete left sided examination   ○ Iatrogenic perforation  ○ 
Colorectal cancer on histology   ○ Crohn’s disease   ○ 
UC group ONLY (score should be less than 5) 
 Bowel frequency (day)    Urgency of defecation 
1-3    0  Hurry    1
 4-6    1  Immediately   2 
7-9    2  Incontinence   3 
>9    3 
 
Bowel frequency (night)    General Well Being  
1-3    1  Very well   0 
4-6    2  Slightly below par  1 
      Poor    2 
Blood in Stool      Very poor   3 
 Trace    1  Terrible    4 
 Occasionally frank  2 
 Usually frank   3 Extracolonic manifestation, 1 per manifestation 
     
Patient name ………………………………….....          Patient date of birth  ………….. 
Assessed by ……………………………………..          Date of assessment   ………….. 
Suitable Yes/No     Informed consent Yes/No      Study ID DISC        …………. 
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Appendix D. DISC Study consent form 
I freely consent to participate in this project   Yes  No 
 
I have had the opportunity to ask questions    Yes  No 
 
I understand that my care will not be affected   Yes  No 
if I choose not to participate 
 
I understand I can withdraw at any time    Yes  No 
 
I give permission for my GP to be informed    Yes  No 
 
I am happy for the samples to be stored after    Yes  No  
the study has finished in case further testing  
can be carried out later  
 
I understand that relevant sections of my medical notes  Yes  No 
And data collected during the study, may be looked at by 
Individuals from regulatory authorities or from the NHS  
trust, where it is relevant to my taking part in this research. 
I give my permission for these individuals to have access  
to my records. 
 
 
Participant signature …………………………………………..  Date ……………… 
 
Participant name (print) ………………………………………. 
 
 
Researcher signature …………………………………………..  Date ……………… 
 
Researcher name (print) ………………………………………. 
 
 
 
 
1 copy to patient; 1 to research file; 1 to notes 
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Appendix E. DISC Study food frequency questionnaire 
 
Food Frequency Questionnaire 
Name:       
Date:        
 
Thank you for agreeing to take part in the DISC study. 
This is a simple questionnaire designed to help us 
understand what kinds of food you normally eat. It is 
not a test, so there are no right or wrong answers.  
It is your usual diet we are interested in. 
 
All information will be treated in the strictest 
confidence. 
Thank you for your time 
Please turn over and read the instructions for answering questions before completing the 
questionnaire. 
 DISC 
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FFQ Questionnaire 
About the food you eat 
 
The following questions are about the food you usually eat and how often you 
eat certain foods. Please read the following instructions before answering 
the questions.  
For each food there is an amount shown, either a “medium serving” or a 
common household unit such as a slice or teaspoon.  Please put a tick in the 
box to indicate how often, on average, you have eaten the specified amount 
of each food during the past year.   
 
EXAMPLE: 
 
For white bread the amount is one slice, so if you ate 4 or 5 slices a day, you 
should put a tick in the column headed “4-5 per day”. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
BREAD & SAVOURY 
BISCUITS 
(one slice or biscuit) 
Never or 
less than 
once/mont
h 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
White bread and rolls 
 
         
 
EXAMPLE: 
 
For chips, the amount is a “medium serving”, so if you had a helping of chips 
twice a week you should put a tick in the column headed “2-4 per week”. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
POTATOES, RICE & 
PASTA 
(medium serving) 
Never or 
less than 
once/mont
h 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Chips 
 
         
It is your turn to answer now! 
                                            
 316 
Please put a tick in each box to indicate how often, on average, you have 
eaten each food during the past year. 
 
Please estimate your average food use as best you can, and please answer 
every question - do not leave ANY lines blank.  Please put a tick on every 
line. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
19. MEAT & FISH 
(medium serving) 
Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ per 
day 
Beef: roast, steak, mince, stew 
casserole, curry or bolognese 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Beefburgers 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Pork: roast, chops, stew, slice or 
curry 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Lamb: roast, chops, stew or 
curry 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Chicken, turkey or other poultry: 
including fried, casseroles or 
curry 
 
           
  
              1                      
 
           
  
2                     
 
       
      
 3                     
 
           
  
 4                      
 
          
   
5                      
 
            
 
6                      
 
         
    
7                      
 
     
       
8                      
 
        
     
9                      
Bacon 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Ham 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Corned beef, Spam, luncheon 
meats 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sausages 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Savoury pies, e.g. meat pie, pork 
pie, pasties, steak & kidney pie, 
sausage rolls, scotch egg 
 
           
  
              1                      
 
           
  
2                     
 
       
      
 3                     
 
           
  
 4                      
 
          
   
5                      
 
            
 
6                      
 
         
    
7                      
 
     
       
8                      
 
        
     
9                      
 Never 
or less 
than 
once/
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Please check that you have a tick on EVERY line 
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PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
19. MEAT & FISH, 
(continued) 
(medium serving) 
Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ per 
day 
Liver, liver pate, liver sausage 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Fried fish in batter, as in fish 
and chips 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Fish fingers, fish cakes 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Other white fish, fresh or 
frozen, e.g. cod, haddock, plaice, 
sole, halibut 
 
           
  
              1                      
 
           
  
2                     
 
       
      
 3                     
 
           
  
 4                      
 
          
   
5                      
 
            
 
6                      
 
         
    
7                      
 
     
       
8                      
 
        
     
9                      
Oily fish, fresh or canned, e.g. 
mackerel, kippers, tuna, salmon, 
sardines, herring 
 
           
  
              1                      
 
           
  
2                     
 
       
      
 3                     
 
           
  
 4                      
 
          
   
5                      
 
            
 
6                      
 
         
    
7                      
 
     
       
8                      
 
        
     
9                      
Shellfish, e.g. crab, prawns, 
mussels 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
20. BREAD & SAVOURY BISCUITS 
(one slice or biscuit) 
White bread and rolls 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Scones, teacakes, crumpets, 
muffins or croissants 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Brown bread and rolls 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Wholemeal bread and rolls 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cream crackers, cheese biscuits 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Pitta bread, naan bread, chapati  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Garlic bread 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
 Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Please check that you have a tick on EVERY line 
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PLEASE PUT A TICK ON EVERY LINE. 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
21. CEREALS 
(one bowl) 
Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ per 
day 
Porridge, Readybrek 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sugar coated cereals e.g. Sugar 
Puffs, Cocoa Pops, Frosties 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Non-sugar coated cereals e.g. 
Cornflakes, Rice Crispies 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
All Bran, Bran Flakes, Muesli  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Wholegrain cereals e.g. Cheerios, 
Weetabix, Shredded Wheat 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
22. POTATOES, RICE & PASTA 
(medium serving) 
Boiled, mashed, instant or jacket 
potatoes 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Chips, potato waffles 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Roast potatoes 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Yorkshire pudding, pancakes, 
dumpling 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Potato salad 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
White rice  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Brown rice  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
White or green pasta, e.g. 
spaghetti, macaroni, noodles 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Tinned pasta, e.g. spaghetti, 
ravioli, macaroni 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
 Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Please check that you have a tick on EVERY line 
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PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
22. POTATOES, RICE 
& PASTA (continued) 
(medium serving) 
Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Super noodles, pot noodles, pot 
savouries 
 
 
               
1 
 
 
              2 
 
 
             3 
 
 
             4 
 
 
               
5   
 
 
              6  
 
 
               
7 
 
 
               
8 
 
 
               
9 
Wholemeal pasta 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Lasagne, moussaka, cannelloni  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Pizza 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
23. DAIRY PRODUCTS & FATS 
 
       
Single or sour cream 
(tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Double or clotted cream 
(tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Low fat yoghurt, fromage frais 
(125g carton) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Full fat or Greek yoghurt (125g 
carton) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Dairy desserts (125g carton), 
e.g. mousse 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cheese, e.g. Cheddar, Brie, Edam 
(medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cottage cheese, low fat soft 
cheese (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Eggs as boiled, fried, scrambled, 
omelette etc. (one) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Quiche (medium serving) 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
 Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Please check that you have a tick on EVERY line 
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PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
23.(b) The following on 
bread or vegetables 
(teaspoon) 
Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Butter 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Block margarine, e.g. Stork, 
Krona 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Polyunsaturated margarine, e.g. 
Flora sunflower 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Other soft margarine, dairy 
spreads, e.g. Blue Band, Clover 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Low fat spread, e.g. Gold  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
24. SWEETS & SNACKS 
 
        
Sweet biscuits, chocolate, e.g. 
digestive (one) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sweet biscuits, plain, e.g. Nice, 
ginger (one) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cakes e.g. fruit, sponge, sponge 
pudding (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sweet buns & pastries e.g. flapjacks, 
doughnuts, Danish pastries, cream 
cakes (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Fruit pies, tarts, crumbles 
(medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Milk puddings, e.g. rice, custard, 
trifle (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Chocolates (small bar or ¼ pound 
of chocolates) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Ice cream, choc ices (one)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
 Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Please check that you have a tick on EVERY line 
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PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
24. SWEETS & 
SNACKS (continued) 
 
Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Sweets, toffees, mints (one 
packet) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sugar added to tea, coffee, 
cereal (teaspoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Crisps or other packet snacks 
e.g. Wotsits (one packet) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Peanuts or other nuts (one 
packet) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
25. SOUPS, SAUCES AND SPREADS 
 
      
Vegetable soups (bowl)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Meat soups (bowl)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sauces, e.g. white sauce, cheese 
sauce, gravy (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Tomato based sauces, e.g. pasta 
sauces (medium serving) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Tomato ketchup, brown sauce 
(tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Relishes, e. g. pickles, chutney, 
mustard (tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Low calorie, low fat salad cream 
or mayonnaise (tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Salad cream, mayonnaise 
(tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
French dressing (tablespoon)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
 Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Please check that you have a tick on EVERY line 
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PLEASE PUT A TICK ON EVERY LINE. 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
25. SOUPS, SAUCES 
AND SPREADS 
(continued) 
Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
A 
Week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Other salad dressing 
(tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Marmite, Bovril (teaspoon) 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Jam, marmalade, honey, syrup 
(teaspoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Peanut butter (teaspoon) 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Chocolate spread, chocolate nut 
spread (teaspoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Dips, e.g. houmous, cheese and 
chive (tablespoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
26. DRINKS          
Tea (cup)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Coffee, instant or ground (cup)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Coffee whitener, e.g. Coffee-
mate (teaspoon) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cocoa, hot chocolate (cup)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Horlicks, Ovaltine (cup)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Wine (glass)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Beer, lager or cider (half pint)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Port, sherry, vermouth, liqueurs 
(glass) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
 Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Please check that you have a tick on EVERY line 
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PLEASE PUT A TICK ON EVERY LINE. 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
26. DRINKS 
(continued) 
Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Spirits, e.g. gin, brandy, whisky, 
vodka (single) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Low calorie or diet fizzy soft 
drinks (glass) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Fizzy soft drinks, e.g. Coca cola, 
lemonade (glass) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Pure fruit juice (100%), e.g. 
orange, apple juice (glass) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Fruit squash or cordial (glass)  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
27. FRUIT (1 fruit or medium serving)       
*For very seasonal fruits such as strawberries, please estimate your average use when 
the fruit is in season 
Apples 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Pears  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Oranges, satsumas, mandarins, 
tangerines, clementines 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Grapefruit  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Bananas  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Grapes  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Melon  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
*Peaches, plums, apricots, 
nectarines 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
*Strawberries, raspberries, kiwi 
fruit 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
 Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
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PLEASE PUT A TICK ON EVERY LINE. 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
27. FRUIT (continued) 
(1 fruit or medium 
serving) 
Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Tinned fruit  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Dried fruit, e.g. raisins, prunes, 
figs 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
28. VEGETABLES Fresh, frozen or tinned (medium serving) 
Carrots 
 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Spinach  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Broccoli  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Brussels sprouts  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cabbage  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Peas  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Green beans, broad beans, 
runner beans 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Marrow, courgettes  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Cauliflower  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Parsnips, turnips, swedes  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Leeks  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Onions  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Garlic  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
 Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
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PLEASE PUT A TICK ON EVERY LINE. 
 
FOODS & AMOUNTS AVERAGE USE LAST YEAR 
28. VEGETABLES 
Fresh, frozen or tinned 
(continued) 
(medium serving) 
Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Mushrooms  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sweet peppers  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Beansprouts  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Green salad, lettuce, cucumber, 
celery 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Mixed vegetables (frozen or 
tinned) 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Watercress  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Tomatoes  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Sweetcorn  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Beetroot, radishes  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Coleslaw  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Avocado  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Baked Beans  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Dried lentils, beans, peas  
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
Tofu, soya meat, TVP, 
Vegeburger 
 
            
              1                      
 
            
2                     
 
            
 3                     
 
            
 4                      
 
            
5                      
 
            
6                      
 
            
7                      
 
            
8                      
 
            
9                      
 Never 
or less 
than 
once/ 
month 
1-3  
per  
month 
Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Please check that you have a tick on EVERY line 
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YOUR DIET LAST YEAR, continued  
 
29. (a) What type of milk did you most often use? 
 
Select one only 
 
 Full cream……1 
Channel Islands……2 
 Dried milk……3 
Semi-skimmed……4 
Skimmed……5 
 Soya……6 
 Other……7 
None……8 
4/52 
 
29. (b) Approximately, how much milk did you drink each day, including 
milk with tea, coffee, cereals etc? 
 
 None……1 
Quarter of a pint (roughly 125mls)……2 
 Half a pint (roughly 250mls) ……3 
Three quarters of a pint (roughly 375mls) ……4 
     One pint (roughly 500mls) ……5 
       More than one pint (more than 500mls) ……6 
4/53 
 
30.  What kind of fat did you most often use for frying, roasting, 
grilling etc? 
 
Select one only 
 Butter……1 
Lard/dripping……2 
Solid vegetable fat……3 
Margarine……4 
 Vegetable oil……5 
Olive oil……6 
 None……7 
4/54 
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31. How often did you eat food that was fried at home? 
 
Select one only 
 Daily……1 
1-3 times a week……2 
4-6 times a week……3 
 Less than once a week……4 
Never……5 
4/55 
 
32. How often did you eat fried food away from home? 
 
Select one only 
 
 Daily……1 
1-3 times a week……2 
4-6 times a week……3 
 Less than once a week……4 
Never……5 
4/56 
 
33. (a) How often did you add salt to food while cooking? 
Select one only 
 
 Always……1 
Usually……2 
Sometimes……3 
 Rarely……4 
Never……5 
4/57 
 
33. (b) How often did you add salt to any food at the table? 
 
Select one only 
 Always……1 
Usually……2 
Sometimes……3 
 Rarely……4 
Never……5 
4/58 
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34. Do you follow a special diet? 
 Please tick all that apply. 
 
No……1 
Yes, due to a medical condition/allergy……2 
 Yes, to lose weight……3 
Yes, because of personal beliefs ……4 
                                                                                                                     Yes other……5 
4/63 
 
35. Over the last year, how often have you eaten organic foods? 
Select one only. 
 Most days……1 
Once or twice a week……2 
Once a month……3 
 Never/hardly ever……4 
4/64 
 
36. Have you taken any of the following during the past year? 
 
a) Vitamins (e.g. multivitamins, vitamin B, vitamin C, folic acid) 
  
Yes……1 
 No……2 
 
 If YES, what type and when         
4/65 
b) Minerals (e.g. iron, calcium, zinc, magnesium) 
         
Yes……1 
 No……2 
  
If YES, what type and when         
 
4/66 
c) Fish oils (e.g. cod liver oil, omega-3) 
 
Yes……1 
 No……2 
 If YES, what type and when         
4/67 
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d) Other food supplements (e.g. oil of evening primose, starflower oil, 
royal jelly, ginseng) 
 
Yes……1 
No……2 
  
If so, what type and when         
 
4/68 
 
37. During the course of last year, on average, how many times did 
you eat the following foods? 
 
Food Type      Times/week Portion size 
 
Vegetables (not including potatoes)       medium serving 
5/41 
Salads        medium serving 
5/43 
Fruit and fruit products (not including    medium serving 
fruit juice)        or 1 fruit 
              5/45  
Fish and fish products      medium serving 
5/47 
Meat, meat products and meat dishes 
(including bacon, ham and chicken)    medium serving 
5/49 
 
 
38. How often do you eat fruit or vegetables from a garden or 
allotment? 
 
Select one only. 
 Most days……1 
Once or twice a week……2 
Once a month……3 
 Never/hardly ever……4 
5/50 
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39. How would you most commonly eat the following vegetables? 
If you have not eaten the vegetable listed within the last year,  
please tick the ‘Not eaten ‘ box.  
 
Select one box only for each vegetable; 
 
     Raw    Boiled  Boiled       Steamed       Fried   Not eaten 
     < 10mins >10mins 
Asparagus                                                   
Artichoke                                                   
Beansprouts                                                   
Beetroot                                                  
Broad beans                                                  
Broccoli                                                  
Brussel Sprouts                                             
Cauliflower                                              
 
      Raw    Boiled  Boiled       Steamed       Fried   Not eaten 
  < 10mins >10mins 
Cabbage                                                   
Chick Peas                                                   
Courgette                                                   
Curly Kale                                                   
Green Beans                                                   
Leeks                                                    
Lentils                                                   
Lettuce                                                   
 Mixed veg frozen                                              
 Mixed veg canned                                             
Parsnip                                                   
Peas                                                    
Red Kidney Beans                                             
Runner Beans                                             
Spinach fresh                                             
Spinach frozen                                             
Sweetcorn fresh                                             
Sweetcorn canned                                             
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40. For the following foods, please list the top three makes and/or brands 
you most commonly consume.  
If you do not eat this type of food please tick the ‘not eaten’ box.  
 
 
 Bread:    1:       
2:       
3:      Not eaten  
  
Breakfast Cereal 
     1:       
2:       
3:      Not eaten  
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About you and your health 
 
41. For your age, would you say that your health was: 
Please tick one box on the scale of 1 to 5: 
 
  1 2 3 4 5 
very good      very poor 
5/51 
 
42. Which of the following best describes your daily work or other 
daytime activity that you usually do? 
Please tick one box only. 
 
I am usually sitting and do not walk about much……1 
 
I stand or walk about quite a lot, but do not  
have to carry or lift things very often     ……2 
 
I usually lift or carry light loads or have  
to climb stairs or hills often      ……3 
 
I do heavy work or carry heavy loads often    ……4 
5/52 
43. Please give the average number of hours per week you spend doing 
 sports and other activities.      
 
 Please write in the amount for each; if none write “0” 
 
a) Mildly energetic 
(e.g. walking, gardening, playing darts, general 
housework) 
 
_____ hour/s 
b) Moderately energetic 
(e.g. heavy housework or gardening, dancing, golf, 
cycling, leisurely swimming) 
 
_____ hour/s 
c) Vigorous 
(e.g. running, competitive swimming or cycling, 
tennis, football, squash, aerobics)                      5/64 
 
_____ hour/s     
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44. Do you smoke? 
 
Yes, I smoke daily  ……1 
Yes, I smoke occasionally ……2 
No, I used to smoke ……3 
No, I have never smoked ……4 
5/65 
 
44. If yes or you used to smoke, how much, on average, do you (or 
did you) smoke a day? 
Please write in the amount for each; if none write “0” 
 
Cigarettes  ____ 
          Cigars   ____ 
          Ounces tobacco ____ 
5/74 
 
45. In the past 12 months have you taken an alcoholic drink: 
 Please tick one box. 
 
Twice a day or more ……1 
Almost daily   ……2 
Once or twice a week ……3 
Once or twice a month ……4 
Special occasions only ……5 
Not at all   ……6 
5/75 
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46.  In a typical 7-day week, including the weekend, how many 
standard drinks of alcohol do you drink? (see the table below) 
Please write the number in the box below. 
 
I usually drink ____ standard drinks of alcohol per week 
5/76 
 
ONE STANDARD DRINK = ½ pint of beer 
    or ½ pint cider 
    or ½ pint lager  
    or 1 glass of wine, martini, or cinzano 
    or 1 small glass of Sherry or Port 
    or 1 measure of Spirits (gin, whiskey, vodka etc.) 
    or 1 measure liquor 
 
A PINT OF BEER, CIDER, OR LAGER COUNTS AS TWO STANDARD DRINKS 
1 A DOUBLE MEASURE OF SPIRITS COUNTS AS TWO STANDARD 
DRINKS 
 
 
 
47. (a) Do you have any long-term illness, physical or mental health 
 problem or handicap? 
 Yes……1 
 No……2 
5/91 
48. (b) If yes, does this limit your daily activity in any way? 
 
 Yes……1 
 No……2 
5/92 
 
 
THANK YOU FOR TAKING TIME TO COMPLETE THIS 
QUESTIONNAIRE 
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Appendix F. DISC Study lifestyle questionnaire 
 
Life style Questionnaire 
 
Name:       
Date:        
 
 
Thank you for agreeing to take part in this study. This is 
a simple life style questionnaire to give us an idea of 
your physical activity. It is not a test, so there are no 
right or wrong answers.  
All information will be treated in the strictest 
confidence. 
Thank you for your time 
 
Please turn over to complete the questionnaire. 
 
   
 336 
1. We would like to know the type and amount of physical activity involved in 
your work. Please tick what best corresponds to your present activities from the 
following four possibilities: 
 
 Sedentary occupation  _______ 
 
You spend most of your time sitting (such as an office) 
 
 Or Standing occupation _______ 
 
You spend most of your time standing or walking. However, your work does not require 
intense physical effort (e.g. shop assistant, hairdresser, guard etc.) 
 
 Or Physical work   _______ 
 
The work involves some physical effort including handling of heavy objects and use of 
tools (e.g. plumber, cleaner, nurse, instructor, electrician, carpenter etc.) 
 
 Or Heavy Manual work ______ 
 
This involves very vigorous physical activity including handling of very heavy objects 
(e.g. docker, miner, bricklayer, construction worker, etc.) 
 
 
2. In a typical week, during the past 12 months, how many hours did you spend 
on each of the following activities?                 (Put 0 if none) 
 
 Walking, including walking to work, shopping and leisure 
 
In summer ______ hours per week 
 
In winter ______ hours per week 
 
 Cycling, including cycling to work and during leisure time 
 
In summer ______ hours per week 
 
In winter ______ hours per week 
 
 Gardening 
 
In summer ______ hours per week 
 
In winter ______ hours per week 
 
 Housework such as cleaning, washing, cooking, childcare 
 
______ hours per week 
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 Do-it-yourself 
 
______ hours per week 
 
 Other physical exercise such as keep fit, aerobics, swimming, jogging 
 
In summer ______ hours per week 
 
In winter ______ hours per week 
 
 
3. In a typical week during the past year did you practise any of the above 
activities vigorously enough to cause sweating or a faster heartbeat? 
 
Yes ___      No ___      Don’t know  ____ 
 
 If yes, for how many hours per week in total did you practise such vigorous 
physical activity? (Put 0 if none) 
 
_____________hours per week 
 
 
4. In a typical day during the past 12 months, how many floors of stairs did 
you climb? (Put ‘0’ if none) 
 
______ floors per day 
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 Appendix G. Example of results from ANOVA GLM 
analysis  
General Linear Model: AXIN2 POST versus National Starch, Danisco  
 
Factor           Type   Levels  Values 
National Starch  fixed       2  0, 1 
Danisco          fixed       2  0, 1 
 
Analysis of Variance for AXIN2 POST, using Adjusted SS for Tests 
 
Source                   DF   Seq SS   Adj SS   Adj MS      F      P 
AXIN2 PRE                 1  12.6233  11.1931  11.1931  11.71  0.001 
Age                       1   0.1863   0.0001   0.0001   0.00  0.990 
Procedure code            1   0.2551   0.1275   0.1275   0.13  0.716 
Gender code               1   0.1923   0.0166   0.0166   0.02  0.896 
Smoking code              1   0.8134   0.4350   0.4350   0.46  0.503 
Pre BMI                   1   0.7768   1.0708   1.0708   1.12  0.294 
National Starch           1   1.3843   1.4046   1.4046   1.47  0.230 
Danisco                   1   0.1274   0.1622   0.1622   0.17  0.682 
National Starch*Danisco   1   1.6936   1.6936   1.6936   1.77  0.188 
Error                    56  53.5112  53.5112   0.9556 
Total                    65  71.5638 
S = 0.977526   R-Sq = 25.23%   R-Sq(adj) = 13.21% 
 
Term             Coef  SE Coef      T      P 
Constant        0.858    1.127   0.76  0.450 
AXIN2 PRE     0.24165  0.07061   3.42  0.001 
Age           0.00015  0.01192   0.01  0.990 
Procedure co   0.1000   0.2739   0.37  0.716 
Gender code    0.0343   0.2605   0.13  0.896 
Smoking code  -0.1068   0.1583  -0.67  0.503 
Pre BMI       0.02644  0.02498   1.06  0.294 
 
Unusual Observations for AXIN2 POST 
Obs  AXIN2 POST      Fit   SE Fit  Residual  St Resid 
 36     5.38027  3.70281  0.51278   1.67746      2.02 R 
 38     4.77401  2.22279  0.39065   2.55123      2.85 R 
 42     0.79307  2.71488  0.47059  -1.92182     -2.24 R 
R denotes an observation with a large standardized residual. 
 
Means for Covariates 
Covariate          Mean    StDev  Covariate        Mean   StDev 
AXIN2 PRE        2.9273   1.8312  Gender code    0.5000  0.5038 
Age             51.3333  11.4789  Smoking code   0.7727  0.8189 
Procedure code   0.7121   0.4562  Pre BMI       29.7700  5.1639 
 
Least Squares Means for AXIN2 POST 
National Sta           Mean  SE Mean 
0                     2.514   0.1747 
1                     2.217   0.1691 
Danisco 
0                     2.313   0.1719 
1                     2.418   0.1775 
National Sta*Danisco 
0            0        2.635   0.2428 
0            1        2.394   0.2560 
1            0        1.992   0.2525 
1            1        2.442   0.2480 
 
Grouping Information Using Bonferroni Method and 95.0% Confidence 
National 
Starch     N  Mean  Grouping 
0         32   2.5  A 
1         34   2.2  A 
Means that do not share a letter are significantly different. 
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Grouping Information Using Bonferroni Method and 95.0% Confidence 
Danisco   N  Mean  Grouping 
1        32   2.4  A 
0        34   2.3  A 
Means that do not share a letter are significantly different. 
 
Grouping Information Using Bonferroni Method and 95.0% Confidence 
National 
Starch    Danisco   N  Mean  Grouping 
0         0        17   2.6  A 
1         1        17   2.4  A 
0         1        15   2.4  A 
1         0        17   2.0  A 
Means that do not share a letter are significantly different. 
 
 
   
 
Appendix H. Evidence from the literature identifying miRNAs modified by butyrate treatment and whose 
expression is altered in CRC and that may target SFRP1 
miRNA 
Effect of 
butyrate on 
expression 
References 
Expression change 
in CRC 
References 
Evidence that 
miRNA targets 
SFRP1 
References 
miR-7 ↓ 
(Hu et al., 
2011) 
↑ in stool of CRC 
patients 
(Ahmed et al., 2013) 
Significant inverse 
correlation 
(Fu et al., 2012) 
↓ in CRC tumours (Zhang et al., 2013) 
↓ in plasma of CRC 
patients 
(Wang et al., 2013d) 
↑ in adenocarcinoma 
cases 
(Hamfjord et al., 2012) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
 
3
4
0
 
   
 
miR-17 
↓ 
 
(Hu et al., 
2011) 
(Humphreys 
et al., 2013) 
↑ in CRC tissue/cells 
(Ma et al., 2012), 
(Earle et al., 2010), 
(Diosdado et al., 2009) 
Significant inverse 
correlation 
(Fu et al., 2012) ↑ in colon cancer (Tsuchida et al., 2011) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
↑ in rectal cancer (Gaedcke et al., 2012) 
miR-18a 
↓ 
 
(Hu et al., 
2011) 
(Humphreys 
et al., 2013) 
↑ in plasma of CRC 
patients 
(Luo et al., 2013) 
  
↑ in CRC tissue/cells 
(Arndt et al., 2009), 
(Diosdado et al., 
2009), (Motoyama et 
al., 2009) 
↑ in colon cancer 
(Tsuchida et al., 2011), 
(Wang et al., 2010) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
↑ in rectal cancer (Gaedcke et al., 2012) 
 
3
4
1
 
   
 
miR-18b 
↓ 
 
(Hu et al., 
2011) 
(Humphreys 
et al., 2013) 
↑ in colon cancer (Wang et al., 2010) 
  ↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
miR-19a 
↓ 
 
(Hu et al., 
2011) 
(Humphreys 
et al., 2013) 
↑ in colon cancer 
(Wang et al., 2010), 
(Zhang et al., 2012), 
(Tsuchida et al., 2011) 
Significant inverse 
correlation 
(Fu et al., 2012) 
↑ in CRC tissue/cells 
(Diosdado et al., 
2009), 
(Monzo et al., 2008), 
(Bandres et al., 2006) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
miR-19b 
↓ 
 
(Hu et al., 
2011) 
(Humphreys 
et al., 2013) 
↑ in colon cancer (Tsuchida et al., 2011) 
Significant inverse 
correlation 
(Fu et al., 2012) 
 
3
4
2
 
   
 
miR-20a 
↓ 
 
(Hu et al., 
2011) 
(Humphreys 
et al., 2013) 
↑ in plasma of CRC 
patients 
(Luo et al., 2011), 
(Luo et al., 2013) 
Significant inverse 
correlation 
(Fu et al., 2012) 
↑ in CRC tissue 
(Ma et al., 2011), 
(Motoyama et al., 
2009), 
(Earle et al., 2010), 
(Arndt et al., 2009), 
(Diosdado et al., 2009) 
↑ in colon cancer 
(Schetter et al., 2008), 
(Volinia et al., 2006), 
(Schepeler et al., 
2008), 
(Tsuchida et al., 2011) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
miR-20a* ↓ 
(Hu et al., 
2011) 
↑ in colon cancer (Wang et al., 2010)   
 
3
4
3
 
   
 
miR-20b 
↓ 
 
(Hu et al., 
2011) 
(Humphreys 
et al., 2013) 
↓ in colon cancer (Sarver et al., 2009) 
  ↑ in CRC stromal 
tissue 
(Nishida et al., 2012), 
miR-25 
↓ 
 
(Hu et al., 
2011) 
 
 
↑ in CRC tissue/cells 
(Earle et al., 2010), 
(Arndt et al., 2009), 
(Monzo et al., 2008) Significant inverse 
correlation 
(Fu et al., 2012) 
↓ in colon cancer (Li et al., 2013) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
miR-29a ↓ 
(Hu et al., 
2011) 
 
↑ in plasma of CRC 
patients 
(Luo et al., 2013), 
(Huang et al., 2010) Targets SFRP1 
(validated) 
(Fu et al., 2012) 
↑ in CRC tissue/cells 
(Arndt et al., 2009), 
(Monzo et al., 2008) 
 
3
4
4
 
   
 
miR-34a 
↓ 
 
(Hu et al., 
2011) 
↑ in CRC tissue/cells 
(Arndt et al., 2009), 
(Monzo et al., 2008), 
(Nugent et al., 2012), 
(Wang et al., 2012) 
  
↓ in colon cancer 
tissue/cells 
(Roy et al., 2012) 
miR-92a 
↓ 
 
(Hu et al., 
2011) 
(Humphreys 
et al., 2013) 
↑ in plasma of CRC 
patients 
(Luo et al., 2013) 
,(Huang et al., 2010) 
  
↑ CRC tissue/cells (Yamada et al., 2013a) 
↑ in colon cancer 
(Tsuchida et al., 2011), 
(Ma et al., 2011) 
↑ in plasma of CRC 
patients 
(Huang et al., 2010) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
 
3
4
5
 
   
 
miR-93 
↓ 
 
(Hu et al., 
2011) 
 
↑ in CRC tissue 
(Ma et al., 2011), 
(Earle et al., 2010) 
,(Arndt et al., 2009) Significant inverse 
correlation 
(Fu et al., 2012) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
↓ in colon cancer (Xiao et al., 2013) 
miR-95 ↑ 
(Hu et al., 
2011) 
 
↑ in CRC tissue/cells 
(Arndt et al., 2009), 
(Monzo et al., 2008), 
(Huang et al., 2011) 
Significant inverse 
correlation 
(Fu et al., 2012) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
miR-96 
↑ 
 
(Hu et al., 
2011) 
 
↑ in colon cancer (Sarver et al., 2009), 
  
↑ in CRC tissue/cells 
(Arndt et al., 2009), 
(Monzo et al., 2008), 
(Xu et al., 2012), 
(Bandres et al., 2006), 
(Hamfjord et al., 2012) 
 
3
4
6
 
   
 
miR-106a 
↓ 
 
(Hu et al., 
2011) 
(Humphreys 
et al., 2013) 
↑ in CRC tissue/cells 
(Ma et al., 2011), 
(Monzo et al., 2008) 
 
 ↑ in colonic tumours 
(Schetter et al., 2008), 
(Volinia et al., 2006) 
 
↑ in stool of CRC 
patients 
(Link et al., 2010)  
miR-106b ↓ 
(Hu et al., 
2011) 
 
 
↑ in plasma of CRC 
patients 
(Luo et al., 2013) 
  ↑ in colon cancer (Wang et al., 2010) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
 
3
4
7
 
   
 
miR-145 
↓ 
 
(La Rocca et 
al., 2011) 
↑ in plasma of CRC 
patients 
(Luo et al., 2013), 
Significant inverse 
correlation 
(Fu et al., 2012) 
↓ in CRC tissue/cells 
(Wang et al., 2009a), 
(Motoyama et al., 
2009), 
(Earle et al., 2010), 
(Arndt et al., 2009), 
(Slaby et al., 2007), 
(Bandres et al., 2006), 
(Hamfjord et al., 2012), 
(Luo et al., 2011), 
(Ma et al., 2011) 
(Chen et al., 2009), 
↓ in colon cancer 
(Schepeler et al., 
2008) 
↓ in rectal cancer  (Gaedcke et al., 2012) 
3
4
8
 
   
 
miR-183 
↑ 
 
(Hu et al., 
2011) 
 
↑ in CRC tissue/cells 
(Motoyama et al., 
2009), 
(Earle et al., 2010), 
(Arndt et al., 2009), 
(Bandres et al., 2006),   
↑ in colon cancer (Sarver et al., 2009) 
↑ in rectal cancer (Li et al., 2012) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
miR-194 ↑ 
(Hu et al., 
2011) 
 
↑ in CRC tissue/cells (Monzo et al., 2008) 
  
↓ in CRC tissue/cells 
(Chiang et al., 2012), 
(Gaedcke et al., 2012) 
miR-196b ↓ 
(Hu et al., 
2011) 
↑ in colon cancer (Wang et al., 2010)   
 
3
4
9
 
   
 
miR-215 
↑ 
 
(Hu et al., 
2011) 
 
↓ in CRC tissue/cells 
(Earle et al., 2010), 
(Faltejskova et al., 
2012) 
  
↑ in CRC tissue/cells (Monzo et al., 2008) 
↓ in rectal cancer 
(Gaedcke et al., 2012), 
(Chiang et al., 2012) 
miR-221 ↓ 
(Hu et al., 
2011) 
 
↑ in CRC tissue/cells 
(Pu et al., 2010), 
(Wang et al., 2011b) 
  ↑ in colonic tumours (Volinia et al., 2006) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
 
miR-222 ↓ 
(Hu et al., 
2011) 
 
↑ in CRC tissue/cells (Monzo et al., 2008) 
  ↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
miR-300 ↑ 
(Hu et al., 
2011) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012)   
miR-381 ↑ 
(Hu et al., 
2011) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012)   
 
3
5
0
 
   
 
miR-424 ↑ 
(Hu et al., 
2011) 
 
↑ in colon cancer (Wang et al., 2010) 
  
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
↑ in CRC tissue/cells (Wang et al., 2013c) 
miR-487b ↑ 
(Hu et al., 
2011) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012) 
Significant inverse 
correlation 
(Fu et al., 2012) 
miR-492 ↑ 
(Hu et al., 
2011) 
↑ in rectal cancer (Gaedcke et al., 2012)   
miR-874 ↑ 
(Hu et al., 
2011) 
↑ in CRC stromal 
tissue 
(Nishida et al., 2012)   
3
5
1
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